{"128e431cbcec1a9dacc6b10dffc1ea13efbb84b8": [["IntroductionPeople with diabetes have increased susceptibility to most types of infectious diseases.", [["diabetes", "DISEASE", 24, 32], ["infectious diseases", "DISEASE", 80, 99], ["diabetes", "PROBLEM", 24, 32], ["increased susceptibility", "PROBLEM", 38, 62], ["infectious diseases", "PROBLEM", 80, 99], ["diabetes", "OBSERVATION", 24, 32], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["most types", "OBSERVATION_MODIFIER", 66, 76], ["infectious", "OBSERVATION", 80, 90]]], ["Previous studies reported higher Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00125-020-05286-2) contains peer-reviewed but unedited supplementary material, which is available to authorised users. risks for the following infections in people with vs without diabetes: 1.2-to 2.6-fold for pneumonia [1, 2] ; 2.0-to 3.2-fold for sepsis [2] [3] [4] ; 3.0-to 4.3-fold for urinary tract infection [2, 4] ; and 1.8-to 2.0-fold for cellulitis [3, 5] .", [["urinary tract", "ANATOMY", 418, 431], ["infections", "DISEASE", 271, 281], ["diabetes", "DISEASE", 308, 316], ["pneumonia", "DISEASE", 338, 347], ["sepsis", "DISEASE", 377, 383], ["urinary tract infection", "DISEASE", 418, 441], ["cellulitis", "DISEASE", 475, 485], ["people", "ORGANISM", 285, 291], ["urinary tract", "ORGANISM_SUBDIVISION", 418, 431], ["people", "SPECIES", 285, 291], ["Previous studies", "TEST", 0, 16], ["the following infections", "PROBLEM", 257, 281], ["diabetes", "PROBLEM", 308, 316], ["pneumonia", "PROBLEM", 338, 347], ["sepsis", "PROBLEM", 377, 383], ["urinary tract infection", "PROBLEM", 418, 441], ["cellulitis", "PROBLEM", 475, 485], ["pneumonia", "OBSERVATION", 338, 347], ["sepsis", "OBSERVATION", 377, 383], ["urinary tract", "ANATOMY", 418, 431], ["infection", "OBSERVATION", 432, 441], ["cellulitis", "OBSERVATION", 475, 485]]], ["People with diabetes are also more likely to have severe clinical presentation and to succumb after acquiring an infection.", [["diabetes", "DISEASE", 12, 20], ["infection", "DISEASE", 113, 122], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["diabetes", "PROBLEM", 12, 20], ["an infection", "PROBLEM", 110, 122], ["diabetes", "OBSERVATION", 12, 20], ["infection", "OBSERVATION", 113, 122]]], ["For instance, mortality rates due to sepsis was twice as high among people with diabetes than their counterparts without diabetes [6] .", [["sepsis", "DISEASE", 37, 43], ["diabetes", "DISEASE", 80, 88], ["diabetes", "DISEASE", 121, 129], ["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["mortality rates", "PROBLEM", 14, 29], ["sepsis", "PROBLEM", 37, 43], ["diabetes", "PROBLEM", 80, 88], ["diabetes", "PROBLEM", 121, 129], ["sepsis", "OBSERVATION", 37, 43]]], ["In a retrospective analysis of individuals who had acquired the severe acute respiratory syndrome (SARS) coronavirus in China, coexisting diabetes increased the age-and sex-adjusted odds of death by threefold, with a strong correlation between blood glucose and disease severity [7] .", [["blood", "ANATOMY", 244, 249], ["acute respiratory syndrome", "DISEASE", 71, 97], ["SARS", "DISEASE", 99, 103], ["coronavirus", "DISEASE", 105, 116], ["diabetes", "DISEASE", 138, 146], ["death", "DISEASE", 190, 195], ["glucose", "CHEMICAL", 250, 257], ["glucose", "CHEMICAL", 250, 257], ["individuals", "ORGANISM", 31, 42], ["blood", "ORGANISM_SUBSTANCE", 244, 249], ["glucose", "SIMPLE_CHEMICAL", 250, 257], ["the severe acute respiratory syndrome", "PROBLEM", 60, 97], ["SARS", "PROBLEM", 99, 103], ["coronavirus", "PROBLEM", 105, 116], ["coexisting diabetes", "PROBLEM", 127, 146], ["blood glucose", "TEST", 244, 257], ["disease severity", "PROBLEM", 262, 278], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory syndrome", "OBSERVATION", 77, 97]]], ["The high death rates in people with diabetes during the recent coronavirus disease 2019 (COVID- 19) pandemic, especially in those with severe inhospital hyperglycaemia, highlight the vulnerability of diabetic individuals during acute emergencies [8] .", [["death", "DISEASE", 9, 14], ["diabetes", "DISEASE", 36, 44], ["coronavirus disease", "DISEASE", 63, 82], ["hyperglycaemia", "DISEASE", 153, 167], ["diabetic", "DISEASE", 200, 208], ["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30], ["The high death rates", "PROBLEM", 0, 20], ["diabetes", "PROBLEM", 36, 44], ["the recent coronavirus disease", "PROBLEM", 52, 82], ["COVID", "TEST", 89, 94], ["pandemic", "PROBLEM", 100, 108], ["severe inhospital hyperglycaemia", "PROBLEM", 135, 167], ["diabetic individuals", "PROBLEM", 200, 220], ["acute emergencies", "PROBLEM", 228, 245], ["high", "OBSERVATION_MODIFIER", 4, 8], ["coronavirus disease", "OBSERVATION", 63, 82], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["inhospital hyperglycaemia", "OBSERVATION", 142, 167]]], ["The underlying causes for the increased rates of infection in diabetes are multifactorial.", [["infection", "DISEASE", 49, 58], ["diabetes", "DISEASE", 62, 70], ["the increased rates of infection", "PROBLEM", 26, 58], ["diabetes", "PROBLEM", 62, 70], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["rates", "OBSERVATION_MODIFIER", 40, 45], ["infection", "OBSERVATION", 49, 58], ["diabetes", "OBSERVATION", 62, 70]]], ["Hyperglycaemia has inhibitory effects on many components of the immune system, hampers pathogen clearance and affects host inflammatory response [9, 10] .", [["immune system", "ANATOMY", 64, 77], ["Hyperglycaemia", "DISEASE", 0, 14], ["Hyperglycaemia", "PROBLEM", 0, 14], ["inhibitory effects", "PROBLEM", 19, 37], ["the immune system", "PROBLEM", 60, 77], ["hampers pathogen clearance", "PROBLEM", 79, 105], ["inhibitory effects", "OBSERVATION_MODIFIER", 19, 37], ["inflammatory", "OBSERVATION_MODIFIER", 123, 135]]], ["Moreover, diabetes is closely related to other medical conditions such as peripheral artery disease, sensory neuropathy and others that lower barrier defence against infectious agents [11, 12] .IntroductionContemporary studies on the temporal trends of diabetesrelated complications found large declines in the rates of these clinical events in people with diabetes, driven primarily by improvements in risk factor control [13] [14] [15] .", [["peripheral artery", "ANATOMY", 74, 91], ["diabetes", "DISEASE", 10, 18], ["peripheral artery disease", "DISEASE", 74, 99], ["sensory neuropathy", "DISEASE", 101, 119], ["diabetes", "DISEASE", 357, 365], ["peripheral artery", "MULTI-TISSUE_STRUCTURE", 74, 91], ["people", "ORGANISM", 345, 351], ["[13] [14] [15]", "SIMPLE_CHEMICAL", 423, 437], ["people", "SPECIES", 345, 351], ["diabetes", "PROBLEM", 10, 18], ["other medical conditions", "PROBLEM", 41, 65], ["peripheral artery disease", "PROBLEM", 74, 99], ["sensory neuropathy", "PROBLEM", 101, 119], ["Contemporary studies", "TEST", 206, 226], ["diabetesrelated complications", "PROBLEM", 253, 282], ["large declines", "PROBLEM", 289, 303], ["diabetes", "PROBLEM", 357, 365], ["diabetes", "OBSERVATION", 10, 18], ["peripheral artery", "ANATOMY", 74, 91], ["disease", "OBSERVATION", 92, 99], ["sensory neuropathy", "OBSERVATION", 101, 119], ["large", "OBSERVATION_MODIFIER", 289, 294], ["declines", "OBSERVATION_MODIFIER", 295, 303]]], ["However, a recent study in the USA found that while rates of infection-related hospitalisation remained unchanged in people with diabetes, they declined in people without diabetes [2] .", [["infection", "DISEASE", 61, 70], ["diabetes", "DISEASE", 129, 137], ["diabetes", "DISEASE", 171, 179], ["people", "ORGANISM", 117, 123], ["people", "ORGANISM", 156, 162], ["people", "SPECIES", 117, 123], ["people", "SPECIES", 156, 162], ["a recent study", "TEST", 9, 23], ["infection", "PROBLEM", 61, 70], ["diabetes", "PROBLEM", 129, 137], ["diabetes", "PROBLEM", 171, 179], ["infection", "OBSERVATION", 61, 70], ["unchanged", "OBSERVATION_MODIFIER", 104, 113]]], ["This suggests that measures to improve care in people with diabetes may not have been as effective in preventing infection and/or worsening of its clinical course.", [["diabetes", "DISEASE", 59, 67], ["infection", "DISEASE", 113, 122], ["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53], ["diabetes", "PROBLEM", 59, 67], ["infection", "PROBLEM", 113, 122], ["infection", "OBSERVATION", 113, 122], ["worsening", "OBSERVATION_MODIFIER", 130, 139]]], ["To our knowledge, the study in the USA is the only large-scale epidemiological study evaluating trends for infection in people with diabetes and it is not known whether similar trends are apparent in other populations.", [["infection", "DISEASE", 107, 116], ["diabetes", "DISEASE", 132, 140], ["people", "ORGANISM", 120, 126], ["people", "SPECIES", 120, 126], ["the study", "TEST", 18, 27], ["epidemiological study", "TEST", 63, 84], ["infection", "PROBLEM", 107, 116], ["diabetes", "PROBLEM", 132, 140], ["infection", "OBSERVATION", 107, 116]]], ["Here, we describe temporal changes in rates of infection-related hospitalisation using a territory-wide database of people with diabetes in Hong Kong spanning a 16 year period from 2001 to 2016.", [["infection", "DISEASE", 47, 56], ["diabetes", "DISEASE", 128, 136], ["people", "ORGANISM", 116, 122], ["people", "SPECIES", 116, 122], ["temporal changes in rates of infection", "PROBLEM", 18, 56], ["diabetes", "PROBLEM", 128, 136], ["temporal", "OBSERVATION_MODIFIER", 18, 26], ["infection", "OBSERVATION", 47, 56]]], ["We further compared infection rates between people with diabetes and those without diabetes in Hong Kong from 2007 to 2016.Study populationThe Hong Kong Hospital Authority (HKHA) is a statutory body established in 1990 and governs all the public hospitals as well as specialist and general outpatient clinics to provide about 95% of inpatient services for Hong Kong residents [16] .", [["body", "ANATOMY", 194, 198], ["infection", "DISEASE", 20, 29], ["diabetes", "DISEASE", 56, 64], ["diabetes", "DISEASE", 83, 91], ["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50], ["diabetes", "PROBLEM", 56, 64], ["diabetes", "PROBLEM", 83, 91], ["infection", "OBSERVATION", 20, 29]]], ["The Hong Kong Diabetes Surveillance Database (HKDSD) is a population-based cohort of people with diabetes identified from the HKHA electronic medical record system between 1 January 2000 and 31 December 2016.", [["Diabetes", "DISEASE", 14, 22], ["diabetes", "DISEASE", 97, 105], ["people", "ORGANISM", 85, 91], ["people", "SPECIES", 85, 91], ["diabetes", "PROBLEM", 97, 105]]], ["Details of the HKDSD have been described previously [17] .", [["HKDSD", "CANCER", 15, 20], ["HKDSD", "DNA", 15, 20]]], ["In brief, individuals were included in the database if they fulfil laboratory criteria for diabetes (HbA 1c \u226548 mmol/mol [6.5%] or fasting plasma glucose \u22657.0 mmol/ l), were ever prescribed insulin or non-insulin glucose-lowering drugs, and/or were coded to have diabetes by their physicians.", [["plasma", "ANATOMY", 139, 145], ["diabetes", "DISEASE", 91, 99], ["glucose", "CHEMICAL", 146, 153], ["glucose", "CHEMICAL", 213, 220], ["diabetes", "DISEASE", 263, 271], ["glucose", "CHEMICAL", 146, 153], ["glucose", "CHEMICAL", 213, 220], ["plasma", "ORGANISM_SUBSTANCE", 139, 145], ["glucose", "SIMPLE_CHEMICAL", 146, 153], ["insulin", "GENE_OR_GENE_PRODUCT", 190, 197], ["non-insulin", "SIMPLE_CHEMICAL", 201, 212], ["glucose", "SIMPLE_CHEMICAL", 213, 220], ["diabetes", "PROBLEM", 91, 99], ["HbA", "TEST", 101, 104], ["fasting plasma glucose", "TEST", 131, 153], ["insulin", "TREATMENT", 190, 197], ["non-insulin glucose", "TREATMENT", 201, 220], ["lowering drugs", "TREATMENT", 221, 235], ["diabetes", "PROBLEM", 263, 271]]], ["The database excluded women with gestational diabetes.Study populationTo compare the rates of infection-related hospitalisation between people with and without diabetes, summary statistics of hospitalisation for infective causes among the general Hong Kong population were obtained from the Department of Health.", [["gestational diabetes", "DISEASE", 33, 53], ["infection", "DISEASE", 94, 103], ["diabetes", "DISEASE", 160, 168], ["women", "ORGANISM", 22, 27], ["people", "ORGANISM", 136, 142], ["women", "SPECIES", 22, 27], ["people", "SPECIES", 136, 142], ["gestational diabetes", "PROBLEM", 33, 53], ["Study population", "TEST", 54, 70], ["infection", "PROBLEM", 94, 103], ["diabetes", "PROBLEM", 160, 168], ["infective causes", "PROBLEM", 212, 228], ["diabetes", "OBSERVATION", 45, 53], ["infection", "OBSERVATION", 94, 103]]], ["Data on the number of people hospitalised stratified by sex and 5 year age interval in each calendar year over a 10 year period between 1 January 2007 and 31 December 2016 were available; data before 2007 were not available.", [["people", "ORGANISM", 22, 28], ["people", "SPECIES", 22, 28]]], ["The analysis was restricted to people aged 20 years or above.", [["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37], ["The analysis", "TEST", 0, 12]]], ["This study was approved by the local clinical research ethics committee.Study populationEvents ascertainment Infection-related hospitalisations for people in the HKDSD were identified using International Classification of Diseases (ICD), Ninth Revision (ICD-9; http://www.icd9data.com/2007/Volume1/default.htm) codes listed as the principal diagnosis in the hospital discharge summary.", [["people", "ORGANISM", 148, 154], ["people", "SPECIES", 148, 154], ["This study", "TEST", 0, 10], ["Infection", "PROBLEM", 109, 118], ["Diseases (ICD", "TREATMENT", 222, 235], ["Ninth Revision (ICD", "TREATMENT", 238, 257], ["Infection", "OBSERVATION", 109, 118]]], ["Infection types reported in previous literature to be more prevalent in people with diabetes were considered, including pneumonia, influenza, tuberculosis, kidney infection, urinary tract infection, cellulitis, osteomyelitis, foot infection and sepsis (electronic supplementary material [ESM] Table 1 ) [1] [2] [3] [4] [5] .", [["kidney", "ANATOMY", 156, 162], ["urinary tract", "ANATOMY", 174, 187], ["foot", "ANATOMY", 226, 230], ["diabetes", "DISEASE", 84, 92], ["pneumonia", "DISEASE", 120, 129], ["influenza", "DISEASE", 131, 140], ["tuberculosis", "DISEASE", 142, 154], ["kidney infection", "DISEASE", 156, 172], ["urinary tract infection", "DISEASE", 174, 197], ["cellulitis", "DISEASE", 199, 209], ["osteomyelitis", "DISEASE", 211, 224], ["foot infection", "DISEASE", 226, 240], ["sepsis", "DISEASE", 245, 251], ["people", "ORGANISM", 72, 78], ["kidney", "ORGAN", 156, 162], ["urinary tract", "ORGANISM_SUBDIVISION", 174, 187], ["foot", "ORGANISM_SUBDIVISION", 226, 230], ["[1] [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 303, 322], ["people", "SPECIES", 72, 78], ["Infection types", "PROBLEM", 0, 15], ["diabetes", "PROBLEM", 84, 92], ["pneumonia", "PROBLEM", 120, 129], ["influenza", "PROBLEM", 131, 140], ["tuberculosis", "PROBLEM", 142, 154], ["kidney infection", "PROBLEM", 156, 172], ["urinary tract infection", "PROBLEM", 174, 197], ["cellulitis", "PROBLEM", 199, 209], ["osteomyelitis", "PROBLEM", 211, 224], ["foot infection", "PROBLEM", 226, 240], ["sepsis", "PROBLEM", 245, 251], ["pneumonia", "OBSERVATION", 120, 129], ["influenza", "OBSERVATION", 131, 140], ["tuberculosis", "OBSERVATION", 142, 154], ["kidney", "ANATOMY", 156, 162], ["infection", "OBSERVATION", 163, 172], ["urinary tract", "ANATOMY", 174, 187], ["infection", "OBSERVATION", 188, 197], ["cellulitis", "OBSERVATION", 199, 209], ["osteomyelitis", "OBSERVATION", 211, 224], ["foot", "ANATOMY", 226, 230], ["infection", "OBSERVATION", 231, 240], ["sepsis", "OBSERVATION", 245, 251]]], ["Infection-related hospitalisation for the Hong Kong general population were identified based on ICD-10 codes (http://apps.who.int/classifications/icd10/ browse/2016/en) recorded as the principal diagnosis.", [["Infection", "PROBLEM", 0, 9], ["ICD", "TREATMENT", 96, 99]]], ["Data on pneumonia, influenza, tuberculosis, kidney infection and sepsis were available (ESM Table 1 ).Statistical analysisWe calculated age-standardised annual rates of infection-related hospitalisations for people with diabetes between 2001 and 2016, and for people without diabetes between 2007 and 2016.", [["kidney", "ANATOMY", 44, 50], ["pneumonia", "DISEASE", 8, 17], ["influenza", "DISEASE", 19, 28], ["tuberculosis", "DISEASE", 30, 42], ["kidney infection", "DISEASE", 44, 60], ["sepsis", "DISEASE", 65, 71], ["infection", "DISEASE", 169, 178], ["diabetes", "DISEASE", 220, 228], ["diabetes", "DISEASE", 275, 283], ["kidney", "ORGAN", 44, 50], ["people", "ORGANISM", 208, 214], ["people", "ORGANISM", 260, 266], ["people", "SPECIES", 208, 214], ["people", "SPECIES", 260, 266], ["pneumonia", "PROBLEM", 8, 17], ["influenza", "PROBLEM", 19, 28], ["tuberculosis", "PROBLEM", 30, 42], ["kidney infection", "PROBLEM", 44, 60], ["sepsis", "PROBLEM", 65, 71], ["infection", "PROBLEM", 169, 178], ["diabetes", "PROBLEM", 220, 228], ["diabetes", "PROBLEM", 275, 283], ["pneumonia", "OBSERVATION", 8, 17], ["influenza", "OBSERVATION", 19, 28], ["tuberculosis", "OBSERVATION", 30, 42], ["kidney", "ANATOMY", 44, 50], ["infection", "OBSERVATION", 51, 60], ["sepsis", "OBSERVATION", 65, 71], ["infection", "OBSERVATION", 169, 178]]], ["We counted the number of infection-related hospitalisations as the numerator and used the mid-year population for people with/without diabetes as the denominator in each study year.", [["infection", "DISEASE", 25, 34], ["diabetes", "DISEASE", 134, 142], ["people", "ORGANISM", 114, 120], ["people", "SPECIES", 114, 120], ["infection", "PROBLEM", 25, 34], ["diabetes", "PROBLEM", 134, 142], ["infection", "OBSERVATION", 25, 34]]], ["We subtracted the number of infection-related hospitalisations in the HKDSD from the total number of infection-related hospitalisations in the general Hong Kong population to obtain the number of infection-related hospitalisations in people without diabetes in Hong Kong.", [["infection", "DISEASE", 28, 37], ["infection", "DISEASE", 101, 110], ["infection", "DISEASE", 196, 205], ["diabetes", "DISEASE", 249, 257], ["people", "ORGANISM", 234, 240], ["people", "SPECIES", 234, 240], ["infection", "PROBLEM", 28, 37], ["the HKDSD", "PROBLEM", 66, 75], ["infection", "PROBLEM", 101, 110], ["infection", "PROBLEM", 196, 205], ["diabetes", "PROBLEM", 249, 257], ["number", "OBSERVATION_MODIFIER", 18, 24], ["infection", "OBSERVATION", 28, 37], ["infection", "OBSERVATION", 101, 110], ["infection", "OBSERVATION", 196, 205]]], ["A similar method was used to obtain the mid-year population estimates for people without diabetes by subtracting the number for the mid-year population in the HKDSD from the mid-year population estimates for the whole Hong Kong population reported by the Hong Kong Census and Statistics Department.", [["diabetes", "DISEASE", 89, 97], ["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80], ["diabetes", "PROBLEM", 89, 97]]], ["We used joinpoint regression models to describe the trends in rates of infection-related hospitalisations.", [["infection", "DISEASE", 71, 80], ["joinpoint regression models", "TREATMENT", 8, 35], ["infection", "PROBLEM", 71, 80], ["infection", "OBSERVATION", 71, 80]]], ["The joinpoint regression model uses a Monte Carlo permutation test to detect whether there is a significant change in trends during the study period.", [["The joinpoint regression model", "TREATMENT", 0, 30], ["a Monte Carlo permutation test", "TEST", 36, 66], ["a significant change", "PROBLEM", 94, 114], ["the study", "TEST", 132, 141], ["significant", "OBSERVATION_MODIFIER", 96, 107], ["change", "OBSERVATION", 108, 114]]], ["The annual percentage change (APC) was reported for each linear trend segment detected from the joinpoint regression model and the average annual percentage change (AAPC) was reported for the entire study period.", [["The annual percentage change", "PROBLEM", 0, 28], ["each linear trend segment", "PROBLEM", 52, 77], ["average", "OBSERVATION_MODIFIER", 131, 138], ["annual", "OBSERVATION_MODIFIER", 139, 145], ["percentage", "OBSERVATION_MODIFIER", 146, 156]]], ["We used Poisson regression models to calculate the rate ratios of infection-related hospitalisations comparing people with and without diabetes, with adjustment for age and stratification by sex and study year.", [["infection", "DISEASE", 66, 75], ["diabetes", "DISEASE", 135, 143], ["people", "ORGANISM", 111, 117], ["people", "SPECIES", 111, 117], ["Poisson regression models", "TREATMENT", 8, 33], ["infection", "PROBLEM", 66, 75], ["diabetes", "PROBLEM", 135, 143], ["infection", "OBSERVATION", 66, 75]]], ["We undertook a sensitivity analysis excluding people who were newly included in the HKDSD in each study year to assess the effect of incident diabetes on infection trends.", [["diabetes", "DISEASE", 142, 150], ["infection", "DISEASE", 154, 163], ["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52], ["a sensitivity analysis", "TEST", 13, 35], ["incident diabetes", "PROBLEM", 133, 150], ["infection trends", "PROBLEM", 154, 170], ["infection", "OBSERVATION", 154, 163]]], ["All analyses were performed using R (version 3.", [["All analyses", "TEST", 0, 12], ["R (version", "TREATMENT", 34, 44]]], ["During the study period, men had higher rates of hospitalisation for pneumonia, tuberculosis, cellulitis, osteomyelitis and foot infection, and women had higher rates of hospitalisation for kidney infection and urinary tract infection ( Table 1 ).", [["foot", "ANATOMY", 124, 128], ["kidney", "ANATOMY", 190, 196], ["urinary tract", "ANATOMY", 211, 224], ["pneumonia", "DISEASE", 69, 78], ["tuberculosis", "DISEASE", 80, 92], ["cellulitis", "DISEASE", 94, 104], ["osteomyelitis", "DISEASE", 106, 119], ["foot infection", "DISEASE", 124, 138], ["kidney infection", "DISEASE", 190, 206], ["urinary tract infection", "DISEASE", 211, 234], ["men", "ORGANISM", 25, 28], ["foot", "ORGANISM_SUBDIVISION", 124, 128], ["women", "ORGANISM", 144, 149], ["kidney", "ORGAN", 190, 196], ["urinary tract", "ORGANISM_SUBDIVISION", 211, 224], ["men", "SPECIES", 25, 28], ["women", "SPECIES", 144, 149], ["pneumonia", "PROBLEM", 69, 78], ["tuberculosis", "PROBLEM", 80, 92], ["cellulitis", "PROBLEM", 94, 104], ["osteomyelitis", "PROBLEM", 106, 119], ["foot infection", "PROBLEM", 124, 138], ["kidney infection", "PROBLEM", 190, 206], ["urinary tract infection", "PROBLEM", 211, 234], ["pneumonia", "OBSERVATION", 69, 78], ["tuberculosis", "OBSERVATION", 80, 92], ["cellulitis", "OBSERVATION", 94, 104], ["osteomyelitis", "OBSERVATION", 106, 119], ["foot", "ANATOMY", 124, 128], ["infection", "OBSERVATION", 129, 138], ["kidney", "ANATOMY", 190, 196], ["infection", "OBSERVATION", 197, 206], ["urinary tract", "ANATOMY", 211, 224], ["infection", "OBSERVATION", 225, 234]]], ["The rates for influenza and sepsis were similar between the sexes (Table 1 ).", [["influenza", "DISEASE", 14, 23], ["sepsis", "DISEASE", 28, 34], ["The rates", "TEST", 0, 9], ["influenza", "PROBLEM", 14, 23], ["sepsis", "PROBLEM", 28, 34], ["influenza", "OBSERVATION", 14, 23], ["sepsis", "OBSERVATION", 28, 34]]], ["In both men and women, rates of most infection types increased with increasing age, except for cellulitis, which occurred most frequently in the youngest age group of 20-44 years in men (ESM Tables 4, Table 5 ).", [["infection", "DISEASE", 37, 46], ["cellulitis", "DISEASE", 95, 105], ["men", "ORGANISM", 8, 11], ["women", "ORGANISM", 16, 21], ["cellulitis", "PATHOLOGICAL_FORMATION", 95, 105], ["men", "ORGANISM", 182, 185], ["men", "SPECIES", 8, 11], ["women", "SPECIES", 16, 21], ["men", "SPECIES", 182, 185], ["most infection types", "PROBLEM", 32, 52], ["cellulitis", "PROBLEM", 95, 105], ["infection", "OBSERVATION", 37, 46], ["cellulitis", "OBSERVATION", 95, 105]]], ["No consistent time trend was observed for rates of hospitalisation for kidney infection, cellulitis, osteomyelitis or foot infection over the entire surveillance period (Table 1 , Fig. 1c , e-g).", [["kidney", "ANATOMY", 71, 77], ["foot", "ANATOMY", 118, 122], ["kidney infection", "DISEASE", 71, 87], ["cellulitis", "DISEASE", 89, 99], ["osteomyelitis", "DISEASE", 101, 114], ["foot infection", "DISEASE", 118, 132], ["kidney", "ORGAN", 71, 77], ["foot", "ORGANISM_SUBDIVISION", 118, 122], ["kidney infection", "PROBLEM", 71, 87], ["cellulitis", "PROBLEM", 89, 99], ["osteomyelitis", "PROBLEM", 101, 114], ["foot infection", "PROBLEM", 118, 132], ["kidney", "ANATOMY", 71, 77], ["infection", "OBSERVATION", 78, 87], ["cellulitis", "OBSERVATION", 89, 99], ["osteomyelitis", "OBSERVATION", 101, 114], ["foot", "ANATOMY", 118, 122], ["infection", "OBSERVATION", 123, 132]]], ["Exclusion of people with newly diagnosed diabetes in each study year did not affect the trend estimates (ESM Fig. 1 ).Trends in rates of infection-related hospitalisation by sex inTrends in rates of infection-related hospitalisation by age groups in people with diabetes Age-stratified trend analysis was conducted for rates of hospitalisation for pneumonia, tuberculosis, urinary tract infection, cellulitis, foot infection rates of hospitalisation for influenza increased, rates for tuberculosis decreased and rates for pneumonia were static in both sexes, with no joinpoints identified (ESM Table 8 ).", [["urinary tract", "ANATOMY", 373, 386], ["diabetes", "DISEASE", 41, 49], ["infection", "DISEASE", 137, 146], ["infection", "DISEASE", 199, 208], ["diabetes", "DISEASE", 262, 270], ["pneumonia", "DISEASE", 348, 357], ["tuberculosis", "DISEASE", 359, 371], ["urinary tract infection", "DISEASE", 373, 396], ["cellulitis", "DISEASE", 398, 408], ["infection", "DISEASE", 415, 424], ["influenza", "DISEASE", 454, 463], ["tuberculosis", "DISEASE", 485, 497], ["pneumonia", "DISEASE", 522, 531], ["people", "ORGANISM", 13, 19], ["people", "ORGANISM", 250, 256], ["urinary tract", "ORGANISM_SUBDIVISION", 373, 386], ["foot", "ORGANISM_SUBDIVISION", 410, 414], ["people", "SPECIES", 13, 19], ["people", "SPECIES", 250, 256], ["newly diagnosed diabetes", "PROBLEM", 25, 49], ["infection", "PROBLEM", 137, 146], ["infection", "PROBLEM", 199, 208], ["diabetes Age", "PROBLEM", 262, 274], ["trend analysis", "TEST", 286, 300], ["pneumonia", "PROBLEM", 348, 357], ["tuberculosis", "PROBLEM", 359, 371], ["urinary tract infection", "PROBLEM", 373, 396], ["cellulitis", "PROBLEM", 398, 408], ["foot infection", "PROBLEM", 410, 424], ["influenza", "PROBLEM", 454, 463], ["tuberculosis", "PROBLEM", 485, 497], ["pneumonia", "PROBLEM", 522, 531], ["joinpoints", "PROBLEM", 567, 577], ["diabetes", "OBSERVATION", 41, 49], ["infection", "OBSERVATION", 137, 146], ["infection", "OBSERVATION", 199, 208], ["pneumonia", "OBSERVATION", 348, 357], ["tuberculosis", "OBSERVATION", 359, 371], ["urinary tract", "ANATOMY", 373, 386], ["infection", "OBSERVATION", 387, 396], ["cellulitis", "OBSERVATION", 398, 408], ["foot", "ANATOMY", 410, 414], ["infection", "OBSERVATION", 415, 424], ["pneumonia", "OBSERVATION", 522, 531]]], ["Rates of hospitalisation for kidney infection and sepsis increased linearly in women and were stable in men (ESM Table 8 ).", [["kidney", "ANATOMY", 29, 35], ["kidney infection", "DISEASE", 29, 45], ["sepsis", "DISEASE", 50, 56], ["kidney", "ORGAN", 29, 35], ["women", "ORGANISM", 79, 84], ["men", "ORGANISM", 104, 107], ["women", "SPECIES", 79, 84], ["men", "SPECIES", 104, 107], ["kidney infection", "PROBLEM", 29, 45], ["sepsis", "PROBLEM", 50, 56], ["kidney", "ANATOMY", 29, 35], ["infection", "OBSERVATION", 36, 45], ["sepsis", "OBSERVATION", 50, 56], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["linearly", "OBSERVATION_MODIFIER", 67, 75], ["stable", "OBSERVATION_MODIFIER", 94, 100]]], ["Agestratified rates of hospitalisation were calculated for pneumonia, tuberculosis and sepsis, but not for influenza and kidney infection due to small numbers.", [["kidney", "ANATOMY", 121, 127], ["pneumonia", "DISEASE", 59, 68], ["tuberculosis", "DISEASE", 70, 82], ["sepsis", "DISEASE", 87, 93], ["influenza", "DISEASE", 107, 116], ["kidney infection", "DISEASE", 121, 137], ["kidney", "ORGAN", 121, 127], ["pneumonia", "PROBLEM", 59, 68], ["tuberculosis", "PROBLEM", 70, 82], ["sepsis", "PROBLEM", 87, 93], ["influenza", "PROBLEM", 107, 116], ["kidney infection", "PROBLEM", 121, 137], ["small numbers", "PROBLEM", 145, 158], ["pneumonia", "OBSERVATION", 59, 68], ["tuberculosis", "OBSERVATION", 70, 82], ["sepsis", "OBSERVATION", 87, 93], ["not for", "UNCERTAINTY", 99, 106], ["influenza", "OBSERVATION", 107, 116], ["kidney", "ANATOMY", 121, 127], ["infection", "OBSERVATION", 128, 137], ["small", "OBSERVATION_MODIFIER", 145, 150], ["numbers", "OBSERVATION_MODIFIER", 151, 158]]], ["Rates for pneumonia and sepsis mostly increased from 2007 to 2016 in the age groups of 20-44 years and 45-64 years, were unchanged in those aged 65-74 years, and mostly decreased in the oldest age group (ESM Table 8 ).", [["pneumonia", "DISEASE", 10, 19], ["sepsis", "DISEASE", 24, 30], ["pneumonia", "PROBLEM", 10, 19], ["sepsis", "PROBLEM", 24, 30], ["pneumonia", "OBSERVATION", 10, 19], ["sepsis", "OBSERVATION", 24, 30], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["unchanged", "OBSERVATION_MODIFIER", 121, 130], ["mostly", "OBSERVATION_MODIFIER", 162, 168], ["decreased", "OBSERVATION_MODIFIER", 169, 178]]], ["Declines in rates for tuberculosis were detected in almost all age groups (ESM Table 8 ).Trends in rates of infection-related hospitalisation by sex inComparison of rates of infection-related hospitalisation between people with and without diabetes Compared with people without diabetes, those with diabetes had higher rates of hospitalisation for infective causes with age-adjusted rate ratios ranging from 1.3 (95% CI 1.3, 1.4) for pneumonia to 4.9 (95% CI 3.9, 6.2) for kidney infection in men, and from 1.4 (95% CI 1.3, 1.4) for pneumonia to 3.2 (95% 2.8, 3.7) for kidney infection in women, in 2016 (Table 2 and ESM Tables 9, 10 ).", [["kidney", "ANATOMY", 473, 479], ["kidney", "ANATOMY", 569, 575], ["tuberculosis", "DISEASE", 22, 34], ["infection", "DISEASE", 108, 117], ["infection", "DISEASE", 174, 183], ["diabetes", "DISEASE", 240, 248], ["diabetes", "DISEASE", 278, 286], ["diabetes", "DISEASE", 299, 307], ["pneumonia", "DISEASE", 434, 443], ["kidney infection", "DISEASE", 473, 489], ["pneumonia", "DISEASE", 533, 542], ["kidney infection", "DISEASE", 569, 585], ["people", "ORGANISM", 216, 222], ["people", "ORGANISM", 263, 269], ["kidney", "ORGAN", 473, 479], ["men", "ORGANISM", 493, 496], ["kidney", "ORGAN", 569, 575], ["women", "ORGANISM", 589, 594], ["people", "SPECIES", 216, 222], ["people", "SPECIES", 263, 269], ["men", "SPECIES", 493, 496], ["women", "SPECIES", 589, 594], ["tuberculosis", "PROBLEM", 22, 34], ["infection", "PROBLEM", 108, 117], ["infection", "PROBLEM", 174, 183], ["diabetes", "PROBLEM", 240, 248], ["diabetes", "PROBLEM", 278, 286], ["diabetes", "PROBLEM", 299, 307], ["infective causes", "PROBLEM", 348, 364], ["adjusted rate ratios", "TEST", 374, 394], ["CI", "TEST", 417, 419], ["pneumonia", "PROBLEM", 434, 443], ["CI", "TEST", 456, 458], ["kidney infection", "PROBLEM", 473, 489], ["CI", "TEST", 516, 518], ["pneumonia", "PROBLEM", 533, 542], ["kidney infection", "PROBLEM", 569, 585], ["tuberculosis", "OBSERVATION", 22, 34], ["infection", "OBSERVATION", 108, 117], ["infection", "OBSERVATION", 174, 183], ["pneumonia", "OBSERVATION", 434, 443], ["kidney", "ANATOMY", 473, 479], ["infection", "OBSERVATION", 480, 489], ["pneumonia", "OBSERVATION", 533, 542], ["kidney", "ANATOMY", 569, 575], ["infection", "OBSERVATION", 576, 585]]], ["The differences in hospitalisation rates between people with and without diabetes were the greatest in the youngest age group of 20-44 years and became smaller with increasing age (Table 2) .Trends in rates of infection-related hospitalisation by sex inBetween 2007 and 2016, a decrease in the rate ratios of hospitalisation for pneumonia was detected for both sexes (p < 0.001 in men, p = 0.016 in women) ( Table 2 ).", [["diabetes", "DISEASE", 73, 81], ["infection", "DISEASE", 210, 219], ["pneumonia", "DISEASE", 329, 338], ["people", "ORGANISM", 49, 55], ["men", "ORGANISM", 381, 384], ["women", "ORGANISM", 399, 404], ["people", "SPECIES", 49, 55], ["men", "SPECIES", 381, 384], ["women", "SPECIES", 399, 404], ["diabetes", "PROBLEM", 73, 81], ["infection", "PROBLEM", 210, 219], ["pneumonia", "PROBLEM", 329, 338], ["smaller", "OBSERVATION_MODIFIER", 152, 159], ["infection", "OBSERVATION", 210, 219], ["decrease", "OBSERVATION_MODIFIER", 278, 286], ["pneumonia", "OBSERVATION", 329, 338]]], ["In men, the rate ratio of hospitalisation for influenza decreased (p = 0.029) and that for kidney infection increased (p = 0.031) ( Table 2) .", [["kidney", "ANATOMY", 91, 97], ["influenza", "DISEASE", 46, 55], ["kidney infection", "DISEASE", 91, 107], ["men", "ORGANISM", 3, 6], ["kidney", "ORGAN", 91, 97], ["men", "SPECIES", 3, 6], ["influenza", "PROBLEM", 46, 55], ["kidney infection", "PROBLEM", 91, 107], ["kidney", "ANATOMY", 91, 97], ["infection", "OBSERVATION", 98, 107]]], ["No trends in rate ratios of hospitalisation for tuberculosis and sepsis were observed in either sex ( Table 2 ).DiscussionIn this population-based analysis of trends in hospitalisation for infection among people with diabetes in Hong Kong, we report four major observations.", [["tuberculosis", "DISEASE", 48, 60], ["sepsis", "DISEASE", 65, 71], ["infection", "DISEASE", 189, 198], ["diabetes", "DISEASE", 217, 225], ["people", "ORGANISM", 205, 211], ["people", "SPECIES", 205, 211], ["tuberculosis", "PROBLEM", 48, 60], ["sepsis", "PROBLEM", 65, 71], ["infection", "PROBLEM", 189, 198], ["diabetes", "PROBLEM", 217, 225], ["tuberculosis", "OBSERVATION", 48, 60], ["sepsis", "OBSERVATION", 65, 71]]], ["First, rates of hospitalisation were stagnant for the majority of infection types and have increased for influenza in people with diabetes.", [["infection", "DISEASE", 66, 75], ["influenza", "DISEASE", 105, 114], ["diabetes", "DISEASE", 130, 138], ["people", "ORGANISM", 118, 124], ["people", "SPECIES", 118, 124], ["infection types", "PROBLEM", 66, 81], ["influenza", "PROBLEM", 105, 114], ["diabetes", "PROBLEM", 130, 138], ["infection", "OBSERVATION", 66, 75]]], ["Second, there was an age differential in the trends for hospitalisation for infection.", [["infection", "DISEASE", 76, 85], ["infection", "PROBLEM", 76, 85], ["infection", "OBSERVATION", 76, 85]]], ["In the young to middle-aged groups, hospitalisation rates for most infection types increased or remained unchanged, while in the older age groups, infection rates tended to decline over time.", [["infection", "DISEASE", 67, 76], ["infection", "DISEASE", 147, 156], ["hospitalisation rates", "TEST", 36, 57], ["most infection types", "PROBLEM", 62, 82], ["infection rates", "PROBLEM", 147, 162], ["unchanged", "OBSERVATION_MODIFIER", 105, 114], ["infection", "OBSERVATION", 147, 156]]], ["Third, the trends observed among people with diabetes were largely similar to people without diabetes in Hong Kong.", [["diabetes", "DISEASE", 45, 53], ["diabetes", "DISEASE", 93, 101], ["people", "ORGANISM", 33, 39], ["people", "ORGANISM", 78, 84], ["people", "SPECIES", 33, 39], ["people", "SPECIES", 78, 84], ["diabetes", "PROBLEM", 45, 53], ["diabetes", "PROBLEM", 93, 101]]], ["Fourth, rates of hospitalisation for all infection types remained consistently higher in people with vs without diabetes throughout the observation period, and the relative differences in rates were the widest in the youngest age group and smallest in the oldest age group.DiscussionUnchanged or increasing rates of hospitalisation for common diabetes-related infections People with diabetes are more prone to develop infections because diabetes is associated with other conditions, such as obesity, peripheral sensory neuropathy, chronic kidney disease, peripheral artery disease, stroke and congestive heart failure, that are independent risk factors for infection [11, 12] .", [["kidney", "ANATOMY", 539, 545], ["peripheral artery", "ANATOMY", 555, 572], ["heart", "ANATOMY", 604, 609], ["infection", "DISEASE", 41, 50], ["diabetes", "DISEASE", 112, 120], ["diabetes", "DISEASE", 343, 351], ["infections", "DISEASE", 360, 370], ["diabetes", "DISEASE", 383, 391], ["infections", "DISEASE", 418, 428], ["diabetes", "DISEASE", 437, 445], ["obesity", "DISEASE", 491, 498], ["peripheral sensory neuropathy", "DISEASE", 500, 529], ["chronic kidney disease", "DISEASE", 531, 553], ["peripheral artery disease", "DISEASE", 555, 580], ["stroke", "DISEASE", 582, 588], ["congestive heart failure", "DISEASE", 593, 617], ["infection", "DISEASE", 657, 666], ["people", "ORGANISM", 89, 95], ["kidney", "ORGAN", 539, 545], ["peripheral artery", "MULTI-TISSUE_STRUCTURE", 555, 572], ["heart", "ORGAN", 604, 609], ["people", "SPECIES", 89, 95], ["People", "SPECIES", 371, 377], ["hospitalisation", "TREATMENT", 17, 32], ["all infection types", "PROBLEM", 37, 56], ["diabetes", "PROBLEM", 112, 120], ["common diabetes", "PROBLEM", 336, 351], ["related infections", "PROBLEM", 352, 370], ["diabetes", "PROBLEM", 383, 391], ["infections", "PROBLEM", 418, 428], ["diabetes", "PROBLEM", 437, 445], ["other conditions", "PROBLEM", 465, 481], ["obesity", "PROBLEM", 491, 498], ["peripheral sensory neuropathy", "PROBLEM", 500, 529], ["chronic kidney disease", "PROBLEM", 531, 553], ["peripheral artery disease", "PROBLEM", 555, 580], ["stroke", "PROBLEM", 582, 588], ["congestive heart failure", "PROBLEM", 593, 617], ["infection", "PROBLEM", 657, 666], ["infection", "OBSERVATION", 41, 50], ["smallest", "OBSERVATION_MODIFIER", 240, 248], ["infections", "OBSERVATION", 360, 370], ["peripheral", "ANATOMY_MODIFIER", 500, 510], ["sensory neuropathy", "OBSERVATION", 511, 529], ["chronic", "OBSERVATION_MODIFIER", 531, 538], ["kidney", "ANATOMY", 539, 545], ["disease", "OBSERVATION", 546, 553], ["peripheral artery", "ANATOMY", 555, 572], ["disease", "OBSERVATION", 573, 580], ["stroke", "OBSERVATION", 582, 588], ["congestive", "OBSERVATION_MODIFIER", 593, 603], ["heart", "ANATOMY", 604, 609], ["failure", "OBSERVATION", 610, 617]]], ["Several studies have also identified blood glucose control as a risk determinant for hospital admission with an infective cause, independent of confounders including age, smoking and comorbidities [4, 11, 18] .", [["blood", "ANATOMY", 37, 42], ["glucose", "CHEMICAL", 43, 50], ["glucose", "CHEMICAL", 43, 50], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["glucose", "SIMPLE_CHEMICAL", 43, 50], ["Several studies", "TEST", 0, 15], ["blood glucose control", "TREATMENT", 37, 58], ["an infective cause", "PROBLEM", 109, 127], ["comorbidities", "PROBLEM", 183, 196], ["infective", "OBSERVATION", 112, 121]]], ["In many developed regions, including Hong Kong, the rates of diabetes-related morbidities have fallen dramatically in the past 10-20 years, driven by improvements in blood glucose control and progresses in medical care [13] [14] [15] .", [["blood", "ANATOMY", 166, 171], ["diabetes", "DISEASE", 61, 69], ["glucose", "CHEMICAL", 172, 179], ["glucose", "CHEMICAL", 172, 179], ["blood", "ORGANISM_SUBSTANCE", 166, 171], ["glucose", "SIMPLE_CHEMICAL", 172, 179], ["diabetes", "PROBLEM", 61, 69], ["related morbidities", "PROBLEM", 70, 89], ["blood glucose control", "TREATMENT", 166, 187]]], ["It is therefore surprising to find static or even increasing rates of hospitalisation for common infection types despite declining prevalence of upstream risk factors.", [["infection", "DISEASE", 97, 106], ["upstream risk factors", "PROTEIN", 145, 166], ["common infection types", "PROBLEM", 90, 112], ["upstream risk factors", "PROBLEM", 145, 166], ["infection", "OBSERVATION", 97, 106]]], ["In the present study, rates of hospitalisation for infections of the skin, musculoskeletal system and kidney remained unchanged from 2001 to 2016, with increasing trends for sepsis after 2006/2007.", [["skin", "ANATOMY", 69, 73], ["musculoskeletal system", "ANATOMY", 75, 97], ["kidney", "ANATOMY", 102, 108], ["infections", "DISEASE", 51, 61], ["sepsis", "DISEASE", 174, 180], ["skin", "ORGAN", 69, 73], ["kidney", "ORGAN", 102, 108], ["the present study", "TEST", 3, 20], ["infections of the skin, musculoskeletal system", "PROBLEM", 51, 97], ["sepsis", "PROBLEM", 174, 180], ["skin", "ANATOMY", 69, 73], ["musculoskeletal system", "ANATOMY", 75, 97], ["kidney", "ANATOMY", 102, 108], ["unchanged", "OBSERVATION_MODIFIER", 118, 127], ["sepsis", "OBSERVATION", 174, 180]]], ["Over a comparable study period between 2000 and 2015, population surveillance conducted in the USA detected increasing rates of hospitalisation for these infection types in people with diabetes [2] .", [["infection", "DISEASE", 154, 163], ["diabetes", "DISEASE", 185, 193], ["people", "ORGANISM", 173, 179], ["people", "SPECIES", 173, 179], ["population surveillance", "TEST", 54, 77], ["these infection", "PROBLEM", 148, 163], ["diabetes", "PROBLEM", 185, 193], ["infection", "OBSERVATION", 154, 163]]], ["The reason for the divergent trends of kidney infection and urinary tract infection is unclear, but it is possible that the increasing tendency to treat less-severe urinary tract infection in the outpatient setting could contribute to these observations.", [["kidney", "ANATOMY", 39, 45], ["urinary tract", "ANATOMY", 60, 73], ["urinary tract", "ANATOMY", 165, 178], ["kidney infection", "DISEASE", 39, 55], ["urinary tract infection", "DISEASE", 60, 83], ["urinary tract infection", "DISEASE", 165, 188], ["kidney", "ORGAN", 39, 45], ["urinary tract", "ORGANISM_SUBDIVISION", 60, 73], ["urinary tract", "ORGANISM_SUBDIVISION", 165, 178], ["kidney infection", "PROBLEM", 39, 55], ["urinary tract infection", "PROBLEM", 60, 83], ["the increasing tendency", "PROBLEM", 120, 143], ["severe urinary tract infection", "PROBLEM", 158, 188], ["kidney", "ANATOMY", 39, 45], ["infection", "OBSERVATION", 46, 55], ["urinary tract", "ANATOMY", 60, 73], ["infection", "OBSERVATION", 74, 83], ["increasing", "OBSERVATION_MODIFIER", 124, 134], ["severe", "OBSERVATION_MODIFIER", 158, 164], ["urinary tract", "ANATOMY", 165, 178], ["infection", "OBSERVATION", 179, 188]]], ["Discrepancies in coding could also account for the differences.", [["Discrepancies in coding", "PROBLEM", 0, 23], ["could also account for", "UNCERTAINTY", 24, 46]]], ["Overall, our results suggest that the achieved improvements in blood glucose and other risk factors might not have been sufficient to prevent infection and progression to adverse outcome.", [["blood", "ANATOMY", 63, 68], ["glucose", "CHEMICAL", 69, 76], ["infection", "DISEASE", 142, 151], ["glucose", "CHEMICAL", 69, 76], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["glucose", "SIMPLE_CHEMICAL", 69, 76], ["blood glucose", "TEST", 63, 76], ["other risk factors", "PROBLEM", 81, 99], ["infection", "PROBLEM", 142, 151], ["adverse outcome", "PROBLEM", 171, 186], ["infection", "OBSERVATION", 142, 151]]], ["Diabetes education covers various aspects of foot care to prevent foot infection but measures to reduce the risks of other clinically important infections might not have been adequately addressed.DiscussionInfection rates are influenced by other factors, such as changing pathogenicity of the infectious agents, development of resistance to antimicrobial drugs, public health measures and clinical practices, that apply to the entire population irrespective of diabetes status.", [["foot", "ANATOMY", 66, 70], ["Diabetes", "DISEASE", 0, 8], ["foot infection", "DISEASE", 66, 80], ["infections", "DISEASE", 144, 154], ["diabetes", "DISEASE", 461, 469], ["foot", "ORGANISM_SUBDIVISION", 45, 49], ["foot", "ORGANISM_SUBDIVISION", 66, 70], ["Diabetes education", "TREATMENT", 0, 18], ["foot care", "TREATMENT", 45, 54], ["foot infection", "PROBLEM", 66, 80], ["other clinically important infections", "PROBLEM", 117, 154], ["the infectious agents", "TREATMENT", 289, 310], ["antimicrobial drugs", "TREATMENT", 341, 360], ["public health measures", "TREATMENT", 362, 384], ["clinical practices", "TREATMENT", 389, 407], ["diabetes status", "PROBLEM", 461, 476], ["foot", "ANATOMY", 45, 49], ["foot", "ANATOMY", 66, 70], ["infection", "OBSERVATION", 71, 80], ["infectious", "OBSERVATION", 293, 303], ["diabetes", "OBSERVATION", 461, 469]]], ["In the present study, people with and without diabetes experienced marked decline in hospitalisation for tuberculosis, reflecting the successes of public health measures and medical treatment, although the relative difference in rates of tuberculosis between people with and without diabetes has not changed over time.", [["diabetes", "DISEASE", 46, 54], ["tuberculosis", "DISEASE", 105, 117], ["tuberculosis", "DISEASE", 238, 250], ["diabetes", "DISEASE", 283, 291], ["people", "ORGANISM", 22, 28], ["people", "ORGANISM", 259, 265], ["people", "SPECIES", 22, 28], ["people", "SPECIES", 259, 265], ["the present study", "TEST", 3, 20], ["diabetes", "PROBLEM", 46, 54], ["marked decline", "PROBLEM", 67, 81], ["tuberculosis", "PROBLEM", 105, 117], ["public health measures", "TREATMENT", 147, 169], ["medical treatment", "TREATMENT", 174, 191], ["tuberculosis", "PROBLEM", 238, 250], ["diabetes", "PROBLEM", 283, 291], ["without", "UNCERTAINTY", 38, 45], ["marked", "OBSERVATION_MODIFIER", 67, 73], ["decline", "OBSERVATION_MODIFIER", 74, 81], ["tuberculosis", "OBSERVATION", 105, 117], ["tuberculosis", "OBSERVATION", 238, 250]]], ["Similarly, the rate ratios of hospitalisation due to kidney infection or sepsis by diabetes status have remained constant or even increased.", [["kidney", "ANATOMY", 53, 59], ["kidney infection", "DISEASE", 53, 69], ["sepsis", "DISEASE", 73, 79], ["diabetes", "DISEASE", 83, 91], ["kidney", "ORGAN", 53, 59], ["the rate ratios", "TEST", 11, 26], ["kidney infection", "PROBLEM", 53, 69], ["sepsis", "PROBLEM", 73, 79], ["diabetes status", "PROBLEM", 83, 98], ["kidney", "ANATOMY", 53, 59], ["infection", "OBSERVATION", 60, 69], ["sepsis", "OBSERVATION", 73, 79], ["increased", "OBSERVATION_MODIFIER", 130, 139]]], ["In the study in the USA, a rise in the rate ratios for these infection types as well as infections of the skin and musculoskeletal system were also found [2] .", [["skin", "ANATOMY", 106, 110], ["musculoskeletal system", "ANATOMY", 115, 137], ["infection", "DISEASE", 61, 70], ["infections of the skin and musculoskeletal system", "DISEASE", 88, 137], ["skin", "ORGAN", 106, 110], ["the study", "TEST", 3, 12], ["the rate ratios", "TEST", 35, 50], ["these infection types", "PROBLEM", 55, 76], ["infections of the skin and musculoskeletal system", "PROBLEM", 88, 137], ["rise", "OBSERVATION_MODIFIER", 27, 31], ["infection", "OBSERVATION", 61, 70], ["skin", "ANATOMY", 106, 110], ["musculoskeletal system", "ANATOMY", 115, 137]]], ["Sustained risk differential indicates that the increased risks of serious infection in people with diabetes were unaltered by advances in diabetes Table 2 Age-adjusted rate ratios in age-standardised rates of hospitalisation for infection in men and women with diabetes vs without diabetes in 2007 and 2016DiscussionInfection type Rate ratio (95% CI) a Poisson regression models were used to calculate the rate ratios of infection-related hospitalisations comparing people with and without diabetes, with adjustment for age and stratification for sex and studyDiscussionyear therapeutics and that much room exists to narrow the gap in infection rates between people with and without diabetes.DiscussionTrends in rates of hospitalisation for pneumonia and influenza The trends in hospitalisation for pneumonia and influenza deserve further consideration.", [["infection", "DISEASE", 74, 83], ["diabetes", "DISEASE", 99, 107], ["diabetes", "DISEASE", 138, 146], ["infection", "DISEASE", 229, 238], ["diabetes", "DISEASE", 261, 269], ["diabetes", "DISEASE", 281, 289], ["infection", "DISEASE", 421, 430], ["diabetes", "DISEASE", 490, 498], ["infection", "DISEASE", 635, 644], ["diabetes", "DISEASE", 683, 691], ["pneumonia", "DISEASE", 741, 750], ["influenza", "DISEASE", 755, 764], ["pneumonia", "DISEASE", 799, 808], ["influenza", "DISEASE", 813, 822], ["people", "ORGANISM", 87, 93], ["men", "ORGANISM", 242, 245], ["women", "ORGANISM", 250, 255], ["people", "ORGANISM", 466, 472], ["people", "ORGANISM", 659, 665], ["people", "SPECIES", 87, 93], ["men", "SPECIES", 242, 245], ["women", "SPECIES", 250, 255], ["people", "SPECIES", 466, 472], ["people", "SPECIES", 659, 665], ["serious infection", "PROBLEM", 66, 83], ["diabetes", "PROBLEM", 99, 107], ["diabetes Table", "PROBLEM", 138, 152], ["rate ratios", "TEST", 168, 179], ["infection", "PROBLEM", 229, 238], ["diabetes", "PROBLEM", 261, 269], ["diabetes", "PROBLEM", 281, 289], ["Infection type Rate ratio", "TEST", 316, 341], ["a Poisson regression models", "TEST", 351, 378], ["infection", "PROBLEM", 421, 430], ["diabetes", "PROBLEM", 490, 498], ["diabetes", "PROBLEM", 683, 691], ["pneumonia", "PROBLEM", 741, 750], ["influenza", "PROBLEM", 755, 764], ["pneumonia", "PROBLEM", 799, 808], ["influenza", "PROBLEM", 813, 822], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["serious", "OBSERVATION_MODIFIER", 66, 73], ["infection", "OBSERVATION", 74, 83], ["infection", "OBSERVATION", 229, 238], ["infection", "OBSERVATION", 421, 430], ["infection", "OBSERVATION", 635, 644], ["pneumonia", "OBSERVATION", 741, 750], ["influenza", "OBSERVATION", 755, 764], ["pneumonia", "OBSERVATION", 799, 808]]], ["We detected an increase in rates of hospitalisation for pneumonia from 2001 to 2004/2005, after which the rates decreased in men and were unchanged in women.", [["pneumonia", "DISEASE", 56, 65], ["men", "ORGANISM", 125, 128], ["women", "ORGANISM", 151, 156], ["men", "SPECIES", 125, 128], ["women", "SPECIES", 151, 156], ["pneumonia", "PROBLEM", 56, 65], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["pneumonia", "OBSERVATION", 56, 65], ["decreased", "OBSERVATION_MODIFIER", 112, 121], ["unchanged", "OBSERVATION_MODIFIER", 138, 147]]], ["In early-to mid-2003, Hong Kong experienced the SARS epidemic, in which 1750 local residents were infected with the coronavirus and 286 people died [19] .", [["SARS", "DISEASE", 48, 52], ["coronavirus", "DISEASE", 116, 127], ["coronavirus", "ORGANISM", 116, 127], ["people", "ORGANISM", 136, 142], ["coronavirus", "SPECIES", 116, 127], ["people", "SPECIES", 136, 142], ["the SARS epidemic", "PROBLEM", 44, 61]]], ["An increase in health awareness among the general population and a lower medical threshold for hospital admission during the immediate post-SARS period most likely explain the spike in rates of hospitalisation for pneumonia in 2004/2005.", [["SARS", "DISEASE", 140, 144], ["pneumonia", "DISEASE", 214, 223], ["the spike", "PROBLEM", 172, 181], ["pneumonia", "PROBLEM", 214, 223], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["pneumonia", "OBSERVATION", 214, 223]]], ["Stabilisation in rates for pneumonia was also noted in people without diabetes and, contrary to other common infection types, the relative difference in rates between people with and without diabetes diminished during the study period.", [["pneumonia", "DISEASE", 27, 36], ["diabetes", "DISEASE", 70, 78], ["infection", "DISEASE", 109, 118], ["diabetes", "DISEASE", 191, 199], ["people", "ORGANISM", 55, 61], ["people", "ORGANISM", 167, 173], ["people", "SPECIES", 55, 61], ["people", "SPECIES", 167, 173], ["Stabilisation in rates", "PROBLEM", 0, 22], ["pneumonia", "PROBLEM", 27, 36], ["diabetes", "PROBLEM", 70, 78], ["other common infection types", "PROBLEM", 96, 124], ["diabetes diminished", "PROBLEM", 191, 210], ["the study", "TEST", 218, 227], ["pneumonia", "OBSERVATION", 27, 36], ["diabetes", "OBSERVATION", 70, 78], ["infection", "OBSERVATION", 109, 118]]], ["The reasons are unclear but more liberal use of renin-angiotensin-aldosterone system inhibitors and statins, which have been shown to lower the risks of pneumonia, among people with diabetes might contribute to these observations [20, 21] .", [["angiotensin", "CHEMICAL", 54, 65], ["aldosterone", "CHEMICAL", 66, 77], ["statins", "CHEMICAL", 100, 107], ["pneumonia", "DISEASE", 153, 162], ["diabetes", "DISEASE", 182, 190], ["aldosterone", "CHEMICAL", 66, 77], ["statins", "CHEMICAL", 100, 107], ["renin-angiotensin-aldosterone", "GENE_OR_GENE_PRODUCT", 48, 77], ["statins", "SIMPLE_CHEMICAL", 100, 107], ["people", "ORGANISM", 170, 176], ["renin", "PROTEIN", 48, 53], ["people", "SPECIES", 170, 176], ["renin", "TEST", 48, 53], ["angiotensin-aldosterone system inhibitors", "TREATMENT", 54, 95], ["statins", "TREATMENT", 100, 107], ["pneumonia", "PROBLEM", 153, 162], ["diabetes", "PROBLEM", 182, 190], ["pneumonia", "OBSERVATION", 153, 162]]], ["In contrast to the stable trends for pneumonia, we observed rising trends in hospitalisation for influenza in people with and without diabetes.", [["pneumonia", "DISEASE", 37, 46], ["influenza", "DISEASE", 97, 106], ["diabetes", "DISEASE", 134, 142], ["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116], ["pneumonia", "PROBLEM", 37, 46], ["rising trends", "PROBLEM", 60, 73], ["influenza", "PROBLEM", 97, 106], ["diabetes", "PROBLEM", 134, 142], ["stable", "OBSERVATION_MODIFIER", 19, 25], ["pneumonia", "OBSERVATION", 37, 46], ["rising", "OBSERVATION_MODIFIER", 60, 66]]], ["Diabetes is associated with a greater hazard of severe influenza [22, 23] .", [["Diabetes", "DISEASE", 0, 8], ["influenza", "DISEASE", 55, 64], ["Diabetes", "PROBLEM", 0, 8], ["severe influenza", "PROBLEM", 48, 64], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["influenza", "OBSERVATION", 55, 64]]], ["International guidelines recommend annual vaccination against influenza in people with diabetes [24] , although whether people with diabetes derive the same level of protection as do people without diabetes remains inconclusive [25] .", [["influenza", "DISEASE", 62, 71], ["diabetes", "DISEASE", 87, 95], ["diabetes", "DISEASE", 132, 140], ["diabetes", "DISEASE", 198, 206], ["people", "ORGANISM", 75, 81], ["people", "ORGANISM", 120, 126], ["people", "SPECIES", 75, 81], ["people", "SPECIES", 120, 126], ["people", "SPECIES", 183, 189], ["annual vaccination", "TREATMENT", 35, 53], ["influenza", "PROBLEM", 62, 71], ["diabetes", "PROBLEM", 87, 95], ["diabetes", "PROBLEM", 132, 140], ["diabetes", "PROBLEM", 198, 206]]], ["The Hong Kong Government influenza vaccination programme launched in 2004 prioritised free or subsidised immunisation to all people with diabetes [26] .", [["diabetes", "DISEASE", 137, 145], ["people", "ORGANISM", 125, 131], ["people", "SPECIES", 125, 131], ["The Hong Kong Government influenza vaccination programme", "TREATMENT", 0, 56], ["diabetes", "PROBLEM", 137, 145]]], ["Despite widespread promotion of the programme, only 12% of the general population were vaccinated in the most recent survey in 2015/16, although we have no information on the vaccination rates in people with diabetes [27] .", [["diabetes", "DISEASE", 208, 216], ["people", "ORGANISM", 196, 202], ["people", "SPECIES", 196, 202], ["diabetes", "PROBLEM", 208, 216], ["widespread", "OBSERVATION_MODIFIER", 8, 18]]], ["The dramatic increase in annual rates of hospitalisation for influenza in both people with and without diabetes in Hong Kong could reflect increases in transmissibility and pathogenicity of the virus, compounded by increasing population density and overcrowding.", [["influenza", "DISEASE", 61, 70], ["diabetes", "DISEASE", 103, 111], ["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85], ["The dramatic increase", "PROBLEM", 0, 21], ["influenza", "PROBLEM", 61, 70], ["diabetes", "PROBLEM", 103, 111], ["increases in transmissibility and pathogenicity of the virus", "PROBLEM", 139, 199], ["increasing population density", "PROBLEM", 215, 244], ["overcrowding", "PROBLEM", 249, 261], ["dramatic", "OBSERVATION_MODIFIER", 4, 12], ["increase", "OBSERVATION_MODIFIER", 13, 21], ["without", "UNCERTAINTY", 95, 102], ["diabetes", "OBSERVATION", 103, 111], ["increases", "OBSERVATION_MODIFIER", 139, 148], ["virus", "OBSERVATION", 194, 199], ["increasing", "OBSERVATION_MODIFIER", 215, 225], ["population", "OBSERVATION_MODIFIER", 226, 236], ["density", "OBSERVATION", 237, 244], ["overcrowding", "OBSERVATION_MODIFIER", 249, 261]]], ["Changes in clinical practice, in particular more frequent testing for influenza in people presenting with respiratory tract symptoms, could also explain the escalating trend.DiscussionAge differential in trends of hospitalisation for infection In the present study, we found that rates of hospitalisation for most infections decreased in the older age groups (aged \u226565 years) but were stable or increased among the young and middle-aged groups.", [["respiratory tract", "ANATOMY", 106, 123], ["influenza", "DISEASE", 70, 79], ["respiratory tract symptoms", "DISEASE", 106, 132], ["infection", "DISEASE", 234, 243], ["infections", "DISEASE", 314, 324], ["people", "ORGANISM", 83, 89], ["tract", "ORGANISM_SUBDIVISION", 118, 123], ["people", "SPECIES", 83, 89], ["influenza", "PROBLEM", 70, 79], ["respiratory tract symptoms", "PROBLEM", 106, 132], ["infection", "PROBLEM", 234, 243], ["the present study", "TEST", 247, 264], ["most infections", "PROBLEM", 309, 324], ["respiratory tract", "ANATOMY", 106, 123], ["escalating", "OBSERVATION_MODIFIER", 157, 167], ["infection", "OBSERVATION", 234, 243], ["stable", "OBSERVATION_MODIFIER", 385, 391], ["increased", "OBSERVATION_MODIFIER", 395, 404], ["middle", "ANATOMY_MODIFIER", 425, 431]]], ["Our results are consistent with the study in the USA, which reported rising trends for hospitalisation rates for many infection types in the younger age groups (aged 18-44 years) with diabetes despite the decline in their older counterparts [2] .", [["infection", "DISEASE", 118, 127], ["diabetes", "DISEASE", 184, 192], ["the study", "TEST", 32, 41], ["many infection types", "PROBLEM", 113, 133], ["diabetes", "PROBLEM", 184, 192], ["consistent with", "UNCERTAINTY", 16, 31], ["infection", "OBSERVATION", 118, 127]]], ["The lack of improvement shown in trends in the young people is evident across a range of diabetes-related complications and mortality rates in earlier analyses [17, 28] .", [["diabetes", "DISEASE", 89, 97], ["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59], ["diabetes", "PROBLEM", 89, 97], ["related complications", "PROBLEM", 98, 119], ["mortality rates", "TEST", 124, 139], ["improvement", "OBSERVATION_MODIFIER", 12, 23]]], ["Young people with diabetes have higher blood glucose levels than older people due to a combination of poorer treatment adherence and therapeutic inertia [29] .", [["blood", "ANATOMY", 39, 44], ["diabetes", "DISEASE", 18, 26], ["glucose", "CHEMICAL", 45, 52], ["glucose", "CHEMICAL", 45, 52], ["people", "ORGANISM", 6, 12], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["glucose", "SIMPLE_CHEMICAL", 45, 52], ["people", "ORGANISM", 71, 77], ["people", "SPECIES", 6, 12], ["people", "SPECIES", 71, 77], ["diabetes", "PROBLEM", 18, 26], ["higher blood glucose levels", "PROBLEM", 32, 59], ["poorer treatment adherence", "TREATMENT", 102, 128], ["therapeutic inertia", "PROBLEM", 133, 152]]], ["Young people also tend to delay seeking medical care, leading to more severe and clinically advanced presentation of medical conditions including infection.", [["infection", "DISEASE", 146, 155], ["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["medical conditions", "PROBLEM", 117, 135], ["infection", "PROBLEM", 146, 155], ["infection", "OBSERVATION", 146, 155]]], ["It is conceivable that these health-compromising behaviours of young people has not changed significantly over time, and that current approaches to managing diabetes have not been effective in improving health indices in this group.", [["diabetes", "DISEASE", 157, 165], ["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75], ["managing diabetes", "PROBLEM", 148, 165]]], ["The differential infection risk associated with diabetes in younger vs older age groups is likely due to the lower background rates among the young general population.", [["infection", "DISEASE", 17, 26], ["diabetes", "DISEASE", 48, 56], ["The differential infection risk", "PROBLEM", 0, 31], ["diabetes", "PROBLEM", 48, 56], ["the lower background rates", "PROBLEM", 105, 131], ["differential", "OBSERVATION_MODIFIER", 4, 16], ["infection", "OBSERVATION", 17, 26], ["likely due to", "UNCERTAINTY", 91, 104]]], ["Nonetheless, the three-to fourfold increase in rates of hospitalisation for pneumonia, sevenfold increase in rates for tuberculosis, and six-to 11-fold increase in rates for generalised sepsis in young people with diabetes aged 20-44 years relative to their age-matched counterparts without diabetes highlights the unmet needs in these young individuals and calls for focused preventive strategies.DiscussionLimitations This study has several limitations.", [["pneumonia", "DISEASE", 76, 85], ["tuberculosis", "DISEASE", 119, 131], ["sepsis", "DISEASE", 186, 192], ["diabetes", "DISEASE", 214, 222], ["diabetes", "DISEASE", 291, 299], ["people", "ORGANISM", 202, 208], ["people", "SPECIES", 202, 208], ["pneumonia", "PROBLEM", 76, 85], ["sevenfold increase in rates", "PROBLEM", 87, 114], ["tuberculosis", "PROBLEM", 119, 131], ["generalised sepsis", "PROBLEM", 174, 192], ["diabetes", "PROBLEM", 214, 222], ["diabetes", "PROBLEM", 291, 299], ["This study", "TEST", 420, 430], ["increase", "OBSERVATION_MODIFIER", 35, 43], ["pneumonia", "OBSERVATION", 76, 85], ["sevenfold", "OBSERVATION_MODIFIER", 87, 96], ["increase", "OBSERVATION_MODIFIER", 97, 105], ["tuberculosis", "OBSERVATION", 119, 131], ["generalised", "OBSERVATION_MODIFIER", 174, 185], ["sepsis", "OBSERVATION", 186, 192]]], ["First, the HKDSD comprises people who attended public hospitals and clinics operated by the HKHA and does not include people who presented to the private health sector.", [["people", "ORGANISM", 27, 33], ["people", "ORGANISM", 118, 124], ["people", "SPECIES", 27, 33], ["people", "SPECIES", 118, 124]]], ["The HKHA covers about 95% of health services in Hong Kong and the exclusion of the small proportion of people with diabetes treated in private should have minimal impact on trend estimates.", [["HKHA", "DISEASE", 4, 8], ["diabetes", "DISEASE", 115, 123], ["people", "ORGANISM", 103, 109], ["people", "SPECIES", 103, 109], ["diabetes", "PROBLEM", 115, 123], ["small", "OBSERVATION_MODIFIER", 83, 88], ["diabetes", "OBSERVATION", 115, 123]]], ["Second, the HKDSD is an administrative database subjected to issues of validity.", [["HKDSD", "DNA", 12, 17]]], ["For instance, people who were prescribed glucoselowering drugs, such as metformin, for conditions other than diabetes could be included although the number is deemed small.", [["metformin", "CHEMICAL", 72, 81], ["diabetes", "DISEASE", 109, 117], ["metformin", "CHEMICAL", 72, 81], ["people", "ORGANISM", 14, 20], ["metformin", "SIMPLE_CHEMICAL", 72, 81], ["people", "SPECIES", 14, 20], ["glucoselowering drugs", "TREATMENT", 41, 62], ["metformin", "TREATMENT", 72, 81], ["conditions", "PROBLEM", 87, 97], ["diabetes", "PROBLEM", 109, 117], ["small", "OBSERVATION_MODIFIER", 166, 171]]], ["Furthermore, we could not differentiate type 1 diabetes from type 2 diabetes in the HKDSD, although over 98% of Hong Kong Chinese with diabetes have type 2 diabetes [30] .", [["diabetes", "DISEASE", 47, 55], ["type 2 diabetes", "DISEASE", 61, 76], ["HKDSD", "DISEASE", 84, 89], ["diabetes", "DISEASE", 135, 143], ["type 2 diabetes", "DISEASE", 149, 164], ["type 1 diabetes", "PROBLEM", 40, 55], ["type 2 diabetes", "PROBLEM", 61, 76], ["diabetes", "PROBLEM", 135, 143], ["type 2 diabetes", "PROBLEM", 149, 164], ["diabetes", "OBSERVATION", 47, 55], ["diabetes", "OBSERVATION", 68, 76]]], ["Third, the increasing number of people with newly diagnosed diabetes each year could affect the trend estimates.", [["diabetes", "DISEASE", 60, 68], ["people", "ORGANISM", 32, 38], ["people", "SPECIES", 32, 38], ["newly diagnosed diabetes", "PROBLEM", 44, 68], ["increasing", "OBSERVATION_MODIFIER", 11, 21], ["number", "OBSERVATION_MODIFIER", 22, 28], ["diabetes", "OBSERVATION", 60, 68]]], ["In the sensitivity analysis, excluding those newly included in the HKDSD each study year did not yield any significant difference in the trends of infection-related hospitalisation.", [["infection", "DISEASE", 147, 156], ["the sensitivity analysis", "TEST", 3, 27], ["infection", "PROBLEM", 147, 156], ["significant", "OBSERVATION_MODIFIER", 107, 118], ["difference", "OBSERVATION", 119, 129], ["infection", "OBSERVATION", 147, 156]]], ["Fourth, we relied on diagnostic codes listed as principal diagnosis for event count and infections recorded as a secondary diagnosis were not included, leading to potential under-estimation of event rates.", [["infections", "DISEASE", 88, 98], ["event count", "TEST", 72, 83], ["infections", "PROBLEM", 88, 98]]], ["This limited the scope of the study to evaluate the trends in rates of nosocomial infections, which are more likely to be entered as secondary diagnosis.", [["nosocomial infections", "DISEASE", 71, 92], ["the study", "TEST", 26, 35], ["nosocomial infections", "PROBLEM", 71, 92], ["nosocomial infections", "OBSERVATION", 71, 92], ["more likely", "UNCERTAINTY", 104, 115]]], ["Fifth, people with diabetes could be more readily admitted to hospital than people without diabetes due to the greater care-seeking tendency of the former group and lower threshold for admitting people with chronic diseases such as diabetes.", [["diabetes", "DISEASE", 19, 27], ["diabetes", "DISEASE", 91, 99], ["chronic diseases", "DISEASE", 207, 223], ["diabetes", "DISEASE", 232, 240], ["people", "ORGANISM", 7, 13], ["people", "ORGANISM", 76, 82], ["people", "ORGANISM", 195, 201], ["people", "SPECIES", 7, 13], ["people", "SPECIES", 76, 82], ["people", "SPECIES", 195, 201], ["diabetes", "PROBLEM", 19, 27], ["diabetes", "PROBLEM", 91, 99], ["chronic diseases", "PROBLEM", 207, 223], ["diabetes", "PROBLEM", 232, 240], ["diabetes", "OBSERVATION", 19, 27], ["chronic", "OBSERVATION_MODIFIER", 207, 214], ["diseases", "OBSERVATION", 215, 223], ["diabetes", "OBSERVATION", 232, 240]]], ["This was evident for hospitalisation for pneumonia around the time of the SARS epidemic.", [["pneumonia", "DISEASE", 41, 50], ["SARS", "DISEASE", 74, 78], ["pneumonia", "PROBLEM", 41, 50], ["the SARS epidemic", "PROBLEM", 70, 87], ["pneumonia", "OBSERVATION", 41, 50]]], ["Sixth, data for hospital admission of people without diabetes were not available before 2007 and the available data only captured hospitalisation for a limited range of infection diagnoses.", [["diabetes", "DISEASE", 53, 61], ["infection", "DISEASE", 169, 178], ["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44], ["diabetes", "PROBLEM", 53, 61], ["infection diagnoses", "PROBLEM", 169, 188], ["infection", "OBSERVATION", 169, 178]]], ["The comparison of rates between people with and without diabetes across the full surveillance period was not possible, resulting in a significantly shorter time period for trend analysis.", [["diabetes", "DISEASE", 56, 64], ["people", "ORGANISM", 32, 38], ["people", "SPECIES", 32, 38], ["diabetes", "PROBLEM", 56, 64], ["trend analysis", "TEST", 172, 186]]], ["Seventh, analysis of people without diabetes was based on aggregate data.", [["diabetes", "DISEASE", 36, 44], ["people", "ORGANISM", 21, 27], ["people", "SPECIES", 21, 27], ["diabetes", "PROBLEM", 36, 44], ["aggregate data", "TEST", 58, 72]]], ["In addition, different ICD coding systems were used to identify infectionrelated hospitalisation in people with diabetes and in people without diabetes.", [["diabetes", "DISEASE", 112, 120], ["diabetes", "DISEASE", 143, 151], ["people", "ORGANISM", 100, 106], ["people", "ORGANISM", 128, 134], ["people", "SPECIES", 100, 106], ["people", "SPECIES", 128, 134], ["different ICD coding systems", "TREATMENT", 13, 41], ["diabetes", "PROBLEM", 112, 120], ["diabetes", "PROBLEM", 143, 151]]], ["This would have affected the estimates of incidence rate ratios, although our estimates are similar to figures reported by others.", [["incidence rate ratios", "PROBLEM", 42, 63]]], ["Last, the study described the trends in Hong Kong and results may not be generalisable to other regions.ConclusionsWe observed unchanged or increasing rates of hospitalisation for most types of diabetes-related infection, except for decline in rates for tuberculosis and urinary tract infection, among people with diabetes in Hong Kong over a 16-year period.", [["urinary tract", "ANATOMY", 271, 284], ["diabetes", "DISEASE", 194, 202], ["infection", "DISEASE", 211, 220], ["tuberculosis", "DISEASE", 254, 266], ["urinary tract infection", "DISEASE", 271, 294], ["diabetes", "DISEASE", 314, 322], ["urinary tract", "ORGANISM_SUBDIVISION", 271, 284], ["people", "ORGANISM", 302, 308], ["people", "SPECIES", 302, 308], ["the study", "TEST", 6, 15], ["diabetes", "PROBLEM", 194, 202], ["related infection", "PROBLEM", 203, 220], ["decline in rates", "PROBLEM", 233, 249], ["tuberculosis", "PROBLEM", 254, 266], ["urinary tract infection", "PROBLEM", 271, 294], ["diabetes", "PROBLEM", 314, 322], ["unchanged", "OBSERVATION_MODIFIER", 127, 136], ["increasing", "OBSERVATION_MODIFIER", 140, 150], ["diabetes", "OBSERVATION", 194, 202], ["infection", "OBSERVATION", 211, 220], ["tuberculosis", "OBSERVATION", 254, 266], ["urinary tract", "ANATOMY", 271, 284], ["infection", "OBSERVATION", 285, 294]]], ["Improvements in diabetes care have not translated to narrowing of relative differences in rates of hospitalisation for most infection types when comparing people with and without diabetes during this time.", [["diabetes", "DISEASE", 16, 24], ["infection", "DISEASE", 124, 133], ["diabetes", "DISEASE", 179, 187], ["people", "ORGANISM", 155, 161], ["people", "SPECIES", 155, 161], ["diabetes care", "TREATMENT", 16, 29], ["most infection types", "PROBLEM", 119, 139], ["diabetes", "PROBLEM", 179, 187], ["diabetes", "OBSERVATION", 16, 24]]], ["The recent COVID-19 global outbreak has revealed the toll of diabetes and other chronic diseases on the healthcare system during acute emergencies.", [["diabetes", "DISEASE", 61, 69], ["chronic diseases", "DISEASE", 80, 96], ["The recent COVID", "TEST", 0, 16], ["diabetes", "PROBLEM", 61, 69], ["other chronic diseases", "PROBLEM", 74, 96], ["acute emergencies", "PROBLEM", 129, 146], ["diabetes", "OBSERVATION", 61, 69], ["chronic", "OBSERVATION_MODIFIER", 80, 87], ["diseases", "OBSERVATION", 88, 96]]], ["Greater efforts directed towards infection prevention and control in people with diabetes are urgently needed to reduce their risks of developing and progressing to serious infections.", [["infection", "DISEASE", 33, 42], ["diabetes", "DISEASE", 81, 89], ["infections", "DISEASE", 173, 183], ["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75], ["infection prevention", "TREATMENT", 33, 53], ["diabetes", "PROBLEM", 81, 89], ["serious infections", "PROBLEM", 165, 183], ["serious", "OBSERVATION_MODIFIER", 165, 172], ["infections", "OBSERVATION", 173, 183]]]], "ae072e0f04db143d038aa090e714f31e0c8c34bc": [["IntroductionHuman bocavirus (HBoV) is a newly discovered parvovirus that was first identified in Sweden from pooled nasopharyngeal aspirate specimens by large-scale molecular virus screening [1] .", [["nasopharyngeal aspirate specimens", "ANATOMY", 116, 149], ["IntroductionHuman bocavirus", "ORGANISM", 0, 27], ["HBoV", "ORGANISM", 29, 33], ["parvovirus", "ORGANISM", 57, 67], ["nasopharyngeal aspirate specimens", "ORGANISM_SUBSTANCE", 116, 149], ["HBoV", "SPECIES", 29, 33], ["IntroductionHuman bocavirus (HBoV", "PROBLEM", 0, 33], ["a newly discovered parvovirus", "PROBLEM", 38, 67], ["pooled nasopharyngeal aspirate specimens", "TEST", 109, 149], ["parvovirus", "OBSERVATION", 57, 67], ["nasopharyngeal", "ANATOMY", 116, 130]]], ["Increasing evidences are emerging to support its role as an etiologic agent in lower respiratory tract infection (LRTI) [2, 3, 4, 5] .IntroductionHBoV is frequently detected in patients with acute respiratory tract infection [6, 7, 8] , including in those who are having wheezing, croup, cough, rhinorrhea and fever [2, 9] .", [["lower respiratory tract", "ANATOMY", 79, 102], ["respiratory tract", "ANATOMY", 197, 214], ["lower respiratory tract infection", "DISEASE", 79, 112], ["LRTI", "DISEASE", 114, 118], ["acute respiratory tract infection", "DISEASE", 191, 224], ["wheezing", "DISEASE", 271, 279], ["croup", "DISEASE", 281, 286], ["cough", "DISEASE", 288, 293], ["rhinorrhea", "DISEASE", 295, 305], ["fever", "DISEASE", 310, 315], ["lower respiratory", "ORGANISM_SUBDIVISION", 79, 96], ["tract", "ORGANISM_SUBDIVISION", 97, 102], ["patients", "ORGANISM", 177, 185], ["tract", "ORGANISM_SUBDIVISION", 209, 214], ["patients", "SPECIES", 177, 185], ["an etiologic agent", "TREATMENT", 57, 75], ["lower respiratory tract infection", "PROBLEM", 79, 112], ["acute respiratory tract infection", "PROBLEM", 191, 224], ["wheezing", "PROBLEM", 271, 279], ["croup", "PROBLEM", 281, 286], ["cough", "PROBLEM", 288, 293], ["rhinorrhea", "PROBLEM", 295, 305], ["fever", "PROBLEM", 310, 315], ["lower", "ANATOMY_MODIFIER", 79, 84], ["respiratory tract", "ANATOMY", 85, 102], ["acute", "OBSERVATION_MODIFIER", 191, 196], ["respiratory tract", "ANATOMY", 197, 214], ["infection", "OBSERVATION", 215, 224], ["wheezing", "OBSERVATION", 271, 279], ["rhinorrhea", "OBSERVATION", 295, 305]]], ["A number of epidemiological and clinical investigations have been conducted to assess HBoV-related illness; its clinical features have been reported, which resembled those of respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections [10] .", [["HBoV-related illness", "DISEASE", 86, 106], ["respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections", "DISEASE", 175, 252], ["HBoV", "ORGANISM", 86, 90], ["respiratory syncytial virus", "ORGANISM", 175, 202], ["RSV", "ORGANISM", 204, 207], ["human metapneumovirus", "ORGANISM", 213, 234], ["hMPV", "ORGANISM", 236, 240], ["human", "SPECIES", 213, 218], ["metapneumovirus", "SPECIES", 219, 234], ["respiratory syncytial virus", "SPECIES", 175, 202], ["RSV", "SPECIES", 204, 207], ["human metapneumovirus", "SPECIES", 213, 234], ["hMPV", "SPECIES", 236, 240], ["clinical investigations", "TEST", 32, 55], ["HBoV", "PROBLEM", 86, 90], ["related illness", "PROBLEM", 91, 106], ["respiratory syncytial virus (RSV)", "PROBLEM", 175, 208], ["human metapneumovirus (hMPV) infections", "PROBLEM", 213, 252], ["respiratory syncytial virus", "OBSERVATION", 175, 202]]], ["The most frequent clinical diagnoses associated with respiratory HBoV are general upper respiratory tract infections, bronchiolitis, pneumonia, bronchitis and asthma exacerbation [2] .", [["upper respiratory tract", "ANATOMY", 82, 105], ["respiratory HBoV", "DISEASE", 53, 69], ["upper respiratory tract infections", "DISEASE", 82, 116], ["bronchiolitis", "DISEASE", 118, 131], ["pneumonia", "DISEASE", 133, 142], ["bronchitis", "DISEASE", 144, 154], ["asthma", "DISEASE", 159, 165], ["HBoV", "ORGANISM", 65, 69], ["upper respiratory", "ORGANISM_SUBDIVISION", 82, 99], ["tract", "ORGANISM_SUBDIVISION", 100, 105], ["respiratory HBoV", "PROBLEM", 53, 69], ["general upper respiratory tract infections", "PROBLEM", 74, 116], ["bronchiolitis", "PROBLEM", 118, 131], ["pneumonia", "PROBLEM", 133, 142], ["bronchitis", "PROBLEM", 144, 154], ["asthma exacerbation", "PROBLEM", 159, 178], ["respiratory HBoV", "OBSERVATION", 53, 69], ["upper", "ANATOMY_MODIFIER", 82, 87], ["respiratory tract", "ANATOMY", 88, 105], ["infections", "OBSERVATION", 106, 116], ["bronchiolitis", "OBSERVATION", 118, 131], ["pneumonia", "OBSERVATION", 133, 142], ["bronchitis", "OBSERVATION", 144, 154], ["asthma", "OBSERVATION", 159, 165]]], ["Nevertheless, few data are available related to physical characteristics and clinical severity for children with HBoV-positive LRTIs [7] .IntroductionIn this study we aimed to assess the relationship between the HBoV viral load in respiratory tract and clinical characteristics.", [["respiratory tract", "ANATOMY", 231, 248], ["HBoV-positive LRTIs", "DISEASE", 113, 132], ["children", "ORGANISM", 99, 107], ["HBoV", "ORGANISM", 113, 117], ["HBoV", "ORGANISM", 212, 216], ["respiratory tract", "ORGANISM_SUBDIVISION", 231, 248], ["children", "SPECIES", 99, 107], ["HBoV", "TEST", 113, 117], ["this study", "TEST", 153, 163], ["the HBoV viral load in respiratory tract", "PROBLEM", 208, 248], ["HBoV", "OBSERVATION", 212, 216], ["viral load", "OBSERVATION", 217, 227], ["respiratory tract", "ANATOMY", 231, 248]]], ["To achieve this goal, we conducted the study to compare the clinical characteristics, cytokine/chemokine data in respiratory tract aspirates between two groups of children who had HBoV infection with either high or low viral load.Research subjects and respiratory tract aspirates collectionThe study population was hospitalized (in the Department of Respiratory Medicine, Children's Hospital, Chongqing Medical University) and underwent bronchoscopy.", [["respiratory tract aspirates", "ANATOMY", 113, 140], ["respiratory tract aspirates", "ANATOMY", 252, 279], ["HBoV infection", "DISEASE", 180, 194], ["respiratory tract aspirates", "MULTI-TISSUE_STRUCTURE", 113, 140], ["children", "ORGANISM", 163, 171], ["HBoV", "ORGANISM", 180, 184], ["respiratory tract aspirates", "MULTI-TISSUE_STRUCTURE", 252, 279], ["cytokine", "PROTEIN", 86, 94], ["chemokine", "PROTEIN", 95, 104], ["children", "SPECIES", 163, 171], ["HBoV", "SPECIES", 180, 184], ["the study", "TEST", 35, 44], ["cytokine/chemokine data", "TEST", 86, 109], ["respiratory tract aspirates", "PROBLEM", 113, 140], ["HBoV infection", "PROBLEM", 180, 194], ["high or low viral load", "PROBLEM", 207, 229], ["Research subjects and respiratory tract aspirates collection", "PROBLEM", 230, 290], ["bronchoscopy", "TEST", 437, 449], ["respiratory tract", "ANATOMY", 113, 130], ["infection", "OBSERVATION", 185, 194], ["viral load", "OBSERVATION", 219, 229], ["respiratory tract", "ANATOMY", 252, 269]]], ["The study was conducted from April 2006 to March 2009.", [["The study", "TEST", 0, 9]]], ["A total of 186 sequential respiratory tract aspirate samples were collected.", [["respiratory tract aspirate samples", "ANATOMY", 26, 60], ["respiratory tract aspirate samples", "CANCER", 26, 60], ["sequential respiratory tract aspirate samples", "TEST", 15, 60]]], ["Informed consent was properly obtained from each patient's guardians.", [["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56]]], ["The informed consent was written and signed by guardian before bronchoscopy.", [["bronchoscopy", "TEST", 63, 75]]], ["This study was approved by the Ethical Committee of Chongqing Medical University.Research subjects and respiratory tract aspirates collectionOn admission, the medical history and physical examination of the children were properly obtained and recorded systematically.", [["respiratory tract aspirates", "ANATOMY", 103, 130], ["children", "ORGANISM", 207, 215], ["children", "SPECIES", 207, 215], ["This study", "TEST", 0, 10], ["Research subjects and respiratory tract aspirates", "PROBLEM", 81, 130], ["physical examination", "TEST", 179, 199], ["respiratory tract", "ANATOMY", 103, 120]]], ["In this study, we defined LRTI as having following characteristics: presence of wheezing, crackling rales, dyspnea, and/or obstruction of the airways, with or without fever, and presence of upper airway symptoms characterized by rhinorrhea and bronchitic cough.", [["airways", "ANATOMY", 142, 149], ["airway", "ANATOMY", 196, 202], ["LRTI", "DISEASE", 26, 30], ["wheezing", "DISEASE", 80, 88], ["crackling rales", "DISEASE", 90, 105], ["dyspnea", "DISEASE", 107, 114], ["obstruction of the airways", "DISEASE", 123, 149], ["fever", "DISEASE", 167, 172], ["airway symptoms", "DISEASE", 196, 211], ["rhinorrhea", "DISEASE", 229, 239], ["cough", "DISEASE", 255, 260], ["airways", "MULTI-TISSUE_STRUCTURE", 142, 149], ["upper airway", "ORGANISM_SUBDIVISION", 190, 202], ["this study", "TEST", 3, 13], ["wheezing", "PROBLEM", 80, 88], ["crackling rales", "PROBLEM", 90, 105], ["dyspnea", "PROBLEM", 107, 114], ["obstruction of the airways", "PROBLEM", 123, 149], ["fever", "PROBLEM", 167, 172], ["upper airway symptoms", "PROBLEM", 190, 211], ["rhinorrhea", "PROBLEM", 229, 239], ["bronchitic cough", "PROBLEM", 244, 260], ["wheezing", "OBSERVATION", 80, 88], ["dyspnea", "OBSERVATION", 107, 114], ["obstruction", "OBSERVATION", 123, 134], ["airways", "ANATOMY", 142, 149], ["upper", "ANATOMY_MODIFIER", 190, 195], ["airway", "ANATOMY", 196, 202], ["symptoms", "OBSERVATION", 203, 211], ["rhinorrhea", "OBSERVATION", 229, 239], ["bronchitic cough", "OBSERVATION", 244, 260]]], ["All patients with suspected LRTI underwent chest radiography.", [["chest", "ANATOMY", 43, 48], ["LRTI", "DISEASE", 28, 32], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["chest radiography", "TEST", 43, 60], ["chest", "ANATOMY", 43, 48]]], ["Pneumonia was defined as the presence of focal infiltration or lung consolidation presented in chest radiography.Respiratory tract aspirates preparationAfter respiratory tract aspirates were collected, the aspirates were gently mixed with Pasteur pipette and revolve for a while until they were evenly mixed, then 0.5 ml of each aspirate was transferred to another tube for cytokine analysis.", [["lung", "ANATOMY", 63, 67], ["chest", "ANATOMY", 95, 100], ["Respiratory tract aspirates", "ANATOMY", 113, 140], ["respiratory tract aspirates", "ANATOMY", 158, 185], ["aspirates", "ANATOMY", 206, 215], ["aspirate", "ANATOMY", 329, 337], ["Pneumonia", "DISEASE", 0, 9], ["lung", "ORGAN", 63, 67], ["chest", "ORGANISM_SUBDIVISION", 95, 100], ["Respiratory tract aspirates", "MULTI-TISSUE_STRUCTURE", 113, 140], ["tract aspirates", "MULTI-TISSUE_STRUCTURE", 170, 185], ["tube", "TISSUE", 365, 369], ["cytokine", "PROTEIN", 374, 382], ["Pneumonia", "PROBLEM", 0, 9], ["focal infiltration", "PROBLEM", 41, 59], ["lung consolidation", "PROBLEM", 63, 81], ["chest radiography", "TEST", 95, 112], ["Respiratory tract aspirates", "TEST", 113, 140], ["respiratory tract aspirates", "PROBLEM", 158, 185], ["the aspirates", "TEST", 202, 215], ["Pasteur pipette", "TREATMENT", 239, 254], ["each aspirate", "TEST", 324, 337], ["cytokine analysis", "TEST", 374, 391], ["focal", "OBSERVATION_MODIFIER", 41, 46], ["infiltration", "OBSERVATION", 47, 59], ["lung", "ANATOMY", 63, 67], ["consolidation", "OBSERVATION", 68, 81], ["chest", "ANATOMY", 95, 100], ["tract", "OBSERVATION_MODIFIER", 125, 130], ["tract aspirates", "OBSERVATION", 170, 185]]], ["Four volumes of 0.1% dithiothreitol was added to the 0.5 ml respiratory tract aspirates, then gently mixed with Pasteur pipette, votexed 15 seconds and shook 15 minutes on bench rocker.", [["respiratory tract aspirates", "ANATOMY", 60, 87], ["dithiothreitol", "CHEMICAL", 21, 35], ["dithiothreitol", "CHEMICAL", 21, 35], ["dithiothreitol", "SIMPLE_CHEMICAL", 21, 35], ["dithiothreitol", "TREATMENT", 21, 35], ["the 0.5 ml respiratory tract aspirates", "TREATMENT", 49, 87], ["Pasteur pipette", "TREATMENT", 112, 127]]], ["The suspension was subsequently filtered through 48 mm nylon gauze to remove mucus and debris without removing any cells, and then it was centrifuged at 1500 rpm for 10 minutes.", [["mucus", "ANATOMY", 77, 82], ["cells", "ANATOMY", 115, 120], ["mucus", "ORGANISM_SUBSTANCE", 77, 82], ["cells", "CELL", 115, 120], ["The suspension", "TREATMENT", 0, 14], ["48 mm nylon gauze", "TREATMENT", 49, 66], ["mucus", "PROBLEM", 77, 82], ["debris", "PROBLEM", 87, 93], ["any cells", "TREATMENT", 111, 120], ["suspension", "OBSERVATION_MODIFIER", 4, 14], ["debris", "OBSERVATION", 87, 93]]], ["The cell free supernatant was stored at 280uC for cytokine assay.", [["cell", "ANATOMY", 4, 8], ["supernatant", "ANATOMY", 14, 25], ["cell", "CELL", 4, 8], ["cytokine", "PROTEIN", 50, 58], ["cytokine assay", "TEST", 50, 64], ["cell", "OBSERVATION_MODIFIER", 4, 8], ["free", "OBSERVATION_MODIFIER", 9, 13]]], ["The cell pellet was resuspended for viral antigen detection using direct fluorescent assay inmediately.", [["cell pellet", "ANATOMY", 4, 15], ["cell", "CELL", 4, 8], ["The cell pellet", "TREATMENT", 0, 15], ["viral antigen detection", "TEST", 36, 59], ["direct fluorescent assay", "TEST", 66, 90], ["cell pellet", "OBSERVATION", 4, 15]]], ["The rest of aspirates were stored at 280uC before virus detection by polymerase chain reaction (PCR) assay.Real-time PCR for HBoVNucleic acids were extracted from 200 mL of the aspirates using the QIAamp DNA mini kit (Qiagen, USA) and the samples were eluted in 200 mL of RNasefree water.", [["aspirates", "ANATOMY", 12, 21], ["aspirates", "ANATOMY", 177, 186], ["samples", "ANATOMY", 239, 246], ["HBoVNucleic acids", "CHEMICAL", 125, 142], ["HBoVNucleic acids", "CHEMICAL", 125, 142], ["HBoVNucleic acids", "SIMPLE_CHEMICAL", 125, 142], ["aspirates", "TEST", 12, 21], ["virus detection", "TEST", 50, 65], ["polymerase chain reaction", "TEST", 69, 94], ["PCR", "TEST", 96, 99], ["HBoVNucleic acids", "TREATMENT", 125, 142], ["the aspirates", "TEST", 173, 186], ["the QIAamp DNA mini kit", "TREATMENT", 193, 216], ["the samples", "TEST", 235, 246], ["RNasefree water", "TREATMENT", 272, 287]]], ["The PCR assay targeted the NP-1 gene of HBoV.", [["NP-1", "GENE_OR_GENE_PRODUCT", 27, 31], ["HBoV", "ORGANISM", 40, 44], ["NP-1 gene", "DNA", 27, 36], ["HBoV", "SPECIES", 40, 44], ["The PCR assay", "TEST", 0, 13], ["the NP", "TREATMENT", 23, 29], ["HBoV", "PROBLEM", 40, 44], ["HBoV", "OBSERVATION", 40, 44]]], ["The 20-mL amplification reaction contained 5 mL of sample DNA, 10 mL of TaqMan universal PCR master mix (PE Applied Biosystems), 0.1 mL of bovine serum albumin (20 mg/mL), 300 nmol/L each primer (Boca-forward, GGA AGA GAC ACT GGC AGA CAA; and Boca-reverse, GGG TGT TCC TGA TGA TAT GAG C), and 150 nmol/L Boca probe (FAM-CTG CGG CTC CTG CTC CTG TGA T-TAMRA).", [["sample", "ANATOMY", 51, 57], ["serum", "ANATOMY", 146, 151], ["CAA", "CHEMICAL", 234, 237], ["DNA", "CELLULAR_COMPONENT", 58, 61], ["bovine", "ORGANISM", 139, 145], ["serum", "ORGANISM_SUBSTANCE", 146, 151], ["albumin", "SIMPLE_CHEMICAL", 152, 159], ["Boca-forward, GGA AGA GAC ACT GGC AGA CAA; and Boca-reverse, GGG TGT TCC TGA TGA TAT GAG C", "DNA", 196, 286], ["bovine", "SPECIES", 139, 145], ["bovine", "SPECIES", 139, 145], ["The 20-mL amplification reaction", "TREATMENT", 0, 32], ["sample DNA", "TREATMENT", 51, 61], ["TaqMan universal PCR master mix (PE Applied Biosystems", "TREATMENT", 72, 126], ["bovine serum albumin", "TREATMENT", 139, 159], ["Boca", "TEST", 196, 200], ["GGA AGA", "TEST", 210, 217], ["GGC", "TEST", 226, 229], ["CAA", "TEST", 234, 237], ["Boca-", "TEST", 243, 248], ["GGG", "TEST", 257, 260], ["TGT TCC", "TEST", 261, 268], ["TGA", "TEST", 269, 272], ["TGA", "TEST", 273, 276], ["C", "TEST", 285, 286], ["L Boca probe", "TREATMENT", 302, 314], ["FAM", "TEST", 316, 319], ["CTG CGG", "TEST", 320, 327], ["CTC", "TEST", 328, 331], ["CTG", "TEST", 332, 335], ["CTC", "TEST", 336, 339], ["CTG", "TEST", 340, 343]]], ["For standardizing the quantification, a plasmid (NPSC3.1) containing the HBoV NP-1 gene was used in serial dilutions covering a range of 6 logs.", [["plasmid", "ANATOMY", 40, 47], ["HBoV", "ORGANISM", 73, 77], ["NP-1", "GENE_OR_GENE_PRODUCT", 78, 82], ["plasmid", "DNA", 40, 47], ["NPSC3", "DNA", 49, 54], ["HBoV NP-1 gene", "DNA", 73, 87], ["a plasmid (NPSC3", "TREATMENT", 38, 54], ["the HBoV NP", "TREATMENT", 69, 80], ["HBoV", "OBSERVATION", 73, 77]]], ["The criteria for a positive reaction were defined as the cycle threshold ,40 cycles and fluorescence count .0.5.", [["a positive reaction", "PROBLEM", 17, 36], ["the cycle threshold", "TEST", 53, 72], ["fluorescence count", "TEST", 88, 106]]], ["The minimum genome viral load that would allow reproducible quantification was 10 copies per reaction, which corresponds to 500 copies/mL of respiratory tract aspirates.", [["respiratory tract aspirates", "ANATOMY", 141, 168], ["The minimum genome viral load", "PROBLEM", 0, 29], ["respiratory tract aspirates", "PROBLEM", 141, 168], ["viral load", "OBSERVATION", 19, 29], ["respiratory tract", "ANATOMY", 141, 158], ["aspirates", "OBSERVATION", 159, 168]]], ["The analyses were performed at a diagnostic laboratory, where rigorous measures were implemented to prevent contamination.Means of diagnosis for other virusesViral antigens were analyzed for adenovirus (ADV), influenza virus A and B (Flu-A and B), parainfluenza virus 1, 2 and 3 (PIV 1-3) and RSV using direct fluorescent assay (D3 direct fluorescent assay RESPIRATORY VIRUSES SCREENING & ID KIT, DIAGNOSTIC HYBRIDS, Germany); PCR was used for the detection of ADV; reverse transcription-PCR was used for the detection of rhinovirus (RV), RSV, human coronaviruses OC43 (HCoV), Flu-A and B, PIV 1-3 and hMPV.", [["Viral", "ORGANISM", 158, 163], ["adenovirus", "ORGANISM", 191, 201], ["ADV", "ORGANISM", 203, 206], ["influenza virus A", "ORGANISM", 209, 226], ["B", "GENE_OR_GENE_PRODUCT", 231, 232], ["Flu-A and B)", "ORGANISM", 234, 246], ["parainfluenza virus 1", "ORGANISM", 248, 269], ["3", "GENE_OR_GENE_PRODUCT", 277, 278], ["PIV 1-3", "ORGANISM", 280, 287], ["RSV", "ORGANISM", 293, 296], ["rhinovirus", "ORGANISM", 522, 532], ["RSV", "ORGANISM", 539, 542], ["human", "ORGANISM", 544, 549], ["coronaviruses OC43", "ORGANISM", 550, 568], ["HCoV", "GENE_OR_GENE_PRODUCT", 570, 574], ["Flu-A", "ORGANISM", 577, 582], ["B", "CELL", 587, 588], ["PIV 1-3", "ORGANISM", 590, 597], ["hMPV", "ORGANISM", 602, 606], ["Viral antigens", "PROTEIN", 158, 172], ["KIT", "PROTEIN", 392, 395], ["influenza virus", "SPECIES", 209, 224], ["parainfluenza virus 1", "SPECIES", 248, 269], ["RSV", "SPECIES", 293, 296], ["RSV", "SPECIES", 539, 542], ["human", "SPECIES", 544, 549], ["adenovirus", "SPECIES", 191, 201], ["ADV", "SPECIES", 203, 206], ["influenza virus A", "SPECIES", 209, 226], ["parainfluenza virus 1", "SPECIES", 248, 269], ["RSV", "SPECIES", 293, 296], ["ADV", "SPECIES", 461, 464], ["RV", "SPECIES", 534, 536], ["RSV", "SPECIES", 539, 542], ["human coronaviruses OC43", "SPECIES", 544, 568], ["HCoV", "SPECIES", 570, 574], ["Flu-A", "SPECIES", 577, 582], ["hMPV", "SPECIES", 602, 606], ["The analyses", "TEST", 0, 12], ["rigorous measures", "TREATMENT", 62, 79], ["contamination", "PROBLEM", 108, 121], ["other viruses", "PROBLEM", 145, 158], ["Viral antigens", "TEST", 158, 172], ["adenovirus", "PROBLEM", 191, 201], ["influenza virus A", "PROBLEM", 209, 226], ["Flu", "TEST", 234, 237], ["parainfluenza virus", "TEST", 248, 267], ["PIV", "TEST", 280, 283], ["RSV", "TREATMENT", 293, 296], ["direct fluorescent assay", "TEST", 303, 327], ["PCR", "TEST", 427, 430], ["ADV", "PROBLEM", 461, 464], ["PCR", "TEST", 488, 491], ["the detection", "TEST", 505, 518], ["rhinovirus", "PROBLEM", 522, 532], ["RV", "TEST", 534, 536], ["RSV", "PROBLEM", 539, 542], ["human coronaviruses OC43", "TEST", 544, 568], ["HCoV", "TEST", 570, 574], ["Flu", "TEST", 577, 580], ["PIV", "TEST", 590, 593], ["hMPV", "PROBLEM", 602, 606], ["viruses", "OBSERVATION", 151, 158], ["rhinovirus", "OBSERVATION", 522, 532]]], ["DNA was extracted from 200 mL of the aspirates using the QIAamp DNA mini kit (Qiagen, USA) and was eluted in 200 mL AE buffer.", [["aspirates", "ANATOMY", 37, 46], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "PROBLEM", 0, 3], ["the aspirates", "TEST", 33, 46], ["the QIAamp DNA mini kit", "TREATMENT", 53, 76], ["200 mL", "OBSERVATION_MODIFIER", 23, 29], ["aspirates", "OBSERVATION", 37, 46]]], ["RNA was extracted from 140 mL of the aspirates using the QIAamp Virus RNA Mini kit (Qiagen, USA), and samples were eluted in 60 mL of RNase-free water.", [["aspirates", "ANATOMY", 37, 46], ["samples", "ANATOMY", 102, 109], ["RNase", "GENE_OR_GENE_PRODUCT", 134, 139], ["RNA", "RNA", 0, 3], ["RNase", "PROTEIN", 134, 139], ["the aspirates", "TEST", 33, 46], ["the QIAamp Virus RNA", "TREATMENT", 53, 73], ["samples", "TEST", 102, 109], ["RNase-free water", "TREATMENT", 134, 150], ["140 mL", "OBSERVATION_MODIFIER", 23, 29], ["aspirates", "OBSERVATION", 37, 46]]], ["Reverse transcription of 0.5 mg of each RNA was performed in a final reaction of 10 mL that contained 25-pmol Oligo dT primer, 50 pmol random 6-mers, 56PrimeScript Buffer and 0.5 mL PrimeScript RT Enzyme Mix (TaKaRa, Japan).", [["Reverse transcription", "TREATMENT", 0, 21], ["Oligo dT primer", "TREATMENT", 110, 125], ["56PrimeScript Buffer", "TREATMENT", 150, 170]]], ["Amplification was performed with a Bio-Rad thermal cycler, using commercially available master mixes (Promega, USA) and standard protocols.", [["a Bio-Rad thermal cycler", "TREATMENT", 33, 57], ["standard protocols", "TREATMENT", 120, 138]]], ["All PCR assays were performed using 2 ml of cDNA/DNA and 1 mM of each primer.", [["DNA", "CELLULAR_COMPONENT", 49, 52], ["cDNA/DNA", "DNA", 44, 52], ["All PCR assays", "TEST", 0, 14], ["cDNA/DNA", "TREATMENT", 44, 52], ["each primer", "TREATMENT", 65, 76]]], ["In addition, the primer sequences, PCR protocols and other viral detection methods are described elsewhere [11] .", [["primer sequences", "DNA", 17, 33], ["the primer sequences", "TEST", 13, 33], ["PCR protocols", "TEST", 35, 48], ["other viral detection methods", "TEST", 53, 82]]], ["The unclassified RVs were identified as RVs.", [["RVs", "CANCER", 17, 20], ["The unclassified RVs", "PROBLEM", 0, 20], ["RVs", "TEST", 40, 43], ["unclassified", "OBSERVATION_MODIFIER", 4, 16], ["RVs", "OBSERVATION", 17, 20]]], ["A patient was considered to be positive for the virus only if having at least one positive result from the two methods.Bacterial isolationBacterial/yeast diagnostic samples were processed immediately in a qualitative and semi-quantitative ways using standard microbiological methods [12, 13] .", [["samples", "ANATOMY", 165, 172], ["patient", "ORGANISM", 2, 9], ["patient", "SPECIES", 2, 9], ["yeast", "SPECIES", 148, 153], ["yeast", "SPECIES", 148, 153], ["the virus", "PROBLEM", 44, 53], ["Bacterial isolationBacterial/yeast diagnostic samples", "PROBLEM", 119, 172], ["yeast diagnostic", "OBSERVATION", 148, 164]]], ["For all samples, macroscopically distinct colonies were isolated in pure culture and standard methods for identification, typing, and sensitivity patterns were used.Cytokine/chemokine analysisBy following the instructions, respiratory tract aspirates were tested for interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) by enzyme linked immunosorbent assay (ELISA) (BD Pharmingen, USA).", [["samples", "ANATOMY", 8, 15], ["colonies", "ANATOMY", 42, 50], ["respiratory tract aspirates", "ANATOMY", 223, 250], ["colonies", "CELL", 42, 50], ["respiratory tract aspirates", "MULTI-TISSUE_STRUCTURE", 223, 250], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 267, 280], ["IL-6", "GENE_OR_GENE_PRODUCT", 282, 286], ["interleukin-8", "GENE_OR_GENE_PRODUCT", 289, 302], ["IL-8", "GENE_OR_GENE_PRODUCT", 304, 308], ["interleukin-10", "GENE_OR_GENE_PRODUCT", 314, 328], ["IL-10", "GENE_OR_GENE_PRODUCT", 330, 335], ["Cytokine", "PROTEIN", 165, 173], ["chemokine", "PROTEIN", 174, 183], ["interleukin-6 (IL-6", "PROTEIN", 267, 286], ["interleukin-8 (IL-8", "PROTEIN", 289, 308], ["interleukin-10 (IL-10", "PROTEIN", 314, 335], ["all samples", "TEST", 4, 15], ["macroscopically distinct colonies", "PROBLEM", 17, 50], ["pure culture", "TEST", 68, 80], ["identification", "TEST", 106, 120], ["typing", "TEST", 122, 128], ["Cytokine/chemokine analysisBy", "TREATMENT", 165, 194], ["respiratory tract aspirates", "TEST", 223, 250], ["interleukin", "TEST", 267, 278], ["IL", "TEST", 282, 284], ["interleukin", "TEST", 289, 300], ["IL", "TEST", 304, 306], ["interleukin", "TEST", 314, 325], ["enzyme linked immunosorbent assay", "TEST", 340, 373], ["respiratory tract", "ANATOMY", 223, 240]]], ["Each sample was measured in duplicate using VARIOSKAN FLASH (Thermo) by following manufacturer's instructions.", [["sample", "ANATOMY", 5, 11], ["Each sample", "TEST", 0, 11]]], ["The concentration of each cytokine was determined by interpolation from the corresponding standard curve.", [["cytokine", "PROTEIN", 26, 34], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["When the values were below the detection threshold, the minimum detectable level was assigned.Statistical analysisData on the descriptive characteristics of the patients were analyzed by x2, Fisher's exact test.", [["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 161, 169], ["Fisher's exact test", "TEST", 191, 210]]], ["Non-parametric tests and median values were used for those variables, because they were not normally distributed, such as cytokine/chemokine concentrations.", [["cytokine", "PROTEIN", 122, 130], ["chemokine", "PROTEIN", 131, 140], ["Non-parametric tests", "TEST", 0, 20], ["median values", "TEST", 25, 38], ["cytokine/chemokine concentrations", "TREATMENT", 122, 155]]], ["SPSS (version 17.0) was used for all analysis.Frequency and distribution of HBoV detectionThe patient demographics and clinical information were summarized in Table 1 .", [["HBoV", "ORGANISM", 76, 80], ["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["HBoV", "SPECIES", 76, 80], ["all analysis", "TEST", 33, 45], ["HBoV detection", "TEST", 76, 90], ["HBoV detection", "OBSERVATION", 76, 90]]], ["HBoV DNA was detected by PCR in 31 out of 186 patient's samples (24.6%).", [["samples", "ANATOMY", 56, 63], ["HBoV", "ORGANISM", 0, 4], ["DNA", "CELLULAR_COMPONENT", 5, 8], ["patient", "ORGANISM", 46, 53], ["samples", "CANCER", 56, 63], ["HBoV DNA", "DNA", 0, 8], ["patient", "SPECIES", 46, 53], ["HBoV", "SPECIES", 0, 4], ["HBoV DNA", "PROBLEM", 0, 8], ["PCR", "TEST", 25, 28], ["patient's samples", "TEST", 46, 63]]], ["All samples were also tested for the other respiratory viruses, including RSV (32.8%), RV (22.4%), hMPV (2.4%), FLU (20%), HPIV (44%), HCoV (1.6%) and ADV (4.8%).", [["samples", "ANATOMY", 4, 11], ["respiratory viruses", "DISEASE", 43, 62], ["hMPV", "DISEASE", 99, 103], ["FLU", "CHEMICAL", 112, 115], ["ADV", "CHEMICAL", 151, 154], ["FLU", "CHEMICAL", 112, 115], ["RSV", "ORGANISM", 74, 77], ["hMPV", "ORGANISM", 99, 103], ["RSV", "SPECIES", 74, 77], ["RV", "SPECIES", 87, 89], ["hMPV", "SPECIES", 99, 103], ["HPIV", "SPECIES", 123, 127], ["HCoV", "SPECIES", 135, 139], ["ADV", "SPECIES", 151, 154], ["All samples", "TEST", 0, 11], ["the other respiratory viruses", "PROBLEM", 33, 62], ["RSV", "TEST", 74, 77], ["RV", "TEST", 87, 89], ["hMPV", "TEST", 99, 103], ["FLU", "TEST", 112, 115], ["HPIV", "TEST", 123, 127], ["HCoV", "TEST", 135, 139], ["ADV", "TEST", 151, 154], ["respiratory viruses", "ANATOMY", 43, 62]]], ["Among all 31 HBoV-positive samples, 12 samples (38.71%) were only being detected for HBoV, while in other 19 samples there were one more virus were being detected besides HBoV.", [["samples", "ANATOMY", 27, 34], ["samples", "ANATOMY", 39, 46], ["samples", "ANATOMY", 109, 116], ["HBoV", "ORGANISM", 13, 17], ["samples", "CANCER", 39, 46], ["HBoV", "ORGANISM", 85, 89], ["samples", "CANCER", 109, 116], ["HBoV", "ORGANISM", 171, 175], ["HBoV", "SPECIES", 85, 89], ["HBoV", "SPECIES", 171, 175], ["HBoV", "TEST", 13, 17], ["HBoV", "PROBLEM", 85, 89], ["one more virus", "PROBLEM", 128, 142], ["HBoV", "PROBLEM", 171, 175]]], ["It was noticed that the most common coinfection viruses with HBoV were RSV (in 4 children), RV (in 3 children) and ADV (in 2 children).Frequency and distribution of HBoV detectionHBoV DNA was detected all year round, seasonal distribution of HBoV was noted during October through March.", [["coinfection", "DISEASE", 36, 47], ["HBoV", "DISEASE", 61, 65], ["ADV", "CHEMICAL", 115, 118], ["HBoV", "DISEASE", 242, 246], ["HBoV", "ORGANISM", 61, 65], ["RSV", "ORGANISM", 71, 74], ["children", "ORGANISM", 81, 89], ["children", "ORGANISM", 101, 109], ["children", "ORGANISM", 125, 133], ["HBoV", "ORGANISM", 165, 169], ["DNA", "CELLULAR_COMPONENT", 184, 187], ["HBoV", "ORGANISM", 242, 246], ["HBoV detectionHBoV DNA", "DNA", 165, 187], ["children", "SPECIES", 81, 89], ["children", "SPECIES", 101, 109], ["children", "SPECIES", 125, 133], ["RSV", "SPECIES", 71, 74], ["ADV", "SPECIES", 115, 118], ["HBoV", "SPECIES", 165, 169], ["HBoV", "SPECIES", 242, 246], ["HBoV", "PROBLEM", 61, 65], ["RSV", "PROBLEM", 71, 74], ["HBoV detectionHBoV DNA", "PROBLEM", 165, 187], ["HBoV", "PROBLEM", 242, 246], ["RV", "ANATOMY", 92, 94], ["distribution", "OBSERVATION_MODIFIER", 149, 161], ["HBoV detectionHBoV", "OBSERVATION", 165, 183], ["HBoV", "OBSERVATION", 242, 246]]], ["The period from January to March was the seasonal peak that overlapped with the period of RSV peak, which may explained that why RSV was being the most common co-infection virus with HBoV.Clinical data of patients with or without HBoVFor the purpose of the analysis, the patients were divided into two groups: those with HBoV infection and those without HBoV infection.", [["co-infection", "DISEASE", 159, 171], ["HBoV", "DISEASE", 183, 187], ["HBoV", "DISEASE", 230, 234], ["HBoV infection", "DISEASE", 321, 335], ["HBoV infection", "DISEASE", 354, 368], ["RSV", "ORGANISM", 90, 93], ["RSV", "ORGANISM", 129, 132], ["HBoV", "ORGANISM", 183, 187], ["patients", "ORGANISM", 205, 213], ["HBoV", "ORGANISM", 230, 234], ["patients", "ORGANISM", 271, 279], ["HBoV", "ORGANISM", 321, 325], ["HBoV", "ORGANISM", 354, 358], ["patients", "SPECIES", 205, 213], ["patients", "SPECIES", 271, 279], ["RSV", "SPECIES", 90, 93], ["RSV", "SPECIES", 129, 132], ["HBoV", "SPECIES", 183, 187], ["HBoV", "SPECIES", 230, 234], ["HBoV", "SPECIES", 321, 325], ["HBoV", "SPECIES", 354, 358], ["RSV peak", "PROBLEM", 90, 98], ["RSV", "PROBLEM", 129, 132], ["HBoV", "PROBLEM", 183, 187], ["HBoV", "PROBLEM", 230, 234], ["the analysis", "TEST", 253, 265], ["HBoV infection", "PROBLEM", 321, 335], ["HBoV infection", "PROBLEM", 354, 368], ["RSV peak", "OBSERVATION", 90, 98], ["infection", "OBSERVATION", 326, 335], ["infection", "OBSERVATION", 359, 368]]], ["The most frequent respiratory symptoms/signs (present in .50%) seen in HBoV-positive patients were cough and wheezing.", [["respiratory", "ANATOMY", 18, 29], ["HBoV-positive", "DISEASE", 71, 84], ["cough", "DISEASE", 99, 104], ["wheezing", "DISEASE", 109, 117], ["HBoV", "ORGANISM", 71, 75], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["The most frequent respiratory symptoms", "PROBLEM", 0, 38], ["signs", "PROBLEM", 39, 44], ["HBoV", "TEST", 71, 75], ["cough", "PROBLEM", 99, 104], ["wheezing", "PROBLEM", 109, 117], ["cough", "OBSERVATION", 99, 104]]], ["Significantly high frequency of wheezing (90.322% vs. 72.903%, p = 0.04) and dyspnea (41.935% vs. 13.548%, p = 0.001) were noted in 31 HBoV-positive patients, in comparison with 155 HBoV-negative patients.", [["wheezing", "DISEASE", 32, 40], ["dyspnea", "DISEASE", 77, 84], ["HBoV", "ORGANISM", 135, 139], ["patients", "ORGANISM", 149, 157], ["HBoV", "ORGANISM", 182, 186], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 149, 157], ["patients", "SPECIES", 196, 204], ["HBoV", "SPECIES", 135, 139], ["HBoV", "SPECIES", 182, 186], ["wheezing", "PROBLEM", 32, 40], ["p", "TEST", 63, 64], ["dyspnea", "PROBLEM", 77, 84], ["p", "TEST", 107, 108], ["HBoV", "TEST", 135, 139], ["HBoV", "TEST", 182, 186], ["high", "OBSERVATION_MODIFIER", 14, 18]]], ["Furthermore a significant difference was noted in the length of hospital stay between HBoVpositive and HBoV-negative patients ( Table 2 ).", [["HBoV", "ORGANISM", 103, 107], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["a significant difference", "PROBLEM", 12, 36], ["HBoVpositive", "TEST", 86, 98], ["HBoV", "TEST", 103, 107], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["difference", "OBSERVATION", 26, 36]]], ["In general, the clinical findings were more severe in patients with HBoV infection.Clinical characteristics of patients who had positive HBoV with or without co-infection with other viruses or bacteriaThe clinical characteristics of children who had detectable HBoV with or without co-infection with other viruses or bacteria were shown in Table 3 and Table 4 .", [["HBoV infection", "DISEASE", 68, 82], ["patients", "ORGANISM", 54, 62], ["HBoV", "ORGANISM", 68, 72], ["patients", "ORGANISM", 111, 119], ["HBoV", "ORGANISM", 137, 141], ["children", "ORGANISM", 233, 241], ["HBoV", "ORGANISM", 261, 265], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 111, 119], ["children", "SPECIES", 233, 241], ["HBoV", "SPECIES", 68, 72], ["HBoV", "SPECIES", 137, 141], ["HBoV", "SPECIES", 261, 265], ["HBoV infection", "PROBLEM", 68, 82], ["positive HBoV", "PROBLEM", 128, 141], ["co-infection", "PROBLEM", 158, 170], ["other viruses", "PROBLEM", 176, 189], ["bacteria", "PROBLEM", 193, 201], ["detectable HBoV", "PROBLEM", 250, 265], ["co-infection", "PROBLEM", 282, 294], ["other viruses", "PROBLEM", 300, 313], ["bacteria", "PROBLEM", 317, 325], ["more severe", "OBSERVATION_MODIFIER", 39, 50], ["infection", "OBSERVATION", 73, 82], ["bacteria", "OBSERVATION", 193, 201]]], ["In table 3, the two groups were similar in all clinical manifestations, duration of hospitalization and wheezing.Clinical characteristics of patients who had positive HBoV with or without co-infection with other viruses or bacteriaAmong all HBoV-positive samples, 67.74% were also positive for bacteria.", [["samples", "ANATOMY", 255, 262], ["wheezing", "DISEASE", 104, 112], ["patients", "ORGANISM", 141, 149], ["HBoV", "ORGANISM", 167, 171], ["HBoV", "ORGANISM", 241, 245], ["patients", "SPECIES", 141, 149], ["HBoV", "SPECIES", 167, 171], ["wheezing", "PROBLEM", 104, 112], ["positive HBoV", "PROBLEM", 158, 171], ["co-infection", "PROBLEM", 188, 200], ["other viruses", "PROBLEM", 206, 219], ["bacteriaAmong", "PROBLEM", 223, 236], ["all HBoV", "TEST", 237, 245], ["bacteria", "PROBLEM", 294, 302], ["wheezing", "OBSERVATION", 104, 112], ["HBoV", "OBSERVATION", 167, 171]]], ["No significant difference was found in whether it was associated with bacteria or not (Table 4) .", [["bacteria", "PROBLEM", 70, 78], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["Therefore, our findings did not support the existence of significant interactions between HBoV and other respiratory viruses or bacteria.", [["HBoV", "ORGANISM", 90, 94], ["HBoV", "SPECIES", 90, 94], ["significant interactions between HBoV and other respiratory viruses", "PROBLEM", 57, 124], ["bacteria", "PROBLEM", 128, 136], ["significant", "OBSERVATION_MODIFIER", 57, 68], ["interactions", "OBSERVATION", 69, 81], ["respiratory", "ANATOMY", 105, 116], ["viruses", "OBSERVATION", 117, 124]]], ["This finding clearly suggested the pathogenic potential of HBoV in young children with LRTI.Clinical characteristics of patients who had positive HBoV with or without co-infection with other viruses or bacteriaQuantitative analysis of HBoV DNA in the respiratory aspirates Absolute quantification of DNA by qPCR revealed that the HBoV viral load in HBoV-positive patients varied very broadly, ranged from ,500 to 1610 9 copies per mL of sample material, with median value of 9912 (figure 1).", [["respiratory aspirates", "ANATOMY", 251, 272], ["HBoV", "DISEASE", 59, 63], ["LRTI", "DISEASE", 87, 91], ["HBoV", "ORGANISM", 59, 63], ["children", "ORGANISM", 73, 81], ["patients", "ORGANISM", 120, 128], ["HBoV", "ORGANISM", 146, 150], ["HBoV", "ORGANISM", 235, 239], ["DNA", "CELLULAR_COMPONENT", 240, 243], ["DNA", "CELLULAR_COMPONENT", 300, 303], ["HBoV", "ORGANISM", 330, 334], ["HBoV", "ORGANISM", 349, 353], ["patients", "ORGANISM", 363, 371], ["HBoV DNA", "DNA", 235, 243], ["children", "SPECIES", 73, 81], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 363, 371], ["HBoV", "SPECIES", 59, 63], ["HBoV", "SPECIES", 146, 150], ["HBoV", "SPECIES", 235, 239], ["HBoV", "SPECIES", 330, 334], ["HBoV", "SPECIES", 349, 353], ["HBoV", "PROBLEM", 59, 63], ["LRTI", "PROBLEM", 87, 91], ["positive HBoV", "PROBLEM", 137, 150], ["co-infection", "PROBLEM", 167, 179], ["other viruses", "PROBLEM", 185, 198], ["bacteriaQuantitative analysis", "TEST", 202, 231], ["HBoV DNA", "PROBLEM", 235, 243], ["the respiratory aspirates", "TEST", 247, 272], ["DNA", "PROBLEM", 300, 303], ["qPCR", "TEST", 307, 311], ["the HBoV viral load", "TEST", 326, 345], ["HBoV", "TEST", 349, 353], ["sample material", "TEST", 437, 452], ["median value", "TEST", 459, 471], ["HBoV", "OBSERVATION", 59, 63], ["LRTI", "OBSERVATION", 87, 91], ["HBoV DNA", "OBSERVATION", 235, 243], ["respiratory", "ANATOMY", 251, 262], ["aspirates", "OBSERVATION", 263, 272]]], ["The median viral load which was found in patients with sole HBoV infection was not higher than those who had co-infection with other respiratory viruses (p = 0.2517).", [["HBoV infection", "DISEASE", 60, 74], ["co-infection", "DISEASE", 109, 121], ["respiratory viruses", "DISEASE", 133, 152], ["patients", "ORGANISM", 41, 49], ["HBoV", "ORGANISM", 60, 64], ["patients", "SPECIES", 41, 49], ["HBoV", "SPECIES", 60, 64], ["The median viral load", "TEST", 0, 21], ["sole HBoV infection", "PROBLEM", 55, 74], ["co-infection", "PROBLEM", 109, 121], ["other respiratory viruses", "PROBLEM", 127, 152], ["median", "OBSERVATION", 4, 10], ["viral load", "OBSERVATION", 11, 21], ["infection", "OBSERVATION", 65, 74], ["respiratory viruses", "OBSERVATION", 133, 152]]], ["A recent review suggested if serum samples were not available for PCR, and then the probable next best option was the quantitative PCR with a cutoff of .10 4 copies/mL of respiratory tract secretions [14] .", [["serum samples", "ANATOMY", 29, 42], ["respiratory tract secretions", "ANATOMY", 171, 199], ["serum samples", "ORGANISM_SUBSTANCE", 29, 42], ["A recent review", "TEST", 0, 15], ["serum samples", "TEST", 29, 42], ["PCR", "TEST", 66, 69], ["the quantitative PCR", "TEST", 114, 134], ["a cutoff", "TEST", 140, 148], ["respiratory tract secretions", "PROBLEM", 171, 199], ["respiratory tract", "ANATOMY", 171, 188]]], ["Several previous studies reported that increased serum HBoV IgM and IgG had been found in most of patients who had high HBoV load (.10 4 copies/mL) in respiratory tract secretions, which was associated with respiratory symptoms [2, 15, 16] .", [["serum", "ANATOMY", 49, 54], ["respiratory tract secretions", "ANATOMY", 151, 179], ["respiratory", "ANATOMY", 207, 218], ["respiratory tract secretions", "DISEASE", 151, 179], ["respiratory symptoms", "DISEASE", 207, 227], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["HBoV", "ORGANISM", 55, 59], ["IgM", "GENE_OR_GENE_PRODUCT", 60, 63], ["IgG", "GENE_OR_GENE_PRODUCT", 68, 71], ["patients", "ORGANISM", 98, 106], ["HBoV", "ORGANISM", 120, 124], ["respiratory tract", "ORGANISM_SUBDIVISION", 151, 168], ["secretions", "ORGANISM_SUBSTANCE", 169, 179], ["serum HBoV IgM", "PROTEIN", 49, 63], ["IgG", "PROTEIN", 68, 71], ["patients", "SPECIES", 98, 106], ["HBoV", "SPECIES", 55, 59], ["Several previous studies", "TEST", 0, 24], ["increased serum HBoV IgM", "PROBLEM", 39, 63], ["IgG", "TEST", 68, 71], ["high HBoV load", "PROBLEM", 115, 129], ["respiratory tract secretions", "PROBLEM", 151, 179], ["respiratory symptoms", "PROBLEM", 207, 227], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["HBoV load", "OBSERVATION", 120, 129], ["respiratory tract", "ANATOMY", 151, 168], ["secretions", "OBSERVATION", 169, 179]]], ["Therefore the HBoV-positive samples were divided into 2 non-overlapping populations: one group of 15 samples with a high viral load (.10 4 copies/mL) and one group of 16 samples with a low viral load (,10 4 copies/mL).Clinical characteristics of patients with high HBoV viral loadHigh HBoV viral load was detected in 15 patients.", [["samples", "ANATOMY", 28, 35], ["samples", "ANATOMY", 101, 108], ["samples", "ANATOMY", 170, 177], ["HBoV", "ORGANISM", 14, 18], ["patients", "ORGANISM", 246, 254], ["HBoV", "ORGANISM", 265, 269], ["HBoV", "ORGANISM", 285, 289], ["patients", "ORGANISM", 320, 328], ["patients", "SPECIES", 246, 254], ["patients", "SPECIES", 320, 328], ["the HBoV", "TEST", 10, 18], ["a high viral load", "PROBLEM", 114, 131], ["a low viral load", "PROBLEM", 183, 199], ["high HBoV viral load", "PROBLEM", 260, 280], ["High HBoV viral load", "PROBLEM", 280, 300], ["viral load", "OBSERVATION", 290, 300]]], ["The comparisons of demographics and clinical data among patients who were shedding high HBoV (.10 4 copies/mL of respiratory tract aspirates) and those who were shedding low HBoV were shown in table 5.", [["respiratory tract aspirates", "ANATOMY", 113, 140], ["HBoV", "DISEASE", 88, 92], ["HBoV", "DISEASE", 174, 178], ["patients", "ORGANISM", 56, 64], ["HBoV", "ORGANISM", 88, 92], ["respiratory tract", "ORGANISM_SUBDIVISION", 113, 130], ["aspirates", "MULTI-TISSUE_STRUCTURE", 131, 140], ["HBoV", "ORGANISM", 174, 178], ["patients", "SPECIES", 56, 64], ["HBoV", "SPECIES", 174, 178], ["shedding high HBoV", "PROBLEM", 74, 92], ["respiratory tract aspirates", "PROBLEM", 113, 140], ["shedding low HBoV", "PROBLEM", 161, 178], ["respiratory tract", "ANATOMY", 113, 130]]], ["In HBoV-positive patients, the distributions of age and gender were not different between the two groups.", [["HBoV-positive", "DISEASE", 3, 16], ["HBoV", "ORGANISM", 3, 7], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["HBoV", "TEST", 3, 7], ["positive patients", "OBSERVATION_MODIFIER", 8, 25]]], ["Almost all of HBoV-positive patients presented cough and wheezing.", [["HBoV-positive", "DISEASE", 14, 27], ["cough", "DISEASE", 47, 52], ["wheezing", "DISEASE", 57, 65], ["HBoV", "ORGANISM", 14, 18], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["HBoV", "TEST", 14, 18], ["cough", "PROBLEM", 47, 52], ["wheezing", "PROBLEM", 57, 65], ["HBoV", "OBSERVATION", 14, 18], ["positive", "OBSERVATION_MODIFIER", 19, 27], ["cough", "OBSERVATION", 47, 52], ["wheezing", "OBSERVATION", 57, 65]]], ["Nonspecific lower respiratory tract symptoms, such as fever and rhinorrhea, had no significant correlation with HBoV viral load.", [["lower respiratory tract", "ANATOMY", 12, 35], ["lower respiratory tract symptoms", "DISEASE", 12, 44], ["fever", "DISEASE", 54, 59], ["rhinorrhea", "DISEASE", 64, 74], ["lower", "ORGANISM_SUBDIVISION", 12, 17], ["respiratory tract", "ORGANISM_SUBDIVISION", 18, 35], ["HBoV", "ORGANISM", 112, 116], ["HBoV", "SPECIES", 112, 116], ["Nonspecific lower respiratory tract symptoms", "PROBLEM", 0, 44], ["fever", "PROBLEM", 54, 59], ["rhinorrhea", "PROBLEM", 64, 74], ["HBoV viral load", "PROBLEM", 112, 127], ["lower", "ANATOMY_MODIFIER", 12, 17], ["respiratory tract", "ANATOMY", 18, 35], ["rhinorrhea", "OBSERVATION", 64, 74], ["viral load", "OBSERVATION", 117, 127]]], ["However, the symptoms observed in patients with serious LRTIs, like tachypnea, dyspnea and cyanosis, were presented more frequently in children with high HBoV viral loads, and the meanCytokine/chemokine concentrationCytokine/chemokine concentrations of the respiratory tract aspirates from patients with HBoV infection were shown in Table 6 .", [["respiratory tract aspirates", "ANATOMY", 257, 284], ["LRTIs", "DISEASE", 56, 61], ["tachypnea", "DISEASE", 68, 77], ["dyspnea", "DISEASE", 79, 86], ["cyanosis", "DISEASE", 91, 99], ["HBoV infection", "DISEASE", 304, 318], ["patients", "ORGANISM", 34, 42], ["children", "ORGANISM", 135, 143], ["HBoV", "ORGANISM", 154, 158], ["meanCytokine", "GENE_OR_GENE_PRODUCT", 180, 192], ["concentrationCytokine", "GENE_OR_GENE_PRODUCT", 203, 224], ["respiratory tract", "ORGANISM_SUBDIVISION", 257, 274], ["patients", "ORGANISM", 290, 298], ["HBoV", "ORGANISM", 304, 308], ["meanCytokine", "PROTEIN", 180, 192], ["chemokine", "PROTEIN", 193, 202], ["chemokine", "PROTEIN", 225, 234], ["patients", "SPECIES", 34, 42], ["children", "SPECIES", 135, 143], ["patients", "SPECIES", 290, 298], ["HBoV", "SPECIES", 154, 158], ["HBoV", "SPECIES", 304, 308], ["the symptoms", "PROBLEM", 9, 21], ["serious LRTIs", "PROBLEM", 48, 61], ["tachypnea", "PROBLEM", 68, 77], ["dyspnea", "PROBLEM", 79, 86], ["cyanosis", "PROBLEM", 91, 99], ["high HBoV viral loads", "PROBLEM", 149, 170], ["the meanCytokine", "TREATMENT", 176, 192], ["chemokine concentrationCytokine/chemokine concentrations", "TREATMENT", 193, 249], ["the respiratory tract aspirates", "PROBLEM", 253, 284], ["HBoV infection", "PROBLEM", 304, 318], ["serious", "OBSERVATION_MODIFIER", 48, 55], ["LRTIs", "OBSERVATION", 56, 61], ["tachypnea", "OBSERVATION", 68, 77], ["cyanosis", "OBSERVATION", 91, 99], ["viral loads", "OBSERVATION", 159, 170], ["respiratory tract", "ANATOMY", 257, 274], ["HBoV infection", "OBSERVATION", 304, 318]]], ["In patients with high HBoV viral load, IL-8 level was found higher than those who had low HBoV viral load.", [["patients", "ORGANISM", 3, 11], ["HBoV", "ORGANISM", 22, 26], ["IL-8", "GENE_OR_GENE_PRODUCT", 39, 43], ["HBoV", "ORGANISM", 90, 94], ["IL", "PROTEIN", 39, 41], ["patients", "SPECIES", 3, 11], ["HBoV", "SPECIES", 90, 94], ["high HBoV viral load", "PROBLEM", 17, 37], ["IL", "TEST", 39, 41], ["low HBoV viral load", "PROBLEM", 86, 105], ["viral load", "OBSERVATION", 27, 37], ["viral load", "OBSERVATION", 95, 105]]], ["The IL-6 and IL-10 levels were very similar between the two groups.Cytokine/chemokine concentrationIn order to identify whether the potential co-infections would influence the cytokine production and the biological significance of IL-8, IL-6 and IL-10, we compared IL-8, IL-6 and IL-10 productions between patients with only HBoV detection, and patients with HBoV and other viruses or bacteria detection, no significant differences were found (table 7 and table 8 ).Association of HBoV in respiratory tract aspirates, duration of hospitalization and days of wheezingLonger duration of hospitalization and days of wheezing were found among children with high HBoV loads (table 5).", [["respiratory tract aspirates", "ANATOMY", 489, 516], ["HBoV and other viruses", "DISEASE", 359, 381], ["wheezing", "DISEASE", 613, 621], ["IL-6", "GENE_OR_GENE_PRODUCT", 4, 8], ["IL-10", "GENE_OR_GENE_PRODUCT", 13, 18], ["IL-8", "GENE_OR_GENE_PRODUCT", 231, 235], ["IL-6", "GENE_OR_GENE_PRODUCT", 237, 241], ["IL-10", "GENE_OR_GENE_PRODUCT", 246, 251], ["IL-8", "GENE_OR_GENE_PRODUCT", 265, 269], ["IL-6", "GENE_OR_GENE_PRODUCT", 271, 275], ["IL-10", "GENE_OR_GENE_PRODUCT", 280, 285], ["patients", "ORGANISM", 306, 314], ["HBoV", "ORGANISM", 325, 329], ["patients", "ORGANISM", 345, 353], ["HBoV", "ORGANISM", 359, 363], ["HBoV", "ORGANISM", 481, 485], ["respiratory tract", "ORGANISM_SUBDIVISION", 489, 506], ["children", "ORGANISM", 639, 647], ["HBoV", "ORGANISM", 658, 662], ["Cytokine", "PROTEIN", 67, 75], ["chemokine", "PROTEIN", 76, 85], ["cytokine", "PROTEIN", 176, 184], ["IL", "PROTEIN", 246, 248], ["IL", "PROTEIN", 280, 282], ["patients", "SPECIES", 306, 314], ["patients", "SPECIES", 345, 353], ["children", "SPECIES", 639, 647], ["HBoV", "SPECIES", 325, 329], ["HBoV", "SPECIES", 359, 363], ["The IL", "TEST", 0, 6], ["Cytokine/chemokine concentrationIn order", "TREATMENT", 67, 107], ["the potential co-infections", "PROBLEM", 128, 155], ["the cytokine production", "TEST", 172, 195], ["IL", "TEST", 231, 233], ["IL", "TEST", 237, 239], ["IL", "TEST", 246, 248], ["IL", "TEST", 265, 267], ["IL", "TEST", 271, 273], ["HBoV detection", "TEST", 325, 339], ["HBoV", "PROBLEM", 359, 363], ["other viruses", "PROBLEM", 368, 381], ["bacteria detection", "PROBLEM", 385, 403], ["HBoV in respiratory tract aspirates", "PROBLEM", 481, 516], ["wheezing", "PROBLEM", 613, 621], ["high HBoV loads", "PROBLEM", 653, 668], ["co-infections", "OBSERVATION", 142, 155], ["HBoV", "OBSERVATION", 481, 485], ["respiratory tract", "ANATOMY", 489, 506]]], ["Then we looked at the correlation between viral loads and duration of hospital stay and days of wheezing, we searched for additional evidence of etiology by studying whether the viral load of HBoV was unrelated or correlated to the days of hospitalization and presented wheezing.", [["wheezing", "DISEASE", 96, 104], ["HBoV", "DISEASE", 192, 196], ["wheezing", "DISEASE", 270, 278], ["HBoV", "ORGANISM", 192, 196], ["HBoV", "SPECIES", 192, 196], ["wheezing", "PROBLEM", 96, 104], ["the viral load of HBoV", "PROBLEM", 174, 196], ["wheezing", "PROBLEM", 270, 278], ["wheezing", "OBSERVATION", 270, 278]]], ["And we found that the days of wheezing showed a direct correlation with viral load (Correlation coefficient = 0.538.", [["wheezing", "DISEASE", 30, 38], ["wheezing", "PROBLEM", 30, 38], ["viral load", "TEST", 72, 82]]], ["P = 0.003) (Figure 2 ).DiscussionIn this study, 24.6% of patients with serious lower respiratory tract illness were detected having HBoV in their respiratory tract aspirates.", [["lower respiratory tract", "ANATOMY", 79, 102], ["respiratory tract aspirates", "ANATOMY", 146, 173], ["lower respiratory tract illness", "DISEASE", 79, 110], ["patients", "ORGANISM", 57, 65], ["lower", "ORGANISM_SUBDIVISION", 79, 84], ["respiratory tract", "ORGANISM_SUBDIVISION", 85, 102], ["HBoV", "ORGANISM", 132, 136], ["respiratory tract", "ORGANISM_SUBDIVISION", 146, 163], ["aspirates", "MULTI-TISSUE_STRUCTURE", 164, 173], ["patients", "SPECIES", 57, 65], ["HBoV", "SPECIES", 132, 136], ["this study", "TEST", 36, 46], ["serious lower respiratory tract illness", "PROBLEM", 71, 110], ["HBoV", "PROBLEM", 132, 136], ["respiratory tract", "ANATOMY", 85, 102], ["respiratory tract", "ANATOMY", 146, 163]]], ["We confirmed that HBoV was frequently detected in children with severe LRTIs.", [["LRTIs", "DISEASE", 71, 76], ["HBoV", "ORGANISM", 18, 22], ["children", "ORGANISM", 50, 58], ["children", "SPECIES", 50, 58], ["HBoV", "SPECIES", 18, 22], ["HBoV", "PROBLEM", 18, 22], ["severe LRTIs", "PROBLEM", 64, 76], ["HBoV", "OBSERVATION", 18, 22], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["LRTIs", "OBSERVATION", 71, 76]]], ["Wheezing was one of the most common symptoms presented by HBoV-positive patient.", [["Wheezing", "DISEASE", 0, 8], ["HBoV-positive", "DISEASE", 58, 71], ["HBoV", "ORGANISM", 58, 62], ["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79], ["Wheezing", "PROBLEM", 0, 8], ["the most common symptoms", "PROBLEM", 20, 44], ["HBoV", "TEST", 58, 62]]], ["HBoV at a high load could be an etiologic agent for LRTIs, which led to more severe lower respiratory tract symptom, longer hospitalization, and longer duration of wheezing.DiscussionHBoVs have been detected worldwide, low HBoV viral load was usually more frequently detected than high HBoV viral load in children [17, 18, 19] , its role as a pathogen in respiratory tract was often questioned.", [["lower respiratory tract", "ANATOMY", 84, 107], ["respiratory tract", "ANATOMY", 355, 372], ["HBoV", "DISEASE", 0, 4], ["LRTIs", "DISEASE", 52, 57], ["lower respiratory tract symptom", "DISEASE", 84, 115], ["wheezing", "DISEASE", 164, 172], ["HBoV", "ORGANISM", 0, 4], ["lower", "ORGANISM_SUBDIVISION", 84, 89], ["respiratory tract", "ORGANISM_SUBDIVISION", 90, 107], ["HBoV", "ORGANISM", 223, 227], ["HBoV", "ORGANISM", 286, 290], ["children", "ORGANISM", 305, 313], ["respiratory tract", "ORGANISM_SUBDIVISION", 355, 372], ["children", "SPECIES", 305, 313], ["HBoV", "SPECIES", 0, 4], ["HBoV", "SPECIES", 223, 227], ["HBoV", "PROBLEM", 0, 4], ["LRTIs", "PROBLEM", 52, 57], ["more severe lower respiratory tract symptom", "PROBLEM", 72, 115], ["wheezing", "PROBLEM", 164, 172], ["low HBoV viral load", "PROBLEM", 219, 238], ["high HBoV viral load", "PROBLEM", 281, 301], ["a pathogen in respiratory tract", "PROBLEM", 341, 372], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["lower", "ANATOMY_MODIFIER", 84, 89], ["respiratory tract", "ANATOMY", 90, 107], ["respiratory tract", "ANATOMY", 355, 372]]], ["However, HBoV at a high load were clearly suggested for being an etiologic agent for respiratory tract disease [2] .", [["respiratory tract", "ANATOMY", 85, 102], ["respiratory tract disease", "DISEASE", 85, 110], ["HBoV", "ORGANISM", 9, 13], ["HBoV", "SPECIES", 9, 13], ["HBoV", "PROBLEM", 9, 13], ["respiratory tract disease", "PROBLEM", 85, 110]]], ["In our study, fifteen out of thirty-one HBoV-positive patients who had high HBoV viral loads, presented acute primary infection.", [["HBoV viral loads", "DISEASE", 76, 92], ["acute primary infection", "DISEASE", 104, 127], ["HBoV", "ORGANISM", 40, 44], ["patients", "ORGANISM", 54, 62], ["HBoV", "ORGANISM", 76, 80], ["patients", "SPECIES", 54, 62], ["our study", "TEST", 3, 12], ["high HBoV viral loads", "PROBLEM", 71, 92], ["acute primary infection", "PROBLEM", 104, 127], ["HBoV viral loads", "OBSERVATION", 76, 92], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["primary", "OBSERVATION_MODIFIER", 110, 117], ["infection", "OBSERVATION", 118, 127]]], ["Symptoms, duration of hospitalization were compared among patients who had LRTI with or without HBoV infection.", [["LRTI", "DISEASE", 75, 79], ["HBoV infection", "DISEASE", 96, 110], ["patients", "ORGANISM", 58, 66], ["HBoV", "ORGANISM", 96, 100], ["patients", "SPECIES", 58, 66], ["HBoV", "SPECIES", 96, 100], ["Symptoms", "PROBLEM", 0, 8], ["LRTI", "PROBLEM", 75, 79], ["HBoV infection", "PROBLEM", 96, 110], ["infection", "OBSERVATION", 101, 110]]], ["Clinical characteristic of children who had HBoV detection with or without detection of bacteria.DiscussionClinical data HBoV without bacteria detection (n = 10)DiscussionHBoV with bacteria detection (n = 21) P We found that in patients of LRTIs with HBoV infection needed longer hospital stay.", [["LRTIs", "DISEASE", 240, 245], ["HBoV infection", "DISEASE", 251, 265], ["children", "ORGANISM", 27, 35], ["HBoV", "ORGANISM", 44, 48], ["patients", "ORGANISM", 228, 236], ["HBoV", "ORGANISM", 251, 255], ["children", "SPECIES", 27, 35], ["patients", "SPECIES", 228, 236], ["HBoV", "SPECIES", 44, 48], ["HBoV", "SPECIES", 251, 255], ["HBoV detection", "TEST", 44, 58], ["bacteria", "PROBLEM", 88, 96], ["bacteria detection", "TEST", 134, 152], ["bacteria detection", "TEST", 181, 199], ["LRTIs", "PROBLEM", 240, 245], ["HBoV infection", "PROBLEM", 251, 265], ["bacteria", "OBSERVATION", 88, 96], ["LRTIs", "OBSERVATION", 240, 245], ["infection", "OBSERVATION", 256, 265]]], ["These findings suggested that HBoV was one of the common pathogens for children with serious LRTIs.", [["HBoV", "DISEASE", 30, 34], ["LRTIs", "DISEASE", 93, 98], ["HBoV", "ORGANISM", 30, 34], ["children", "ORGANISM", 71, 79], ["children", "SPECIES", 71, 79], ["HBoV", "SPECIES", 30, 34], ["HBoV", "PROBLEM", 30, 34], ["serious LRTIs", "PROBLEM", 85, 98], ["HBoV", "OBSERVATION", 30, 34], ["serious", "OBSERVATION_MODIFIER", 85, 92], ["LRTIs", "OBSERVATION", 93, 98]]], ["Although, increasing number of studies suggested the pathogenic potential of HBoV in young children with respiratory tract infections, however HBoVs were frequently detected in asymptomatic children's respiratory tract secretions, which may raise some justifiable concerns for etiology [1, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] .", [["respiratory tract", "ANATOMY", 105, 122], ["respiratory tract secretions", "ANATOMY", 201, 229], ["HBoV", "DISEASE", 77, 81], ["respiratory tract infections", "DISEASE", 105, 133], ["respiratory tract secretions", "DISEASE", 201, 229], ["HBoV", "ORGANISM", 77, 81], ["children", "ORGANISM", 91, 99], ["tract", "ORGANISM_SUBDIVISION", 117, 122], ["HBoVs", "GENE_OR_GENE_PRODUCT", 143, 148], ["children", "ORGANISM", 190, 198], ["respiratory tract", "ORGANISM_SUBDIVISION", 201, 218], ["secretions", "ORGANISM_SUBSTANCE", 219, 229], ["[20] [21] [22] [23] [24] [25] [26] [27] [28] [29]", "SIMPLE_CHEMICAL", 290, 339], ["children", "SPECIES", 91, 99], ["children", "SPECIES", 190, 198], ["HBoV", "SPECIES", 77, 81], ["studies", "TEST", 31, 38], ["HBoV", "PROBLEM", 77, 81], ["respiratory tract infections", "PROBLEM", 105, 133], ["HBoVs", "TEST", 143, 148], ["asymptomatic children's respiratory tract secretions", "PROBLEM", 177, 229], ["increasing", "OBSERVATION_MODIFIER", 10, 20], ["HBoV", "OBSERVATION", 77, 81], ["respiratory tract", "ANATOMY", 105, 122], ["infections", "OBSERVATION", 123, 133], ["respiratory tract", "ANATOMY", 201, 218]]], ["The variation of HBoV detection in these studies was likely attributable to multiple factors, such as patient's age, season, geographic location, primer sensitivity, laboratory technique, true variation in incidence of HBoV, and methods used in sample collection.", [["sample", "ANATOMY", 245, 251], ["HBoV", "DISEASE", 219, 223], ["HBoV", "ORGANISM", 17, 21], ["patient", "ORGANISM", 102, 109], ["HBoV", "ORGANISM", 219, 223], ["patient", "SPECIES", 102, 109], ["HBoV", "SPECIES", 17, 21], ["HBoV", "SPECIES", 219, 223], ["HBoV detection", "TEST", 17, 31], ["these studies", "TEST", 35, 48], ["multiple factors", "PROBLEM", 76, 92], ["primer sensitivity", "TEST", 146, 164], ["laboratory technique", "TEST", 166, 186], ["HBoV", "PROBLEM", 219, 223], ["methods", "TREATMENT", 229, 236], ["sample collection", "TEST", 245, 262], ["HBoV", "OBSERVATION", 17, 21], ["likely attributable to", "UNCERTAINTY", 53, 75], ["multiple", "OBSERVATION_MODIFIER", 76, 84], ["factors", "OBSERVATION", 85, 92], ["HBoV", "OBSERVATION", 219, 223]]], ["Some studies suggested that persistent virus shedding was therefore being a reasonable explanation for the high occurrence of HBoV in healthy subjects [20] .", [["HBoV", "DISEASE", 126, 130], ["HBoV", "ORGANISM", 126, 130], ["HBoV", "SPECIES", 126, 130], ["Some studies", "TEST", 0, 12], ["persistent virus shedding", "PROBLEM", 28, 53], ["HBoV", "PROBLEM", 126, 130], ["persistent", "OBSERVATION_MODIFIER", 28, 38], ["virus", "OBSERVATION", 39, 44]]], ["Moreover failure for follow-up on HBoV-positive asymptomatic children also led to high occurrence of HBoV detection in asymptomatic children.", [["HBoV", "DISEASE", 101, 105], ["HBoV", "ORGANISM", 34, 38], ["children", "ORGANISM", 61, 69], ["HBoV", "ORGANISM", 101, 105], ["children", "ORGANISM", 132, 140], ["children", "SPECIES", 61, 69], ["children", "SPECIES", 132, 140], ["HBoV", "SPECIES", 101, 105], ["Moreover failure", "PROBLEM", 0, 16], ["HBoV", "TEST", 34, 38], ["HBoV detection", "PROBLEM", 101, 115], ["failure", "OBSERVATION", 9, 16]]], ["Recently, an in vitro study of HBoV infection in pseudostratified epithelial cells was established to confirm the virus uptake, transcription, and replication [30] .", [["pseudostratified epithelial cells", "ANATOMY", 49, 82], ["HBoV infection", "DISEASE", 31, 45], ["HBoV", "ORGANISM", 31, 35], ["pseudostratified epithelial cells", "CELL", 49, 82], ["pseudostratified epithelial cells", "CELL_TYPE", 49, 82], ["HBoV", "SPECIES", 31, 35], ["an in vitro study", "TEST", 10, 27], ["HBoV infection", "PROBLEM", 31, 45], ["pseudostratified epithelial cells", "PROBLEM", 49, 82], ["the virus uptake", "PROBLEM", 110, 126], ["HBoV", "ANATOMY", 31, 35], ["infection", "OBSERVATION", 36, 45], ["pseudostratified epithelial cells", "OBSERVATION", 49, 82]]], ["This study supports the concept that HBoV is a respiratory pathogen.DiscussionIn agreement with previous studies, co-infection with other pathogens was common in HBoV-positive patients in our study, but no significant differences were found in term of frequencies of specific respiratory symptoms, duration of hospitalization, wheezing and the cytokine production in patients with HBoV infection only and patients with co-infection with other viruses or bacteria.", [["respiratory", "ANATOMY", 276, 287], ["HBoV", "DISEASE", 37, 41], ["respiratory pathogen", "DISEASE", 47, 67], ["co-infection", "DISEASE", 114, 126], ["HBoV-positive", "DISEASE", 162, 175], ["respiratory symptoms", "DISEASE", 276, 296], ["wheezing", "DISEASE", 327, 335], ["HBoV infection", "DISEASE", 381, 395], ["co-infection", "DISEASE", 419, 431], ["HBoV", "ORGANISM", 37, 41], ["HBoV", "ORGANISM", 162, 166], ["patients", "ORGANISM", 176, 184], ["patients", "ORGANISM", 367, 375], ["HBoV", "ORGANISM", 381, 385], ["patients", "ORGANISM", 405, 413], ["cytokine", "PROTEIN", 344, 352], ["patients", "SPECIES", 176, 184], ["patients", "SPECIES", 367, 375], ["patients", "SPECIES", 405, 413], ["HBoV", "SPECIES", 37, 41], ["HBoV", "SPECIES", 162, 166], ["HBoV", "SPECIES", 381, 385], ["This study", "TEST", 0, 10], ["HBoV", "PROBLEM", 37, 41], ["a respiratory pathogen", "PROBLEM", 45, 67], ["previous studies", "TEST", 96, 112], ["co-infection", "PROBLEM", 114, 126], ["other pathogens", "PROBLEM", 132, 147], ["HBoV", "TEST", 162, 166], ["our study", "TEST", 188, 197], ["significant differences", "PROBLEM", 206, 229], ["specific respiratory symptoms", "PROBLEM", 267, 296], ["wheezing", "PROBLEM", 327, 335], ["the cytokine production", "PROBLEM", 340, 363], ["HBoV infection", "PROBLEM", 381, 395], ["co-infection", "PROBLEM", 419, 431], ["other viruses", "PROBLEM", 437, 450], ["bacteria", "PROBLEM", 454, 462], ["HBoV", "OBSERVATION", 37, 41], ["respiratory pathogen", "OBSERVATION", 47, 67], ["infection", "OBSERVATION", 386, 395]]], ["Clearly, our results indicated potential co-infections will not influence clinical outcome of HBoV infection in respiratory tract.", [["respiratory tract", "ANATOMY", 112, 129], ["HBoV infection", "DISEASE", 94, 108], ["HBoV", "ORGANISM", 94, 98], ["respiratory tract", "ORGANISM_SUBDIVISION", 112, 129], ["HBoV", "SPECIES", 94, 98], ["potential co-infections", "PROBLEM", 31, 54], ["HBoV infection in respiratory tract", "PROBLEM", 94, 129], ["co-infections", "OBSERVATION", 41, 54], ["HBoV infection", "OBSERVATION", 94, 108], ["respiratory tract", "ANATOMY", 112, 129]]], ["This finding strongly suggested the pathogenic potential of HBoV in young children with LRTI.DiscussionBecause virus co-infection would not increase illness duration or severity in virus-induced respiratory disease in our study or the others [20, [31] [32] [33] [34] .", [["respiratory", "ANATOMY", 195, 206], ["HBoV", "DISEASE", 60, 64], ["LRTI", "DISEASE", 88, 92], ["co-infection", "DISEASE", 117, 129], ["illness", "DISEASE", 149, 156], ["respiratory disease", "DISEASE", 195, 214], ["HBoV", "ORGANISM", 60, 64], ["children", "ORGANISM", 74, 82], ["[31] [32] [33", "SIMPLE_CHEMICAL", 247, 260], ["children", "SPECIES", 74, 82], ["HBoV", "SPECIES", 60, 64], ["HBoV", "PROBLEM", 60, 64], ["LRTI", "PROBLEM", 88, 92], ["DiscussionBecause virus co-infection", "PROBLEM", 93, 129], ["severity in virus", "PROBLEM", 169, 186], ["respiratory disease", "PROBLEM", 195, 214], ["our study", "TEST", 218, 227], ["HBoV", "OBSERVATION", 60, 64], ["LRTI", "OBSERVATION", 88, 92], ["respiratory disease", "OBSERVATION", 195, 214]]], ["Therefore the more severe lower respiratory tract symptom presented in high HBoV viral load patients may solely depend on HBoV viral load.", [["lower respiratory tract", "ANATOMY", 26, 49], ["lower", "ORGANISM_SUBDIVISION", 26, 31], ["respiratory tract", "ORGANISM_SUBDIVISION", 32, 49], ["HBoV", "ORGANISM", 76, 80], ["patients", "ORGANISM", 92, 100], ["HBoV", "ORGANISM", 122, 126], ["patients", "SPECIES", 92, 100], ["HBoV", "SPECIES", 122, 126], ["the more severe lower respiratory tract symptom", "PROBLEM", 10, 57], ["high HBoV viral load patients", "PROBLEM", 71, 100], ["HBoV viral load", "PROBLEM", 122, 137], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["lower", "ANATOMY_MODIFIER", 26, 31], ["respiratory tract", "ANATOMY", 32, 49], ["viral load", "OBSERVATION", 81, 91], ["HBoV viral load", "OBSERVATION", 122, 137]]], ["In our study, HBoV viral load did not show significant influence on the presentations of upper respiratory tract infection symptoms, such as cough, rhinorrhea, however high HBoV viral load led to more severe lower respiratory tract symptoms and longer hospitalization.", [["upper respiratory tract", "ANATOMY", 89, 112], ["lower respiratory tract", "ANATOMY", 208, 231], ["respiratory tract infection", "DISEASE", 95, 122], ["cough", "DISEASE", 141, 146], ["rhinorrhea", "DISEASE", 148, 158], ["lower respiratory tract symptoms", "DISEASE", 208, 240], ["HBoV", "ORGANISM", 14, 18], ["upper respiratory", "ORGANISM_SUBDIVISION", 89, 106], ["tract", "ORGANISM_SUBDIVISION", 107, 112], ["HBoV", "ORGANISM", 173, 177], ["lower", "ORGANISM_SUBDIVISION", 208, 213], ["respiratory tract", "ORGANISM_SUBDIVISION", 214, 231], ["HBoV", "SPECIES", 14, 18], ["our study", "TEST", 3, 12], ["HBoV viral load", "TEST", 14, 29], ["upper respiratory tract infection symptoms", "PROBLEM", 89, 131], ["cough", "PROBLEM", 141, 146], ["rhinorrhea", "PROBLEM", 148, 158], ["high HBoV viral load", "PROBLEM", 168, 188], ["more severe lower respiratory tract symptoms", "PROBLEM", 196, 240], ["upper", "ANATOMY_MODIFIER", 89, 94], ["respiratory tract", "ANATOMY", 95, 112], ["infection", "OBSERVATION", 113, 122], ["severe", "OBSERVATION_MODIFIER", 201, 207], ["lower", "ANATOMY_MODIFIER", 208, 213], ["respiratory tract", "ANATOMY", 214, 231]]], ["It was also indicated in vitro studies that viral infection resulted in the high IL-8 level and other pro-inflammatory molecules; these cytokines were likely to bring in additional neutrophils and also to cause hyper-responsiveness in bronchus, which could contribute to the severity of both upper and lower respiratory symptoms during the viral infection.", [["neutrophils", "ANATOMY", 181, 192], ["bronchus", "ANATOMY", 235, 243], ["respiratory", "ANATOMY", 308, 319], ["viral infection", "DISEASE", 44, 59], ["viral infection", "DISEASE", 340, 355], ["IL-8", "GENE_OR_GENE_PRODUCT", 81, 85], ["neutrophils", "CELL", 181, 192], ["bronchus", "ORGAN", 235, 243], ["upper", "ORGANISM_SUBDIVISION", 292, 297], ["IL-8", "PROTEIN", 81, 85], ["pro-inflammatory molecules", "PROTEIN", 102, 128], ["cytokines", "PROTEIN", 136, 145], ["neutrophils", "CELL_TYPE", 181, 192], ["vitro studies", "TEST", 25, 38], ["viral infection", "PROBLEM", 44, 59], ["other pro-inflammatory molecules", "PROBLEM", 96, 128], ["hyper-responsiveness in bronchus", "PROBLEM", 211, 243], ["both upper and lower respiratory symptoms", "PROBLEM", 287, 328], ["the viral infection", "PROBLEM", 336, 355], ["viral", "OBSERVATION_MODIFIER", 44, 49], ["infection", "OBSERVATION", 50, 59], ["pro-inflammatory molecules", "OBSERVATION", 102, 128], ["bronchus", "ANATOMY", 235, 243], ["upper", "ANATOMY_MODIFIER", 292, 297], ["lower", "ANATOMY_MODIFIER", 302, 307], ["respiratory", "ANATOMY", 308, 319], ["symptoms", "OBSERVATION", 320, 328], ["viral", "OBSERVATION_MODIFIER", 340, 345], ["infection", "OBSERVATION", 346, 355]]], ["In our study, the IL-8 level was significantly higher in patients with high HBoV viral loads that those who with low viral load.", [["IL-8", "GENE_OR_GENE_PRODUCT", 18, 22], ["patients", "ORGANISM", 57, 65], ["HBoV", "ORGANISM", 76, 80], ["IL-8", "PROTEIN", 18, 22], ["patients", "SPECIES", 57, 65], ["HBoV", "SPECIES", 76, 80], ["our study", "TEST", 3, 12], ["the IL-8 level", "TEST", 14, 28], ["high HBoV viral loads", "PROBLEM", 71, 92], ["low viral load", "PROBLEM", 113, 127], ["higher", "OBSERVATION_MODIFIER", 47, 53], ["HBoV viral loads", "OBSERVATION", 76, 92], ["viral load", "OBSERVATION", 117, 127]]], ["Overall, our findings indicated that the high HBoV viral loads played an important role in the severity of LRTIs, the symptoms and the duration of hospital stay.DiscussionNo previous studies showed the distinctive clinical signs that help to differentiate HBoV-positive infections from other viral infections [35, 36] .", [["LRTIs", "DISEASE", 107, 112], ["HBoV-positive infections", "DISEASE", 256, 280], ["viral infections", "DISEASE", 292, 308], ["HBoV", "ORGANISM", 46, 50], ["HBoV", "ORGANISM", 256, 260], ["the high HBoV viral loads", "PROBLEM", 37, 62], ["LRTIs", "PROBLEM", 107, 112], ["the symptoms", "PROBLEM", 114, 126], ["previous studies", "TEST", 174, 190], ["the distinctive clinical signs", "PROBLEM", 198, 228], ["HBoV", "PROBLEM", 256, 260], ["positive infections", "PROBLEM", 261, 280], ["other viral infections", "PROBLEM", 286, 308], ["viral loads", "OBSERVATION", 51, 62], ["LRTIs", "OBSERVATION", 107, 112]]], ["In our study, main clinical symptoms in HBoVpositive patients included cough (100%), wheezing (90.32%), and fever (41.94%).", [["HBoVpositive", "DISEASE", 40, 52], ["cough", "DISEASE", 71, 76], ["wheezing", "DISEASE", 85, 93], ["fever", "DISEASE", 108, 113], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["our study", "TEST", 3, 12], ["main clinical symptoms", "PROBLEM", 14, 36], ["cough", "PROBLEM", 71, 76], ["wheezing", "PROBLEM", 85, 93], ["fever", "PROBLEM", 108, 113]]], ["Although the existence of HBoV was not directly associated with the illness, some studies showed wheezing was the main manifestation of HBoV infection [2, 4, [37] [38] [39] .", [["HBoV", "DISEASE", 26, 30], ["wheezing", "DISEASE", 97, 105], ["HBoV infection", "DISEASE", 136, 150], ["HBoV", "ORGANISM", 26, 30], ["HBoV", "ORGANISM", 136, 140], ["HBoV", "SPECIES", 26, 30], ["HBoV", "SPECIES", 136, 140], ["HBoV", "PROBLEM", 26, 30], ["the illness", "PROBLEM", 64, 75], ["some studies", "TEST", 77, 89], ["wheezing", "PROBLEM", 97, 105], ["HBoV infection", "PROBLEM", 136, 150], ["HBoV", "OBSERVATION", 26, 30], ["wheezing", "OBSERVATION", 97, 105], ["HBoV infection", "OBSERVATION", 136, 150]]], ["Our data was consistent with the findings in these studies and support the fact that wheezing was one of the most common symptoms presented in HBoV-positive patients.", [["wheezing", "DISEASE", 85, 93], ["HBoV-positive", "DISEASE", 143, 156], ["HBoV", "ORGANISM", 143, 147], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["Our data", "TEST", 0, 8], ["these studies", "TEST", 45, 58], ["wheezing", "PROBLEM", 85, 93], ["the most common symptoms", "PROBLEM", 105, 129], ["HBoV", "TEST", 143, 147], ["consistent with", "UNCERTAINTY", 13, 28], ["wheezing", "OBSERVATION", 85, 93]]], ["We also investigated the relationship between HBoV viral load and duration of wheezing, we found that the days of wheezing correlated with viral load.", [["wheezing", "DISEASE", 78, 86], ["wheezing", "DISEASE", 114, 122], ["HBoV", "ORGANISM", 46, 50], ["HBoV", "SPECIES", 46, 50], ["HBoV viral load", "PROBLEM", 46, 61], ["wheezing", "PROBLEM", 78, 86], ["wheezing", "PROBLEM", 114, 122], ["viral load", "PROBLEM", 139, 149], ["viral load", "OBSERVATION", 51, 61], ["viral load", "OBSERVATION", 139, 149]]], ["Emily et al documented that persistent HBoV shedding, may increase the duration of respiratory symptoms [6] .", [["respiratory", "ANATOMY", 83, 94], ["HBoV shedding", "DISEASE", 39, 52], ["respiratory symptoms", "DISEASE", 83, 103], ["HBoV", "ORGANISM", 39, 43], ["HBoV", "SPECIES", 39, 43], ["persistent HBoV shedding", "PROBLEM", 28, 52], ["respiratory symptoms", "PROBLEM", 83, 103], ["persistent", "OBSERVATION_MODIFIER", 28, 38], ["HBoV", "OBSERVATION", 39, 43]]], ["This report may explain the link between HBoV load and persistent wheezing.", [["HBoV load", "DISEASE", 41, 50], ["wheezing", "DISEASE", 66, 74], ["HBoV", "ORGANISM", 41, 45], ["HBoV load", "PROBLEM", 41, 50], ["persistent wheezing", "PROBLEM", 55, 74], ["persistent", "OBSERVATION_MODIFIER", 55, 65], ["wheezing", "OBSERVATION", 66, 74]]], ["Because our study is a comprehensive clinical observation on HBoV-positive patients with severe LRTIs, failure of follow-up was one of the limitations to our study, which may led to the loss of some important data, such as the impact of persistent viral shedding on the infection prognosis during the acute viral infection.", [["HBoV-positive", "DISEASE", 61, 74], ["LRTIs", "DISEASE", 96, 101], ["infection", "DISEASE", 270, 279], ["acute viral infection", "DISEASE", 301, 322], ["HBoV", "ORGANISM", 61, 65], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["our study", "TEST", 8, 17], ["HBoV", "TEST", 61, 65], ["severe LRTIs", "PROBLEM", 89, 101], ["our study", "TEST", 154, 163], ["persistent viral shedding", "PROBLEM", 237, 262], ["the infection prognosis", "PROBLEM", 266, 289], ["the acute viral infection", "PROBLEM", 297, 322], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["LRTIs", "OBSERVATION", 96, 101], ["persistent", "OBSERVATION_MODIFIER", 237, 247], ["viral", "OBSERVATION", 248, 253], ["infection", "OBSERVATION", 270, 279], ["acute", "OBSERVATION_MODIFIER", 301, 306], ["viral", "OBSERVATION_MODIFIER", 307, 312], ["infection", "OBSERVATION", 313, 322]]], ["It is also important to assess the asthma development in these cases if possible.", [["asthma", "DISEASE", 35, 41], ["the asthma development", "PROBLEM", 31, 53], ["asthma", "OBSERVATION", 35, 41]]], ["Cytokine/chemokine concentrations of respiratory tract aspirates in children who had HBoV detection with or without detection of bacteria.Author ContributionsCytokine/chemokine (pg/mL) HBoV without bacteria detection (n = 10) HBoV with bacteria detection (n = 21) P", [["respiratory tract aspirates", "ANATOMY", 37, 64], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["respiratory tract aspirates", "MULTI-TISSUE_STRUCTURE", 37, 64], ["children", "ORGANISM", 68, 76], ["HBoV", "ORGANISM", 85, 89], ["Cytokine", "GENE_OR_GENE_PRODUCT", 158, 166], ["HBoV", "ORGANISM", 185, 189], ["HBoV", "ORGANISM", 226, 230], ["Cytokine", "PROTEIN", 0, 8], ["chemokine", "PROTEIN", 9, 18], ["Cytokine", "PROTEIN", 158, 166], ["chemokine", "PROTEIN", 167, 176], ["children", "SPECIES", 68, 76], ["HBoV", "SPECIES", 85, 89], ["Cytokine/chemokine concentrations", "TREATMENT", 0, 33], ["respiratory tract aspirates", "PROBLEM", 37, 64], ["HBoV detection", "TEST", 85, 99], ["bacteria", "PROBLEM", 129, 137], ["Cytokine/chemokine (pg/mL)", "TREATMENT", 158, 184], ["HBoV", "TEST", 185, 189], ["bacteria detection", "TEST", 198, 216], ["HBoV", "PROBLEM", 226, 230], ["bacteria detection", "TEST", 236, 254], ["respiratory tract", "ANATOMY", 37, 54], ["bacteria", "OBSERVATION", 129, 137]]]], "367513318afe8fb0b7bb336bfc1f7d4533ee7690": [["In his later years he also became an expert in the \"One Health\" perspective, particularly how animal health is linked to human health, and he was remaining active and even passionate, looking forward to understand the interactive ecology of pathogenicity and antibiotic resistance until the day of his death.", [["death", "DISEASE", 302, 307], ["human", "ORGANISM", 121, 126], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["antibiotic resistance", "TREATMENT", 259, 280], ["his death", "PROBLEM", 298, 307]]]], "PMC7382331": [["IntroductionThe core competencies necessary for future professionals include problem solving based on complexity and collaborative approaches (Organisation for Economic Co-operation & Development, 2015).", [["future professionals", "TREATMENT", 48, 68], ["problem solving", "TREATMENT", 77, 92]]], ["Educational researchers (e.g., Barnett, 2007; Harland & Pickering, 2010) stress that such skills and abilities (the how?), as well as knowledge (the what?), are insufficient to educate a person for society and the world.", [["person", "SPECIES", 187, 193]]], ["The ontological dimension encompasses the issues related to values that education should foster (Harland & Pickering, 2010).", [["ontological dimension", "OBSERVATION_MODIFIER", 4, 25]]], ["Value-based education seeks to address these issues and concentrates on values transfer due to their integration into the curriculum.", [["Value", "TEST", 0, 5], ["these issues", "PROBLEM", 39, 51]]], ["Yazdani and Akbarilakeh (2017) discussed that value-based education could only convey factual knowledge of values and ethics.", [["Yazdani", "TREATMENT", 0, 7]]], ["Nevertheless, value-based education indicates problem solving as one of the possibilities to develop values.IntroductionValues guide and affect personal behavior encompassing the ethical aspects of solutions (Roccas, Sagiv, & Navon, 2017; Schwartz, 1992, 2012; Verplanken & Holland, 2002).", [["value", "TEST", 14, 19]]], ["Most of the problem solving models (e.g., Newell & Simon, 1972; Jonassen, 1997) utilize a rational economic approach.", [["a rational economic approach", "TREATMENT", 88, 116]]], ["Though, research by Shepherd, Patzelt, and Baron (2013), Baron, Zhao, and Miao (2015) has affirmed that contemporary business decision makers rather often leave aside ethical issues and moral values.", [["moral values", "TEST", 186, 198]]], ["Thus, \u2018ethical disengagement fallacy\u2019 (Sternberg, 2017, p.7) occurs as people think that ethics is more relevant to others.", [["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77]]], ["In the face of such disengagement, ethical issues lose their prominence.IntroductionThe analysis of the literature revealed a wide field of problem solving research presenting a range of more theoretical insights rather empirical evidence.", [["such disengagement", "PROBLEM", 15, 33], ["ethical issues", "PROBLEM", 35, 49], ["The analysis", "TEST", 84, 96], ["disengagement", "OBSERVATION", 20, 33], ["prominence", "OBSERVATION", 61, 71], ["wide", "OBSERVATION_MODIFIER", 126, 130]]], ["To address this gap, the following issues need to be investigated: When, how, and why a problem solver should take into account values during problem solving?", [["this gap", "PROBLEM", 11, 19]]], ["The substantiation consists of several parts.", [["several", "OBSERVATION_MODIFIER", 31, 38], ["parts", "OBSERVATION_MODIFIER", 39, 44]]], ["First, different approaches to solving problems were examined.", [["solving problems", "PROBLEM", 31, 47]]], ["Third, drawing on the effect of values when solving a problem and their creative potential, the authors of this paper claim that the identification of values and their choice for a solution need to be specified in the process of problem solving.", [["a solution", "TREATMENT", 179, 189]]], ["As a synthesis of conclusions coming from the literature review and conceptual extensions regarding values, the authors of the paper created the coherent framework of problem solving through values (so called 4W).IntroductionThe novelty of the 4W framework is exposed by several contributions.", [["several", "OBSERVATION_MODIFIER", 271, 278]]], ["Unlike in most models of problem solving, the first stage encompass the identification of a problem, an analysis of a context and the perspectives that influence the whole process, i.e.", [["an analysis", "TEST", 101, 112], ["most models", "OBSERVATION_MODIFIER", 10, 21]]], ["The stage \u2018What is the basis for a solution?\u2019 focus on values identification and their choice.", [["a solution", "TREATMENT", 33, 43], ["values identification", "TEST", 55, 76]]], ["The specificity of the 4W framework allows expecting its successful practical application.", [["its successful practical application", "TREATMENT", 53, 89]]], ["The sources appropriate for this review was very limited in scope (N = 2).MethodologyWe implemented the second search only with the same set of the integrated keywords.", [["this review", "TEST", 28, 39]]], ["The inclusion criteria were the same except the date; this criterion was extended up to 10 years.", [["The inclusion criteria", "TEST", 0, 22]]], ["Second, some of them conducted empirical research in order to identify the process of studies participants\u2019 problem solving.", [["participants", "SPECIES", 94, 106]]], ["We present the principal results of the conducted literature review in the part \u2018The background of the conceptual framework\u2019.Different approaches of how to solve a problem ::: The background of the conceptual frameworkResearchers from different fields focus on problem solving.", [["different", "OBSERVATION_MODIFIER", 235, 244], ["fields", "OBSERVATION_MODIFIER", 245, 251]]], ["The weakness of this model is that these phases do not necessarily follow one another, and several can coincide.", [["The weakness", "PROBLEM", 0, 12], ["weakness", "OBSERVATION", 4, 12]]], ["Certainly, it may be necessary to return to the previous phases for further analysis.", [["further analysis", "TEST", 68, 84]]], ["According to Basadur et al. (1994), problem solving consists of problem generation, problem formulation, problem solving, and solution implementation stages.", [["problem formulation", "TREATMENT", 84, 103]]], ["For example, problem-based learning employs such stages as introduction of the problem, problem analysis and learning issues, discovery and reporting, solution presentation and evaluation (Chua, Tan, & Liu, 2016).", [["the problem", "PROBLEM", 75, 86], ["problem analysis", "TEST", 88, 104], ["evaluation", "TEST", 177, 187]]], ["These steps reflect the essential idea of problem solving: a search for the solution from the initial state to the desirable state.", [["the solution", "TREATMENT", 72, 84]]], ["The identification of a problem and its contextual elements, the generation of alternatives to a problem solution, the evaluation of these alternatives according to specific criteria, the choice of an alternative for a solution, the implementation, and monitoring of the solution are the main proceeding steps in problem solving.Value-based approaches relevant for problem solving ::: The background of the conceptual framework", [["a problem", "PROBLEM", 22, 31], ["a problem solution", "TREATMENT", 95, 113], ["the evaluation", "TEST", 115, 129], ["these alternatives", "TREATMENT", 133, 151], ["a solution", "TREATMENT", 217, 227], ["the solution", "TREATMENT", 267, 279], ["Value", "TEST", 329, 334]]]], "PMC7396720": [["IntroductionThe epidemic of novel coronavirus disease 2019 (COVID-19) was caused by a new coronavirus occurred in December 2019, and now has spread worldwide and turned into a global pandemic [1].", [["coronavirus disease", "DISEASE", 34, 53], ["COVID-19", "CHEMICAL", 60, 68], ["coronavirus", "DISEASE", 90, 101], ["coronavirus", "ORGANISM", 34, 45], ["coronavirus", "ORGANISM", 90, 101], ["coronavirus disease 2019 (COVID-19", "SPECIES", 34, 68], ["novel coronavirus disease", "PROBLEM", 28, 53], ["COVID", "TEST", 60, 65], ["a new coronavirus", "PROBLEM", 84, 101], ["coronavirus disease", "OBSERVATION", 34, 53], ["new", "OBSERVATION_MODIFIER", 86, 89], ["coronavirus", "OBSERVATION", 90, 101]]], ["The COVID-19 was quickly discovered to be caused by a coronavirus later named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1], which belongs to the \u03b2 coronavirus family.", [["COVID-19", "CHEMICAL", 4, 12], ["coronavirus", "DISEASE", 54, 65], ["acute respiratory syndrome coronavirus", "DISEASE", 85, 123], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 78, 125], ["SARS-CoV-2", "ORGANISM", 127, 137], ["\u03b2 coronavirus", "ORGANISM", 165, 178], ["COVID-19", "DNA", 4, 12], ["\u03b2 coronavirus family", "PROTEIN", 165, 185], ["coronavirus", "SPECIES", 54, 65], ["\u03b2 coronavirus", "SPECIES", 165, 178], ["COVID-19", "SPECIES", 4, 12], ["severe acute respiratory syndrome coronavirus", "SPECIES", 78, 123], ["SARS-CoV-2", "SPECIES", 127, 137], ["\u03b2 coronavirus", "SPECIES", 165, 178], ["The COVID", "TEST", 0, 9], ["a coronavirus", "PROBLEM", 52, 65], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 78, 123], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["respiratory syndrome", "OBSERVATION", 91, 111]]], ["It is the seventh known coronavirus to infect humans; four of these coronaviruses (229E, NL63, OC43, and HKU1) only cause slight symptoms of the common cold.", [["coronavirus", "ORGANISM", 24, 35], ["humans", "ORGANISM", 46, 52], ["coronaviruses", "ORGANISM", 68, 81], ["NL63", "GENE_OR_GENE_PRODUCT", 89, 93], ["OC43", "GENE_OR_GENE_PRODUCT", 95, 99], ["HKU1", "GENE_OR_GENE_PRODUCT", 105, 109], ["humans", "SPECIES", 46, 52], ["humans", "SPECIES", 46, 52], ["these coronaviruses", "TEST", 62, 81], ["NL63", "TEST", 89, 93], ["OC43", "TEST", 95, 99], ["slight symptoms", "PROBLEM", 122, 137], ["the common cold", "PROBLEM", 141, 156], ["coronavirus", "OBSERVATION", 24, 35], ["slight", "OBSERVATION_MODIFIER", 122, 128], ["common", "OBSERVATION_MODIFIER", 145, 151], ["cold", "OBSERVATION", 152, 156]]], ["Conversely, the other three, SARS-CoV, MERS-CoV, and SARS-CoV-2, are able to cause severe symptoms and even death, with fatality rates of 10%, 37%, and 5%, respectively.IntroductionAlthough a large number of studies and clinical trials are being launched on COVID-19 around the world [2, 3], no evidence from randomized clinical trials has shown that any potential therapy improves outcomes in patients [4].", [["death", "DISEASE", 108, 113], ["SARS-CoV", "ORGANISM", 29, 37], ["MERS-CoV", "ORGANISM", 39, 47], ["SARS-CoV-2", "ORGANISM", 53, 63], ["patients", "ORGANISM", 394, 402], ["patients", "SPECIES", 394, 402], ["SARS-CoV", "SPECIES", 29, 37], ["MERS-CoV", "SPECIES", 39, 47], ["SARS-CoV", "SPECIES", 53, 61], ["SARS", "TEST", 29, 33], ["CoV", "TEST", 34, 37], ["MERS", "TEST", 39, 43], ["CoV", "TEST", 44, 47], ["severe symptoms", "PROBLEM", 83, 98], ["fatality rates", "TEST", 120, 134], ["studies", "TEST", 208, 215], ["clinical trials", "TREATMENT", 220, 235], ["COVID", "TEST", 258, 263], ["large", "OBSERVATION_MODIFIER", 192, 197], ["no evidence", "UNCERTAINTY", 292, 303]]], ["As the epidemic spreads, it is critical to find a specific therapeutic for COVID-19, and vaccines targeting various SARS-CoV-2 proteins are under development.IntroductionSARS-CoV-2 is a single-stranded RNA-enveloped virus [5].", [["COVID-19", "CHEMICAL", 75, 83], ["SARS-CoV-2", "ORGANISM", 116, 126], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 158, 180], ["SARS-CoV-2 proteins", "PROTEIN", 116, 135], ["IntroductionSARS-CoV-2", "DNA", 158, 180], ["COVID", "TEST", 75, 80], ["vaccines", "TREATMENT", 89, 97], ["various SARS", "PROBLEM", 108, 120], ["IntroductionSARS", "TEST", 158, 174], ["a single-stranded RNA", "TREATMENT", 184, 205]]], ["An RNA-based metagenomic next-generation sequencing approach has been applied to characterize its entire genome, which is 29,881 bp in length (GenBank no. MN908947), encoding 9860 amino acids [6].", [["amino acids", "CHEMICAL", 180, 191], ["amino acids", "CHEMICAL", 180, 191], ["amino acids", "AMINO_ACID", 180, 191], ["An RNA", "TEST", 0, 6], ["metagenomic next-generation sequencing approach", "TREATMENT", 13, 60], ["bp", "TEST", 129, 131], ["amino acids", "TEST", 180, 191]]], ["Gene fragments express structural and nonstructural proteins.", [["fragments", "ANATOMY", 5, 14], ["Gene fragments", "DNA", 0, 14], ["structural and nonstructural proteins", "PROTEIN", 23, 60], ["Gene fragments express structural and nonstructural proteins", "PROBLEM", 0, 60], ["fragments", "OBSERVATION", 5, 14], ["nonstructural proteins", "OBSERVATION", 38, 60]]], ["The S, E, M, and N genes encode structural proteins, whereas nonstructural proteins, such as 3-chymotrypsin-like protease, papain-like protease, and RNA-dependent RNA polymerase, are encoded by the ORF region [7].IntroductionA large number of glycosylated S proteins cover the surface of SARS-CoV-2 and bind to the host cell receptor angiotensin-converting enzyme 2 (ACE2), mediating viral cell entry [8].", [["surface", "ANATOMY", 277, 284], ["cell", "ANATOMY", 320, 324], ["cell", "ANATOMY", 390, 394], ["angiotensin", "CHEMICAL", 334, 345], ["3-chymotrypsin-like protease", "GENE_OR_GENE_PRODUCT", 93, 121], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 123, 143], ["glycosylated S proteins", "GENE_OR_GENE_PRODUCT", 243, 266], ["surface", "CELLULAR_COMPONENT", 277, 284], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 288, 298], ["cell", "CELL", 320, 324], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 334, 365], ["ACE2", "GENE_OR_GENE_PRODUCT", 367, 371], ["cell", "CELL", 390, 394], ["S, E, M, and N genes", "DNA", 4, 24], ["structural proteins", "PROTEIN", 32, 51], ["nonstructural proteins", "PROTEIN", 61, 83], ["3-chymotrypsin-like protease", "PROTEIN", 93, 121], ["papain-like protease", "PROTEIN", 123, 143], ["RNA-dependent RNA polymerase", "PROTEIN", 149, 177], ["ORF region", "DNA", 198, 208], ["glycosylated S proteins", "PROTEIN", 243, 266], ["host cell receptor angiotensin-converting enzyme 2", "PROTEIN", 315, 365], ["ACE2", "PROTEIN", 367, 371], ["SARS-CoV", "SPECIES", 288, 296], ["The S, E, M, and N genes encode structural proteins", "PROBLEM", 0, 51], ["nonstructural proteins", "TEST", 61, 83], ["chymotrypsin", "TEST", 95, 107], ["protease", "TREATMENT", 113, 121], ["papain", "TREATMENT", 123, 129], ["protease", "TREATMENT", 135, 143], ["RNA-dependent RNA polymerase", "PROBLEM", 149, 177], ["glycosylated S proteins", "TREATMENT", 243, 266], ["SARS", "PROBLEM", 288, 292], ["CoV", "TEST", 293, 296], ["angiotensin", "TEST", 334, 345], ["enzyme", "TEST", 357, 363], ["mediating viral cell entry", "TREATMENT", 374, 400], ["host cell", "OBSERVATION", 315, 324], ["viral cell", "OBSERVATION", 384, 394]]], ["When the S protein binds to the receptor, TM protease serine 2 (TMPRSS2), a type 2 TM serine protease located on the host cell membrane, promotes virus entry into the cell by activating the S protein.", [["cell membrane", "ANATOMY", 122, 135], ["cell", "ANATOMY", 167, 171], ["serine", "CHEMICAL", 54, 60], ["serine", "CHEMICAL", 86, 92], ["TM protease serine 2", "GENE_OR_GENE_PRODUCT", 42, 62], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 64, 71], ["cell membrane", "CELLULAR_COMPONENT", 122, 135], ["cell", "CELL", 167, 171], ["S protein", "PROTEIN", 9, 18], ["TM protease serine 2", "PROTEIN", 42, 62], ["TMPRSS2", "PROTEIN", 64, 71], ["type 2 TM serine protease", "PROTEIN", 76, 101], ["S protein", "PROTEIN", 190, 199], ["TM protease serine", "TREATMENT", 42, 60], ["TMPRSS2", "TEST", 64, 71], ["a type 2 TM serine protease", "TREATMENT", 74, 101], ["the host cell membrane", "TREATMENT", 113, 135], ["host cell membrane", "OBSERVATION", 117, 135]]], ["Once the virus enters the cell, the viral RNA is released, polyproteins are translated from the RNA genome, and replication and transcription of the viral RNA genome occur via protein cleavage and assembly of the replicase\u2013transcriptase complex.", [["cell", "ANATOMY", 26, 30], ["cell", "CELL", 26, 30], ["replicase\u2013transcriptase", "GENE_OR_GENE_PRODUCT", 213, 236], ["viral RNA", "RNA", 36, 45], ["RNA genome", "DNA", 96, 106], ["viral RNA genome", "DNA", 149, 165], ["replicase\u2013transcriptase complex", "PROTEIN", 213, 244], ["the virus", "PROBLEM", 5, 14], ["the viral RNA", "PROBLEM", 32, 45], ["polyproteins", "TREATMENT", 59, 71], ["replication", "TREATMENT", 112, 123], ["the viral RNA genome", "PROBLEM", 145, 165], ["protein cleavage", "TREATMENT", 176, 192], ["the replicase\u2013transcriptase complex", "TREATMENT", 209, 244], ["virus", "OBSERVATION", 9, 14], ["viral RNA", "OBSERVATION", 36, 45], ["RNA genome", "OBSERVATION", 96, 106], ["viral RNA genome", "OBSERVATION", 149, 165]]], ["Viral RNA is replicated, and structural proteins are synthesized, assembled, and packaged in the host cell, after which viral particles are released (Fig. 1d) [9].IntroductionThese proteins are critical to the viral life cycle and provide potential targets for drug therapies.", [["cell", "ANATOMY", 102, 106], ["cell", "CELL", 102, 106], ["Viral RNA", "RNA", 0, 9], ["structural proteins", "PROTEIN", 29, 48], ["host cell", "CELL_TYPE", 97, 106], ["Viral RNA", "PROBLEM", 0, 9], ["viral particles", "PROBLEM", 120, 135], ["the viral life cycle", "TREATMENT", 206, 226], ["drug therapies", "TREATMENT", 261, 275], ["RNA", "OBSERVATION", 6, 9], ["host cell", "OBSERVATION", 97, 106], ["viral particles", "OBSERVATION", 120, 135]]], ["For example, ACE2-based peptide, 3CLpro inhibitor (3CLpro-1), and a novel vinylsulfone protease inhibitor have been experimentally demonstrated to be effective against SARS-CoV-2 [10].", [["3CLpro-1", "CHEMICAL", 51, 59], ["vinylsulfone", "CHEMICAL", 74, 86], ["vinylsulfone", "CHEMICAL", 74, 86], ["ACE2", "GENE_OR_GENE_PRODUCT", 13, 17], ["3CLpro", "SIMPLE_CHEMICAL", 33, 39], ["3CLpro-1", "GENE_OR_GENE_PRODUCT", 51, 59], ["vinylsulfone protease", "GENE_OR_GENE_PRODUCT", 74, 95], ["ACE2", "PROTEIN", 13, 17], ["SARS-CoV", "SPECIES", 168, 176], ["ACE2", "TEST", 13, 17], ["3CLpro inhibitor", "TREATMENT", 33, 49], ["3CLpro", "TREATMENT", 51, 57], ["a novel vinylsulfone protease inhibitor", "TREATMENT", 66, 105]]], ["The SARS-CoV-2 S protein is highly conserved among all human coronaviruses (HCoVs) and is involved in receptor recognition, viral attachment, and entry into host cells.", [["cells", "ANATOMY", 162, 167], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 4, 16], ["human", "ORGANISM", 55, 60], ["coronaviruses", "ORGANISM", 61, 74], ["HCoVs", "CANCER", 76, 81], ["host cells", "CELL", 157, 167], ["SARS-CoV-2 S protein", "PROTEIN", 4, 24], ["host cells", "CELL_TYPE", 157, 167], ["human", "SPECIES", 55, 60], ["SARS-CoV", "SPECIES", 4, 12], ["human coronaviruses", "SPECIES", 55, 74], ["The SARS", "TEST", 0, 8], ["CoV-2 S protein", "TEST", 9, 24], ["viral attachment", "PROBLEM", 124, 140], ["host cells", "OBSERVATION", 157, 167]]], ["Due to its indispensable functions, it represents one of the most important targets for COVID-19 vaccine and therapeutic research.", [["COVID-19 vaccine", "TREATMENT", 88, 104], ["therapeutic research", "TREATMENT", 109, 129]]], ["In this review, we summarize advances in research of the SARS-CoV-2 S protein and its therapeutic targeting.Structure of the S1 subunit ::: Structure of the S proteinThe binding of virus particles to cell receptors on the surface of the host cell is the initiation of virus infection; therefore, receptor recognition is an important determinant of viral entry and a drug design target.Structure of the S1 subunit ::: Structure of the S proteinRBD situated in the S1 subunit binds to the cell receptor ACE2 in the region of aminopeptidase N. The S1 region contains the NTD and CTD, and atomic details at the binding interface demonstrate key residue substitutions in SARS-CoV-2-CTD.", [["cell", "ANATOMY", 200, 204], ["surface", "ANATOMY", 222, 229], ["cell", "ANATOMY", 242, 246], ["cell", "ANATOMY", 487, 491], ["SARS", "DISEASE", 57, 61], ["infection", "DISEASE", 274, 283], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 57, 69], ["cell", "CELL", 200, 204], ["surface", "CELLULAR_COMPONENT", 222, 229], ["host cell", "CELL", 237, 246], ["S proteinRBD", "GENE_OR_GENE_PRODUCT", 434, 446], ["cell", "CELL", 487, 491], ["ACE2", "GENE_OR_GENE_PRODUCT", 501, 505], ["aminopeptidase N.", "GENE_OR_GENE_PRODUCT", 523, 540], ["SARS-CoV-2 S protein", "PROTEIN", 57, 77], ["S1 subunit", "PROTEIN", 125, 135], ["S protein", "PROTEIN", 157, 166], ["cell receptors", "PROTEIN", 200, 214], ["S1 subunit", "PROTEIN", 402, 412], ["S proteinRBD", "PROTEIN", 434, 446], ["S1 subunit", "PROTEIN", 463, 473], ["cell receptor", "PROTEIN", 487, 500], ["ACE2", "PROTEIN", 501, 505], ["aminopeptidase", "PROTEIN", 523, 537], ["S1 region", "PROTEIN", 545, 554], ["NTD", "PROTEIN", 568, 571], ["CTD", "PROTEIN", 576, 579], ["CTD", "PROTEIN", 677, 680], ["the SARS", "TEST", 53, 61], ["CoV", "TEST", 62, 65], ["virus particles", "TREATMENT", 181, 196], ["virus infection", "PROBLEM", 268, 283], ["the S proteinRBD", "PROBLEM", 430, 446], ["key residue substitutions in SARS", "PROBLEM", 637, 670], ["S1", "ANATOMY", 125, 127], ["virus particles", "OBSERVATION", 181, 196], ["cell receptors", "OBSERVATION", 200, 214], ["surface", "OBSERVATION_MODIFIER", 222, 229], ["host cell", "OBSERVATION", 237, 246], ["virus", "OBSERVATION_MODIFIER", 268, 273], ["infection", "OBSERVATION", 274, 283], ["S1", "ANATOMY", 402, 404], ["S1", "ANATOMY", 463, 465], ["S1", "ANATOMY", 545, 547], ["region", "ANATOMY_MODIFIER", 548, 554], ["NTD", "OBSERVATION", 568, 571], ["residue substitutions", "OBSERVATION", 641, 662]]], ["In addition, the SARS-CoV-2 S CTD binding interface has more residues that directly interact with the receptor ACE2 than does SARS-RBD (21 versus 17), and a larger surface area is buried with SARS-CoV-2 S CTD in complex with ACE2 than with SARS S RBD.", [["surface area", "ANATOMY", 164, 176], ["SARS-RBD", "DISEASE", 126, 134], ["RBD", "DISEASE", 247, 250], ["ACE2", "GENE_OR_GENE_PRODUCT", 111, 115], ["ACE2", "GENE_OR_GENE_PRODUCT", 225, 229], ["SARS-CoV-2 S CTD", "PROTEIN", 17, 33], ["ACE2", "PROTEIN", 111, 115], ["RBD", "PROTEIN", 131, 134], ["SARS-CoV-2 S CTD", "PROTEIN", 192, 208], ["ACE2", "PROTEIN", 225, 229], ["SARS S RBD", "PROTEIN", 240, 250], ["the SARS", "TEST", 13, 21], ["the receptor ACE2", "TEST", 98, 115], ["a larger surface area", "PROBLEM", 155, 176], ["SARS", "PROBLEM", 192, 196], ["CoV", "TEST", 197, 200], ["SARS S RBD", "PROBLEM", 240, 250], ["larger", "OBSERVATION_MODIFIER", 157, 163], ["surface", "OBSERVATION_MODIFIER", 164, 171], ["RBD", "OBSERVATION", 247, 250]]], ["Mutations of key residues play an important role in enhancing the interaction with ACE2.", [["ACE2", "GENE_OR_GENE_PRODUCT", 83, 87], ["ACE2", "PROTEIN", 83, 87], ["Mutations of key residues", "PROBLEM", 0, 25]]], ["F486 in SARS-CoV-2, instead of I472 in SARS RBD, forms strong aromatic\u2013aromatic interactions with ACE2 Y83, and E484 in SARS-CoV-2-CTD, instead of P470 in SARS RBD, forms ionic interactions with K31, which leads to higher affinity for receptor binding than RBD of SARS-CoV (Fig. 2d) [15, 16, 20, 21].Structure of the S1 subunit ::: Structure of the S proteinThe RBD region is a critical target for neutralizing antibodies (nAbs), and SARS-CoV-2 and SARS-CoV RBD are ~73%\u201376% similar in sequence.", [["F486", "CHEMICAL", 0, 4], ["SARS", "DISEASE", 8, 12], ["SARS RBD", "DISEASE", 39, 47], ["E484", "CHEMICAL", 112, 116], ["P470", "CHEMICAL", 147, 151], ["SARS", "DISEASE", 155, 159], ["SARS", "DISEASE", 264, 268], ["SARS-CoV-2", "ORGANISM", 8, 18], ["ACE2", "GENE_OR_GENE_PRODUCT", 98, 102], ["P470", "AMINO_ACID", 147, 151], ["K31", "SIMPLE_CHEMICAL", 195, 198], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 264, 272], ["nAbs", "GENE_OR_GENE_PRODUCT", 423, 427], ["SARS-CoV-2", "ORGANISM", 434, 444], ["SARS-CoV", "ORGANISM", 449, 457], ["RBD", "ORGANISM", 458, 461], ["F486", "DNA", 0, 4], ["I472", "DNA", 31, 35], ["SARS RBD", "PROTEIN", 39, 47], ["ACE2", "PROTEIN", 98, 102], ["Y83", "PROTEIN", 103, 106], ["E484", "PROTEIN", 112, 116], ["CTD", "PROTEIN", 131, 134], ["P470", "PROTEIN", 147, 151], ["SARS RBD", "PROTEIN", 155, 163], ["K31", "PROTEIN", 195, 198], ["RBD", "PROTEIN", 257, 260], ["S1 subunit", "PROTEIN", 317, 327], ["S protein", "PROTEIN", 349, 358], ["RBD region", "PROTEIN", 362, 372], ["neutralizing antibodies", "PROTEIN", 398, 421], ["nAbs", "PROTEIN", 423, 427], ["SARS-CoV RBD", "PROTEIN", 449, 461], ["SARS-CoV", "SPECIES", 8, 16], ["SARS-CoV", "SPECIES", 264, 272], ["SARS-CoV", "SPECIES", 434, 442], ["SARS-CoV", "SPECIES", 449, 457], ["SARS", "TEST", 8, 12], ["CoV", "TEST", 13, 16], ["SARS RBD", "PROBLEM", 39, 47], ["ACE2", "TEST", 98, 102], ["SARS", "TEST", 120, 124], ["CoV", "TEST", 125, 128], ["CTD", "PROBLEM", 131, 134], ["SARS RBD", "PROBLEM", 155, 163], ["K31", "TREATMENT", 195, 198], ["receptor binding", "PROBLEM", 235, 251], ["SARS", "PROBLEM", 264, 268], ["neutralizing antibodies", "TEST", 398, 421], ["SARS", "TEST", 434, 438], ["CoV", "TEST", 439, 442], ["SARS", "TEST", 449, 453], ["CoV RBD", "TEST", 454, 461], ["S1", "ANATOMY", 317, 319], ["RBD", "ANATOMY", 362, 365], ["region", "ANATOMY_MODIFIER", 366, 372]]], ["Nine ACE2-contacting residues in CoV RBD are fully conserved, and four are partially conserved.", [["ACE2", "GENE_OR_GENE_PRODUCT", 5, 9], ["CoV RBD", "GENE_OR_GENE_PRODUCT", 33, 40], ["ACE2", "PROTEIN", 5, 9], ["CoV RBD", "PROTEIN", 33, 40], ["CoV RBD", "OBSERVATION", 33, 40]]], ["Analysis of the RBM (receptor-binding motif, a portion of RBD making direct contacts with ACE2) of SARS-CoV and SARS-CoV-2 revealed that most residues essential for ACE2 binding in the SARS-CoV S protein are conserved in the SARS-CoV-2 S protein.", [["RBM", "GENE_OR_GENE_PRODUCT", 16, 19], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 99, 107], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 112, 122], ["ACE2", "GENE_OR_GENE_PRODUCT", 165, 169], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 185, 195], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 225, 237], ["RBM (receptor-binding motif", "PROTEIN", 16, 43], ["RBD", "PROTEIN", 58, 61], ["ACE2", "PROTEIN", 90, 94], ["ACE2", "PROTEIN", 165, 169], ["SARS-CoV S protein", "PROTEIN", 185, 203], ["SARS-CoV-2 S protein", "PROTEIN", 225, 245], ["SARS-CoV", "SPECIES", 99, 107], ["SARS-CoV", "SPECIES", 185, 193], ["the RBM (receptor-binding motif", "TREATMENT", 12, 43], ["RBD", "PROBLEM", 58, 61], ["SARS", "PROBLEM", 99, 103], ["CoV", "TEST", 104, 107], ["SARS", "PROBLEM", 112, 116], ["CoV", "TEST", 117, 120], ["most residues", "PROBLEM", 137, 150], ["ACE2 binding", "PROBLEM", 165, 177], ["the SARS", "TEST", 181, 189], ["CoV S protein", "TEST", 190, 203], ["the SARS", "TEST", 221, 229], ["CoV", "TEST", 230, 233]]], ["However, some studies showed that murine monoclonal antibodies (mAbs) and polyclonal antibodies against SARS-RBD are unable to interact with the SARS-CoV-2 S protein, revealing differences in antigenicity between SARS-CoV and SARS-CoV-2 [20].", [["murine", "ORGANISM", 34, 40], ["SARS-RBD", "GENE_OR_GENE_PRODUCT", 104, 112], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 145, 157], ["SARS-CoV", "ORGANISM", 213, 221], ["SARS-CoV-2", "ORGANISM", 226, 236], ["murine monoclonal antibodies", "PROTEIN", 34, 62], ["mAbs", "PROTEIN", 64, 68], ["polyclonal antibodies", "PROTEIN", 74, 95], ["RBD", "PROTEIN", 109, 112], ["SARS-CoV-2 S protein", "PROTEIN", 145, 165], ["murine", "SPECIES", 34, 40], ["SARS-CoV", "SPECIES", 213, 221], ["SARS-CoV", "SPECIES", 226, 234], ["some studies", "TEST", 9, 21], ["murine monoclonal antibodies", "TEST", 34, 62], ["mAbs", "TEST", 64, 68], ["polyclonal antibodies", "TEST", 74, 95], ["SARS", "PROBLEM", 104, 108], ["RBD", "PROBLEM", 109, 112], ["the SARS", "TEST", 141, 149], ["CoV", "TEST", 150, 153], ["S protein", "TEST", 156, 165], ["differences in antigenicity", "PROBLEM", 177, 204], ["SARS", "TEST", 213, 217], ["CoV", "TEST", 218, 221], ["SARS", "TEST", 226, 230], ["CoV", "TEST", 231, 234]]], ["Similarly, a SARS-CoV RBD-specific antibody failed to block infection mediated by the S protein of SL-CoV\u2013SHC014 [22], which suggests that the S1 RBD may not be an ideal drug target due to the highly mutable characteristic of broad-spectrum anti-CoV drugs.Structure of the S2 subunit ::: Structure of the S proteinThe S2 subunit, composed successively of a FP, HR1, HR2, TM domain, and cytoplasmic domain fusion (CT), is responsible for viral fusion and entry.Structure of the S2 subunit ::: Structure of the S proteinFP is a short segment of 15\u201320 conserved amino acids of the viral family, composed mainly of hydrophobic residues, such as glycine (G) or alanine (A), which anchor to the target membrane when the S protein adopts the prehairpin conformation.", [["cytoplasmic", "ANATOMY", 386, 397], ["membrane", "ANATOMY", 696, 704], ["infection", "DISEASE", 60, 69], ["amino acids", "CHEMICAL", 559, 570], ["glycine", "CHEMICAL", 641, 648], ["alanine", "CHEMICAL", 656, 663], ["amino acids", "CHEMICAL", 559, 570], ["glycine", "CHEMICAL", 641, 648], ["alanine", "CHEMICAL", 656, 663], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["SL-CoV", "GENE_OR_GENE_PRODUCT", 99, 105], ["anti-CoV drugs", "SIMPLE_CHEMICAL", 241, 255], ["S2", "GENE_OR_GENE_PRODUCT", 273, 275], ["S2", "GENE_OR_GENE_PRODUCT", 318, 320], ["HR1", "GENE_OR_GENE_PRODUCT", 361, 364], ["HR2", "GENE_OR_GENE_PRODUCT", 366, 369], ["cytoplasmic", "ORGANISM_SUBSTANCE", 386, 397], ["S2", "GENE_OR_GENE_PRODUCT", 477, 479], ["S proteinFP", "GENE_OR_GENE_PRODUCT", 509, 520], ["amino acids", "AMINO_ACID", 559, 570], ["glycine", "AMINO_ACID", 641, 648], ["(G)", "GENE_OR_GENE_PRODUCT", 649, 652], ["alanine", "AMINO_ACID", 656, 663], ["A", "AMINO_ACID", 665, 666], ["membrane", "CELLULAR_COMPONENT", 696, 704], ["SARS-CoV RBD-specific antibody", "PROTEIN", 13, 43], ["S protein", "PROTEIN", 86, 95], ["S1 RBD", "PROTEIN", 143, 149], ["S2 subunit", "PROTEIN", 273, 283], ["S protein", "PROTEIN", 305, 314], ["S2 subunit", "PROTEIN", 318, 328], ["FP", "PROTEIN", 357, 359], ["HR1", "PROTEIN", 361, 364], ["HR2", "PROTEIN", 366, 369], ["TM domain", "PROTEIN", 371, 380], ["cytoplasmic domain fusion", "PROTEIN", 386, 411], ["CT", "PROTEIN", 413, 415], ["S2 subunit", "PROTEIN", 477, 487], ["S proteinFP", "PROTEIN", 509, 520], ["15\u201320 conserved amino acids", "PROTEIN", 543, 570], ["viral family", "PROTEIN", 578, 590], ["S protein", "PROTEIN", 714, 723], ["prehairpin", "PROTEIN", 735, 745], ["SARS-CoV", "SPECIES", 13, 21], ["a SARS-CoV RBD", "PROBLEM", 11, 25], ["specific antibody", "PROBLEM", 26, 43], ["block infection", "PROBLEM", 54, 69], ["the S protein", "TEST", 82, 95], ["SL", "TEST", 99, 101], ["CoV\u2013SHC014", "TEST", 102, 112], ["the S1 RBD", "PROBLEM", 139, 149], ["broad-spectrum anti-CoV drugs", "TREATMENT", 226, 255], ["a FP", "TEST", 355, 359], ["HR1", "TEST", 361, 364], ["HR2", "TEST", 366, 369], ["cytoplasmic domain fusion (CT", "TEST", 386, 415], ["viral fusion", "TREATMENT", 437, 449], ["the S proteinFP", "TEST", 505, 520], ["hydrophobic residues", "PROBLEM", 611, 631], ["glycine (G) or alanine (A)", "TREATMENT", 641, 667], ["S2", "ANATOMY", 273, 275], ["responsible for", "UNCERTAINTY", 421, 436], ["viral fusion", "OBSERVATION", 437, 449], ["S2", "ANATOMY", 477, 479], ["amino acids", "OBSERVATION", 559, 570], ["viral", "OBSERVATION", 578, 583], ["hydrophobic residues", "OBSERVATION", 611, 631]]], ["Previous research has shown that FP plays an essential role in mediating membrane fusion by disrupting and connecting lipid bilayers of the host cell membrane [23].Structure of the S2 subunit ::: Structure of the S proteinHR1 and HR2 are composed of a repetitive heptapeptide: HPPHCPC, where H is a hydrophobic or traditionally bulky residue, P is a polar or hydrophilic residue, and C is another charged residue [24].", [["membrane", "ANATOMY", 73, 81], ["lipid bilayers", "ANATOMY", 118, 132], ["cell membrane", "ANATOMY", 145, 158], ["FP", "CHEMICAL", 33, 35], ["H", "CHEMICAL", 292, 293], ["FP", "GENE_OR_GENE_PRODUCT", 33, 35], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["lipid bilayers", "CELLULAR_COMPONENT", 118, 132], ["cell membrane", "CELLULAR_COMPONENT", 145, 158], ["S2", "GENE_OR_GENE_PRODUCT", 181, 183], ["S proteinHR1", "GENE_OR_GENE_PRODUCT", 213, 225], ["HR2", "GENE_OR_GENE_PRODUCT", 230, 233], ["HPPHCPC", "SIMPLE_CHEMICAL", 277, 284], ["C", "SIMPLE_CHEMICAL", 384, 385], ["S2 subunit", "PROTEIN", 181, 191], ["S proteinHR1", "PROTEIN", 213, 225], ["HR2", "PROTEIN", 230, 233], ["mediating membrane fusion", "TREATMENT", 63, 88], ["the S proteinHR1", "TEST", 209, 225], ["a repetitive heptapeptide", "TREATMENT", 250, 275], ["HPPHCPC", "TREATMENT", 277, 284], ["a hydrophobic or traditionally bulky residue", "PROBLEM", 297, 341], ["a polar or hydrophilic residue", "PROBLEM", 348, 378], ["another charged residue", "PROBLEM", 389, 412], ["membrane fusion", "OBSERVATION", 73, 88], ["host cell membrane", "OBSERVATION", 140, 158], ["S2", "ANATOMY", 181, 183], ["bulky residue", "OBSERVATION", 328, 341], ["hydrophilic residue", "OBSERVATION", 359, 378]]], ["HR1 and HR2 form the six-helical bundle (6-HB) (Fig. 2e), which is essential for the viral fusion and entry function of the S2 subunit [13].", [["HR1", "GENE_OR_GENE_PRODUCT", 0, 3], ["HR2", "GENE_OR_GENE_PRODUCT", 8, 11], ["HR1", "PROTEIN", 0, 3], ["HR2", "PROTEIN", 8, 11], ["six-helical bundle", "PROTEIN", 21, 39], ["HB", "PROTEIN", 43, 45], ["S2 subunit", "PROTEIN", 124, 134], ["HR1", "TEST", 0, 3], ["the viral fusion", "TREATMENT", 81, 97], ["viral fusion", "OBSERVATION", 85, 97]]], ["HR1 is located at the C-terminus of a hydrophobic FP, and HR2 is located at the N-terminus of the TM domain [25].", [["C", "CHEMICAL", 22, 23], ["N", "CHEMICAL", 80, 81], ["HR1", "GENE_OR_GENE_PRODUCT", 0, 3], ["HR2", "GENE_OR_GENE_PRODUCT", 58, 61], ["HR1", "PROTEIN", 0, 3], ["C-terminus", "PROTEIN", 22, 32], ["hydrophobic FP", "PROTEIN", 38, 52], ["HR2", "PROTEIN", 58, 61], ["N-terminus", "PROTEIN", 80, 90], ["TM domain", "PROTEIN", 98, 107]]], ["The downstream TM domain anchors the S protein to the viral membrane, and the S2 subunit ends in a CT tail [14].Structure of the S2 subunit ::: Structure of the S proteinRBD binds to ACE2, and S2 changes conformation by inserting FP into the target cell membrane, exposing the prehairpin coiled-coil of the HR1 domain and triggering interaction between the HR2 domain and HR1 trimer to form 6-HB, thus bringing the viral envelope and cell membrane into proximity for viral fusion and entry [26].", [["membrane", "ANATOMY", 60, 68], ["cell membrane", "ANATOMY", 249, 262], ["cell membrane", "ANATOMY", 434, 447], ["6-HB", "CHEMICAL", 391, 395], ["viral membrane", "CELLULAR_COMPONENT", 54, 68], ["S2", "GENE_OR_GENE_PRODUCT", 129, 131], ["S proteinRBD", "GENE_OR_GENE_PRODUCT", 161, 173], ["ACE2", "GENE_OR_GENE_PRODUCT", 183, 187], ["S2", "GENE_OR_GENE_PRODUCT", 193, 195], ["cell membrane", "CELLULAR_COMPONENT", 249, 262], ["6-HB", "SIMPLE_CHEMICAL", 391, 395], ["cell membrane", "CELLULAR_COMPONENT", 434, 447], ["TM domain", "PROTEIN", 15, 24], ["S protein", "PROTEIN", 37, 46], ["S2 subunit ends", "PROTEIN", 78, 93], ["S2 subunit", "PROTEIN", 129, 139], ["S proteinRBD", "PROTEIN", 161, 173], ["ACE2", "PROTEIN", 183, 187], ["S2", "PROTEIN", 193, 195], ["FP", "PROTEIN", 230, 232], ["prehairpin coiled-coil", "PROTEIN", 277, 299], ["HR1 domain", "PROTEIN", 307, 317], ["HR2 domain", "PROTEIN", 357, 367], ["HR1 trimer", "PROTEIN", 372, 382], ["HB", "PROTEIN", 393, 395], ["The downstream TM domain anchors", "TREATMENT", 0, 32], ["a CT tail", "TEST", 97, 106], ["ACE2", "TEST", 183, 187], ["S2 changes conformation", "TREATMENT", 193, 216], ["the prehairpin coiled", "TREATMENT", 273, 294], ["the HR1 domain", "PROBLEM", 303, 317], ["the HR2 domain", "PROBLEM", 353, 367], ["the viral envelope", "PROBLEM", 411, 429], ["viral fusion", "TREATMENT", 467, 479], ["viral membrane", "OBSERVATION", 54, 68], ["S2", "ANATOMY", 129, 131], ["S2", "ANATOMY", 193, 195], ["target cell membrane", "OBSERVATION", 242, 262], ["viral envelope", "OBSERVATION", 415, 429], ["cell membrane", "OBSERVATION", 434, 447], ["viral fusion", "OBSERVATION", 467, 479]]], ["HR1 forms a homotrimeric assembly in which three highly conserved hydrophobic grooves on the surface that bind to HR2 are exposed.", [["surface", "ANATOMY", 93, 100], ["HR1", "GENE_OR_GENE_PRODUCT", 0, 3], ["surface", "CELLULAR_COMPONENT", 93, 100], ["HR2", "GENE_OR_GENE_PRODUCT", 114, 117], ["HR1", "PROTEIN", 0, 3], ["hydrophobic grooves", "PROTEIN", 66, 85], ["HR2", "PROTEIN", 114, 117], ["hydrophobic", "OBSERVATION_MODIFIER", 66, 77], ["grooves", "OBSERVATION_MODIFIER", 78, 85]]], ["The HR2 domain forms both a rigid helix and a flexible loop to interact with the HR1 domain.", [["HR2 domain", "PROTEIN", 4, 14], ["HR1 domain", "PROTEIN", 81, 91], ["a rigid helix", "PROBLEM", 26, 39], ["a flexible loop", "TREATMENT", 44, 59], ["rigid helix", "OBSERVATION", 28, 39], ["flexible loop", "OBSERVATION", 46, 59]]], ["In the postfusion hairpin conformation of CoVs, there are many strong interactions between the HR1 and HR2 domains inside the helical region, which is designated the \u201cfusion core region\u201d (HR1core and HR2core regions, respectively).Structure of the S2 subunit ::: Structure of the S proteinTargeting the heptad repeat (HR) has attracted the greatest interest in therapeutic drug discovery.", [["CoVs", "GENE_OR_GENE_PRODUCT", 42, 46], ["HR1", "GENE_OR_GENE_PRODUCT", 95, 98], ["S2", "GENE_OR_GENE_PRODUCT", 248, 250], ["CoVs", "PROTEIN", 42, 46], ["HR1", "PROTEIN", 95, 98], ["HR2 domains", "PROTEIN", 103, 114], ["helical region", "PROTEIN", 126, 140], ["\u201cfusion core region", "PROTEIN", 166, 185], ["HR1core", "PROTEIN", 188, 195], ["HR2core regions", "PROTEIN", 200, 215], ["S2 subunit", "PROTEIN", 248, 258], ["S proteinTargeting", "PROTEIN", 280, 298], ["heptad repeat", "PROTEIN", 303, 316], ["CoVs", "PROBLEM", 42, 46], ["hairpin", "OBSERVATION", 18, 25], ["CoVs", "OBSERVATION_MODIFIER", 42, 46], ["many", "OBSERVATION_MODIFIER", 58, 62], ["strong", "OBSERVATION_MODIFIER", 63, 69], ["interactions", "OBSERVATION", 70, 82], ["helical", "ANATOMY_MODIFIER", 126, 133], ["region", "ANATOMY_MODIFIER", 134, 140], ["S2", "ANATOMY", 248, 250], ["greatest", "OBSERVATION_MODIFIER", 340, 348], ["therapeutic", "OBSERVATION_MODIFIER", 361, 372], ["drug discovery", "OBSERVATION", 373, 387]]], ["The S protein is an important target protein for the development of specific drugs, while the S1 RBD domain is part of a highly mutable region and is not an ideal target site for broad-spectrum antiviral inhibitor development [27].", [["S protein", "PROTEIN", 4, 13], ["S1 RBD domain", "PROTEIN", 94, 107], ["specific drugs", "TREATMENT", 68, 82], ["the S1 RBD domain", "PROBLEM", 90, 107], ["broad-spectrum antiviral inhibitor development", "TREATMENT", 179, 225]]], ["In contrast, the HR region of the S2 subunit plays an essential role in HCoV infections and is conserved among HCoVs, as is the mode of interaction between HR1 and HR2 [28].", [["HCoV", "ANATOMY", 72, 76], ["infections", "DISEASE", 77, 87], ["S2", "GENE_OR_GENE_PRODUCT", 34, 36], ["HCoV", "CANCER", 72, 76], ["HCoVs", "GENE_OR_GENE_PRODUCT", 111, 116], ["HR1", "GENE_OR_GENE_PRODUCT", 156, 159], ["HR region", "DNA", 17, 26], ["S2 subunit", "PROTEIN", 34, 44], ["HR1", "PROTEIN", 156, 159], ["HR2", "PROTEIN", 164, 167], ["HCoV", "SPECIES", 72, 76], ["HCoV infections", "PROBLEM", 72, 87], ["HR2", "TEST", 164, 167], ["S2", "ANATOMY", 34, 36], ["essential", "OBSERVATION_MODIFIER", 54, 63], ["infections", "OBSERVATION", 77, 87]]], ["A synthetic peptide derived from the stem region of the ZIKV envelope protein was demonstrated in 2017 to potently inhibit infection by ZIKV and other flaviviruses in vitro [29], implying antiviral efficiency of peptides derived from conserved regions of viral proteins.", [["stem region", "ANATOMY", 37, 48], ["infection", "DISEASE", 123, 132], ["ZIKV", "GENE_OR_GENE_PRODUCT", 56, 60], ["ZIKV envelope protein", "PROTEIN", 56, 77], ["viral proteins", "PROTEIN", 255, 269], ["ZIKV", "SPECIES", 136, 140], ["A synthetic peptide", "TEST", 0, 19], ["the ZIKV envelope protein", "PROBLEM", 52, 77], ["infection", "PROBLEM", 123, 132], ["ZIKV", "PROBLEM", 136, 140], ["antiviral efficiency of peptides", "TREATMENT", 188, 220], ["viral proteins", "PROBLEM", 255, 269], ["stem", "ANATOMY_MODIFIER", 37, 41], ["ZIKV", "OBSERVATION", 56, 60], ["infection", "OBSERVATION", 123, 132], ["antiviral efficiency", "OBSERVATION", 188, 208], ["viral proteins", "OBSERVATION", 255, 269]]], ["Peptides derived from the HR2 region of class I viral fusion proteins of enveloped viruses competitively bind to viral HR1 and effectively inhibit viral infection [22].", [["viral infection", "DISEASE", 147, 162], ["HR2", "GENE_OR_GENE_PRODUCT", 26, 29], ["enveloped viruses", "ORGANISM", 73, 90], ["HR1", "GENE_OR_GENE_PRODUCT", 119, 122], ["HR2 region", "PROTEIN", 26, 36], ["class I viral fusion proteins", "PROTEIN", 40, 69], ["viral HR1", "PROTEIN", 113, 122], ["viral fusion proteins", "TREATMENT", 48, 69], ["enveloped viruses", "PROBLEM", 73, 90], ["viral HR1", "PROBLEM", 113, 122], ["viral infection", "PROBLEM", 147, 162], ["viral fusion", "OBSERVATION", 48, 60]]], ["Therefore, HR1 is a promising target for the development of fusion inhibitors against SARS-CoV-2 infection.Receptor binding ::: Functions of the S proteinAs mentioned above, the SARS-CoV-2 S protein binds to the host cell by recognizing the receptor ACE2 [33].", [["cell", "ANATOMY", 217, 221], ["SARS-CoV-2 infection", "DISEASE", 86, 106], ["HR1", "GENE_OR_GENE_PRODUCT", 11, 14], ["SARS-CoV-2", "ORGANISM", 86, 96], ["S proteinAs", "GENE_OR_GENE_PRODUCT", 145, 156], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 178, 190], ["host cell", "CELL", 212, 221], ["ACE2", "GENE_OR_GENE_PRODUCT", 250, 254], ["HR1", "PROTEIN", 11, 14], ["S proteinAs", "PROTEIN", 145, 156], ["SARS-CoV-2 S protein", "PROTEIN", 178, 198], ["ACE2", "PROTEIN", 250, 254], ["SARS-CoV-2", "SPECIES", 86, 96], ["fusion inhibitors", "TREATMENT", 60, 77], ["SARS", "PROBLEM", 86, 90], ["CoV", "PROBLEM", 91, 94], ["2 infection", "PROBLEM", 95, 106], ["the S proteinAs", "TEST", 141, 156], ["the SARS", "TEST", 174, 182], ["CoV", "TEST", 183, 186], ["the receptor ACE2", "TEST", 237, 254], ["fusion", "OBSERVATION", 60, 66], ["infection", "OBSERVATION", 97, 106], ["host cell", "OBSERVATION", 212, 221]]], ["ACE2 is a homolog of ACE, which converts angiotensin I to angiotensin 1\u20139 [35].", [["angiotensin I", "CHEMICAL", 41, 54], ["angiotensin 1\u20139", "CHEMICAL", 58, 73], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE", "GENE_OR_GENE_PRODUCT", 21, 24], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 41, 54], ["angiotensin 1\u20139 [35]", "GENE_OR_GENE_PRODUCT", 58, 78], ["ACE2", "PROTEIN", 0, 4], ["ACE", "PROTEIN", 21, 24], ["angiotensin I", "PROTEIN", 41, 54], ["a homolog of ACE", "TREATMENT", 8, 24], ["angiotensin", "TEST", 58, 69]]], ["ACE2 is distributed mainly in the lung, intestine, heart, and kidney, and alveolar epithelial type II cells are the major expressing cells [36].", [["lung", "ANATOMY", 34, 38], ["intestine", "ANATOMY", 40, 49], ["heart", "ANATOMY", 51, 56], ["kidney", "ANATOMY", 62, 68], ["alveolar epithelial type II cells", "ANATOMY", 74, 107], ["cells", "ANATOMY", 133, 138], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["lung", "ORGAN", 34, 38], ["intestine", "ORGAN", 40, 49], ["heart", "ORGAN", 51, 56], ["kidney", "ORGAN", 62, 68], ["alveolar epithelial type II cells", "CELL", 74, 107], ["cells", "CELL", 133, 138], ["ACE2", "PROTEIN", 0, 4], ["alveolar epithelial type II cells", "CELL_TYPE", 74, 107], ["major expressing cells", "CELL_TYPE", 116, 138], ["ACE2", "TEST", 0, 4], ["alveolar epithelial type II cells", "PROBLEM", 74, 107], ["lung", "ANATOMY", 34, 38], ["intestine", "ANATOMY", 40, 49], ["heart", "ANATOMY", 51, 56], ["kidney", "ANATOMY", 62, 68], ["alveolar", "ANATOMY_MODIFIER", 74, 82], ["epithelial", "ANATOMY_MODIFIER", 83, 93], ["II cells", "OBSERVATION", 99, 107], ["expressing cells", "OBSERVATION", 122, 138]]], ["ACE2 is also a known receptor for SARS-CoV.", [["SARS", "DISEASE", 34, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["ACE2", "PROTEIN", 0, 4], ["SARS-CoV", "SPECIES", 34, 42], ["SARS", "PROBLEM", 34, 38], ["CoV", "PROBLEM", 39, 42]]], ["The S1 subunit of the SARS-CoV S protein binds with ACE2 to promote the formation of endosomes, which triggers viral fusion activity under low pH (Fig. 1a, b) [37].Receptor binding ::: Functions of the S proteinInteraction between the S protein and ACE2 can be used to identify intermediate hosts of SARS-CoV-2, as ACE2 from different species, such as amphibians, birds, and mammals, has a conserved primary structure [38].", [["endosomes", "ANATOMY", 85, 94], ["SARS", "DISEASE", 300, 304], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 22, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["endosomes", "CELLULAR_COMPONENT", 85, 94], ["S protein", "GENE_OR_GENE_PRODUCT", 235, 244], ["ACE2", "GENE_OR_GENE_PRODUCT", 249, 253], ["SARS-CoV-2", "ORGANISM", 300, 310], ["ACE2", "GENE_OR_GENE_PRODUCT", 315, 319], ["S1 subunit", "PROTEIN", 4, 14], ["SARS-CoV S protein", "PROTEIN", 22, 40], ["ACE2", "PROTEIN", 52, 56], ["S proteinInteraction", "PROTEIN", 202, 222], ["S protein", "PROTEIN", 235, 244], ["ACE2", "PROTEIN", 249, 253], ["ACE2", "PROTEIN", 315, 319], ["SARS-CoV", "SPECIES", 22, 30], ["SARS-CoV", "SPECIES", 300, 308], ["the SARS", "PROBLEM", 18, 26], ["CoV S protein binds", "PROBLEM", 27, 46], ["ACE2", "TREATMENT", 52, 56], ["the formation of endosomes", "PROBLEM", 68, 94], ["viral fusion activity", "PROBLEM", 111, 132], ["the S proteinInteraction", "TREATMENT", 198, 222], ["the S protein and ACE2", "TREATMENT", 231, 253], ["SARS", "PROBLEM", 300, 304], ["CoV", "TEST", 305, 308], ["ACE2", "PROBLEM", 315, 319], ["SARS", "OBSERVATION", 22, 26], ["viral fusion", "OBSERVATION", 111, 123]]], ["Luan et al. compared the binding affinities between ACE2 and SARS-CoV-2 S from mammals, birds, snakes, and turtles and found that the ACE2 of Bovidae and Cricetidae interacted well with SARS-CoV-2 S RBD but that ACE2 from snakes and turtles could not.Receptor binding ::: Functions of the S proteinThe S protein binds to ACE2 through the RBD region of the S1 subunit, mediating viral attachment to host cells in the form of a trimer [15].", [["cells", "ANATOMY", 403, 408], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 61, 73], ["birds", "ORGANISM", 88, 93], ["snakes", "ORGANISM_SUBDIVISION", 95, 101], ["ACE2", "GENE_OR_GENE_PRODUCT", 134, 138], ["Bovidae", "GENE_OR_GENE_PRODUCT", 142, 149], ["Cricetidae", "GENE_OR_GENE_PRODUCT", 154, 164], ["ACE2", "GENE_OR_GENE_PRODUCT", 212, 216], ["snakes", "ORGANISM_SUBDIVISION", 222, 228], ["turtles", "ORGANISM", 233, 240], ["ACE2", "GENE_OR_GENE_PRODUCT", 321, 325], ["host cells", "CELL", 398, 408], ["ACE2", "PROTEIN", 52, 56], ["ACE2", "PROTEIN", 134, 138], ["SARS-CoV-2 S RBD", "PROTEIN", 186, 202], ["ACE2", "PROTEIN", 212, 216], ["S protein", "PROTEIN", 289, 298], ["S protein", "PROTEIN", 302, 311], ["ACE2", "PROTEIN", 321, 325], ["RBD region", "PROTEIN", 338, 348], ["S1 subunit", "PROTEIN", 356, 366], ["host cells", "CELL_TYPE", 398, 408], ["SARS-CoV", "SPECIES", 61, 69], ["SARS-CoV", "SPECIES", 186, 194], ["the binding affinities", "PROBLEM", 21, 43], ["ACE2", "TEST", 52, 56], ["SARS", "TEST", 61, 65], ["CoV", "TEST", 66, 69], ["Cricetidae", "TREATMENT", 154, 164], ["SARS", "PROBLEM", 186, 190], ["2 S RBD", "PROBLEM", 195, 202], ["the S proteinThe S protein binds", "TREATMENT", 285, 317], ["RBD", "OBSERVATION", 338, 341], ["S1", "ANATOMY", 356, 358], ["viral attachment", "OBSERVATION", 378, 394], ["host cells", "OBSERVATION", 398, 408]]], ["SARS-CoV-2 S binds to human ACE2 with a dissociation constant (KD) of 14.7 nM, though that of SARS-CoV S is 325.8 nM [15], indicating that SARS-CoV-2 S is more sensitive to ACE2 than is SARS-CoV S. Through the identification of SARS-CoV-2 proteins, researchers found ~24% difference in S between SARS-CoV-2 and SARS-CoV, whereas that of RBD is ~23% [39].Viral fusion ::: Functions of the S proteinViral fusion refers to fusion of the viral membrane and host cell membrane, resulting in the release of the viral genome into the host cell.", [["membrane", "ANATOMY", 440, 448], ["cell membrane", "ANATOMY", 458, 471], ["cell", "ANATOMY", 532, 536], ["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 94, 98], ["RBD", "DISEASE", 337, 340], ["human", "ORGANISM", 22, 27], ["ACE2", "GENE_OR_GENE_PRODUCT", 28, 32], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 94, 104], ["ACE2", "GENE_OR_GENE_PRODUCT", 173, 177], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 228, 238], ["CoV-2", "ORGANISM", 301, 306], ["SARS-CoV", "ORGANISM", 311, 319], ["S proteinViral", "GENE_OR_GENE_PRODUCT", 388, 402], ["viral membrane", "CELLULAR_COMPONENT", 434, 448], ["host cell membrane", "CELLULAR_COMPONENT", 453, 471], ["host cell", "CELL", 527, 536], ["SARS-CoV-2 S", "DNA", 0, 12], ["human ACE2", "PROTEIN", 22, 32], ["ACE2", "PROTEIN", 173, 177], ["SARS-CoV-2 proteins", "PROTEIN", 228, 247], ["RBD", "PROTEIN", 337, 340], ["S proteinViral fusion", "PROTEIN", 388, 409], ["viral genome", "DNA", 505, 517], ["host cell", "CELL_TYPE", 527, 536], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["SARS-CoV", "SPECIES", 94, 102], ["SARS-CoV", "SPECIES", 186, 194], ["SARS-CoV", "SPECIES", 296, 304], ["SARS-CoV", "SPECIES", 311, 319], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["a dissociation constant", "PROBLEM", 38, 61], ["SARS", "PROBLEM", 94, 98], ["CoV S", "TEST", 99, 104], ["nM", "TEST", 114, 116], ["SARS", "TEST", 139, 143], ["CoV", "TEST", 144, 147], ["ACE2", "TEST", 173, 177], ["SARS", "PROBLEM", 186, 190], ["CoV S.", "PROBLEM", 191, 197], ["SARS", "PROBLEM", 228, 232], ["CoV", "TEST", 233, 236], ["SARS", "TEST", 296, 300], ["CoV", "TEST", 301, 304], ["SARS-CoV", "TEST", 311, 319], ["RBD", "TEST", 337, 340], ["the S proteinViral fusion", "TREATMENT", 384, 409], ["fusion", "TREATMENT", 420, 426], ["the viral membrane", "TREATMENT", 430, 448], ["14.7 nM", "OBSERVATION_MODIFIER", 70, 77], ["fusion", "OBSERVATION", 360, 366], ["viral membrane", "OBSERVATION", 434, 448], ["host cell membrane", "OBSERVATION", 453, 471], ["viral genome", "OBSERVATION", 505, 517], ["host cell", "OBSERVATION", 527, 536]]], ["Cleavage of the SARS-CoV-2 S1 and S2 subunits is the basis of fusion.", [["SARS-CoV-2 S1", "GENE_OR_GENE_PRODUCT", 16, 29], ["S2", "GENE_OR_GENE_PRODUCT", 34, 36], ["SARS-CoV-2 S1 and S2 subunits", "PROTEIN", 16, 45], ["the SARS", "TEST", 12, 20], ["CoV", "TEST", 21, 24], ["S1 and S2 subunits", "TREATMENT", 27, 45], ["fusion", "TREATMENT", 62, 68], ["fusion", "OBSERVATION", 62, 68]]], ["The S protein is cleaved into two parts, the S1 subunit and S2 subunit, by host proteases, and the subunits exist in a noncovalent form until viral fusion occurs [40].", [["S2", "GENE_OR_GENE_PRODUCT", 60, 62], ["S protein", "PROTEIN", 4, 13], ["S1 subunit", "PROTEIN", 45, 55], ["S2 subunit", "PROTEIN", 60, 70], ["host proteases", "PROTEIN", 75, 89], ["The S protein", "TEST", 0, 13], ["the subunits", "TREATMENT", 95, 107], ["viral fusion", "TREATMENT", 142, 154], ["S2", "ANATOMY", 60, 62]]], ["Researchers have found that the specific furin cleavage site is located in the cleavage site of SARS-CoV-2 but not in other SARS-like CoVs [41, 42].", [["SARS", "DISEASE", 124, 128], ["furin", "GENE_OR_GENE_PRODUCT", 41, 46], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 96, 106], ["furin", "PROTEIN", 41, 46], ["SARS-CoV-2", "DNA", 96, 106], ["the specific furin cleavage site", "PROBLEM", 28, 60], ["SARS", "PROBLEM", 96, 100], ["CoV", "TEST", 101, 104], ["SARS", "OBSERVATION", 96, 100]]], ["Mutation of the cleavage site in SARS-CoV-2 or SARS-like CoVs has revealed that the S protein of SARS-CoV-2 exists in an uncleaved state but that the others are mainly in a cleaved state.", [["SARS", "DISEASE", 97, 101], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 33, 43], ["SARS-like CoVs", "GENE_OR_GENE_PRODUCT", 47, 61], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 97, 107], ["SARS-CoV-2 or SARS-like CoVs", "DNA", 33, 61], ["S protein", "PROTEIN", 84, 93], ["SARS-CoV", "SPECIES", 97, 105], ["Mutation of the cleavage site", "PROBLEM", 0, 29], ["SARS", "PROBLEM", 33, 37], ["CoV", "TEST", 38, 41], ["SARS", "PROBLEM", 47, 51], ["CoVs", "PROBLEM", 57, 61], ["the S protein", "TEST", 80, 93], ["SARS", "TEST", 97, 101], ["CoV", "TEST", 102, 105]]], ["SARS-CoV-2 S has multiple furin cleavage sites, which increases the probability of being cleaved by furin-like proteases and thereby enhances its infectivity [43, 44].", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 0, 12], ["furin", "GENE_OR_GENE_PRODUCT", 26, 31], ["furin", "GENE_OR_GENE_PRODUCT", 100, 105], ["SARS-CoV-2 S", "DNA", 0, 12], ["furin cleavage sites", "DNA", 26, 46], ["furin-like proteases", "PROTEIN", 100, 120], ["SARS", "TEST", 0, 4], ["multiple furin cleavage sites", "PROBLEM", 17, 46], ["cleavage sites", "OBSERVATION", 32, 46]]], ["The furin-like cleavage domain is also present in highly pathogenic influenza virus and is related to its pathogenicity, as observed in the avian influenza outbreak in Hong Kong in 1997 [45, 46].", [["influenza virus", "DISEASE", 68, 83], ["avian influenza", "DISEASE", 140, 155], ["furin", "GENE_OR_GENE_PRODUCT", 4, 9], ["influenza virus", "ORGANISM", 68, 83], ["furin-like cleavage domain", "PROTEIN", 4, 30], ["influenza virus", "SPECIES", 68, 83], ["avian influenza", "SPECIES", 140, 155], ["The furin-like cleavage domain", "PROBLEM", 0, 30], ["highly pathogenic influenza virus", "PROBLEM", 50, 83], ["its pathogenicity", "PROBLEM", 102, 119], ["highly", "OBSERVATION_MODIFIER", 50, 56], ["pathogenic", "OBSERVATION_MODIFIER", 57, 67], ["influenza virus", "OBSERVATION", 68, 83]]], ["In addition, host cell proteases such as TMPRSS2 are essential for S protein priming, and they have been shown to be activated in the entry of SARS-CoV and influenza A virus [18, 47, 48].", [["cell", "ANATOMY", 18, 22], ["SARS", "DISEASE", 143, 147], ["host cell", "CELL", 13, 22], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 41, 48], ["S protein", "GENE_OR_GENE_PRODUCT", 67, 76], ["SARS-CoV", "ORGANISM", 143, 151], ["influenza A virus", "ORGANISM", 156, 173], ["host cell proteases", "PROTEIN", 13, 32], ["TMPRSS2", "PROTEIN", 41, 48], ["S protein", "PROTEIN", 67, 76], ["influenza A virus", "SPECIES", 156, 173], ["SARS-CoV", "SPECIES", 143, 151], ["influenza A virus", "SPECIES", 156, 173], ["host cell proteases", "TREATMENT", 13, 32], ["TMPRSS2", "TEST", 41, 48], ["S protein priming", "PROBLEM", 67, 84], ["SARS", "PROBLEM", 143, 147], ["CoV", "PROBLEM", 148, 151], ["influenza A virus", "PROBLEM", 156, 173], ["host cell proteases", "OBSERVATION", 13, 32]]], ["Another host cell protease that has been proven to cleave viral S protein is trypsin [49].", [["cell", "ANATOMY", 13, 17], ["host cell", "CELL", 8, 17], ["viral S protein", "GENE_OR_GENE_PRODUCT", 58, 73], ["trypsin", "GENE_OR_GENE_PRODUCT", 77, 84], ["host cell protease", "PROTEIN", 8, 26], ["viral S protein", "PROTEIN", 58, 73], ["trypsin", "PROTEIN", 77, 84], ["Another host cell protease", "TREATMENT", 0, 26], ["host cell protease", "OBSERVATION", 8, 26]]], ["In summary, the S protein of SARS-CoV-2 is similar to that of SARS-CoV, and host cell proteases are essential for promoting S protein cleavage of both SARS-CoV-2 and SARS-CoV.", [["cell", "ANATOMY", 81, 85], ["SARS", "DISEASE", 29, 33], ["SARS", "DISEASE", 62, 66], ["SARS-CoV-2", "ORGANISM", 29, 39], ["SARS-CoV", "ORGANISM", 62, 70], ["host cell", "CELL", 76, 85], ["SARS-CoV-2", "ORGANISM", 151, 161], ["SARS-CoV", "ORGANISM", 166, 174], ["S protein", "PROTEIN", 16, 25], ["host cell proteases", "PROTEIN", 76, 95], ["S protein", "PROTEIN", 124, 133], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 62, 70], ["SARS-CoV", "SPECIES", 151, 159], ["SARS-CoV", "SPECIES", 166, 174], ["the S protein", "TEST", 12, 25], ["SARS", "TEST", 29, 33], ["CoV", "TEST", 34, 37], ["SARS", "PROBLEM", 62, 66], ["CoV", "TEST", 67, 70], ["host cell proteases", "TEST", 76, 95], ["promoting S protein cleavage", "PROBLEM", 114, 142], ["both SARS", "TEST", 146, 155], ["CoV", "TEST", 156, 159], ["SARS", "PROBLEM", 166, 170]]], ["The presence of a specific furin cleavage site on SARS-CoV-2 S might be one reason that SARS-CoV-2 is more contagious than SARS-CoV.Viral fusion ::: Functions of the S proteinThe formation of 6-HB is essential for viral fusion.", [["SARS", "DISEASE", 88, 92], ["SARS", "DISEASE", 123, 127], ["6-HB", "CHEMICAL", 192, 196], ["6-HB", "CHEMICAL", 192, 196], ["furin", "GENE_OR_GENE_PRODUCT", 27, 32], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 88, 98], ["SARS-CoV", "ORGANISM", 123, 131], ["6-HB", "GENE_OR_GENE_PRODUCT", 192, 196], ["furin cleavage site", "PROTEIN", 27, 46], ["S protein", "PROTEIN", 166, 175], ["HB", "PROTEIN", 194, 196], ["SARS-CoV", "SPECIES", 88, 96], ["SARS-CoV", "SPECIES", 123, 131], ["a specific furin cleavage site", "PROBLEM", 16, 46], ["SARS", "PROBLEM", 88, 92], ["the S protein", "TEST", 162, 175], ["viral fusion", "TREATMENT", 214, 226], ["fusion", "OBSERVATION", 138, 144], ["essential for", "UNCERTAINTY", 200, 213], ["viral fusion", "OBSERVATION", 214, 226]]], ["The FP in the N-terminus of SARS-CoV-2 and the two HR domains on S2 is essential for viral fusion [50].", [["SARS", "DISEASE", 28, 32], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 28, 38], ["S2", "GENE_OR_GENE_PRODUCT", 65, 67], ["N-terminus", "PROTEIN", 14, 24], ["SARS-CoV-2", "DNA", 28, 38], ["HR domains", "DNA", 51, 61], ["S2", "PROTEIN", 65, 67], ["The FP", "TEST", 0, 6], ["SARS", "TEST", 28, 32], ["CoV", "TEST", 33, 36], ["the two HR domains on S2", "PROBLEM", 43, 67], ["viral fusion", "PROBLEM", 85, 97], ["FP", "OBSERVATION_MODIFIER", 4, 6], ["viral fusion", "OBSERVATION", 85, 97]]], ["After cleavage of the S protein, the FP of SARS-CoV-2 is exposed and triggers viral fusion.", [["SARS", "DISEASE", 43, 47], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 43, 53], ["S protein", "PROTEIN", 22, 31], ["SARS-CoV", "SPECIES", 43, 51], ["the S protein", "TEST", 18, 31], ["SARS", "PROBLEM", 43, 47], ["CoV", "TEST", 48, 51], ["viral fusion", "TREATMENT", 78, 90], ["viral fusion", "OBSERVATION", 78, 90]]], ["Under the action of some special ligands, the fusion protein undergoes a conformational change and then inserts into the host cell membrane (Fig. 1c) [51].", [["cell membrane", "ANATOMY", 126, 139], ["cell membrane", "CELLULAR_COMPONENT", 126, 139], ["fusion protein", "PROTEIN", 46, 60], ["some special ligands", "TREATMENT", 20, 40], ["the fusion protein", "TREATMENT", 42, 60], ["host cell membrane", "OBSERVATION", 121, 139]]], ["For example, the ligand for influenza A virus is H+, while the ligand for HIV is a coreceptor such as CCR5 or CXCR4 [14].", [["H+", "CHEMICAL", 49, 51], ["H+", "CHEMICAL", 49, 51], ["influenza A virus", "ORGANISM", 28, 45], ["H+", "SIMPLE_CHEMICAL", 49, 51], ["HIV", "ORGANISM", 74, 77], ["CCR5", "GENE_OR_GENE_PRODUCT", 102, 106], ["CXCR4", "GENE_OR_GENE_PRODUCT", 110, 115], ["CCR5", "PROTEIN", 102, 106], ["CXCR4", "PROTEIN", 110, 115], ["influenza A virus", "SPECIES", 28, 45], ["influenza A virus", "SPECIES", 28, 45], ["HIV", "SPECIES", 74, 77], ["influenza A virus", "PROBLEM", 28, 45], ["HIV", "PROBLEM", 74, 77], ["a coreceptor", "TREATMENT", 81, 93]]], ["The distance between the viral membrane and host cell membrane is shortened, and the HR1 domain of the S protein is in close proximity to the host cell membrane, whereas the HR2 domain is closer to the viral membrane side.", [["membrane", "ANATOMY", 31, 39], ["cell membrane", "ANATOMY", 49, 62], ["cell membrane", "ANATOMY", 147, 160], ["membrane", "ANATOMY", 208, 216], ["viral membrane", "CELLULAR_COMPONENT", 25, 39], ["host cell membrane", "CELLULAR_COMPONENT", 44, 62], ["cell membrane", "CELLULAR_COMPONENT", 147, 160], ["HR2", "GENE_OR_GENE_PRODUCT", 174, 177], ["HR1 domain", "PROTEIN", 85, 95], ["S protein", "PROTEIN", 103, 112], ["HR2 domain", "PROTEIN", 174, 184], ["the HR1 domain", "TEST", 81, 95], ["the S protein", "TEST", 99, 112], ["the HR2 domain", "PROBLEM", 170, 184], ["distance", "OBSERVATION_MODIFIER", 4, 12], ["viral membrane", "OBSERVATION", 25, 39], ["host cell membrane", "OBSERVATION", 44, 62], ["shortened", "OBSERVATION_MODIFIER", 66, 75], ["host cell membrane", "OBSERVATION", 142, 160], ["viral membrane", "OBSERVATION", 202, 216]]], ["Then, HR2 folds back to HR1, the two HR domains form a six-helix structure in an antiparallel format of the fusion core, the viral membrane is pulled toward the host cell membrane and tightly binds to it, and the two membranes fuse [52].Antibodies based on the SARS-CoV-2 S protein ::: Potential drugs targeting the S proteinThe S protein is the main antigen component in all structural proteins of SARS-CoV-2.", [["membrane", "ANATOMY", 131, 139], ["cell membrane", "ANATOMY", 166, 179], ["membranes", "ANATOMY", 217, 226], ["HR2", "GENE_OR_GENE_PRODUCT", 6, 9], ["HR1", "GENE_OR_GENE_PRODUCT", 24, 27], ["membrane", "CELLULAR_COMPONENT", 131, 139], ["cell membrane", "CELLULAR_COMPONENT", 166, 179], ["membranes", "CELLULAR_COMPONENT", 217, 226], ["SARS-CoV-2", "ORGANISM", 399, 409], ["HR2", "PROTEIN", 6, 9], ["HR1", "PROTEIN", 24, 27], ["HR domains", "PROTEIN", 37, 47], ["six-helix structure", "PROTEIN", 55, 74], ["SARS-CoV-2 S protein", "PROTEIN", 261, 281], ["S protein", "PROTEIN", 316, 325], ["S protein", "PROTEIN", 329, 338], ["structural proteins", "PROTEIN", 376, 395], ["SARS-CoV", "SPECIES", 261, 269], ["SARS-CoV", "SPECIES", 399, 407], ["a six-helix structure", "PROBLEM", 53, 74], ["the fusion core", "TREATMENT", 104, 119], ["the viral membrane", "PROBLEM", 121, 139], ["Antibodies", "TEST", 237, 247], ["the SARS", "TEST", 257, 265], ["CoV", "TEST", 266, 269], ["Potential drugs", "TREATMENT", 286, 301], ["CoV", "TEST", 404, 407], ["fusion", "OBSERVATION", 108, 114], ["viral membrane", "OBSERVATION", 125, 139], ["host cell membrane", "OBSERVATION", 161, 179], ["main", "OBSERVATION_MODIFIER", 346, 350]]], ["Unlike other functional proteins of SAS-CoV-2, it is responsible for inducing the host immune response, and nAbs targeting the S protein can induce protective immunity against viral infection.", [["viral infection", "DISEASE", 176, 191], ["SAS-CoV-2", "GENE_OR_GENE_PRODUCT", 36, 45], ["nAbs", "GENE_OR_GENE_PRODUCT", 108, 112], ["nAbs", "PROTEIN", 108, 112], ["S protein", "PROTEIN", 127, 136], ["SAS", "TEST", 36, 39], ["CoV", "TEST", 40, 43], ["nAbs targeting the S protein", "TREATMENT", 108, 136], ["viral infection", "PROBLEM", 176, 191], ["infection", "OBSERVATION", 182, 191]]], ["Similar to SARS-CoV and MERS-CoV, research on nAbs of SARS-CoV-2 mainly includes mAbs, antigen-binding fragments, single-chain variable region fragments, and single-domain antibodies (Nbs), which target S1 RBD, S1-NTD, or S2 regions to prevent S2-mediated fusion [53, 54].", [["SARS", "DISEASE", 11, 15], ["SARS", "DISEASE", 54, 58], ["SARS-CoV", "ORGANISM", 11, 19], ["MERS-CoV", "ORGANISM", 24, 32], ["SARS-CoV-2", "ORGANISM", 54, 64], ["mAbs", "GENE_OR_GENE_PRODUCT", 81, 85], ["antigen-binding fragments", "GENE_OR_GENE_PRODUCT", 87, 112], ["Nbs", "GENE_OR_GENE_PRODUCT", 184, 187], ["S1-NTD", "GENE_OR_GENE_PRODUCT", 211, 217], ["S2", "GENE_OR_GENE_PRODUCT", 244, 246], ["nAbs", "DNA", 46, 50], ["mAbs", "PROTEIN", 81, 85], ["antigen-binding fragments", "DNA", 87, 112], ["single-chain variable region fragments", "DNA", 114, 152], ["single-domain antibodies", "PROTEIN", 158, 182], ["Nbs", "PROTEIN", 184, 187], ["RBD", "PROTEIN", 206, 209], ["S1", "PROTEIN", 211, 213], ["NTD", "PROTEIN", 214, 217], ["S2 regions", "PROTEIN", 222, 232], ["S2", "PROTEIN", 244, 246], ["SARS-CoV", "SPECIES", 11, 19], ["MERS-CoV", "SPECIES", 24, 32], ["SARS-CoV", "SPECIES", 54, 62], ["SARS", "TEST", 11, 15], ["CoV", "TEST", 16, 19], ["SARS", "PROBLEM", 54, 58], ["CoV", "TEST", 59, 62], ["mAbs", "TEST", 81, 85], ["antigen", "TEST", 87, 94], ["binding fragments", "PROBLEM", 95, 112], ["single-chain variable region fragments", "PROBLEM", 114, 152], ["single-domain antibodies", "TEST", 158, 182], ["S2-mediated fusion", "TREATMENT", 244, 262], ["SARS", "OBSERVATION", 11, 15], ["binding fragments", "OBSERVATION", 95, 112], ["S1", "ANATOMY", 211, 213], ["NTD", "ANATOMY", 214, 217], ["S2", "ANATOMY", 222, 224], ["S2", "ANATOMY", 244, 246]]], ["On the other hand, multiple SARS-CoV-2 vaccine types are under development, including RNA/DNA-based formulations, recombinant viral epitopes, adenovirus-based vectors, and purified inactivated virus [55].Antibodies based on the SARS-CoV-2 S protein ::: Potential drugs targeting the S proteinThe sequence and striking structural similarity between the SARS-CoV-2 and SARS-CoV S proteins emphasize the close relationship between these two viruses, which provides the possibility to treat COVID-19 with antibodies targeting the SARS-CoV S protein [56].", [["COVID-19", "CHEMICAL", 487, 495], ["SARS-CoV-2", "ORGANISM", 28, 38], ["DNA", "CELLULAR_COMPONENT", 90, 93], ["adenovirus", "ORGANISM", 142, 152], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 352, 362], ["SARS-CoV S proteins", "GENE_OR_GENE_PRODUCT", 367, 386], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 526, 534], ["recombinant viral epitopes", "PROTEIN", 114, 140], ["SARS-CoV-2 S protein", "PROTEIN", 228, 248], ["S protein", "PROTEIN", 283, 292], ["SARS-CoV-2 and SARS-CoV S proteins", "PROTEIN", 352, 386], ["COVID", "PROTEIN", 487, 492], ["antibodies", "PROTEIN", 501, 511], ["SARS-CoV S protein", "PROTEIN", 526, 544], ["SARS-CoV", "SPECIES", 228, 236], ["SARS-CoV", "SPECIES", 526, 534], ["multiple SARS-CoV-2 vaccine types", "TREATMENT", 19, 52], ["RNA/DNA", "TREATMENT", 86, 93], ["based formulations", "TREATMENT", 94, 112], ["recombinant viral epitopes", "PROBLEM", 114, 140], ["adenovirus-based vectors", "TREATMENT", 142, 166], ["purified inactivated virus", "PROBLEM", 172, 198], ["Antibodies", "TEST", 204, 214], ["the SARS", "TEST", 224, 232], ["CoV", "TEST", 233, 236], ["Potential drugs", "TREATMENT", 253, 268], ["the SARS", "TEST", 348, 356], ["CoV", "TEST", 357, 360], ["SARS-CoV S proteins", "TEST", 367, 386], ["COVID", "TEST", 487, 492], ["antibodies", "TEST", 501, 511], ["the SARS", "TEST", 522, 530], ["CoV S protein", "TEST", 531, 544], ["multiple", "OBSERVATION_MODIFIER", 19, 27], ["SARS", "OBSERVATION", 28, 32], ["viruses", "OBSERVATION", 438, 445]]], ["Compared with SARS-CoV-2 RBD, SARS-CoV-2 interacts with hACE2 via the C-terminal domain (SARS-CoV-2-CTD), showing higher affinity for receptor binding.", [["SARS", "DISEASE", 30, 34], ["C", "CHEMICAL", 70, 71], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 30, 40], ["hACE2", "GENE_OR_GENE_PRODUCT", 56, 61], ["SARS-CoV-2-CTD", "GENE_OR_GENE_PRODUCT", 89, 103], ["RBD", "PROTEIN", 25, 28], ["SARS-CoV-2", "DNA", 30, 40], ["hACE2", "PROTEIN", 56, 61], ["C-terminal domain", "DNA", 70, 87], ["CoV", "PROTEIN", 94, 97], ["CTD", "PROTEIN", 100, 103], ["SARS-CoV", "SPECIES", 14, 22], ["SARS-CoV", "SPECIES", 30, 38], ["SARS", "TEST", 14, 18], ["CoV", "TEST", 19, 22], ["RBD", "PROBLEM", 25, 28], ["SARS", "TEST", 30, 34], ["CoV", "TEST", 35, 38], ["hACE2", "TEST", 56, 61], ["the C-terminal domain", "PROBLEM", 66, 87], ["SARS", "TEST", 89, 93], ["CoV", "TEST", 94, 97], ["receptor binding", "PROBLEM", 134, 150]]], ["RBD can induce highly potent nAb responses and has the potential to be developed as an effective and safe subunit vaccine against SARS-CoV-2.", [["RBD", "DISEASE", 0, 3], ["SARS", "DISEASE", 130, 134], ["nAb", "SIMPLE_CHEMICAL", 29, 32], ["SARS-CoV-2", "ORGANISM", 130, 140], ["RBD", "PROTEIN", 0, 3], ["SARS-CoV", "SPECIES", 130, 138], ["safe subunit vaccine", "TREATMENT", 101, 121], ["SARS", "PROBLEM", 130, 134]]], ["SARS-CoV S polyclonal antibodies obtained from immunized mice completely inhibited the invasion of SARS-CoV S-MLV (murine leukemia virus), whereas the invasion rate of SARS-CoV-2 S-MLV was reduced to ~10% [20].", [["SARS", "DISEASE", 99, 103], ["murine leukemia virus", "DISEASE", 115, 136], ["SARS", "DISEASE", 168, 172], ["mice", "ORGANISM", 57, 61], ["SARS-CoV S-MLV", "ORGANISM", 99, 113], ["murine leukemia virus", "ORGANISM", 115, 136], ["SARS-CoV-2 S-MLV", "ORGANISM", 168, 184], ["SARS-CoV S polyclonal antibodies", "PROTEIN", 0, 32], ["mice", "SPECIES", 57, 61], ["murine", "SPECIES", 115, 121], ["SARS-CoV", "SPECIES", 0, 8], ["mice", "SPECIES", 57, 61], ["SARS-CoV S-MLV", "SPECIES", 99, 113], ["murine leukemia virus", "SPECIES", 115, 136], ["SARS-CoV", "SPECIES", 168, 176], ["SARS", "TEST", 0, 4], ["CoV S polyclonal antibodies", "TEST", 5, 32], ["SARS", "PROBLEM", 99, 103], ["CoV S", "TEST", 104, 109], ["MLV (murine leukemia virus", "PROBLEM", 110, 136], ["the invasion rate", "TEST", 147, 164], ["SARS", "TEST", 168, 172], ["CoV", "TEST", 173, 176], ["MLV", "TREATMENT", 181, 184], ["MLV", "ANATOMY", 110, 113], ["leukemia virus", "OBSERVATION", 122, 136]]], ["The polyclonal anti-SARS S1 antibody T62 inhibits the entry of SARS-CoV S but not that of SARS-CoV-2 S pseudovirus particles [49].", [["SARS", "DISEASE", 63, 67], ["anti-SARS S1", "GENE_OR_GENE_PRODUCT", 15, 27], ["SARS-CoV", "ORGANISM", 63, 71], ["SARS-CoV", "ORGANISM", 90, 98], ["polyclonal anti-SARS S1 antibody T62", "PROTEIN", 4, 40], ["SARS-CoV", "SPECIES", 63, 71], ["SARS-CoV-2 S pseudovirus", "SPECIES", 90, 114], ["The polyclonal anti-SARS S1 antibody", "TEST", 0, 36], ["SARS", "PROBLEM", 63, 67], ["CoV S", "TEST", 68, 73], ["SARS", "PROBLEM", 90, 94], ["CoV", "TEST", 95, 98], ["S pseudovirus particles", "TEST", 101, 124]]], ["Consistently, recent studies have reported similar results, showing that three SARS RBD-directed mAbs, S230, m396, and 80R, were unable to bind to SARS-CoV-2 RBD [16, 20, 21].Antibodies based on the SARS-CoV-2 S protein ::: Potential drugs targeting the S proteinOn the other hand, several mAbs have shown promising results in neutralizing SARS-CoV-2.", [["SARS", "DISEASE", 147, 151], ["80R", "GENE_OR_GENE_PRODUCT", 119, 122], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 340, 350], ["SARS RBD", "PROTEIN", 79, 87], ["mAbs", "PROTEIN", 97, 101], ["S230", "PROTEIN", 103, 107], ["80R", "PROTEIN", 119, 122], ["RBD", "PROTEIN", 158, 161], ["SARS-CoV-2 S protein", "PROTEIN", 199, 219], ["S proteinOn", "PROTEIN", 254, 265], ["mAbs", "PROTEIN", 290, 294], ["SARS-CoV", "SPECIES", 199, 207], ["SARS-CoV", "SPECIES", 340, 348], ["recent studies", "TEST", 14, 28], ["three SARS RBD", "TEST", 73, 87], ["SARS", "TEST", 147, 151], ["CoV", "TEST", 152, 155], ["RBD", "TEST", 158, 161], ["Antibodies", "TEST", 175, 185], ["the SARS", "TEST", 195, 203], ["CoV", "TEST", 204, 207], ["Potential drugs", "TREATMENT", 224, 239], ["neutralizing SARS", "TEST", 327, 344]]], ["CR3022, a SARS-CoV-specific human mAb, binds potently with SARS-CoV-2 (KD of 6.3 nM, measured by BLI in OctetRED96), suggesting that CR3022 has the potential to be developed as candidate therapeutic, alone or in combination with other nAbs, for the prevention and treatment of SARS-CoV-2 infection [57].", [["CR3022", "CHEMICAL", 0, 6], ["CR3022", "CHEMICAL", 133, 139], ["SARS-CoV-2 infection", "DISEASE", 277, 297], ["CR3022", "CHEMICAL", 0, 6], ["CR3022", "CHEMICAL", 133, 139], ["CR3022", "SIMPLE_CHEMICAL", 0, 6], ["SARS-CoV", "ORGANISM", 10, 18], ["human", "ORGANISM", 28, 33], ["mAb", "GENE_OR_GENE_PRODUCT", 34, 37], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 59, 69], ["CR3022", "SIMPLE_CHEMICAL", 133, 139], ["nAbs", "SIMPLE_CHEMICAL", 235, 239], ["SARS-CoV-2", "ORGANISM", 277, 287], ["SARS-CoV-specific human mAb", "PROTEIN", 10, 37], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["SARS-CoV-2", "SPECIES", 277, 287], ["CR3022", "TEST", 0, 6], ["a SARS", "TEST", 8, 14], ["CoV", "TEST", 15, 18], ["specific human mAb", "TEST", 19, 37], ["SARS", "TEST", 59, 63], ["CoV", "TEST", 64, 67], ["KD", "TEST", 71, 73], ["other nAbs", "TREATMENT", 229, 239], ["treatment", "TREATMENT", 264, 273], ["SARS", "PROBLEM", 277, 281], ["CoV-2 infection", "PROBLEM", 282, 297]]], ["A mAb targeting S1 prepared from immunized transgenic mice expressing human Ig variable heavy and light chains has recently been shown to neutralize both SARS-CoV-2 and SARS-CoV infections via an unknown mechanism that is independent of the blockade of RBD\u2013hACE2 interaction [58].", [["infections", "DISEASE", 178, 188], ["mAb", "GENE_OR_GENE_PRODUCT", 2, 5], ["S1", "GENE_OR_GENE_PRODUCT", 16, 18], ["mice", "ORGANISM", 54, 58], ["human", "ORGANISM", 70, 75], ["Ig variable heavy and light chains", "GENE_OR_GENE_PRODUCT", 76, 110], ["SARS-CoV-2", "ORGANISM", 154, 164], ["SARS-CoV", "ORGANISM", 169, 177], ["RBD\u2013hACE2", "GENE_OR_GENE_PRODUCT", 253, 262], ["mAb", "PROTEIN", 2, 5], ["S1", "PROTEIN", 16, 18], ["Ig variable heavy and light chains", "PROTEIN", 76, 110], ["RBD\u2013hACE2", "PROTEIN", 253, 262], ["mice", "SPECIES", 54, 58], ["human", "SPECIES", 70, 75], ["mice", "SPECIES", 54, 58], ["human", "SPECIES", 70, 75], ["SARS-CoV", "SPECIES", 154, 162], ["SARS-CoV", "SPECIES", 169, 177], ["A mAb targeting S1", "TREATMENT", 0, 18], ["Ig variable heavy and light chains", "PROBLEM", 76, 110], ["CoV", "TEST", 159, 162], ["SARS", "PROBLEM", 169, 173], ["CoV infections", "PROBLEM", 174, 188], ["heavy", "OBSERVATION_MODIFIER", 88, 93], ["light chains", "OBSERVATION_MODIFIER", 98, 110]]], ["Recently, many human blocking mAbs (311mab-31B5, 311mab-32D4, 47D11, n3130, n3088, S309, P2C-1F11, P2B-2F6, B38, H4) have been successfully cloned from single memory B cells from recovered COVID-19 patients [58\u201363].", [["memory B cells", "ANATOMY", 159, 173], ["human", "ORGANISM", 15, 20], ["47D11", "GENE_OR_GENE_PRODUCT", 62, 67], ["P2B-2F6", "GENE_OR_GENE_PRODUCT", 99, 106], ["H4", "GENE_OR_GENE_PRODUCT", 113, 115], ["single memory B cells", "CELL", 152, 173], ["patients", "ORGANISM", 198, 206], ["human blocking mAbs", "PROTEIN", 15, 34], ["311mab", "PROTEIN", 36, 42], ["31B5", "PROTEIN", 43, 47], ["311mab", "PROTEIN", 49, 55], ["32D4", "PROTEIN", 56, 60], ["47D11", "PROTEIN", 62, 67], ["n3130", "PROTEIN", 69, 74], ["n3088", "PROTEIN", 76, 81], ["S309", "PROTEIN", 83, 87], ["P2C", "PROTEIN", 89, 92], ["1F11", "PROTEIN", 93, 97], ["P2B", "PROTEIN", 99, 102], ["2F6", "PROTEIN", 103, 106], ["B38", "PROTEIN", 108, 111], ["H4", "PROTEIN", 113, 115], ["single memory B cells", "CELL_TYPE", 152, 173], ["human", "SPECIES", 15, 20], ["patients", "SPECIES", 198, 206], ["human", "SPECIES", 15, 20], ["many human blocking mAbs", "TEST", 10, 34], ["S309", "TEST", 83, 87], ["P2C", "TEST", 89, 92], ["P2B", "TEST", 99, 102], ["B38", "TEST", 108, 111], ["H4", "TEST", 113, 115], ["COVID", "TEST", 189, 194]]], ["These mAbs specifically bind to SARS-CoV-2 S to effectively neutralize infection.", [["infection", "DISEASE", 71, 80], ["mAbs", "GENE_OR_GENE_PRODUCT", 6, 10], ["mAbs", "PROTEIN", 6, 10], ["SARS", "TEST", 32, 36], ["CoV", "TEST", 37, 40], ["neutralize infection", "PROBLEM", 60, 80], ["neutralize", "OBSERVATION_MODIFIER", 60, 70], ["infection", "OBSERVATION", 71, 80]]], ["In addition, sera from SARS patients during rehabilitation or animals specifically immunized with SARS-CoV S1 may cross-neutralize SARS-CoV-2 and reduce S protein-mediated SARS-CoV-2 entry (Fig. 3) [18].Fusion inhibitors ::: Potential drugs targeting the S proteinThe stability of the SARS-CoV-2 S protein is lower than that of SARS-CoV S [42].", [["sera", "ANATOMY", 13, 17], ["SARS", "DISEASE", 23, 27], ["sera", "ORGANISM_SUBSTANCE", 13, 17], ["patients", "ORGANISM", 28, 36], ["SARS-CoV S1", "ORGANISM", 98, 109], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 131, 141], ["S protein", "GENE_OR_GENE_PRODUCT", 153, 162], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 172, 182], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 285, 297], ["S protein", "PROTEIN", 153, 162], ["S protein", "PROTEIN", 255, 264], ["SARS-CoV-2 S protein", "PROTEIN", 285, 305], ["patients", "SPECIES", 28, 36], ["SARS-CoV", "SPECIES", 98, 106], ["SARS-CoV", "SPECIES", 131, 139], ["SARS-CoV", "SPECIES", 328, 336], ["rehabilitation", "TREATMENT", 44, 58], ["SARS", "PROBLEM", 98, 102], ["SARS", "TEST", 131, 135], ["CoV", "TEST", 136, 139], ["S protein", "TEST", 153, 162], ["mediated SARS", "PROBLEM", 163, 176], ["Potential drugs", "TREATMENT", 225, 240], ["the SARS", "TEST", 281, 289], ["CoV", "TEST", 290, 293], ["S protein", "TEST", 296, 305], ["CoV S", "TEST", 333, 338]]], ["The mapping of multiple S sequences of the subgenus Sarbecovirus underscores that the S2 fusion region is more conserved than the S1 subunit and that the S1 subunit is more exposed at the viral surface [16].", [["surface", "ANATOMY", 194, 201], ["S2", "GENE_OR_GENE_PRODUCT", 86, 88], ["S1", "GENE_OR_GENE_PRODUCT", 154, 156], ["multiple S sequences", "DNA", 15, 35], ["S2 fusion region", "DNA", 86, 102], ["S1 subunit", "PROTEIN", 130, 140], ["S1 subunit", "PROTEIN", 154, 164], ["multiple S sequences", "TEST", 15, 35], ["the subgenus Sarbecovirus", "TEST", 39, 64], ["the S2 fusion region", "PROBLEM", 82, 102], ["S2", "ANATOMY", 86, 88], ["fusion", "OBSERVATION", 89, 95], ["S1", "ANATOMY", 154, 156]]], ["The SARS-CoV S2 subunit plays a key role in mediating virus\u2013cell fusion and its integration into host cells, where HR1 and HR2 interact to form 6-HB, thus enabling the virus to bind to and fuse with the cell membrane [28].Fusion inhibitors ::: Potential drugs targeting the S proteinSequence alignment shows that SARS-CoV-2 HR2 has the same sequence as SARS-CoV HR2.", [["virus\u2013cell", "ANATOMY", 54, 64], ["cells", "ANATOMY", 102, 107], ["cell membrane", "ANATOMY", 203, 216], ["SARS", "DISEASE", 4, 8], ["6-HB", "CHEMICAL", 144, 148], ["SARS-CoV S2", "GENE_OR_GENE_PRODUCT", 4, 15], ["virus\u2013cell", "CELL", 54, 64], ["host cells", "CELL", 97, 107], ["HR1", "GENE_OR_GENE_PRODUCT", 115, 118], ["HR2", "GENE_OR_GENE_PRODUCT", 123, 126], ["6-HB", "SIMPLE_CHEMICAL", 144, 148], ["cell membrane", "CELLULAR_COMPONENT", 203, 216], ["SARS-CoV-2 HR2", "GENE_OR_GENE_PRODUCT", 313, 327], ["SARS-CoV HR2", "GENE_OR_GENE_PRODUCT", 353, 365], ["SARS-CoV S2 subunit", "PROTEIN", 4, 23], ["host cells", "CELL_TYPE", 97, 107], ["HR1", "PROTEIN", 115, 118], ["HR2", "PROTEIN", 123, 126], ["S proteinSequence alignment", "DNA", 274, 301], ["SARS-CoV-2 HR2", "DNA", 313, 327], ["SARS-CoV HR2", "PROTEIN", 353, 365], ["SARS-CoV", "SPECIES", 4, 12], ["SARS-CoV", "SPECIES", 353, 361], ["The SARS", "PROBLEM", 0, 8], ["mediating virus\u2013cell fusion", "TREATMENT", 44, 71], ["HR1", "TEST", 115, 118], ["the virus", "PROBLEM", 164, 173], ["Fusion inhibitors", "TREATMENT", 222, 239], ["Potential drugs", "TREATMENT", 244, 259], ["the S proteinSequence alignment", "TEST", 270, 301], ["SARS", "TEST", 313, 317], ["CoV", "TEST", 318, 321]]], ["Therefore, SARS-CoV-2 HR2P (1168\u20131203 residues) was designed to inhibit SARS-CoV-2 fusion and entry into a target cell.", [["cell", "ANATOMY", 114, 118], ["1168\u20131203 residues", "CHEMICAL", 28, 46], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 72, 82], ["cell", "CELL", 114, 118], ["SARS-CoV-2 HR2P", "DNA", 11, 26], ["target cell", "CELL_TYPE", 107, 118], ["SARS", "TEST", 11, 15], ["CoV", "TEST", 16, 19], ["CoV-2 fusion", "TREATMENT", 77, 89], ["target cell", "OBSERVATION", 107, 118]]], ["Surprisingly, HR2P showed inhibitory activity against SARS-CoV-2 S-mediated fusion and SARS-CoV-2 pseudovirus, with IC50 values of 0.18 and 0.98 \u03bcM, respectively [13].", [["HR2P", "CHEMICAL", 14, 18], ["HR2P", "SIMPLE_CHEMICAL", 14, 18], ["SARS-CoV-2", "ORGANISM", 87, 97], ["pseudovirus", "ORGANISM", 98, 109], ["HR2P", "PROTEIN", 14, 18], ["SARS-CoV", "SPECIES", 54, 62], ["SARS-CoV-2 pseudovirus", "SPECIES", 87, 109], ["HR2P", "TEST", 14, 18], ["inhibitory activity", "PROBLEM", 26, 45], ["SARS", "PROBLEM", 54, 58], ["CoV", "TEST", 59, 62], ["mediated fusion", "PROBLEM", 67, 82], ["SARS", "TEST", 87, 91], ["CoV", "TEST", 92, 95], ["IC50 values", "TEST", 116, 127]]], ["Notably, EK1 is a pancoronavirus fusion inhibitor targeting the HR1 domain of HCoV S [22].", [["EK1", "CHEMICAL", 9, 12], ["EK1", "GENE_OR_GENE_PRODUCT", 9, 12], ["EK1", "PROTEIN", 9, 12], ["HR1 domain", "PROTEIN", 64, 74], ["EK1", "TEST", 9, 12], ["a pancoronavirus fusion inhibitor", "TREATMENT", 16, 49]]], ["The X-ray crystal structure of the 6-HB core of the SARS-CoV-2 S2 subunit HR1 and HR2 domains has been solved, indicating that several mutant residues in the HR1 region may be related to enhanced interaction in the HR2 region [64].", [["SARS", "DISEASE", 52, 56], ["SARS-CoV-2 S2", "GENE_OR_GENE_PRODUCT", 52, 65], ["HR1", "GENE_OR_GENE_PRODUCT", 74, 77], ["HR2", "GENE_OR_GENE_PRODUCT", 82, 85], ["SARS-CoV-2 S2 subunit", "PROTEIN", 52, 73], ["HR1", "PROTEIN", 74, 77], ["HR2 domains", "PROTEIN", 82, 93], ["HR1 region", "PROTEIN", 158, 168], ["HR2 region", "PROTEIN", 215, 225], ["The X-ray crystal structure", "TEST", 0, 27], ["the SARS", "TEST", 48, 56], ["CoV", "TEST", 57, 60], ["several mutant residues in the HR1 region", "PROBLEM", 127, 168], ["enhanced interaction in the HR2 region", "PROBLEM", 187, 225], ["SARS", "OBSERVATION", 52, 56], ["several", "OBSERVATION_MODIFIER", 127, 134], ["mutant residues", "OBSERVATION", 135, 150], ["HR1", "ANATOMY", 158, 161], ["region", "ANATOMY_MODIFIER", 162, 168], ["may be related to", "UNCERTAINTY", 169, 186], ["enhanced", "OBSERVATION_MODIFIER", 187, 195]]], ["Subsequently, EK1C4, a lipopeptide derived from EK1, was generated and verified to inhibit SARS-CoV-2 S-mediated cell\u2013cell fusion.", [["cell\u2013cell", "ANATOMY", 113, 122], ["EK1C4", "CHEMICAL", 14, 19], ["EK1C4", "GENE_OR_GENE_PRODUCT", 14, 19], ["EK1", "GENE_OR_GENE_PRODUCT", 48, 51], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 91, 103], ["cell\u2013cell", "CELL", 113, 122], ["EK1C4", "PROTEIN", 14, 19], ["EK1", "PROTEIN", 48, 51], ["SARS", "TEST", 91, 95], ["CoV", "TEST", 96, 99], ["mediated cell\u2013cell fusion", "TREATMENT", 104, 129], ["cell\u2013cell", "ANATOMY", 113, 122], ["fusion", "OBSERVATION", 123, 129]]], ["As expected, the entry of SARS-CoV-2 S pseudovirus was also inhibited by EK1C4, with an IC50 of 15.8 nM, ~149-fold more potent than the original EK1 peptide.", [["SARS", "DISEASE", 26, 30], ["EK1C4", "CHEMICAL", 73, 78], ["SARS-CoV-2 S pseudovirus", "ORGANISM", 26, 50], ["EK1C4", "SIMPLE_CHEMICAL", 73, 78], ["EK1 peptide", "GENE_OR_GENE_PRODUCT", 145, 156], ["SARS-CoV-2 S pseudovirus", "SPECIES", 26, 50], ["SARS-CoV-2 S pseudovirus", "TEST", 26, 50], ["an IC50", "TEST", 85, 92], ["nM", "TEST", 101, 103], ["15.8 nM", "OBSERVATION_MODIFIER", 96, 103]]], ["Another sequence-based lipopeptide fusion inhibitor, IPB02, potently inhibits SARS-CoV-2 S protein-mediated cell\u2013cell fusion and pseudovirus infection [65].Fusion inhibitors ::: Potential drugs targeting the S proteinIn addition to peptide fusion inhibitors, nelfinavir mesylate (Viracept), a currently prescribed anti-HIV protease inhibitor, suppresses both SARS-CoV-2 S and SARS-CoV S-mediated cell\u2013cell fusion.", [["cell\u2013cell", "ANATOMY", 108, 117], ["cell\u2013cell", "ANATOMY", 396, 405], ["IPB02", "CHEMICAL", 53, 58], ["pseudovirus infection", "DISEASE", 129, 150], ["nelfinavir mesylate", "CHEMICAL", 259, 278], ["Viracept", "CHEMICAL", 280, 288], ["nelfinavir mesylate", "CHEMICAL", 259, 278], ["Viracept", "CHEMICAL", 280, 288], ["IPB02", "SIMPLE_CHEMICAL", 53, 58], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 78, 88], ["cell\u2013cell", "CELL", 108, 117], ["pseudovirus", "ORGANISM", 129, 140], ["S proteinIn", "GENE_OR_GENE_PRODUCT", 208, 219], ["nelfinavir mesylate", "SIMPLE_CHEMICAL", 259, 278], ["Viracept", "SIMPLE_CHEMICAL", 280, 288], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 376, 386], ["cell\u2013cell", "CELL", 396, 405], ["SARS-CoV-2 S protein", "PROTEIN", 78, 98], ["S proteinIn", "PROTEIN", 208, 219], ["Another sequence", "TEST", 0, 16], ["based lipopeptide fusion inhibitor", "TREATMENT", 17, 51], ["IPB02", "TEST", 53, 58], ["SARS", "TEST", 78, 82], ["CoV", "TEST", 83, 86], ["S protein", "TEST", 89, 98], ["cell\u2013cell fusion", "PROBLEM", 108, 124], ["pseudovirus infection", "PROBLEM", 129, 150], ["Potential drugs", "TREATMENT", 178, 193], ["the S proteinIn", "TREATMENT", 204, 219], ["peptide fusion inhibitors", "TREATMENT", 232, 257], ["nelfinavir mesylate (Viracept", "TREATMENT", 259, 288], ["anti-HIV protease inhibitor", "TREATMENT", 314, 341], ["CoV", "TEST", 364, 367], ["SARS", "PROBLEM", 376, 380], ["CoV S-mediated cell\u2013cell fusion", "TREATMENT", 381, 412]]], ["Viracept is the first reported small molecule fusion inhibitor in addition to peptide fusion inhibitors.", [["Viracept", "CHEMICAL", 0, 8], ["Viracept", "SIMPLE_CHEMICAL", 0, 8], ["Viracept", "TREATMENT", 0, 8], ["small molecule fusion inhibitor", "TREATMENT", 31, 62], ["peptide fusion inhibitors", "TREATMENT", 78, 103], ["molecule fusion", "OBSERVATION", 37, 52]]], ["Moreover, nelfinavir may inhibit the function of TMPRSS2 involved in activation of the S protein [66].", [["nelfinavir", "CHEMICAL", 10, 20], ["nelfinavir", "CHEMICAL", 10, 20], ["nelfinavir", "SIMPLE_CHEMICAL", 10, 20], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 49, 56], ["TMPRSS2", "PROTEIN", 49, 56], ["S protein", "PROTEIN", 87, 96], ["nelfinavir", "TREATMENT", 10, 20], ["TMPRSS2", "PROBLEM", 49, 56], ["the S protein", "TEST", 83, 96]]], ["This discovery makes possible clinical applications of anti-SARS-CoV-2 therapeutics, especially in the early stage of infection.Protease inhibitors targeting SARS-CoV-2 S cleavage sites ::: Potential drugs targeting the S proteinSARS-CoV-2 entry requires cleavage of the S protein at the S1/S2 and S2 sites.", [["infection", "DISEASE", 118, 127], ["anti-SARS-CoV-2", "ORGANISM", 55, 70], ["Protease", "GENE_OR_GENE_PRODUCT", 128, 136], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 158, 168], ["CoV-2", "GENE_OR_GENE_PRODUCT", 234, 239], ["S2", "GENE_OR_GENE_PRODUCT", 291, 293], ["S2", "GENE_OR_GENE_PRODUCT", 298, 300], ["S proteinSARS", "PROTEIN", 220, 233], ["S protein", "PROTEIN", 271, 280], ["S1/S2 and S2 sites", "DNA", 288, 306], ["anti-SARS", "TREATMENT", 55, 64], ["CoV-2 therapeutics", "TREATMENT", 65, 83], ["infection", "PROBLEM", 118, 127], ["Protease inhibitors", "TREATMENT", 128, 147], ["SARS-CoV", "TEST", 158, 166], ["Potential drugs", "TREATMENT", 190, 205], ["the S proteinSARS", "TEST", 216, 233], ["the S protein", "TREATMENT", 267, 280], ["early stage", "OBSERVATION_MODIFIER", 103, 114], ["infection", "OBSERVATION", 118, 127], ["S1", "ANATOMY", 288, 290], ["S2", "ANATOMY", 291, 293], ["S2", "ANATOMY", 298, 300]]], ["Proteolysis by TMPRSS2 and cathepsin B and L plays an important role in priming SARS-CoV-2 S for entry.", [["TMPRSS2", "GENE_OR_GENE_PRODUCT", 15, 22], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 27, 38], ["L", "GENE_OR_GENE_PRODUCT", 43, 44], ["TMPRSS2", "PROTEIN", 15, 22], ["cathepsin B and L", "PROTEIN", 27, 44], ["Proteolysis", "TEST", 0, 11], ["TMPRSS2", "TEST", 15, 22], ["cathepsin B and L plays", "TREATMENT", 27, 50]]], ["Camostat mesilate is a potent serine protease inhibitor of TMPRSS2.", [["Camostat mesilate", "CHEMICAL", 0, 17], ["Camostat mesilate", "CHEMICAL", 0, 17], ["serine", "CHEMICAL", 30, 36], ["Camostat mesilate", "SIMPLE_CHEMICAL", 0, 17], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 59, 66], ["TMPRSS2", "PROTEIN", 59, 66], ["Camostat mesilate", "TREATMENT", 0, 17], ["a potent serine protease inhibitor", "TREATMENT", 21, 55], ["TMPRSS2", "PROBLEM", 59, 66]]], ["Utilizing research on the SARS-CoV and SARS-CoV-2 cell entry mechanism, it has been demonstrated that SARS-CoV-2 cellular entry can be blocked by camostat mesilate [18, 67].", [["cell", "ANATOMY", 50, 54], ["cellular", "ANATOMY", 113, 121], ["SARS", "DISEASE", 26, 30], ["camostat mesilate", "CHEMICAL", 146, 163], ["camostat mesilate", "CHEMICAL", 146, 163], ["CoV", "ORGANISM", 31, 34], ["CoV-2 cell", "CELL", 44, 54], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 102, 112], ["cellular", "CELL", 113, 121], ["camostat mesilate", "SIMPLE_CHEMICAL", 146, 163], ["SARS-CoV", "SPECIES", 26, 34], ["the SARS", "TEST", 22, 30], ["SARS", "TEST", 39, 43], ["SARS", "PROBLEM", 102, 106]]], ["There are currently five clinical trials registered to evaluate the efficacy of camostat mesilate (ClinicalTrials.gov Identifier: NCT04321096, NCT04353284, NCT04338906, NCT04355052, NCT04374019).", [["camostat mesilate", "CHEMICAL", 80, 97], ["camostat mesilate", "CHEMICAL", 80, 97], ["camostat mesilate", "SIMPLE_CHEMICAL", 80, 97], ["camostat mesilate", "TREATMENT", 80, 97]]], ["In addition, cathepsins in lysosomes are crucial for SARS-CoV entry via endocytosis.", [["lysosomes", "ANATOMY", 27, 36], ["cathepsins", "GENE_OR_GENE_PRODUCT", 13, 23], ["lysosomes", "CELLULAR_COMPONENT", 27, 36], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 53, 61], ["cathepsins", "PROTEIN", 13, 23], ["SARS-CoV", "SPECIES", 53, 61], ["cathepsins", "TREATMENT", 13, 23], ["SARS", "PROBLEM", 53, 57]]], ["E-64d, an inhibitor of cathepsin L, blocks infection with SARS-CoV and SARS-CoV-2 PsV [68\u201370].", [["E-64d", "CHEMICAL", 0, 5], ["infection", "DISEASE", 43, 52], ["SARS", "DISEASE", 58, 62], ["E-64d", "CHEMICAL", 0, 5], ["E-64d", "SIMPLE_CHEMICAL", 0, 5], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 23, 34], ["SARS-CoV", "ORGANISM", 58, 66], ["SARS-CoV-2", "ORGANISM", 71, 81], ["PsV", "ORGANISM", 82, 85], ["cathepsin L", "PROTEIN", 23, 34], ["SARS-CoV", "SPECIES", 58, 66], ["SARS-CoV-2 PsV", "SPECIES", 71, 85], ["E", "TEST", 0, 1], ["cathepsin L", "TREATMENT", 23, 34], ["blocks infection", "PROBLEM", 36, 52], ["SARS", "PROBLEM", 58, 62], ["CoV", "TEST", 63, 66], ["SARS", "TEST", 71, 75], ["CoV", "TEST", 76, 79], ["PsV", "TEST", 82, 85], ["infection", "OBSERVATION", 43, 52]]], ["Future trials with COVID-19 patients may help to confirm the efficacy of E-64d therapy.Protease inhibitors targeting SARS-CoV-2 S cleavage sites ::: Potential drugs targeting the S proteinPhosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is the main enzyme synthesizing PI(3,5)P2 in early endosomes [71].", [["early endosomes", "ANATOMY", 285, 300], ["E-64d", "CHEMICAL", 73, 78], ["S proteinPhosphatidylinositol 3-phosphate", "CHEMICAL", 179, 220], ["E-64d", "CHEMICAL", 73, 78], ["S proteinPhosphatidylinositol 3-phosphate", "CHEMICAL", 179, 220], ["PI(3,5)P2", "CHEMICAL", 272, 281], ["patients", "ORGANISM", 28, 36], ["E-64d", "SIMPLE_CHEMICAL", 73, 78], ["Protease", "GENE_OR_GENE_PRODUCT", 87, 95], ["S proteinPhosphatidylinositol 3-phosphate 5-kinase", "GENE_OR_GENE_PRODUCT", 179, 229], ["PIKfyve", "GENE_OR_GENE_PRODUCT", 231, 238], ["PI(3,5)P2", "GENE_OR_GENE_PRODUCT", 272, 281], ["early endosomes", "CELLULAR_COMPONENT", 285, 300], ["SARS-CoV-2 S cleavage sites", "DNA", 117, 144], ["S proteinPhosphatidylinositol 3-phosphate 5-kinase", "PROTEIN", 179, 229], ["PIKfyve", "PROTEIN", 231, 238], ["PI(3,5)P2", "PROTEIN", 272, 281], ["patients", "SPECIES", 28, 36], ["COVID", "TREATMENT", 19, 24], ["E-64d therapy", "TREATMENT", 73, 86], ["Protease inhibitors", "TREATMENT", 87, 106], ["SARS", "PROBLEM", 117, 121], ["Potential drugs", "TREATMENT", 149, 164], ["the S proteinPhosphatidylinositol", "TREATMENT", 175, 208], ["phosphate", "TREATMENT", 211, 220]]], ["Apilimod, a potent inhibitor of PIKfyve35, can significantly reduce the entry of SARS-CoV S pseudovirus into 293/hACE2 cells via early endosomes in a dose-dependent manner [49].", [["293/hACE2 cells", "ANATOMY", 109, 124], ["early endosomes", "ANATOMY", 129, 144], ["Apilimod", "CHEMICAL", 0, 8], ["PIKfyve35", "CHEMICAL", 32, 41], ["SARS", "DISEASE", 81, 85], ["Apilimod", "CHEMICAL", 0, 8], ["Apilimod", "SIMPLE_CHEMICAL", 0, 8], ["PIKfyve35", "GENE_OR_GENE_PRODUCT", 32, 41], ["SARS-CoV S pseudovirus", "ORGANISM", 81, 103], ["hACE2 cells", "CELL", 113, 124], ["early endosomes", "CELLULAR_COMPONENT", 129, 144], ["293/hACE2 cells", "CELL_LINE", 109, 124], ["CoV S pseudovirus", "SPECIES", 86, 103], ["SARS-CoV S pseudovirus", "SPECIES", 81, 103], ["Apilimod", "TREATMENT", 0, 8], ["a potent inhibitor of PIKfyve35", "TREATMENT", 10, 41], ["SARS", "PROBLEM", 81, 85], ["CoV S pseudovirus", "TEST", 86, 103]]], ["Treating 293/hACE2 cells with another PIKfyve inhibitor, YM201636 [72], also had a similar effect.", [["293/hACE2 cells", "ANATOMY", 9, 24], ["YM201636", "CHEMICAL", 57, 65], ["YM201636", "CHEMICAL", 57, 65], ["293/hACE2 cells", "CELL", 9, 24], ["PIKfyve", "GENE_OR_GENE_PRODUCT", 38, 45], ["YM201636", "SIMPLE_CHEMICAL", 57, 65], ["293/hACE2 cells", "CELL_LINE", 9, 24], ["another PIKfyve inhibitor", "TEST", 30, 55]]], ["Moreover, a major downstream effector of PI(3,5)P2, two-pore channel subtype 2 (TPC2) [73], is important for SARS-CoV-2 entry, and tetrandrine (an inhibitor of TPC2) inhibits the activity of SARS-CoV-2 S pseudovirus.Protease inhibitors targeting SARS-CoV-2 S cleavage sites ::: Potential drugs targeting the S proteinFurin (proprotein convertase (PC) subtilisin kexin 3, PCSK3), as a member of the PC family, catalyzes the hydrolysis of peptide and protein substrates at paired basic residues [74].", [["tetrandrine", "CHEMICAL", 131, 142], ["PI(3,5)P2", "CHEMICAL", 41, 50], ["tetrandrine", "CHEMICAL", 131, 142], ["PI(3,5)P2", "GENE_OR_GENE_PRODUCT", 41, 50], ["two-pore channel subtype 2", "GENE_OR_GENE_PRODUCT", 52, 78], ["TPC2", "GENE_OR_GENE_PRODUCT", 80, 84], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 109, 119], ["tetrandrine", "SIMPLE_CHEMICAL", 131, 142], ["TPC2", "GENE_OR_GENE_PRODUCT", 160, 164], ["SARS-CoV-2 S pseudovirus", "ORGANISM", 191, 215], ["Protease", "GENE_OR_GENE_PRODUCT", 216, 224], ["S proteinFurin", "GENE_OR_GENE_PRODUCT", 308, 322], ["proprotein convertase (PC) subtilisin kexin 3", "GENE_OR_GENE_PRODUCT", 324, 369], ["PCSK3", "GENE_OR_GENE_PRODUCT", 371, 376], ["PC", "GENE_OR_GENE_PRODUCT", 398, 400], ["PI(3,5)P2", "PROTEIN", 41, 50], ["TPC2", "PROTEIN", 160, 164], ["SARS-CoV-2 S cleavage sites", "DNA", 246, 273], ["S proteinFurin", "PROTEIN", 308, 322], ["proprotein convertase (PC) subtilisin kexin 3", "PROTEIN", 324, 369], ["PCSK3", "PROTEIN", 371, 376], ["PC family", "PROTEIN", 398, 407], ["SARS-CoV-2 S pseudovirus", "SPECIES", 191, 215], ["SARS", "TEST", 109, 113], ["tetrandrine", "TREATMENT", 131, 142], ["an inhibitor of TPC2", "TREATMENT", 144, 164], ["SARS", "PROBLEM", 191, 195], ["CoV", "TEST", 196, 199], ["pseudovirus", "PROBLEM", 204, 215], ["Protease inhibitors", "TREATMENT", 216, 235], ["SARS-CoV", "TEST", 246, 254], ["Potential drugs", "TREATMENT", 278, 293], ["the S proteinFurin (proprotein convertase (PC) subtilisin kexin", "TREATMENT", 304, 367], ["the hydrolysis of peptide and protein substrates", "TREATMENT", 419, 467]]], ["Strikingly, SARS-CoV-2 S harbors a furin cleavage site (682\u2013685 residues) at the S1/S2 boundary, which may increase the efficiency of SARS-CoV-2 transmission [75].", [["furin", "GENE_OR_GENE_PRODUCT", 35, 40], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 134, 144], ["SARS-CoV-2 S", "DNA", 12, 24], ["furin cleavage site", "DNA", 35, 54], ["S1/S2 boundary", "DNA", 81, 95], ["SARS", "PROBLEM", 12, 16], ["a furin cleavage site", "PROBLEM", 33, 54], ["SARS", "PROBLEM", 134, 138], ["S2", "ANATOMY", 84, 86]]], ["The furin-like cleavage site in the S protein of SARS-CoV-2 may have implications for the viral life cycle and pathogenicity.", [["furin", "GENE_OR_GENE_PRODUCT", 4, 9], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 49, 59], ["furin", "PROTEIN", 4, 9], ["S protein", "PROTEIN", 36, 45], ["The furin-like cleavage site", "PROBLEM", 0, 28], ["the viral life cycle", "PROBLEM", 86, 106], ["pathogenicity", "PROBLEM", 111, 124]]], ["Therefore, furin inhibitors can be used as a drug therapy for SARS-CoV-2 [41].", [["SARS", "DISEASE", 62, 66], ["furin", "GENE_OR_GENE_PRODUCT", 11, 16], ["SARS-CoV", "SPECIES", 62, 70], ["furin inhibitors", "TREATMENT", 11, 27], ["a drug therapy", "TREATMENT", 43, 57], ["SARS", "PROBLEM", 62, 66], ["CoV", "TEST", 67, 70]]], ["Patent literature since 1994 describes the use of furin or its inhibitors in the treatment of diseases, and some furin inhibitors that have been reported, including \u03b1-1-PDX (\u03b11-antitrypsin Portland) [76], hexa-D-arginine(D6R) [77], serpin proteinase inhibitor 8 (PI8) [78], and a peptidomimetic furin inhibitor [79].Future aspects of the development of antivirus drugs targeting the SARS-Cov-2 S proteinThe SARS-CoV-2 S protein binds to the host cell receptor and induces virus\u2013cell membrane fusion, which plays a vital role in the process of virus invasion.", [["cell", "ANATOMY", 446, 450], ["virus\u2013cell membrane", "ANATOMY", 472, 491], ["hexa-D-arginine", "CHEMICAL", 205, 220], ["D6R", "CHEMICAL", 221, 224], ["hexa-D-arginine", "CHEMICAL", 205, 220], ["furin", "GENE_OR_GENE_PRODUCT", 50, 55], ["furin", "GENE_OR_GENE_PRODUCT", 113, 118], ["\u03b1-1-PDX", "SIMPLE_CHEMICAL", 165, 172], ["\u03b11-antitrypsin Portland) [76]", "SIMPLE_CHEMICAL", 174, 203], ["hexa-D-arginine", "SIMPLE_CHEMICAL", 205, 220], ["D6R) [77]", "SIMPLE_CHEMICAL", 221, 230], ["serpin proteinase inhibitor 8", "SIMPLE_CHEMICAL", 232, 261], ["PI8) [78]", "SIMPLE_CHEMICAL", 263, 272], ["furin", "GENE_OR_GENE_PRODUCT", 295, 300], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 383, 393], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 407, 417], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 441, 459], ["virus\u2013cell membrane", "CELLULAR_COMPONENT", 472, 491], ["PDX", "PROTEIN", 169, 172], ["\u03b11", "PROTEIN", 174, 176], ["SARS-Cov-2 S protein", "PROTEIN", 383, 403], ["SARS-CoV-2 S protein", "PROTEIN", 407, 427], ["host cell receptor", "PROTEIN", 441, 459], ["furin", "TREATMENT", 50, 55], ["its inhibitors", "TREATMENT", 59, 73], ["diseases", "PROBLEM", 94, 102], ["some furin inhibitors", "TREATMENT", 108, 129], ["PDX", "TEST", 169, 172], ["hexa", "TEST", 205, 209], ["serpin proteinase inhibitor", "TREATMENT", 232, 259], ["a peptidomimetic furin inhibitor", "TREATMENT", 278, 310], ["antivirus drugs", "TREATMENT", 353, 368], ["the SARS", "TEST", 379, 387], ["Cov", "TEST", 388, 391], ["The SARS", "TEST", 403, 411], ["CoV", "TEST", 412, 415], ["the host cell receptor", "TREATMENT", 437, 459], ["virus\u2013cell membrane fusion", "TREATMENT", 472, 498], ["virus invasion", "PROBLEM", 543, 557], ["diseases", "OBSERVATION", 94, 102], ["antivirus", "OBSERVATION", 353, 362], ["host cell", "OBSERVATION", 441, 450], ["membrane fusion", "OBSERVATION", 483, 498], ["virus invasion", "OBSERVATION", 543, 557]]], ["Moreover, the high affinity between the S protein and ACE2 increases the infectivity of SARS-CoV-2.", [["SARS", "DISEASE", 88, 92], ["ACE2", "GENE_OR_GENE_PRODUCT", 54, 58], ["SARS-CoV-2", "ORGANISM", 88, 98], ["S protein", "PROTEIN", 40, 49], ["ACE2", "PROTEIN", 54, 58], ["SARS-CoV", "SPECIES", 88, 96], ["the high affinity", "PROBLEM", 10, 27], ["the S protein", "TEST", 36, 49], ["ACE2", "TEST", 54, 58], ["CoV", "TEST", 93, 96], ["high affinity", "OBSERVATION_MODIFIER", 14, 27]]], ["Mammals including pangolins, pets (dogs and cats), and members of Cricetidae may be important for determining key residues for association with S from SARS-CoV and SARS-CoV-2 [80].", [["SARS", "DISEASE", 151, 155], ["pangolins", "GENE_OR_GENE_PRODUCT", 18, 27], ["dogs", "ORGANISM", 35, 39], ["cats", "ORGANISM", 44, 48], ["Cricetidae", "GENE_OR_GENE_PRODUCT", 66, 76], ["SARS-CoV", "ORGANISM", 151, 159], ["SARS-CoV-2", "ORGANISM", 164, 174], ["dogs", "SPECIES", 35, 39], ["cats", "SPECIES", 44, 48], ["SARS-CoV", "SPECIES", 151, 159], ["SARS-CoV", "SPECIES", 164, 172], ["Cricetidae", "TREATMENT", 66, 76], ["CoV", "TEST", 169, 172]]], ["Further understanding of the structure and function of SARS-CoV-2 S will allow for additional information regarding invasion and pathogenesis of the virus, which will support the discovery of antiviral therapeutics and precision vaccine design.Future aspects of the development of antivirus drugs targeting the SARS-Cov-2 S proteinStructural information will also assist in evaluating mutations of the SARS-CoV-2 S protein and will help in determining whether these residues have surface exposure and map to known antibody epitopes of S proteins from other coronaviruses.", [["surface", "ANATOMY", 480, 487], ["SARS", "DISEASE", 55, 59], ["SARS", "DISEASE", 402, 406], ["SARS-CoV-2", "ORGANISM", 55, 65], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 402, 414], ["surface", "CELLULAR_COMPONENT", 480, 487], ["antibody epitopes of S proteins", "GENE_OR_GENE_PRODUCT", 514, 545], ["coronaviruses", "ORGANISM", 557, 570], ["SARS-CoV-2 S protein", "PROTEIN", 402, 422], ["antibody epitopes", "PROTEIN", 514, 531], ["S proteins", "PROTEIN", 535, 545], ["SARS-CoV", "SPECIES", 55, 63], ["SARS", "PROBLEM", 55, 59], ["CoV", "TEST", 60, 63], ["invasion", "PROBLEM", 116, 124], ["the virus", "PROBLEM", 145, 154], ["antiviral therapeutics", "TREATMENT", 192, 214], ["precision vaccine design", "TREATMENT", 219, 243], ["antivirus drugs", "TREATMENT", 281, 296], ["the SARS", "PROBLEM", 307, 315], ["the SARS", "TEST", 398, 406], ["CoV", "TEST", 407, 410], ["these residues", "PROBLEM", 460, 474], ["surface exposure", "PROBLEM", 480, 496], ["known antibody epitopes", "PROBLEM", 508, 531], ["S proteins", "PROBLEM", 535, 545], ["other coronaviruses", "PROBLEM", 551, 570], ["antivirus", "OBSERVATION", 281, 290]]], ["In addition, structural knowledge ensures that the proteins produced by constructs are homogeneous and participate in the prefusion conformation, which should maintain the most neutralization-sensitive epitopes when used as a candidate vaccine or B-cell probe for isolating neutralizing human mAbs.", [["B-cell", "ANATOMY", 247, 253], ["B-cell", "CELL", 247, 253], ["human", "ORGANISM", 287, 292], ["mAbs", "GENE_OR_GENE_PRODUCT", 293, 297], ["neutralizing human mAbs", "PROTEIN", 274, 297], ["human", "SPECIES", 287, 292], ["human", "SPECIES", 287, 292], ["a candidate vaccine", "TREATMENT", 224, 243], ["B-cell probe", "TREATMENT", 247, 259], ["isolating neutralizing human mAbs", "TREATMENT", 264, 297], ["homogeneous", "OBSERVATION_MODIFIER", 87, 98], ["prefusion conformation", "OBSERVATION", 122, 144]]], ["Furthermore, atomic-level details will enable the design and screening of small molecules that inhibit fusion.", [["small molecules", "PROBLEM", 74, 89], ["small", "OBSERVATION_MODIFIER", 74, 79]]], ["Since SARS-CoV-2 and SARS-CoV RBD domains share 75% amino acid sequence identity, future work will be necessary to evaluate whether any of these Abs neutralize newly emerged coronavirus.", [["amino acid", "CHEMICAL", 52, 62], ["amino acid", "CHEMICAL", 52, 62], ["SARS-CoV-2", "ORGANISM", 6, 16], ["SARS-CoV", "ORGANISM", 21, 29], ["amino acid", "AMINO_ACID", 52, 62], ["Abs", "GENE_OR_GENE_PRODUCT", 145, 148], ["coronavirus", "ORGANISM", 174, 185], ["SARS-CoV-2 and SARS-CoV RBD domains", "DNA", 6, 41], ["Abs", "PROTEIN", 145, 148], ["SARS-CoV", "SPECIES", 21, 29], ["SARS", "TEST", 6, 10], ["CoV", "TEST", 11, 14], ["SARS", "PROBLEM", 21, 25], ["CoV RBD domains", "TEST", 26, 41], ["amino acid sequence identity", "PROBLEM", 52, 80], ["coronavirus", "PROBLEM", 174, 185]]], ["Overall, interaction between the S protein of SARS-CoV-2 and ACE2 should be further studied to contribute elucidation of the mechanism of SARS-CoV-2 infection.", [["infection", "DISEASE", 149, 158], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 46, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["SARS-CoV-2", "ORGANISM", 138, 148], ["S protein", "PROTEIN", 33, 42], ["SARS-CoV-2", "PROTEIN", 46, 56], ["ACE2", "PROTEIN", 61, 65], ["SARS-CoV", "SPECIES", 46, 54], ["SARS-CoV-2", "SPECIES", 138, 148], ["SARS", "PROBLEM", 46, 50], ["ACE2", "TREATMENT", 61, 65], ["SARS", "PROBLEM", 138, 142], ["CoV-2 infection", "PROBLEM", 143, 158], ["SARS", "OBSERVATION", 138, 142], ["infection", "OBSERVATION", 149, 158]]], ["Similarly, focusing on high expression of the S protein or its receptor binding region is also of great significance for the development of vaccines.Future aspects of the development of antivirus drugs targeting the SARS-Cov-2 S proteinThe S2 subunit of SARS-CoV-2 shows 88% sequence homology with the SARS-CoV S2 domain and is structurally conserved.", [["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 216, 226], ["S2", "GENE_OR_GENE_PRODUCT", 240, 242], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 254, 264], ["S protein", "PROTEIN", 46, 55], ["SARS-Cov-2 S protein", "PROTEIN", 216, 236], ["S2 subunit", "PROTEIN", 240, 250], ["SARS-CoV-2", "PROTEIN", 254, 264], ["SARS-CoV S2 domain", "PROTEIN", 302, 320], ["SARS-CoV", "SPECIES", 254, 262], ["SARS-CoV", "SPECIES", 302, 310], ["the S protein", "PROBLEM", 42, 55], ["vaccines", "TREATMENT", 140, 148], ["antivirus drugs", "TREATMENT", 186, 201], ["the SARS", "TEST", 212, 220], ["Cov", "TEST", 221, 224], ["SARS", "TEST", 254, 258], ["CoV", "TEST", 259, 262], ["the SARS", "TEST", 298, 306], ["antivirus", "OBSERVATION", 186, 195]]], ["Therefore, the development of antibodies targeting this functional motif may cross-bind and neutralize these two viruses and related CoVs.", [["CoVs", "GENE_OR_GENE_PRODUCT", 133, 137], ["antibodies", "PROTEIN", 30, 40], ["antibodies", "TREATMENT", 30, 40], ["this functional motif", "PROBLEM", 51, 72], ["viruses", "OBSERVATION", 113, 120]]], ["Antiviral peptides prevent SARS-CoV-2 membrane fusion and can potentially be used for the prevention and treatment of infection.", [["membrane", "ANATOMY", 38, 46], ["infection", "DISEASE", 118, 127], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["Antiviral peptides", "TREATMENT", 0, 18], ["SARS", "PROBLEM", 27, 31], ["CoV-2 membrane fusion", "TREATMENT", 32, 53], ["infection", "PROBLEM", 118, 127], ["infection", "OBSERVATION", 118, 127]]], ["It is worth mentioning that EK1C4, which targets the highly conserved HR1 domain of the S2 subunit, is expected to have therapeutic potential against SARS-CoV-2.", [["EK1C4", "CHEMICAL", 28, 33], ["EK1C4", "GENE_OR_GENE_PRODUCT", 28, 33], ["S2", "GENE_OR_GENE_PRODUCT", 88, 90], ["SARS-CoV-2", "ORGANISM", 150, 160], ["EK1C4", "PROTEIN", 28, 33], ["HR1 domain", "PROTEIN", 70, 80], ["S2 subunit", "PROTEIN", 88, 98], ["SARS-CoV", "SPECIES", 150, 158], ["SARS", "PROBLEM", 150, 154], ["CoV", "TEST", 155, 158]]], ["More importantly, EK1C4 can be used as a nasal drop, which increases its medicinal properties, it possesses a high genetic barrier to resistance, and does not easily induce drug-resistant mutations.", [["nasal", "ANATOMY", 41, 46], ["EK1C4", "CHEMICAL", 18, 23], ["EK1C4", "SIMPLE_CHEMICAL", 18, 23], ["EK1C4", "PROTEIN", 18, 23], ["a nasal drop", "PROBLEM", 39, 51], ["resistant mutations", "PROBLEM", 178, 197], ["nasal", "ANATOMY", 41, 46], ["drop", "OBSERVATION", 47, 51], ["medicinal properties", "OBSERVATION_MODIFIER", 73, 93]]], ["On the other hand, peptide fusion inhibitors may not be widely used clinically and have low bioavailability.", [["peptide fusion inhibitors", "TREATMENT", 19, 44], ["fusion", "OBSERVATION", 27, 33]]], ["Therefore, the development of oral small molecule fusion inhibitors is a major direction.Future aspects of the development of antivirus drugs targeting the SARS-Cov-2 S proteinIn the course of virus epidemics, the ability to adapt to external pressure is an important factor affecting the spread of the virus.", [["oral", "ANATOMY", 30, 34], ["SARS", "DISEASE", 156, 160], ["oral", "ORGANISM_SUBDIVISION", 30, 34], ["SARS-Cov-2 S proteinIn", "DNA", 156, 178], ["oral small molecule fusion inhibitors", "TREATMENT", 30, 67], ["antivirus drugs", "TREATMENT", 126, 141], ["the SARS", "TEST", 152, 160], ["Cov", "TEST", 161, 164], ["virus epidemics", "PROBLEM", 193, 208], ["external pressure", "TEST", 234, 251], ["the virus", "PROBLEM", 299, 308], ["small molecule", "OBSERVATION", 35, 49], ["fusion inhibitors", "OBSERVATION", 50, 67], ["antivirus", "OBSERVATION", 126, 135]]], ["Regarding the envelope S protein, recombination or mutation in the gene of its RBD can occur to promote transmission between different hosts and lead to a higher fatality rate [81].", [["RBD", "GENE_OR_GENE_PRODUCT", 79, 82], ["envelope S protein", "PROTEIN", 14, 32], ["RBD", "PROTEIN", 79, 82], ["the envelope S protein", "TREATMENT", 10, 32], ["mutation", "PROBLEM", 51, 59], ["its RBD", "PROBLEM", 75, 82]]], ["Mutation of the aspartate (D) at position 614 to glycine (G614) results in a more pathogenic strain of SARS-CoV-2 [82], which makes it more difficult to develop antibodies or vaccines that target nonconservative regions.", [["aspartate", "CHEMICAL", 16, 25], ["glycine", "CHEMICAL", 49, 56], ["G614", "CHEMICAL", 58, 62], ["SARS", "DISEASE", 103, 107], ["aspartate", "CHEMICAL", 16, 25], ["glycine", "CHEMICAL", 49, 56], ["aspartate", "AMINO_ACID", 16, 25], ["D", "AMINO_ACID", 27, 28], ["position 614", "AMINO_ACID", 33, 45], ["glycine", "AMINO_ACID", 49, 56], ["G614", "AMINO_ACID", 58, 62], ["SARS-CoV-2", "ORGANISM", 103, 113], ["aspartate (D)", "PROTEIN", 16, 29], ["antibodies", "PROTEIN", 161, 171], ["SARS-CoV", "SPECIES", 103, 111], ["Mutation of the aspartate (D) at position", "PROBLEM", 0, 41], ["a more pathogenic strain of SARS", "PROBLEM", 75, 107], ["CoV", "TEST", 108, 111], ["antibodies", "PROBLEM", 161, 171], ["vaccines", "TREATMENT", 175, 183]]], ["To effectively prevent disease, combinations of different mAbs that identify different epitopes on the SARS-CoV-2 S surface can be assessed to neutralize a wide range of isolates, including escape mutants [83].Future aspects of the development of antivirus drugs targeting the SARS-Cov-2 S proteinCurrently, no specific therapeutic or prophylactic has been used clinically to treat or prevent SARS-CoV-2 infection.", [["SARS", "DISEASE", 277, 281], ["SARS-CoV-2 infection", "DISEASE", 393, 413], ["SARS-CoV-2", "ORGANISM", 393, 403], ["mAbs", "PROTEIN", 58, 62], ["epitopes", "PROTEIN", 87, 95], ["SARS-CoV-2", "SPECIES", 393, 403], ["disease", "PROBLEM", 23, 30], ["different mAbs", "TREATMENT", 48, 62], ["different epitopes", "PROBLEM", 77, 95], ["the SARS", "TEST", 99, 107], ["escape mutants", "PROBLEM", 190, 204], ["antivirus drugs", "TREATMENT", 247, 262], ["the SARS", "TEST", 273, 281], ["prophylactic", "TREATMENT", 335, 347], ["SARS", "PROBLEM", 393, 397], ["CoV", "PROBLEM", 398, 401], ["2 infection", "PROBLEM", 402, 413], ["disease", "OBSERVATION", 23, 30], ["antivirus", "OBSERVATION", 247, 256], ["infection", "OBSERVATION", 404, 413]]], ["Nonspecific antiviral drugs, such as IFN-\u03b1 (recombinant human IFN-\u03b11b, IFN-\u03b12a), remdesivir, chloroquine, favipiravir, and lopinavir\u2013ritonavir (Aluvia), have been clinically used to treat COVID-19 in China [84].", [["IFN-\u03b1", "CHEMICAL", 37, 42], ["IFN-\u03b11b, IFN-\u03b12a", "CHEMICAL", 62, 78], ["remdesivir", "CHEMICAL", 81, 91], ["chloroquine", "CHEMICAL", 93, 104], ["favipiravir", "CHEMICAL", 106, 117], ["lopinavir\u2013ritonavir", "CHEMICAL", 123, 142], ["Aluvia", "CHEMICAL", 144, 150], ["remdesivir", "CHEMICAL", 81, 91], ["chloroquine", "CHEMICAL", 93, 104], ["favipiravir", "CHEMICAL", 106, 117], ["lopinavir\u2013ritonavir", "CHEMICAL", 123, 142], ["Aluvia", "CHEMICAL", 144, 150], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 37, 42], ["human", "ORGANISM", 56, 61], ["IFN-\u03b11b", "GENE_OR_GENE_PRODUCT", 62, 69], ["IFN-\u03b12a", "SIMPLE_CHEMICAL", 71, 78], ["remdesivir", "SIMPLE_CHEMICAL", 81, 91], ["chloroquine", "SIMPLE_CHEMICAL", 93, 104], ["favipiravir", "SIMPLE_CHEMICAL", 106, 117], ["lopinavir\u2013ritonavir", "SIMPLE_CHEMICAL", 123, 142], ["Aluvia", "SIMPLE_CHEMICAL", 144, 150], ["IFN", "PROTEIN", 37, 40], ["\u03b1", "PROTEIN", 41, 42], ["IFN", "PROTEIN", 62, 65], ["IFN", "PROTEIN", 71, 74], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["Nonspecific antiviral drugs", "TREATMENT", 0, 27], ["IFN", "TEST", 37, 40], ["recombinant human IFN", "TREATMENT", 44, 65], ["IFN", "TREATMENT", 71, 74], ["remdesivir", "TREATMENT", 81, 91], ["chloroquine", "TREATMENT", 93, 104], ["favipiravir", "TREATMENT", 106, 117], ["lopinavir\u2013ritonavir (Aluvia)", "TREATMENT", 123, 151], ["COVID", "TEST", 188, 193], ["antiviral drugs", "OBSERVATION", 12, 27]]], ["Nevertheless, NIAID-VRC scientists are developing a candidate vaccine expressing SARS-CoV-2 S protein in mRNA vaccine platform technology.", [["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 81, 93], ["SARS-CoV-2 S protein", "PROTEIN", 81, 101], ["a candidate vaccine", "TREATMENT", 50, 69], ["CoV", "TEST", 86, 89]]], ["Clinical trials of the vaccine are expected in the coming months.", [["the vaccine", "TREATMENT", 19, 30]]], ["Continued strengthening of the monitoring of the SARS-CoV-2 S protein is of great significance for subsequent new drug development and protection against COVID-19.", [["SARS", "DISEASE", 49, 53], ["COVID-19", "CHEMICAL", 154, 162], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 49, 61], ["SARS-CoV-2 S protein", "PROTEIN", 49, 69], ["the monitoring", "TEST", 27, 41], ["the SARS", "TEST", 45, 53], ["CoV-2 S protein", "TEST", 54, 69], ["COVID", "TEST", 154, 159]]]], "93d4431bafc8d70488255f6e45332e4a4eb28027": [["[3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, successful clinical translation of VSV has been hindered by a number of factors, including neurovirulence, liver toxicity, and variable sensitivity of malignant tumors to VSV oncotherapy.", [["liver", "ANATOMY", 159, 164], ["malignant tumors", "ANATOMY", 203, 219], ["[3] [4] [5] [6", "CHEMICAL", 0, 14], ["liver toxicity", "DISEASE", 159, 173], ["malignant tumors", "DISEASE", 203, 219], ["[3] [4] [5] [6] [7] [8] [9] [10] [11", "SIMPLE_CHEMICAL", 0, 36], ["VSV", "ORGANISM", 87, 90], ["liver", "ORGAN", 159, 164], ["malignant tumors", "CANCER", 203, 219], ["VSV", "ORGANISM", 223, 226], ["VSV", "SPECIES", 87, 90], ["VSV", "SPECIES", 223, 226], ["neurovirulence", "PROBLEM", 143, 157], ["liver toxicity", "PROBLEM", 159, 173], ["malignant tumors", "PROBLEM", 203, 219], ["VSV oncotherapy", "TREATMENT", 223, 238], ["liver", "ANATOMY", 159, 164], ["malignant", "OBSERVATION_MODIFIER", 203, 212], ["tumors", "OBSERVATION", 213, 219], ["VSV oncotherapy", "OBSERVATION", 223, 238]]], ["3, 4, [13] [14] [15] [16] [17] [18] Several studies have attempted to remedy these limitations, with varying degrees of success.", [["3, 4, [13] [14] [15] [16] [17] [18", "SIMPLE_CHEMICAL", 0, 34], ["Several studies", "TEST", 36, 51]]], ["[19] [20] [21] However, additional investigations and new approaches are needed before VSV-based virotherapy can be used clinically to treat human cancers. able to cross the human blood-brain barrier and propagate in the brain, treatment with VSV-FH will allow for mitigation of neurotoxicity because most normal neuronal cells lack surface expression of CD46, [27] [28] [29] [30] which VSV-FH uses for cellular entry by virtue of its oncolytic MV attribute.", [["cancers", "ANATOMY", 147, 154], ["blood-brain barrier", "ANATOMY", 180, 199], ["brain", "ANATOMY", 221, 226], ["neuronal cells", "ANATOMY", 313, 327], ["surface", "ANATOMY", 333, 340], ["cellular", "ANATOMY", 403, 411], ["cancers", "DISEASE", 147, 154], ["neurotoxicity", "DISEASE", 279, 292], ["VSV", "ORGANISM", 87, 90], ["human", "ORGANISM", 141, 146], ["cancers", "CANCER", 147, 154], ["human", "ORGANISM", 174, 179], ["blood-", "MULTI-TISSUE_STRUCTURE", 180, 186], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 186, 199], ["brain", "ORGAN", 221, 226], ["VSV", "ORGANISM", 243, 246], ["neuronal cells", "CELL", 313, 327], ["surface", "CELLULAR_COMPONENT", 333, 340], ["CD46", "GENE_OR_GENE_PRODUCT", 355, 359], ["[27] [28] [29] [30]", "SIMPLE_CHEMICAL", 361, 380], ["VSV", "ORGANISM", 387, 390], ["cellular", "CELL", 403, 411], ["normal neuronal cells", "CELL_TYPE", 306, 327], ["CD46", "PROTEIN", 355, 359], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 174, 179], ["VSV", "SPECIES", 87, 90], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 174, 179], ["VSV", "SPECIES", 243, 246], ["MV", "SPECIES", 445, 447], ["additional investigations", "TEST", 24, 49], ["new approaches", "TREATMENT", 54, 68], ["VSV-based virotherapy", "TREATMENT", 87, 108], ["human cancers", "PROBLEM", 141, 154], ["VSV", "TREATMENT", 243, 246], ["neurotoxicity", "PROBLEM", 279, 292], ["CD46", "TEST", 355, 359], ["cancers", "OBSERVATION", 147, 154], ["brain", "ANATOMY", 186, 191], ["brain", "ANATOMY", 221, 226]]], ["22, 25, 26 VSV-FH has a robust and rapid lytic cycle attributable to the VSV platform and a preferential tropism for CD46-overexpressed cells from the MV platform.", [["cells", "ANATOMY", 136, 141], ["VSV", "ORGANISM", 11, 14], ["VSV", "ORGANISM", 73, 76], ["CD46", "GENE_OR_GENE_PRODUCT", 117, 121], ["cells", "CELL", 136, 141], ["CD46", "PROTEIN", 117, 121], ["VSV", "SPECIES", 73, 76], ["MV", "SPECIES", 151, 153], ["a robust and rapid lytic cycle", "PROBLEM", 22, 52], ["the VSV platform", "TEST", 69, 85], ["CD46", "TEST", 117, 121], ["overexpressed cells", "PROBLEM", 122, 141]]], ["CD46 is ubiquitously expressed in all nucleated cells; however, its overexpression has been reported in human tumor cells and tissues, including HPBCs.", [["nucleated cells", "ANATOMY", 38, 53], ["tumor cells", "ANATOMY", 110, 121], ["tissues", "ANATOMY", 126, 133], ["HPBCs", "ANATOMY", 145, 150], ["tumor", "DISEASE", 110, 115], ["CD46", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 48, 53], ["human", "ORGANISM", 104, 109], ["tumor cells", "CELL", 110, 121], ["tissues", "TISSUE", 126, 133], ["HPBCs", "CELL", 145, 150], ["CD46", "PROTEIN", 0, 4], ["nucleated cells", "CELL_TYPE", 38, 53], ["human tumor cells", "CELL_TYPE", 104, 121], ["HPBCs", "CELL_TYPE", 145, 150], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["CD46", "PROBLEM", 0, 4], ["all nucleated cells", "PROBLEM", 34, 53], ["HPBCs", "TEST", 145, 150], ["all", "OBSERVATION_MODIFIER", 34, 37], ["nucleated cells", "OBSERVATION", 38, 53], ["tumor cells", "OBSERVATION", 110, 121]]], ["[31] [32] [33] [34] [35] [36] [37] We have previously shown that hybrid VSV-FH mediates a higher degree of human tumor selectivity, which is strongly associated with the number of CD46 molecules expressed on target cells.", [["tumor", "ANATOMY", 113, 118], ["cells", "ANATOMY", 215, 220], ["tumor", "DISEASE", 113, 118], ["[31] [32] [33] [34] [35] [36] [37", "SIMPLE_CHEMICAL", 0, 33], ["VSV", "ORGANISM", 72, 75], ["human", "ORGANISM", 107, 112], ["tumor", "CANCER", 113, 118], ["CD46", "GENE_OR_GENE_PRODUCT", 180, 184], ["cells", "CELL", 215, 220], ["CD46 molecules", "PROTEIN", 180, 194], ["target cells", "CELL_TYPE", 208, 220], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["hybrid VSV", "PROBLEM", 65, 75], ["human tumor selectivity", "PROBLEM", 107, 130], ["CD46 molecules", "PROBLEM", 180, 194], ["higher degree", "OBSERVATION_MODIFIER", 90, 103], ["tumor selectivity", "OBSERVATION", 113, 130]]], ["26 We also demonstrated that the multifaceted mechanisms of cancer-cell killing by VSV-FH are enhanced because of its inherent fusogenic activity.", [["cancer", "ANATOMY", 60, 66], ["cell", "ANATOMY", 67, 71], ["cancer", "DISEASE", 60, 66], ["cancer-cell", "CELL", 60, 71], ["VSV-FH", "ORGANISM", 83, 89], ["VSV", "SPECIES", 83, 86], ["cancer", "PROBLEM", 60, 66], ["cell killing", "PROBLEM", 67, 79], ["multifaceted", "OBSERVATION_MODIFIER", 33, 45], ["cancer", "OBSERVATION", 60, 66], ["cell killing", "OBSERVATION", 67, 79], ["inherent", "OBSERVATION_MODIFIER", 118, 126], ["fusogenic activity", "OBSERVATION", 127, 145]]], ["25, 26 Furthermore, we showed that treatment with VSV-FH has the added benefit of being well-tolerated and less neurotoxic in laboratory rodents than parental wild-type (wt)-VSV, which causes severe encephalitis in laboratory animals.", [["VSV-FH", "CHEMICAL", 50, 56], ["neurotoxic", "DISEASE", 112, 122], ["encephalitis", "DISEASE", 199, 211], ["VSV-FH", "ORGANISM", 50, 56], ["wild-type (wt)-VSV", "ORGANISM", 159, 177], ["VSV", "SPECIES", 50, 53], ["VSV", "SPECIES", 174, 177], ["VSV", "TREATMENT", 50, 53], ["less neurotoxic", "PROBLEM", 107, 122], ["VSV", "PROBLEM", 174, 177], ["severe encephalitis in laboratory animals", "PROBLEM", 192, 233], ["severe", "OBSERVATION_MODIFIER", 192, 198], ["encephalitis", "OBSERVATION", 199, 211]]], ["25, 26 HPBCs have extremely high rates of mortality and are increasing in incidence.", [["HPBCs", "TEST", 7, 12], ["extremely high rates of mortality", "PROBLEM", 18, 51], ["increasing", "OBSERVATION_MODIFIER", 60, 70]]], ["38 HBPCs.VSV-FH-eGFP Infectivity in HBPC CellsAs previously described, the oncolytic virus VSV-FH-enhanced green fluorescent protein (eGFP) was generated by substitution of the VSV-Cell-Killing Activity of VSV-FH-eGFPTo further investigate the difference in the infectivity and CPE ofVSV-FH Safety Studies in CD46 Transgenic MiceTo determine whether VSV-FH is causally associated with liver damage and liver toxicity in animal models.", [["HBPCs", "ANATOMY", 3, 8], ["liver", "ANATOMY", 385, 390], ["liver", "ANATOMY", 402, 407], ["FH", "DISEASE", 354, 356], ["liver damage", "DISEASE", 385, 397], ["liver toxicity", "DISEASE", 402, 416], ["HBPCs", "CANCER", 3, 8], ["VSV-FH-eGFP", "ORGANISM", 9, 20], ["HBPC CellsAs", "CELL", 36, 48], ["oncolytic virus VSV", "ORGANISM", 75, 94], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 107, 132], ["eGFP", "GENE_OR_GENE_PRODUCT", 134, 138], ["VSV", "ORGANISM", 177, 180], ["Cell", "CELL", 181, 185], ["VSV-FH-eGFPTo", "ORGANISM", 206, 219], ["CD46", "GENE_OR_GENE_PRODUCT", 309, 313], ["VSV-FH", "ORGANISM", 350, 356], ["liver", "ORGAN", 385, 390], ["liver", "ORGAN", 402, 407], ["oncolytic virus VSV-FH-enhanced green fluorescent protein", "PROTEIN", 75, 132], ["eGFP", "PROTEIN", 134, 138], ["CD46", "PROTEIN", 309, 313], ["oncolytic virus VSV", "SPECIES", 75, 94], ["VSV", "SPECIES", 9, 12], ["HBPC", "SPECIES", 36, 40], ["VSV", "SPECIES", 91, 94], ["VSV", "SPECIES", 350, 353], ["VSV", "TEST", 9, 12], ["FH-eGFP Infectivity in HBPC CellsAs", "PROBLEM", 13, 48], ["the oncolytic virus VSV", "TEST", 71, 94], ["enhanced green fluorescent protein", "PROBLEM", 98, 132], ["the VSV", "TEST", 173, 180], ["the infectivity", "PROBLEM", 258, 273], ["CPE ofVSV", "TEST", 278, 287], ["liver damage", "PROBLEM", 385, 397], ["liver toxicity", "PROBLEM", 402, 416], ["causally associated with", "UNCERTAINTY", 360, 384], ["liver", "ANATOMY", 385, 390], ["damage", "OBSERVATION", 391, 397], ["liver", "ANATOMY", 402, 407], ["toxicity", "OBSERVATION", 408, 416]]], ["Analyses of multiple toxicology parameters, including complete blood counts (CBC), serum chemistry, and liver function tests, were performed at 2, 21, and 45 days after treatment.", [["blood", "ANATOMY", 63, 68], ["serum", "ANATOMY", 83, 88], ["liver", "ANATOMY", 104, 109], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["liver", "ORGAN", 104, 109], ["multiple toxicology parameters", "TEST", 12, 42], ["complete blood counts", "TEST", 54, 75], ["CBC", "TEST", 77, 80], ["serum chemistry", "TEST", 83, 98], ["liver function tests", "TEST", 104, 124], ["treatment", "TREATMENT", 169, 178], ["liver", "ANATOMY", 104, 109]]], ["As shown in Figure although body weight consistently increased from 4 days after injection until the end of the study ( Figure 4B ).VSV-FH Safety Studies in CD46 Transgenic MiceAs shown in Figure Collectively, these data indicate that intrahepatic injection of VSV-FH did not elicit significant liver toxicity in the treated animals (100% survival) or result in impairment (Kaplan-Meier method, P<.05).Oncolytic Activity of VSV-FH Against HBPC XenograftsHep3B ( Hep3B cohort resulted in a significant difference in overall survival (P=.01Oncolytic Activity of VSV-FH Against HBPC Xenografts[ Figure 5C ]), indicating effectiveness of treatment with VSV-FH.DiscussionIn this study, we evaluated whether treatment with oncolytic VSV-FH could trigger a potent cytotoxicity effect in HBPC cell lines in vitro and in vivo using animal models.", [["body", "ANATOMY", 28, 32], ["intrahepatic", "ANATOMY", 235, 247], ["liver", "ANATOMY", 295, 300], ["Hep3B", "ANATOMY", 462, 467], ["HBPC cell lines", "ANATOMY", 780, 795], ["VSV-FH", "CHEMICAL", 261, 267], ["liver toxicity", "DISEASE", 295, 309], ["VSV-FH", "CHEMICAL", 727, 733], ["body", "ORGANISM_SUBDIVISION", 28, 32], ["VSV", "ORGANISM", 132, 135], ["CD46", "GENE_OR_GENE_PRODUCT", 157, 161], ["intrahepatic", "IMMATERIAL_ANATOMICAL_ENTITY", 235, 247], ["VSV-FH", "ORGANISM", 261, 267], ["liver", "ORGAN", 295, 300], ["VSV", "ORGANISM", 424, 427], ["HBPC XenograftsHep3B", "CELL", 439, 459], ["Hep3B", "CANCER", 462, 467], ["VSV", "ORGANISM", 560, 563], ["VSV", "ORGANISM", 649, 652], ["VSV-FH", "ORGANISM", 727, 733], ["HBPC cell lines", "CELL", 780, 795], ["CD46", "PROTEIN", 157, 161], ["HBPC cell lines", "CELL_LINE", 780, 795], ["VSV", "SPECIES", 132, 135], ["VSV", "SPECIES", 261, 264], ["VSV", "SPECIES", 424, 427], ["VSV", "SPECIES", 649, 652], ["VSV", "SPECIES", 727, 730], ["HBPC", "SPECIES", 780, 784], ["body weight", "TEST", 28, 39], ["the study", "TEST", 108, 117], ["significant liver toxicity", "PROBLEM", 283, 309], ["HBPC XenograftsHep3B ( Hep3B cohort", "TREATMENT", 439, 474], ["P", "TEST", 533, 534], ["Oncolytic Activity of VSV", "TREATMENT", 538, 563], ["HBPC Xenografts", "TREATMENT", 575, 590], ["treatment", "TREATMENT", 634, 643], ["VSV", "TREATMENT", 649, 652], ["this study", "TEST", 669, 679], ["oncolytic VSV", "TREATMENT", 717, 730], ["a potent cytotoxicity effect", "PROBLEM", 748, 776], ["HBPC cell lines", "TREATMENT", 780, 795], ["intrahepatic", "ANATOMY", 235, 247], ["significant", "OBSERVATION_MODIFIER", 283, 294], ["liver", "ANATOMY", 295, 300], ["toxicity", "OBSERVATION", 301, 309], ["cell lines", "OBSERVATION", 785, 795]]], ["We conducted a causality assessment in the context of potential VSV-FH-induced liver damage and toxicity in a human CD46 transgenic mouse model, expressing murine interferon alpha receptor (CD46 IFN\u03b1R wt/wt).", [["liver", "ANATOMY", 79, 84], ["FH", "DISEASE", 68, 70], ["liver damage", "DISEASE", 79, 91], ["toxicity", "DISEASE", 96, 104], ["VSV", "ORGANISM", 64, 67], ["liver", "ORGAN", 79, 84], ["human", "ORGANISM", 110, 115], ["CD46", "GENE_OR_GENE_PRODUCT", 116, 120], ["mouse", "ORGANISM", 132, 137], ["murine", "ORGANISM", 156, 162], ["interferon alpha receptor", "GENE_OR_GENE_PRODUCT", 163, 188], ["CD46", "GENE_OR_GENE_PRODUCT", 190, 194], ["CD46", "PROTEIN", 116, 120], ["murine interferon alpha receptor", "PROTEIN", 156, 188], ["CD46 IFN\u03b1R", "PROTEIN", 190, 200], ["human", "SPECIES", 110, 115], ["mouse", "SPECIES", 132, 137], ["murine", "SPECIES", 156, 162], ["VSV", "SPECIES", 64, 67], ["human", "SPECIES", 110, 115], ["mouse", "SPECIES", 132, 137], ["a causality assessment", "TEST", 13, 35], ["potential VSV", "PROBLEM", 54, 67], ["FH", "PROBLEM", 68, 70], ["liver damage", "PROBLEM", 79, 91], ["toxicity", "PROBLEM", 96, 104], ["a human CD46 transgenic mouse model", "TREATMENT", 108, 143], ["expressing murine interferon alpha receptor", "TREATMENT", 145, 188], ["VSV", "OBSERVATION", 64, 67], ["liver", "ANATOMY", 79, 84], ["damage", "OBSERVATION", 85, 91]]], ["This particular mouse strain has been shown to be susceptible to infections by viruses that use human CD46 as entry receptor, including measles virus, VSV-FH and some adenoviruses.", [["infections", "DISEASE", 65, 75], ["mouse", "ORGANISM", 16, 21], ["human", "ORGANISM", 96, 101], ["CD46", "GENE_OR_GENE_PRODUCT", 102, 106], ["measles virus", "ORGANISM", 136, 149], ["VSV-FH", "ORGANISM", 151, 157], ["adenoviruses", "ORGANISM", 167, 179], ["human CD46", "PROTEIN", 96, 106], ["entry receptor", "PROTEIN", 110, 124], ["mouse", "SPECIES", 16, 21], ["human", "SPECIES", 96, 101], ["measles virus", "SPECIES", 136, 149], ["mouse", "SPECIES", 16, 21], ["human", "SPECIES", 96, 101], ["measles virus", "SPECIES", 136, 149], ["VSV", "SPECIES", 151, 154], ["This particular mouse strain", "PROBLEM", 0, 28], ["infections", "PROBLEM", 65, 75], ["viruses", "PROBLEM", 79, 86], ["human CD46", "TREATMENT", 96, 106], ["entry receptor", "TREATMENT", 110, 124], ["measles virus", "PROBLEM", 136, 149], ["some adenoviruses", "PROBLEM", 162, 179], ["infections", "OBSERVATION", 65, 75], ["adenoviruses", "OBSERVATION", 167, 179]]], ["30,45 46 Additionally, we compared cytotoxic effects of VSV-FH with that of another recombinant, neuro-attenuated VSV that is currently being evaluated in a clinical trial (VSV-hIFN\u03b2-NIS).", [["VSV-FH", "CHEMICAL", 56, 62], ["VSV", "ORGANISM", 56, 59], ["-FH", "SIMPLE_CHEMICAL", 59, 62], ["VSV", "ORGANISM", 114, 117], ["VSV", "ORGANISM", 173, 176], ["\u03b2-NIS", "GENE_OR_GENE_PRODUCT", 181, 186], ["NIS", "PROTEIN", 183, 186], ["VSV", "SPECIES", 56, 59], ["VSV", "SPECIES", 114, 117], ["neuro-attenuated VSV", "PROBLEM", 97, 117], ["VSV", "TEST", 173, 176]]], ["14 In this study, we showed that VSV-FH High intrahepatic doses of VSV-FH in healthy transgenic mice expressing human CD46 were found to be manageable, safe, and tolerable.DiscussionThere was a no statistically significant increase in liver enzyme levels (ALT, AST), granulocytes, and total bilirubin at the end of study, but not in alkaline phosphatase.", [["liver", "ANATOMY", 235, 240], ["granulocytes", "ANATOMY", 267, 279], ["bilirubin", "CHEMICAL", 291, 300], ["bilirubin", "CHEMICAL", 291, 300], ["VSV-FH", "ORGANISM", 33, 39], ["VSV-FH", "ORGANISM", 67, 73], ["mice", "ORGANISM", 96, 100], ["human", "ORGANISM", 112, 117], ["CD46", "GENE_OR_GENE_PRODUCT", 118, 122], ["liver", "ORGAN", 235, 240], ["ALT", "SIMPLE_CHEMICAL", 256, 259], ["AST", "SIMPLE_CHEMICAL", 261, 264], ["granulocytes", "CELL", 267, 279], ["bilirubin", "SIMPLE_CHEMICAL", 291, 300], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 333, 353], ["human CD46", "PROTEIN", 112, 122], ["liver enzyme", "PROTEIN", 235, 247], ["ALT", "PROTEIN", 256, 259], ["AST", "PROTEIN", 261, 264], ["granulocytes", "CELL_TYPE", 267, 279], ["alkaline phosphatase", "PROTEIN", 333, 353], ["mice", "SPECIES", 96, 100], ["human", "SPECIES", 112, 117], ["VSV", "SPECIES", 33, 36], ["VSV", "SPECIES", 67, 70], ["mice", "SPECIES", 96, 100], ["human", "SPECIES", 112, 117], ["this study", "TEST", 6, 16], ["VSV", "TEST", 33, 36], ["human CD46", "TEST", 112, 122], ["statistically significant increase in liver enzyme levels", "PROBLEM", 197, 254], ["ALT", "TEST", 256, 259], ["AST", "TEST", 261, 264], ["granulocytes", "TEST", 267, 279], ["total bilirubin", "TEST", 285, 300], ["study", "TEST", 315, 320], ["alkaline phosphatase", "TEST", 333, 353], ["intrahepatic", "ANATOMY", 45, 57], ["no", "UNCERTAINTY", 194, 196], ["significant", "OBSERVATION_MODIFIER", 211, 222], ["increase", "OBSERVATION_MODIFIER", 223, 231], ["liver", "ANATOMY", 235, 240], ["granulocytes", "ANATOMY", 267, 279]]], ["In the absence of severe toxic effects, we deduced that these increases may not result in clinically significant sequelae and could have been confounded by blood hemolysis from the terminal cardiac puncture, which is known to interfere with the measurement of liverSusceptibility and Effect of VSV-FH in HBPC CellsVSV-FH-eGFP was used to infect 5\u00d710 5Viral Particle Production in HBPC CellsTo determine the production of VSV-FH infectious particles,Viability Assay for HBPC Cells After Infection With VSV-FHFor cell viability assays, 1.Animal StudiesUnder a Mayo Clinic Institutional Animal Care and UseAnimal StudiesCommittee-approved protocol, we conducted the following in vivo evaluations.Studies in CD46 Transgenic MiceTo assess potential toxicity, especially hepatotoxicity, 30", [["blood", "ANATOMY", 156, 161], ["cardiac", "ANATOMY", 190, 197], ["Cells", "ANATOMY", 474, 479], ["cell", "ANATOMY", 511, 515], ["blood hemolysis", "DISEASE", 156, 171], ["toxicity", "DISEASE", 744, 752], ["hepatotoxicity", "DISEASE", 765, 779], ["blood", "ORGANISM_SUBSTANCE", 156, 161], ["cardiac puncture", "MULTI-TISSUE_STRUCTURE", 190, 206], ["VSV-FH", "ORGANISM", 294, 300], ["HBPC CellsVSV-FH-eGFP", "ORGANISM", 304, 325], ["HBPC CellsTo", "CELL", 380, 392], ["VSV", "ORGANISM", 421, 424], ["HBPC Cells", "CELL", 469, 479], ["VSV", "ORGANISM", 501, 504], ["FHFor cell", "CELL", 505, 515], ["CD46", "GENE_OR_GENE_PRODUCT", 704, 708], ["CD46", "PROTEIN", 704, 708], ["VSV", "SPECIES", 294, 297], ["HBPC", "SPECIES", 304, 308], ["HBPC", "SPECIES", 380, 384], ["VSV", "SPECIES", 421, 424], ["HBPC", "SPECIES", 469, 473], ["VSV", "SPECIES", 501, 504], ["severe toxic effects", "PROBLEM", 18, 38], ["clinically significant sequelae", "PROBLEM", 90, 121], ["blood hemolysis", "PROBLEM", 156, 171], ["the terminal cardiac puncture", "TEST", 177, 206], ["liverSusceptibility", "PROBLEM", 260, 279], ["VSV", "TEST", 294, 297], ["VSV", "PROBLEM", 421, 424], ["FH infectious particles", "PROBLEM", 425, 448], ["Viability Assay", "TEST", 449, 464], ["HBPC Cells", "PROBLEM", 469, 479], ["Infection", "PROBLEM", 486, 495], ["VSV", "TEST", 501, 504], ["FHFor cell viability assays", "TEST", 505, 532], ["vivo evaluations", "TEST", 676, 692], ["Studies", "TEST", 693, 700], ["potential toxicity", "PROBLEM", 734, 752], ["hepatotoxicity", "PROBLEM", 765, 779], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["toxic effects", "OBSERVATION", 25, 38], ["blood hemolysis", "OBSERVATION", 156, 171], ["terminal", "OBSERVATION_MODIFIER", 181, 189], ["cardiac", "ANATOMY", 190, 197], ["puncture", "OBSERVATION", 198, 206]]]], "f65bee8a6e0de7af3d87f01064036410a32f5924": [["After determining immunological vigor for individuals, it is necessary to replenish immune defects and restore them to normalcy for individuals with depressed immunological scores.", [["depressed", "DISEASE", 149, 158], ["immune defects", "PROBLEM", 84, 98], ["depressed immunological scores", "PROBLEM", 149, 179]]], ["This chapter provides methods of immunological restoration in animal models and introduces some similar attempts in humans.", [["humans", "ORGANISM", 116, 122], ["humans", "SPECIES", 116, 122], ["humans", "SPECIES", 116, 122], ["immunological restoration", "TREATMENT", 33, 58], ["immunological restoration", "OBSERVATION", 33, 58]]], ["The effect of any immunological restoration varies with the individual and must therefore verified.", [["any immunological restoration", "PROBLEM", 14, 43]]], ["Currently, the proposed immune scoring system proposed is useful to determine whether the methods employed are effective for the restoration of immune functions.IntroductionA decade ago, centenarians used to appear mainly in fairy stories.", [["immune functions", "PROBLEM", 144, 160]]], ["Nowadays centenarians are not uncommon and there are more than 30,000 centenarians in Japan.", [["not", "UNCERTAINTY", 26, 29]]], ["In many countries, the mean life span has increased steadily during the first half of the 20 th century, however, this has not been the case in Japan.", [["increased", "OBSERVATION_MODIFIER", 42, 51], ["steadily", "OBSERVATION_MODIFIER", 52, 60]]], ["The increase in the mean lifespan was outstanding in the second half of the 20 th century (after the Second World War) in Japan.", [["the mean lifespan", "TREATMENT", 16, 33], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["mean lifespan", "OBSERVATION", 20, 33]]], ["This pronounced improvement is attributed to rapid progress of medicine including antibiotics and sufficient food supply including the supply of proteins.IntroductionWHO reports that a \"healthy\" life span is generally 6-10 years shorter than the mean lifespan.", [["medicine", "TREATMENT", 63, 71], ["antibiotics", "TREATMENT", 82, 93], ["attributed to", "UNCERTAINTY", 31, 44], ["rapid", "OBSERVATION_MODIFIER", 45, 50]]], ["This means that many elderly people suffer from some diseases for several years before death.IntroductionIt is well known that the incidence of cancer, cardiovascular disease, neurovascular disease and infection increases with age.", [["cancer", "ANATOMY", 144, 150], ["cardiovascular", "ANATOMY", 152, 166], ["neurovascular", "ANATOMY", 176, 189], ["death", "DISEASE", 87, 92], ["cancer", "DISEASE", 144, 150], ["cardiovascular disease", "DISEASE", 152, 174], ["neurovascular disease", "DISEASE", 176, 197], ["infection", "DISEASE", 202, 211], ["people", "ORGANISM", 29, 35], ["cancer", "CANCER", 144, 150], ["cardiovascular", "ANATOMICAL_SYSTEM", 152, 166], ["neurovascular", "MULTI-TISSUE_STRUCTURE", 176, 189], ["people", "SPECIES", 29, 35], ["some diseases", "PROBLEM", 48, 61], ["death", "PROBLEM", 87, 92], ["cancer", "PROBLEM", 144, 150], ["cardiovascular disease", "PROBLEM", 152, 174], ["neurovascular disease", "PROBLEM", 176, 197], ["infection", "PROBLEM", 202, 211], ["cancer", "OBSERVATION", 144, 150], ["cardiovascular", "ANATOMY", 152, 166], ["disease", "OBSERVATION", 167, 174], ["neurovascular", "ANATOMY", 176, 189], ["disease", "OBSERVATION", 190, 197], ["infection", "OBSERVATION", 202, 211]]], ["Autopsy examinations have revealed that the largest cause of death in the elderly is infections such as bronchopneumonia and urinary tract infection (Table 1a and 1b).", [["urinary tract", "ANATOMY", 125, 138], ["death", "DISEASE", 61, 66], ["infections", "DISEASE", 85, 95], ["bronchopneumonia", "DISEASE", 104, 120], ["urinary tract infection", "DISEASE", 125, 148], ["urinary tract", "ORGANISM_SUBDIVISION", 125, 138], ["Autopsy examinations", "TEST", 0, 20], ["death", "PROBLEM", 61, 66], ["infections", "PROBLEM", 85, 95], ["bronchopneumonia", "PROBLEM", 104, 120], ["urinary tract infection", "PROBLEM", 125, 148], ["largest", "OBSERVATION_MODIFIER", 44, 51], ["death", "OBSERVATION", 61, 66], ["infections", "OBSERVATION", 85, 95], ["bronchopneumonia", "OBSERVATION", 104, 120], ["urinary tract", "ANATOMY", 125, 138], ["infection", "OBSERVATION", 139, 148]]], ["The occurrence of severe acute respiratory syndrome (SARS) in south Asia and China in the winter of 2003 clearly indicated that the fatality rate was high, approximately 50%, in people over 65 years of age (Table 1c ) .", [["acute respiratory syndrome", "DISEASE", 25, 51], ["SARS", "DISEASE", 53, 57], ["people", "ORGANISM", 178, 184], ["people", "SPECIES", 178, 184], ["severe acute respiratory syndrome", "PROBLEM", 18, 51], ["the fatality rate", "TEST", 128, 145], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["respiratory syndrome", "OBSERVATION", 31, 51]]], ["With regard to infection, Pawelec et al. (2004) suggested that chronic antigenic stimulation could lead to an increased prev- alence of senescent dysfunctional T-cells, and therefore contribute to more general alterations in the immune system.", [["T-cells", "ANATOMY", 160, 167], ["immune system", "ANATOMY", 229, 242], ["infection", "DISEASE", 15, 24], ["T-cells", "CELL", 160, 167], ["immune system", "ANATOMICAL_SYSTEM", 229, 242], ["senescent dysfunctional T-cells", "CELL_TYPE", 136, 167], ["infection", "PROBLEM", 15, 24], ["chronic antigenic stimulation", "PROBLEM", 63, 92], ["senescent dysfunctional T-cells", "PROBLEM", 136, 167], ["general alterations in the immune system", "PROBLEM", 202, 242], ["infection", "OBSERVATION", 15, 24], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["antigenic stimulation", "OBSERVATION", 71, 92], ["increased", "OBSERVATION_MODIFIER", 110, 119]]], ["Furthermore, elderly people face an indefinite number of problems such as pain in the shoulder, arm or leg, dizziness, staggering and headaches.", [["shoulder", "ANATOMY", 86, 94], ["arm", "ANATOMY", 96, 99], ["leg", "ANATOMY", 103, 106], ["pain", "DISEASE", 74, 78], ["dizziness", "DISEASE", 108, 117], ["headaches", "DISEASE", 134, 143], ["people", "ORGANISM", 21, 27], ["shoulder", "ORGANISM_SUBDIVISION", 86, 94], ["arm", "ORGANISM_SUBDIVISION", 96, 99], ["leg", "ORGANISM_SUBDIVISION", 103, 106], ["people", "SPECIES", 21, 27], ["pain in the shoulder, arm or leg", "PROBLEM", 74, 106], ["dizziness", "PROBLEM", 108, 117], ["staggering", "PROBLEM", 119, 129], ["headaches", "PROBLEM", 134, 143], ["shoulder", "ANATOMY", 86, 94], ["arm", "ANATOMY", 96, 99], ["leg", "ANATOMY", 103, 106], ["dizziness", "OBSERVATION", 108, 117], ["headaches", "OBSERVATION", 134, 143]]], ["In addition, chronic inflammatory symptoms such as bronchitis, laryngitis or adenoiditis are very common in the elderly.IntroductionAn age-related increase in various diseases is causally related with the age-related decline of immune functions ).", [["bronchitis", "DISEASE", 51, 61], ["laryngitis", "DISEASE", 63, 73], ["adenoiditis", "DISEASE", 77, 88], ["chronic inflammatory symptoms", "PROBLEM", 13, 42], ["bronchitis", "PROBLEM", 51, 61], ["laryngitis", "PROBLEM", 63, 73], ["adenoiditis", "PROBLEM", 77, 88], ["various diseases", "PROBLEM", 159, 175], ["chronic", "OBSERVATION_MODIFIER", 13, 20], ["inflammatory", "OBSERVATION_MODIFIER", 21, 33], ["bronchitis", "OBSERVATION", 51, 61], ["laryngitis", "OBSERVATION", 63, 73], ["increase", "OBSERVATION_MODIFIER", 147, 155], ["various", "OBSERVATION_MODIFIER", 159, 166], ["diseases", "OBSERVATION", 167, 175], ["immune functions", "OBSERVATION", 228, 244]]], ["Indefinite problems are attributable to variable causes including various diseases and psychological stress, but one of the major causes is inadequate adaptation to variable stresses from the external environment.", [["Indefinite problems", "PROBLEM", 0, 19], ["variable causes", "PROBLEM", 40, 55], ["various diseases", "PROBLEM", 66, 82], ["psychological stress", "PROBLEM", 87, 107], ["variable stresses", "PROBLEM", 165, 182], ["various", "OBSERVATION_MODIFIER", 66, 73], ["diseases", "OBSERVATION", 74, 82]]], ["Nervous, endocrine and immune systems work together to maintain the internal environment, when the body is exposed to the stresses from physical, psychological and biological surroundings.", [["endocrine", "ANATOMY", 9, 18], ["body", "ANATOMY", 99, 103], ["Nervous", "ANATOMICAL_SYSTEM", 0, 7], ["endocrine", "ANATOMICAL_SYSTEM", 9, 18], ["body", "ORGANISM_SUBDIVISION", 99, 103]]], ["In the elderly, however, the function of all these three systems declines with age, resulting in improper adaptation to stress.", [["stress", "PROBLEM", 120, 126], ["improper adaptation", "OBSERVATION", 97, 116]]], ["Therefore, restoration of immunological function would be quite helpful for the elderly not only to prevent infection, but also maintain their internal environment at the time of exposure to stress.", [["infection", "DISEASE", 108, 117], ["immunological function", "TEST", 26, 48], ["infection", "PROBLEM", 108, 117], ["stress", "PROBLEM", 191, 197], ["infection", "OBSERVATION", 108, 117]]], ["In other words, immunological restoration is expected to be effective for the improvement of the QOL in the elderly.IntroductionImmunological restoration requires 2 steps.", [["immunological restoration", "PROBLEM", 16, 41], ["IntroductionImmunological restoration", "TREATMENT", 116, 153]]], ["The first is to assess immunological parameters or functions to determine the extent of the age-related decline of immune functions of each individual.", [["immunological parameters", "TEST", 23, 47]]], ["To this end, we require a measuring method to express the level of immunological vigor as a simple numeral that anybody can understand.", [["a measuring method", "TREATMENT", 24, 42], ["immunological vigor", "PROBLEM", 67, 86]]], ["The second is to select adequate methods to restore immunological functions and to check the effectiveness of the selected immunological restoration by the measure- ment method mentioned above, because the effectiveness of immunological restoration differs based on the individual and the method of restoration (Fig. 1) .", [["the selected immunological restoration", "TREATMENT", 110, 148], ["immunological restoration", "TREATMENT", 223, 248], ["restoration (Fig", "TREATMENT", 299, 315]]], ["Thus, this chapter deals with the following; (1) the measurement method to assess the immunological level of individuals, (2) causes of immunological suppression, (3) possible methods of immunological restoration in elderly people.Assessment of Immunological Level as a WholeThe immune system comprises various functions and consists of many types of cells that perform various functions, and it is difficult to select immunological parameters that are suitable for the assessment of immune functions in healthy people and patients suffering from various diseases.Assessment of Immunological Level as a WholeFrom a functional viewpoint, there exist parameters such as cell mediated immunity, humoral immunity, cytokine production, proliferative activity of T-cell and B-cells, antigen presentation of dendritic cells and so on.", [["cells", "ANATOMY", 351, 356], ["cell", "ANATOMY", 668, 672], ["T-cell", "ANATOMY", 757, 763], ["B-cells", "ANATOMY", 768, 775], ["dendritic cells", "ANATOMY", 801, 816], ["people", "ORGANISM", 224, 230], ["cells", "CELL", 351, 356], ["people", "ORGANISM", 512, 518], ["patients", "ORGANISM", 523, 531], ["cell", "CELL", 668, 672], ["T-cell", "CELL", 757, 763], ["B-cells", "CELL", 768, 775], ["dendritic cells", "CELL", 801, 816], ["cytokine", "PROTEIN", 710, 718], ["T-cell and B-cells", "CELL_TYPE", 757, 775], ["dendritic cells", "CELL_TYPE", 801, 816], ["people", "SPECIES", 224, 230], ["people", "SPECIES", 512, 518], ["patients", "SPECIES", 523, 531], ["the measurement method", "TEST", 49, 71], ["immunological suppression", "PROBLEM", 136, 161], ["immunological restoration", "TREATMENT", 187, 212], ["Immunological Level", "TEST", 245, 264], ["many types of cells", "PROBLEM", 337, 356], ["immunological parameters", "TEST", 419, 443], ["the assessment", "TEST", 466, 480], ["various diseases", "PROBLEM", 547, 563], ["cell mediated immunity", "PROBLEM", 668, 690], ["humoral immunity", "TEST", 692, 708], ["cytokine production", "PROBLEM", 710, 729], ["dendritic cells", "PROBLEM", 801, 816], ["various", "OBSERVATION_MODIFIER", 547, 554], ["diseases", "OBSERVATION", 555, 563], ["dendritic cells", "OBSERVATION", 801, 816]]], ["Cells comprising the immune system are T-cells and their subpopulations, B-cells and their subpopulations, NK-cells, NKT-cells, macrophages and dendritic cells.", [["Cells", "ANATOMY", 0, 5], ["immune system", "ANATOMY", 21, 34], ["T-cells", "ANATOMY", 39, 46], ["B-cells", "ANATOMY", 73, 80], ["subpopulations", "ANATOMY", 91, 105], ["NK-cells", "ANATOMY", 107, 115], ["NKT-cells", "ANATOMY", 117, 126], ["macrophages", "ANATOMY", 128, 139], ["dendritic cells", "ANATOMY", 144, 159], ["Cells", "CELL", 0, 5], ["T-cells", "CELL", 39, 46], ["B-cells", "CELL", 73, 80], ["NK-cells", "CELL", 107, 115], ["NKT-cells", "CELL", 117, 126], ["macrophages", "CELL", 128, 139], ["dendritic cells", "CELL", 144, 159], ["T-cells", "CELL_TYPE", 39, 46], ["B-cells", "CELL_TYPE", 73, 80], ["NK-cells", "CELL_TYPE", 107, 115], ["NKT-cells", "CELL_TYPE", 117, 126], ["macrophages", "CELL_TYPE", 128, 139], ["dendritic cells", "CELL_TYPE", 144, 159], ["Cells", "TEST", 0, 5], ["the immune system", "TEST", 17, 34], ["their subpopulations", "TEST", 51, 71], ["their subpopulations", "TEST", 85, 105], ["NKT", "TEST", 117, 120], ["macrophages", "PROBLEM", 128, 139], ["dendritic cells", "PROBLEM", 144, 159], ["subpopulations", "OBSERVATION_MODIFIER", 91, 105], ["NKT", "ANATOMY", 117, 120], ["macrophages", "ANATOMY", 128, 139], ["dendritic cells", "OBSERVATION", 144, 159]]], ["None of these may be excluded for the assessment of the immunological level as a whole.Assessment of Immunological Level as a WholeAnother important aspect is to determine which immune cells or parameters play a key role in the age-related decline of immune function.", [["immune cells", "ANATOMY", 178, 190], ["immune cells", "CELL", 178, 190], ["immune cells", "CELL_TYPE", 178, 190], ["the assessment", "TEST", 34, 48], ["immune function", "PROBLEM", 251, 266], ["may be excluded", "UNCERTAINTY", 14, 29], ["immune function", "OBSERVATION", 251, 266]]], ["We have been studying the immunological aspect of aging for many years and have confirmed that immune functions are susceptible to aging, diseases and stress.", [["immune functions", "PROBLEM", 95, 111], ["diseases", "PROBLEM", 138, 146], ["stress", "PROBLEM", 151, 157]]], ["For the past 30 years, many studies including ours have shown that the age-related decline mainly occurs in Tcell-dependent immune functions and is relatively small in functions of other cells such as B-cells, macrophages and NK-cells (Makinodan and Kay 1980; Hirokawa 1992; Linton and Dorshkind 2004; Hirokawa et al. 2006) .", [["cells", "ANATOMY", 187, 192], ["B-cells", "ANATOMY", 201, 208], ["macrophages", "ANATOMY", 210, 221], ["NK-cells", "ANATOMY", 226, 234], ["Tcell", "CELL", 108, 113], ["cells", "CELL", 187, 192], ["B-cells", "CELL", 201, 208], ["macrophages", "CELL", 210, 221], ["NK-cells", "CELL", 226, 234], ["Makinodan", "CELL", 236, 245], ["B-cells", "CELL_TYPE", 201, 208], ["macrophages", "CELL_TYPE", 210, 221], ["NK-cells", "CELL_TYPE", 226, 234], ["many studies", "TEST", 23, 35], ["related decline", "PROBLEM", 75, 90], ["other cells", "PROBLEM", 181, 192], ["B-cells", "TEST", 201, 208], ["macrophages", "TEST", 210, 221], ["immune functions", "OBSERVATION", 124, 140], ["relatively", "OBSERVATION_MODIFIER", 148, 158], ["small", "OBSERVATION_MODIFIER", 159, 164]]], ["Therefore, when considering the age-related change of immunological functions, the immunological assessment can be focused on parameters that are related to T-cell-dependent functions.", [["T-cell", "ANATOMY", 157, 163], ["T-cell", "CELL", 157, 163], ["the immunological assessment", "TEST", 79, 107]]], ["We have reported that the age-related change in the T-cell-dependent immune system is observed in a decrease in the T-cells number, a change in the T-cell subpopulations and a qualitative change in T-cells such as a decline in proliferative capacity and a change in cytokine production (Fig. 2) .Assessment of Immunological Level as a WholeTherefore, the number of whole T-cells and their subpopulations, and the proliferative activity of T-cells are useful parameters to assess the extent Na\u00efve T Memory T (CD4 + CD45RA + cells), number of memory T-cells (CD4 + CD45RO + cells), and the ratio of na\u00efve T-cells to memory T-cells (N/M ratio).", [["T-cell", "ANATOMY", 52, 58], ["T-cells", "ANATOMY", 116, 123], ["T-cell", "ANATOMY", 148, 154], ["T-cells", "ANATOMY", 198, 205], ["whole T-cells", "ANATOMY", 365, 378], ["T-cells", "ANATOMY", 439, 446], ["Na\u00efve T Memory T (CD4 + CD45RA + cells", "ANATOMY", 490, 528], ["memory T-cells", "ANATOMY", 541, 555], ["CD4 + CD45RO + cells", "ANATOMY", 557, 577], ["na\u00efve T-cells", "ANATOMY", 597, 610], ["memory T-cells", "ANATOMY", 614, 628], ["T-cell", "CELL", 52, 58], ["T-cells", "CELL", 116, 123], ["T-cell", "CELL", 148, 154], ["T-cells", "CELL", 198, 205], ["T-cells", "CELL", 371, 378], ["T-cells", "CELL", 439, 446], ["T Memory T", "GENE_OR_GENE_PRODUCT", 496, 506], ["CD4", "GENE_OR_GENE_PRODUCT", 508, 511], ["CD45RA", "GENE_OR_GENE_PRODUCT", 514, 520], ["memory T-cells", "CELL", 541, 555], ["CD4", "GENE_OR_GENE_PRODUCT", 557, 560], ["CD45RO", "GENE_OR_GENE_PRODUCT", 563, 569], ["na\u00efve T-cells", "CELL", 597, 610], ["memory T-cells", "CELL", 614, 628], ["T-cells", "CELL_TYPE", 116, 123], ["T-cell subpopulations", "CELL_TYPE", 148, 169], ["T-cells", "CELL_TYPE", 198, 205], ["cytokine", "PROTEIN", 266, 274], ["whole T-cells", "CELL_TYPE", 365, 378], ["T-cells", "CELL_TYPE", 439, 446], ["Na\u00efve T Memory T (CD4 + CD45RA + cells", "CELL_TYPE", 490, 528], ["memory T-cells", "CELL_TYPE", 541, 555], ["CD4", "PROTEIN", 557, 560], ["CD45RO", "PROTEIN", 563, 569], ["na\u00efve T-cells", "CELL_TYPE", 597, 610], ["memory T-cells", "CELL_TYPE", 614, 628], ["a change in the T-cell subpopulations", "PROBLEM", 132, 169], ["a qualitative change in T-cells", "PROBLEM", 174, 205], ["a decline in proliferative capacity", "PROBLEM", 214, 249], ["a change in cytokine production", "PROBLEM", 254, 285], ["Immunological Level", "TEST", 310, 329], ["the extent", "TEST", 479, 489], ["CD4", "TEST", 508, 511], ["cells", "TEST", 523, 528], ["CD4", "TEST", 557, 560], ["cells", "TEST", 572, 577], ["the ratio", "TEST", 584, 593], ["N/M ratio", "TEST", 630, 639], ["decrease", "OBSERVATION_MODIFIER", 100, 108], ["change", "OBSERVATION_MODIFIER", 134, 140], ["T-cell subpopulations", "OBSERVATION", 148, 169], ["proliferative capacity", "OBSERVATION", 227, 249], ["change", "OBSERVATION_MODIFIER", 256, 262], ["cytokine production", "OBSERVATION", 266, 285]]], ["The proliferative activity of T-cells was measured by nonspecific stimulation of T-cells by anti-CD3 monoclonal antibody.", [["T-cells", "ANATOMY", 30, 37], ["T-cells", "ANATOMY", 81, 88], ["T-cells", "CELL", 30, 37], ["T-cells", "CELL", 81, 88], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 92, 100], ["T-cells", "CELL_TYPE", 30, 37], ["T-cells", "CELL_TYPE", 81, 88], ["anti-CD3 monoclonal antibody", "PROTEIN", 92, 120], ["anti-CD3 monoclonal antibody", "TEST", 92, 120], ["proliferative", "OBSERVATION_MODIFIER", 4, 17], ["activity", "OBSERVATION_MODIFIER", 18, 26]]], ["We defined a new indicator, T-cell proliferation index (TCPI) using the number and proliferative activity of T-cells, as described later.Assessment of Immunological Level as a WholeIn addition to T-cells, the number of B-cells and NK-cells was included for this assessment, since these cells are counterparts of immune functions.Assessment of Immunological Level as a WholeCytokine production is another important aspect of immunological function.", [["T-cell", "ANATOMY", 28, 34], ["T-cells", "ANATOMY", 109, 116], ["T-cells", "ANATOMY", 196, 203], ["B-cells", "ANATOMY", 219, 226], ["NK-cells", "ANATOMY", 231, 239], ["cells", "ANATOMY", 286, 291], ["T-cell", "CELL", 28, 34], ["T-cells", "CELL", 109, 116], ["T-cells", "CELL", 196, 203], ["B-cells", "CELL", 219, 226], ["NK-cells", "CELL", 231, 239], ["cells", "CELL", 286, 291], ["WholeCytokine", "GENE_OR_GENE_PRODUCT", 368, 381], ["T-cells", "CELL_TYPE", 109, 116], ["T-cells", "CELL_TYPE", 196, 203], ["B-cells", "CELL_TYPE", 219, 226], ["NK-cells", "CELL_TYPE", 231, 239], ["Immunological Level", "TEST", 151, 170], ["this assessment", "TEST", 257, 272], ["new", "OBSERVATION_MODIFIER", 13, 16], ["proliferative activity", "OBSERVATION", 83, 105]]], ["Among many cytokines, information on Th1/Th2 balance is helpful for understanding health and disease condition.", [["cytokines", "PROTEIN", 11, 20], ["cytokines", "OBSERVATION", 11, 20]]], ["Therefore, we employed 3 interleukins; IL-2 and IFNg as the Th1 group, and IL-4 as the Th2 group.Assessment of Immunological Level as a WholeHere, we have ten parameters to assess the extent of age-related decline in immunological functions (hereafter referred to as the scoring of immunological vigor: SIV) of individuals as shown in Fig. 3 .", [["IL-2", "GENE_OR_GENE_PRODUCT", 39, 43], ["IFNg", "GENE_OR_GENE_PRODUCT", 48, 52], ["IL-4", "GENE_OR_GENE_PRODUCT", 75, 79], ["SIV", "ORGANISM", 303, 306], ["interleukins", "PROTEIN", 25, 37], ["IL", "PROTEIN", 39, 41], ["IFNg", "PROTEIN", 48, 52], ["IL-4", "PROTEIN", 75, 79], ["IL", "TREATMENT", 39, 41], ["IFNg", "TREATMENT", 48, 52], ["IL", "TEST", 75, 77], ["related decline in immunological functions", "PROBLEM", 198, 240]]], ["Values of immunological parameters are given a score from 1 to 3.", [["immunological parameters", "TEST", 10, 34], ["a score", "TEST", 45, 52]]], ["SIV-10 is then classified into 5 grades as shown in Table 2 .", [["SIV-10", "ORGANISM", 0, 6], ["SIV-10", "SPECIES", 0, 6], ["5 grades", "OBSERVATION_MODIFIER", 31, 39]]], ["By the scoring system, 10 parameters can be grouped and expressed numerically as immunological score or grade in a plain style.", [["immunological score", "TEST", 81, 100]]], ["The value of each immunological parameter falls within a range specified in a database and each parameter was scored into 3 grades based on its value.", [["The value", "TEST", 0, 9], ["a database", "TEST", 76, 86]]], ["In particular, values in the range of a cumulative frequency less than 10% of values observed for healthy subject were scored 1, which indicates a low immunity level; those between 10% and 40% were scored 2, which indicates a moderate immunity level; and those with 40% or higher were scored 3, which indicates a sufficiently high immunity level.", [["values", "TEST", 15, 21], ["a low immunity level", "PROBLEM", 145, 165], ["a moderate immunity level", "PROBLEM", 224, 249], ["low immunity", "OBSERVATION_MODIFIER", 147, 159], ["moderate", "OBSERVATION_MODIFIER", 226, 234]]], ["Since higher scores of CD4/CD8 ratios are frequently observed in very old people and patients suffering from diseases, values greater than 80% of the cumulative frequency were scored 2, which indicates a moderate immunity level.", [["CD4", "GENE_OR_GENE_PRODUCT", 23, 26], ["CD8", "GENE_OR_GENE_PRODUCT", 27, 30], ["people", "ORGANISM", 74, 80], ["patients", "ORGANISM", 85, 93], ["CD4", "PROTEIN", 23, 26], ["CD8", "PROTEIN", 27, 30], ["people", "SPECIES", 74, 80], ["patients", "SPECIES", 85, 93], ["CD4/CD8 ratios", "TEST", 23, 37], ["diseases", "PROBLEM", 109, 117], ["values", "TEST", 119, 125], ["a moderate immunity level", "PROBLEM", 202, 227], ["diseases", "OBSERVATION", 109, 117], ["moderate", "OBSERVATION_MODIFIER", 204, 212], ["immunity level", "OBSERVATION", 213, 227]]], ["We employed 3 options to assess SIV; the first using 10 parameters, named SIV-10; the second using 7 parameters excluding cytokine production, named SIV-7 and the third using 5 parameters composed of T-cell-related functions, named SIV-5 or T-cell immune score.Assessment of Immunological Level as a WholeValues of SIV-10, SIV-7 and SIV-5 were then classified to 5 grades (V\u223cI) according to the total score.", [["T-cell", "ANATOMY", 200, 206], ["T-cell", "ANATOMY", 241, 247], ["SIV", "ORGANISM", 32, 35], ["SIV", "ORGANISM", 74, 77], ["SIV-7", "ORGANISM", 149, 154], ["T-cell", "CELL", 200, 206], ["SIV-5", "ORGANISM", 232, 237], ["T-cell", "CELL", 241, 247], ["SIV-10", "ORGANISM", 315, 321], ["SIV-7", "ORGANISM", 323, 328], ["SIV-5", "ORGANISM", 333, 338], ["cytokine", "PROTEIN", 122, 130], ["SIV", "SPECIES", 32, 35], ["SIV-10", "SPECIES", 315, 321], ["SIV-5", "SPECIES", 333, 338], ["cytokine production", "TEST", 122, 141], ["SIV", "TEST", 149, 152], ["SIV", "TEST", 232, 235], ["Assessment", "TEST", 261, 271], ["Immunological Level", "TEST", 275, 294], ["SIV", "TEST", 315, 318], ["SIV", "TEST", 323, 326]]], ["The observation zone indicates that the level of SIV is average, but needs attention to move up into the safety zone.", [["SIV", "ORGANISM", 49, 52], ["SIV", "SPECIES", 49, 52], ["The observation zone", "TEST", 0, 20], ["SIV", "OBSERVATION", 49, 52]]], ["The warning zone indicates that the level of SIV is not sufficient to maintain health and considerable effort is required to increase the level of SIV.", [["SIV", "ORGANISM", 45, 48], ["SIV", "ORGANISM", 147, 150], ["SIV", "SPECIES", 45, 48], ["SIV", "SPECIES", 147, 150]]], ["The critical zone indicates that the susceptibility to infection is so high that the individual needs to be admitted to an aseptic isolator.T-cell Proliferation Index and Assessment of Immunological AgeWe defined a new parameter, T-cell proliferation index (TCPI) which was calculated by using the number and proliferation activity of T-cells.", [["T-cell", "ANATOMY", 140, 146], ["T-cell", "ANATOMY", 230, 236], ["T-cells", "ANATOMY", 335, 342], ["infection", "DISEASE", 55, 64], ["T-cell", "CELL", 140, 146], ["T-cell", "CELL", 230, 236], ["T-cells", "CELL", 335, 342], ["T-cells", "CELL_TYPE", 335, 342], ["the susceptibility to infection", "PROBLEM", 33, 64], ["an aseptic isolator", "TREATMENT", 120, 139], ["T-cell Proliferation Index", "TEST", 140, 166], ["a new parameter", "TEST", 213, 228], ["infection", "OBSERVATION", 55, 64], ["aseptic isolator", "OBSERVATION", 123, 139], ["cell Proliferation Index", "OBSERVATION", 142, 166], ["proliferation activity", "OBSERVATION", 309, 331]]], ["The number of T-cells is essential for the maintenance of immune function.", [["T-cells", "ANATOMY", 14, 21], ["T-cells", "CELL", 14, 21], ["T-cells", "CELL_TYPE", 14, 21], ["immune function", "OBSERVATION", 58, 73]]], ["In addition, T-cell proliferation is the most essential function of T-cell immunity, including the process of antigen recognition and sequential division of T-cells.", [["T-cell", "ANATOMY", 13, 19], ["T-cell", "ANATOMY", 68, 74], ["T-cells", "ANATOMY", 157, 164], ["T-cell", "CELL", 13, 19], ["T-cell", "CELL", 68, 74], ["T-cells", "CELL", 157, 164], ["T-cells", "CELL_TYPE", 157, 164], ["T-cell proliferation", "PROBLEM", 13, 33], ["antigen recognition", "TEST", 110, 129], ["cell proliferation", "OBSERVATION", 15, 33]]], ["There are 4 types of number and proliferative capacity of T-cells.T-cell Proliferation Index and Assessment of Immunological Age(1) both are sufficient;T-cell Proliferation Index and Assessment of Immunological Age(2) number is sufficient, (3) number is insufficient and proliferative capacity is sufficient; (4) both are insufficient.", [["T-cells", "ANATOMY", 58, 65], ["T-cell", "ANATOMY", 66, 72], ["T-cell", "ANATOMY", 152, 158], ["T-cells", "CELL", 58, 65], ["T-cell", "CELL", 66, 72], ["T-cell", "CELL", 152, 158], ["T-cells", "CELL_TYPE", 58, 65], ["T-cell Proliferation Index", "TEST", 66, 92], ["Assessment", "TEST", 97, 107], ["T-cell Proliferation Index", "TEST", 152, 178], ["proliferative capacity", "PROBLEM", 271, 293], ["4 types", "OBSERVATION_MODIFIER", 10, 17], ["proliferative", "OBSERVATION_MODIFIER", 32, 45], ["capacity", "OBSERVATION_MODIFIER", 46, 54], ["cell Proliferation", "OBSERVATION", 68, 86]]], ["Therefore, we arrived at the conclusion that we needed a new parameter which reflected both the number and proliferative capacity of T-cells.", [["T-cells", "ANATOMY", 133, 140], ["T-cells", "CELL", 133, 140], ["T-cells", "CELL_TYPE", 133, 140], ["a new parameter", "TEST", 55, 70], ["proliferative capacity", "OBSERVATION", 107, 129]]], ["The new parameter was TCPI and was calculated by the following equation.T-cell Proliferation Index and Assessment of Immunological AgeTCPI = T-cell proliferation activity x (T-cell number per \u03bcL/1000) Figure.", [["T-cell", "ANATOMY", 72, 78], ["T-cell", "ANATOMY", 141, 147], ["T-cell", "ANATOMY", 174, 180], ["T-cell", "CELL", 72, 78], ["T-cell", "CELL", 141, 147], ["T-cell Proliferation Index", "TEST", 72, 98], ["Assessment", "TEST", 103, 113], ["Immunological AgeTCPI", "TEST", 117, 138], ["T-cell proliferation activity", "PROBLEM", 141, 170], ["new", "OBSERVATION_MODIFIER", 4, 7], ["cell", "OBSERVATION", 74, 78], ["Proliferation Index", "OBSERVATION", 79, 98], ["cell proliferation", "OBSERVATION", 143, 161]]], ["4 indicates the distribution of TCPI according to age.", [["TCPI", "CANCER", 32, 36], ["TCPI", "PROTEIN", 32, 36], ["TCPI", "TREATMENT", 32, 36]]], ["Although, there is a wide individual variation, the age-related decline of TCPI is obvious and the following equation was obtained.T-cell Proliferation Index and Assessment of Immunological AgeIn other words, we can determine age of individual by the value of TCPI using the following equation.", [["T-cell", "ANATOMY", 131, 137], ["T-cell", "CELL", 131, 137], ["TCPI", "PROTEIN", 75, 79], ["a wide individual variation", "PROBLEM", 19, 46], ["T-cell Proliferation Index", "TEST", 131, 157], ["wide", "OBSERVATION_MODIFIER", 21, 25], ["individual", "OBSERVATION_MODIFIER", 26, 36], ["variation", "OBSERVATION_MODIFIER", 37, 46], ["cell Proliferation Index", "OBSERVATION", 133, 157]]], ["Since the age is calculated from the number of T-cells and their proliferative activity, the age obtained by this equation is hereafter referred to as the immunological age (IA).", [["T-cells", "ANATOMY", 47, 54], ["T-cells", "CELL", 47, 54], ["T-cells", "CELL_TYPE", 47, 54], ["proliferative", "OBSERVATION_MODIFIER", 65, 78], ["activity", "OBSERVATION_MODIFIER", 79, 87]]], ["IA = (2.5348 -TCPI)/0.0174Scoring of Immunological Vigor (SIV) Shows Wide Range of Individual VariationImmunological vigor of 400 healthy people and 300 cancer patients were assessed using the method mentioned above (Fig. 5a ).", [["cancer", "ANATOMY", 153, 159], ["cancer", "DISEASE", 153, 159], ["(2.5348 -TCPI", "CHEMICAL", 5, 18], ["people", "ORGANISM", 138, 144], ["cancer", "CANCER", 153, 159], ["patients", "ORGANISM", 160, 168], ["people", "SPECIES", 138, 144], ["patients", "SPECIES", 160, 168], ["IA", "TEST", 0, 2]]], ["Age-related related decline as observed in SIV-7 was apparent in the healthy population.", [["SIV-7", "ORGANISM", 43, 48], ["related decline", "PROBLEM", 12, 27], ["decline", "OBSERVATION", 20, 27]]], ["However, there was a wide individual The level of SIV-7 ranged between 21 and 14 in the 3 rd decade and between 21 and 12 in the 7 th decade, indicating that individual variation is greater than the difference between young and old people.", [["SIV-7", "ORGANISM", 50, 55], ["people", "ORGANISM", 232, 238], ["people", "SPECIES", 232, 238], ["SIV", "TEST", 50, 53], ["individual variation", "PROBLEM", 158, 178], ["individual variation", "OBSERVATION", 158, 178], ["greater", "OBSERVATION_MODIFIER", 182, 189]]], ["But when observing SIV-7 in cancer patients, we found that the distribution of values was apparently different from that in healthy people and the age-related decline in cancer patients was much steeper than in healthy people.", [["cancer", "ANATOMY", 28, 34], ["cancer", "ANATOMY", 170, 176], ["cancer", "DISEASE", 28, 34], ["cancer", "DISEASE", 170, 176], ["SIV-7", "ORGANISM", 19, 24], ["cancer", "CANCER", 28, 34], ["patients", "ORGANISM", 35, 43], ["people", "ORGANISM", 132, 138], ["cancer", "CANCER", 170, 176], ["patients", "ORGANISM", 177, 185], ["people", "ORGANISM", 219, 225], ["patients", "SPECIES", 35, 43], ["people", "SPECIES", 132, 138], ["patients", "SPECIES", 177, 185], ["people", "SPECIES", 219, 225], ["cancer", "OBSERVATION", 170, 176]]], ["However, it is again apparent that the SIV-7 level of cancer patients showed a wide range of individual variation, although the values were lower as compared with those for healthy people (Hirokawa et al. 2007a (Hirokawa et al. , 2007b .", [["cancer", "ANATOMY", 54, 60], ["cancer", "DISEASE", 54, 60], ["SIV-7", "ORGANISM", 39, 44], ["cancer", "CANCER", 54, 60], ["patients", "ORGANISM", 61, 69], ["people", "ORGANISM", 181, 187], ["patients", "SPECIES", 61, 69], ["people", "SPECIES", 181, 187], ["the SIV", "TEST", 35, 42], ["the values", "TEST", 124, 134], ["cancer", "OBSERVATION", 54, 60], ["wide", "OBSERVATION_MODIFIER", 79, 83], ["individual variation", "OBSERVATION", 93, 113], ["lower", "OBSERVATION_MODIFIER", 140, 145]]], ["Based on the SIV-7 grade, the difference in SIV-7 between healthy people and cancer patients was much obvious (Fig. 5b) .", [["cancer", "ANATOMY", 77, 83], ["cancer", "DISEASE", 77, 83], ["SIV", "ORGANISM", 13, 16], ["SIV-7", "ORGANISM", 44, 49], ["people", "ORGANISM", 66, 72], ["cancer", "CANCER", 77, 83], ["patients", "ORGANISM", 84, 92], ["people", "SPECIES", 66, 72], ["patients", "SPECIES", 84, 92], ["cancer", "PROBLEM", 77, 83], ["cancer", "OBSERVATION", 77, 83]]], ["Most healthy people belonged to Grade IV and III, while cancer patients belonged to Grade III and II, indicating that the immunological deficient state is more serious in cancer patients.", [["cancer", "ANATOMY", 56, 62], ["cancer", "ANATOMY", 171, 177], ["cancer", "DISEASE", 56, 62], ["cancer", "DISEASE", 171, 177], ["people", "ORGANISM", 13, 19], ["cancer", "CANCER", 56, 62], ["patients", "ORGANISM", 63, 71], ["cancer", "CANCER", 171, 177], ["patients", "ORGANISM", 178, 186], ["people", "SPECIES", 13, 19], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 178, 186], ["Grade IV and III, while cancer", "PROBLEM", 32, 62], ["Grade III and II", "PROBLEM", 84, 100], ["the immunological deficient state", "PROBLEM", 118, 151], ["cancer", "OBSERVATION", 56, 62], ["Grade III", "OBSERVATION_MODIFIER", 84, 93], ["cancer", "OBSERVATION", 171, 177]]], ["Thus, considerable attention should be given to the immunological state of cancer patients during treatment ).", [["cancer", "ANATOMY", 75, 81], ["cancer", "DISEASE", 75, 81], ["cancer", "CANCER", 75, 81], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["treatment", "TREATMENT", 98, 107]]], ["6 shows radar graphs of 3 example cases showing the 10 immunological parameters, IA, SIG-10, immunological grade and immunological zone.", [["radar graphs", "TEST", 8, 20], ["SIG", "TEST", 85, 88], ["immunological grade and immunological zone", "PROBLEM", 93, 135]]], ["This figure shows how the immune status of individuals can be understood.Variable Causes Suppress Immunological FunctionsAs presumed from the wide individual variation of immunological vigor, immunological functions are changeable by variable causes: i.e., aging, stress, diseases, life style, food, genetic background etc.Variable Causes Suppress Immunological FunctionsAging is unavoidable cause of immunological decline.", [["Variable Causes", "PROBLEM", 73, 88], ["immunological vigor", "PROBLEM", 171, 190], ["stress, diseases", "PROBLEM", 264, 280], ["Variable Causes", "PROBLEM", 323, 338], ["immunological decline", "PROBLEM", 401, 422], ["immunological vigor", "OBSERVATION", 171, 190], ["unavoidable cause of", "UNCERTAINTY", 380, 400], ["immunological decline", "OBSERVATION", 401, 422]]], ["However, the rate of immunological decline by aging might be accelerated or decelerated by surrounding environmental factors which can be controlled by appropriate intervention.", [["immunological decline", "PROBLEM", 21, 42]]], ["For instance, caloric restriction extended the life span of animal models and enhanced the immunological function of old animals (Heilbronn and Ravussin 2003; Utsuyama et al. 1996) .", [["caloric restriction", "TREATMENT", 14, 33]]], ["Stress is the major cause of immunological decline.", [["immunological decline", "PROBLEM", 29, 50], ["immunological decline", "OBSERVATION", 29, 50]]], ["In other words, stress is life and life is stress (Chrousos GP et al. eds; Stress 1995) .Variable Causes Suppress Immunological FunctionsVarious diseases including minor ones are also factors suppressing immunological functions.", [["Immunological FunctionsVarious diseases", "DISEASE", 114, 153], ["stress", "PROBLEM", 43, 49], ["Variable Causes", "PROBLEM", 89, 104], ["Immunological FunctionsVarious diseases", "PROBLEM", 114, 153], ["minor ones", "PROBLEM", 164, 174]]], ["Incidence of cancer is known to increase with the advancement of age and this is partly caused by a decrease in immune surveillance (Dunn et al. 2002) .", [["cancer", "ANATOMY", 13, 19], ["cancer", "DISEASE", 13, 19], ["cancer", "CANCER", 13, 19], ["cancer", "PROBLEM", 13, 19], ["a decrease in immune surveillance", "PROBLEM", 98, 131], ["cancer", "OBSERVATION", 13, 19], ["increase", "OBSERVATION_MODIFIER", 32, 40], ["decrease", "OBSERVATION_MODIFIER", 100, 108]]], ["In fact, a patient with colonic cancer has a low level of SIV ).", [["colonic cancer", "ANATOMY", 24, 38], ["colonic cancer", "DISEASE", 24, 38], ["patient", "ORGANISM", 11, 18], ["colonic cancer", "CANCER", 24, 38], ["SIV", "ORGANISM", 58, 61], ["patient", "SPECIES", 11, 18], ["colonic cancer", "PROBLEM", 24, 38], ["colonic", "ANATOMY", 24, 31], ["cancer", "OBSERVATION", 32, 38]]], ["But it is obvious that SIV generally recovers in a certain interval after the removal of cancer lesion.", [["cancer lesion", "ANATOMY", 89, 102], ["cancer lesion", "DISEASE", 89, 102], ["SIV", "ORGANISM", 23, 26], ["cancer lesion", "CANCER", 89, 102], ["SIV", "SPECIES", 23, 26], ["SIV", "PROBLEM", 23, 26], ["the removal", "TREATMENT", 74, 85], ["cancer lesion", "PROBLEM", 89, 102], ["SIV", "OBSERVATION", 23, 26], ["cancer", "OBSERVATION", 89, 95]]], ["Thus, it is likely that the presence of cancer suppress the immunological function of the individual.", [["cancer", "ANATOMY", 40, 46], ["cancer", "DISEASE", 40, 46], ["cancer", "CANCER", 40, 46], ["cancer", "PROBLEM", 40, 46], ["cancer", "OBSERVATION", 40, 46]]], ["It is also well known that diabetes mellitus suppresses immunological function.", [["diabetes mellitus", "DISEASE", 27, 44], ["diabetes mellitus", "PROBLEM", 27, 44], ["diabetes", "OBSERVATION", 27, 35]]], ["Various therapies for many kinds of diseases can down-regulate immunological functions.", [["Various therapies", "TREATMENT", 0, 17], ["diseases", "PROBLEM", 36, 44], ["diseases", "OBSERVATION", 36, 44]]], ["One example is surgical operation.", [["surgical operation", "TREATMENT", 15, 33], ["surgical operation", "OBSERVATION", 15, 33]]], ["Chemotherapy for cancer and steroid therapy for autoimmune diseases suppress immune functions.Possible Methods of Immunological RestorationNow we can assess the immunological level by SIV, as mentioned above.", [["cancer", "ANATOMY", 17, 23], ["cancer", "DISEASE", 17, 23], ["steroid", "CHEMICAL", 28, 35], ["autoimmune diseases", "DISEASE", 48, 67], ["steroid", "CHEMICAL", 28, 35], ["cancer", "CANCER", 17, 23], ["steroid", "SIMPLE_CHEMICAL", 28, 35], ["SIV", "ORGANISM", 184, 187], ["SIV", "SPECIES", 184, 187], ["Chemotherapy", "TREATMENT", 0, 12], ["cancer", "PROBLEM", 17, 23], ["steroid therapy", "TREATMENT", 28, 43], ["autoimmune diseases", "PROBLEM", 48, 67], ["immune functions", "PROBLEM", 77, 93], ["Immunological Restoration", "TREATMENT", 114, 139], ["cancer", "OBSERVATION", 17, 23], ["Immunological Restoration", "OBSERVATION", 114, 139]]], ["As observed in Fig. 5 , there is a wide individual variation in the SIV levels.", [["SIV", "ORGANISM", 68, 71], ["a wide individual variation in the SIV levels", "PROBLEM", 33, 78], ["wide", "OBSERVATION_MODIFIER", 35, 39], ["individual", "OBSERVATION_MODIFIER", 40, 50], ["variation", "OBSERVATION_MODIFIER", 51, 60], ["SIV levels", "OBSERVATION", 68, 78]]], ["We presume that individuals with high SIV can live longer and those with low SIV are susceptible to diseases.", [["SIV", "ORGANISM", 38, 41], ["SIV", "ORGANISM", 77, 80], ["SIV", "SPECIES", 38, 41], ["SIV", "SPECIES", 77, 80], ["high SIV", "PROBLEM", 33, 41], ["diseases", "PROBLEM", 100, 108]]], ["Further longitudinal studies are necessary to say something for the prognosis of people with high or low SIV.", [["people", "ORGANISM", 81, 87], ["SIV", "ORGANISM", 105, 108], ["people", "SPECIES", 81, 87], ["Further longitudinal studies", "TEST", 0, 28], ["high or low SIV", "PROBLEM", 93, 108], ["low SIV", "OBSERVATION_MODIFIER", 101, 108]]], ["Roberts-Thomson et al. reported that individuals with reduced immune functions had significantly greater mortality than those whose immune functions were within the normal range.", [["reduced immune functions", "PROBLEM", 54, 78], ["immune functions", "TEST", 132, 148], ["normal range", "OBSERVATION", 165, 177]]], ["Centenarians in Okinawa have significantly high immune functions as compared with controls.", [["significantly high immune functions", "PROBLEM", 29, 64], ["significantly", "OBSERVATION_MODIFIER", 29, 42], ["high immune functions", "OBSERVATION", 43, 64]]], ["Considering these data, it may be inferred that it is desirable to enhance SIV level of individuals with a lower SIV level.", [["SIV", "ORGANISM", 75, 78], ["SIV", "SPECIES", 75, 78], ["a lower SIV level", "PROBLEM", 105, 122]]], ["Here we would like to present our preliminary experience of immunological restoration in humans and its possible methods as determined from experiments using animal models (Hirokawa et al. 2002) .Coping with StressIn daily life, a variety of stresses down-regulate immune functions and in fact, the stresses are the major cause of immunological suppression in our life.", [["humans", "ORGANISM", 89, 95], ["humans", "SPECIES", 89, 95], ["humans", "SPECIES", 89, 95], ["immunological restoration in humans", "PROBLEM", 60, 95], ["stresses down", "PROBLEM", 242, 255], ["immunological suppression", "PROBLEM", 331, 356], ["immunological restoration", "OBSERVATION", 60, 85], ["immunological suppression", "OBSERVATION", 331, 356]]], ["Stresses originate from communication problems at home, office and school, from diseases or injury, from treatment of diseases or from natural disasters.", [["Stresses", "DISEASE", 0, 8], ["injury", "DISEASE", 92, 98], ["communication problems", "PROBLEM", 24, 46], ["injury", "PROBLEM", 92, 98], ["diseases", "PROBLEM", 118, 126]]], ["There are 2 solutions for stress: (a) avoid stress. (b) alleviate the effect of stress.Coping with Stress(a) Avoid stress.", [["stress", "PROBLEM", 44, 50], ["stress", "PROBLEM", 80, 86], ["stress", "PROBLEM", 115, 121]]], ["But it is worthwhile to reconsider the cause of stress and analyze whether or not it is avoidable.Coping with Stress(b) Alleviate stress.Coping with StressIt is interesting to note that the same level of stress has very serious effects in some people, but not in others.", [["people", "ORGANISM", 244, 250], ["people", "SPECIES", 244, 250], ["stress", "PROBLEM", 48, 54], ["Alleviate stress", "PROBLEM", 120, 136]]], ["This means that the magnitude of stress is dependent on the response of individuals.", [["stress", "PROBLEM", 33, 39]]], ["For instances, an academic examination would not be as serious for students who have studied beforehand as it would be for those who have not studied.Coping with StressSinging, running and chattering with friends are mood-altering activities.", [["an academic examination", "TEST", 15, 38]]], ["In this respect, we studied the effect of music in humans and we found that playing the drums in a group could enhance NK activity (Wachi et al. 2006 ).Improvement of Life StyleHabits indicative of an improper life style are poor sleep, overwork, smoking, excessive drinking, irregular meals, deviated food habits and insufficient physical exercise.", [["NK", "ANATOMY", 119, 121], ["smoking", "CHEMICAL", 247, 254], ["humans", "ORGANISM", 51, 57], ["NK", "CELL", 119, 121], ["humans", "SPECIES", 51, 57], ["humans", "SPECIES", 51, 57]]], ["We interviewed more than 50 of young people who showed a lower level of SIV and over 50% of them had improper work habits.Improvement of Life StyleNutrition is an important factor for immunological restoration.", [["people", "ORGANISM", 37, 43], ["SIV", "ORGANISM", 72, 75], ["people", "SPECIES", 37, 43], ["Life StyleNutrition", "TREATMENT", 137, 156], ["immunological restoration", "TREATMENT", 184, 209], ["Life StyleNutrition", "OBSERVATION", 137, 156]]], ["For the last 50 years, the mean life span of Japanese people has extended from 50 to over 80 years.", [["people", "ORGANISM", 54, 60], ["people", "SPECIES", 54, 60]]], ["This rapid increase in life span is partly due to the improvement of food intake, especially, protein.", [["food", "ORGANISM_SUBDIVISION", 69, 73], ["This rapid increase in life span", "PROBLEM", 0, 32], ["rapid", "OBSERVATION_MODIFIER", 5, 10], ["increase", "OBSERVATION_MODIFIER", 11, 19]]], ["Today, people are worried about metabolic syndromes and are making an effort to not eat too much.", [["metabolic syndromes", "DISEASE", 32, 51], ["people", "ORGANISM", 7, 13], ["people", "SPECIES", 7, 13], ["metabolic syndromes", "PROBLEM", 32, 51]]], ["But too much of anything is harmful.Improvement of Life StyleMore than 70 years ago, MaCay (1935) reported the elongation of life span in rats by caloric restriction.", [["rats", "ORGANISM", 138, 142], ["rats", "SPECIES", 138, 142], ["caloric restriction", "TREATMENT", 146, 165]]], ["Many studies have since shown that caloric restriction is effective on several counts; i.e., elongation of lifespan, enhancement of immunological function and alleviation of autoimmune diseases.Improvement of Life StyleOne argument about food restriction or caloric restriction is that it only appears to be effective in animals that are reared in an artificial environment such as a laboratory animal colony (Utsuyama et al.1996) .", [["colony", "ANATOMY", 402, 408], ["autoimmune diseases", "DISEASE", 174, 193], ["Many studies", "TEST", 0, 12], ["caloric restriction", "TREATMENT", 35, 54], ["several counts", "TEST", 71, 85], ["elongation of lifespan", "PROBLEM", 93, 115], ["immunological function", "PROBLEM", 132, 154], ["autoimmune diseases", "PROBLEM", 174, 193], ["Life StyleOne argument", "TREATMENT", 209, 231], ["caloric restriction", "TREATMENT", 258, 277], ["caloric restriction", "OBSERVATION", 35, 54], ["elongation", "OBSERVATION_MODIFIER", 93, 103], ["lifespan", "OBSERVATION_MODIFIER", 107, 115], ["immunological function", "OBSERVATION", 132, 154], ["autoimmune diseases", "OBSERVATION", 174, 193]]], ["In order to test this conjecture, we employed an automatic feeding device that was electrically interlocked with a running wheel: the device provided constant running exercise to the animal and fed a determined amount of diet to each rat (lchikawa et a1.", [["rat", "ORGANISM", 234, 237], ["rat", "SPECIES", 234, 237], ["rat", "SPECIES", 234, 237], ["an automatic feeding device", "TREATMENT", 46, 73], ["the device", "TREATMENT", 130, 140], ["constant running exercise", "TREATMENT", 150, 175]]], ["2000).Improvement of Life StyleRats were individually reared in this automatic feeding device for 18 months from 2 to 20 months of age.", [["Life StyleRats", "TREATMENT", 21, 35], ["this automatic feeding device", "TREATMENT", 64, 93]]], ["At the age of 20 months, the rats were sacrificed and examined for various indices including immunological functions.", [["rats", "ORGANISM", 29, 33], ["rats", "SPECIES", 29, 33], ["various indices", "TEST", 67, 82]]], ["The body weight was almost the same between rats fed ad libitum and those given 80%-restricted diet.", [["body", "ANATOMY", 4, 8], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["rats", "ORGANISM", 44, 48], ["rats", "SPECIES", 44, 48], ["The body weight", "TEST", 0, 15], ["body", "ANATOMY_MODIFIER", 4, 8]]], ["Their body weight was significantly greater than that of rats given 60%-restricted diet.", [["body", "ANATOMY", 6, 10], ["body", "ORGANISM_SUBDIVISION", 6, 10], ["rats", "ORGANISM", 57, 61], ["rats", "SPECIES", 57, 61], ["Their body weight", "TEST", 0, 17]]], ["The body weight of those given 80%-restricted diet together with physical exercise was almost the same as that of rats given 60%-restricted diet without physical exercise.", [["body", "ANATOMY", 4, 8], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["rats", "ORGANISM", 114, 118], ["rats", "SPECIES", 114, 118]]], ["High proliferative response of T-cells was observed in some of rats given 80%-restricted diet together with physical exercise (Fig. 7) .Improvement of Life StyleMeanwhile, studies are ongoing to observe the effect of caloric restriction on various physiological parameters in monkeys (Roth et al. 2002) .", [["T-cells", "ANATOMY", 31, 38], ["T-cells", "CELL", 31, 38], ["rats", "ORGANISM", 63, 67], ["monkeys", "ORGANISM", 276, 283], ["T-cells", "CELL_TYPE", 31, 38], ["rats", "SPECIES", 63, 67], ["High proliferative response of T-cells", "PROBLEM", 0, 38], ["caloric restriction", "TREATMENT", 217, 236], ["proliferative", "OBSERVATION_MODIFIER", 5, 18]]], ["A report provided evidence that CR can delay immune senescence in nonhuman primates, potentially contributing to an extended lifespan by reducing susceptibility to infectious disease (Messaoudi et al. 2006) .Improvement of Life StyleIn humans, the effects of CR on life extension are actually present; it is estimated that CR extends life by 3-13 years.", [["infectious disease", "DISEASE", 164, 182], ["nonhuman", "ORGANISM", 66, 74], ["primates", "ORGANISM", 75, 83], ["humans", "ORGANISM", 236, 242], ["humans", "SPECIES", 236, 242], ["humans", "SPECIES", 236, 242], ["infectious disease", "PROBLEM", 164, 182], ["Life StyleIn humans", "TREATMENT", 223, 242], ["CR on life extension", "TREATMENT", 259, 279]]], ["This extension is much smaller than those achieved by medical and public health intervention, which have been known to extend life by about 30 years in developed countries of the 20 th century (Everitt and Le Couteur, 2007) .Anti-oxidant ChemicalsIt is now commonly believed that oxidative stress, such as that caused by reactive oxygen species and free radicals, is the major cause of aging phenomena and various diseases (Harman 1956; Ames et al. 1993; Wakikawa et al. 1999 ).", [["oxygen", "CHEMICAL", 330, 336], ["oxygen", "CHEMICAL", 330, 336], ["reactive oxygen species", "SIMPLE_CHEMICAL", 321, 344], ["free radicals", "SIMPLE_CHEMICAL", 349, 362], ["public health intervention", "TREATMENT", 66, 92], ["Anti-oxidant Chemicals", "TREATMENT", 225, 247], ["oxidative stress", "PROBLEM", 280, 296], ["reactive oxygen species", "PROBLEM", 321, 344], ["free radicals", "PROBLEM", 349, 362], ["aging phenomena", "PROBLEM", 386, 401], ["various diseases", "PROBLEM", 406, 422], ["much", "OBSERVATION_MODIFIER", 18, 22], ["smaller", "OBSERVATION_MODIFIER", 23, 30], ["oxidative stress", "OBSERVATION", 280, 296], ["reactive", "OBSERVATION_MODIFIER", 321, 329], ["oxygen species", "OBSERVATION", 330, 344], ["free radicals", "OBSERVATION", 349, 362]]], ["The decline of immune function is one of major aging phenomena and constitutes the background of various diseases occurring in the elderly people (Hirokawa 1998) .", [["people", "ORGANISM", 139, 145], ["people", "SPECIES", 139, 145], ["immune function", "PROBLEM", 15, 30], ["major aging phenomena", "PROBLEM", 41, 62], ["various diseases", "PROBLEM", 97, 113], ["immune function", "OBSERVATION", 15, 30], ["various", "OBSERVATION_MODIFIER", 97, 104], ["diseases", "OBSERVATION", 105, 113]]], ["Many investigators assume that oxidative stresses play an important role in the progression of immunological decline during the course of aging (Martin et al. 1996; Meydani et al. 1998 ).", [["oxidative stresses", "PROBLEM", 31, 49], ["immunological decline", "PROBLEM", 95, 116]]], ["Thus, it has been expected that enzymes or substances that compete with oxidative stress are candidates for antiaging medicines.", [["enzymes", "TEST", 32, 39], ["oxidative stress", "PROBLEM", 72, 88], ["antiaging medicines", "TREATMENT", 108, 127]]], ["Antioxidant enzymes are present in our body, e.g., SOD and catalase.", [["body", "ANATOMY", 39, 43], ["body", "ORGANISM_SUBDIVISION", 39, 43], ["SOD", "GENE_OR_GENE_PRODUCT", 51, 54], ["catalase", "GENE_OR_GENE_PRODUCT", 59, 67], ["Antioxidant enzymes", "PROTEIN", 0, 19], ["SOD", "PROTEIN", 51, 54], ["catalase", "PROTEIN", 59, 67], ["Antioxidant enzymes", "TEST", 0, 19], ["catalase", "TEST", 59, 67]]], ["It is possible to enhance the production of these antioxidant enzymes by appropriate physical exercise.", [["antioxidant enzymes", "PROTEIN", 50, 69], ["these antioxidant enzymes", "TEST", 44, 69]]], ["In addition, there are many kinds of supplements that are commercially available as antioxidant chemicals, although effectiveness of most of them has not been proved scientifically.", [["supplements", "TREATMENT", 37, 48], ["antioxidant chemicals", "TREATMENT", 84, 105], ["many", "OBSERVATION_MODIFIER", 23, 27], ["kinds", "OBSERVATION_MODIFIER", 28, 33]]], ["Flavonoids or polyphenols are representative antioxidants contained in many kinds of vegetables, fruits and other foods.", [["vegetables", "ANATOMY", 85, 95], ["fruits", "ANATOMY", 97, 103], ["Flavonoids", "CHEMICAL", 0, 10], ["Flavonoids", "CHEMICAL", 0, 10], ["polyphenols", "CHEMICAL", 14, 25], ["Flavonoids", "SIMPLE_CHEMICAL", 0, 10], ["polyphenols", "SIMPLE_CHEMICAL", 14, 25], ["vegetables", "ORGANISM_SUBDIVISION", 85, 95], ["fruits", "ORGANISM_SUBDIVISION", 97, 103], ["Flavonoids", "TREATMENT", 0, 10], ["polyphenols", "TREATMENT", 14, 25], ["representative antioxidants", "TREATMENT", 30, 57]]], ["Extracted or enriched flavonoids and polyphenols are commercially available as supplements.", [["flavonoids", "CHEMICAL", 22, 32], ["flavonoids", "CHEMICAL", 22, 32], ["polyphenols", "CHEMICAL", 37, 48], ["flavonoids", "SIMPLE_CHEMICAL", 22, 32], ["polyphenols", "SIMPLE_CHEMICAL", 37, 48], ["polyphenols", "TREATMENT", 37, 48], ["enriched flavonoids", "OBSERVATION", 13, 32]]], ["The effectiveness of these supplements requires further study.Anti-oxidant ChemicalsVitamin E (VE) works as an antioxidants.", [["Vitamin E", "CHEMICAL", 84, 93], ["Vitamin E", "CHEMICAL", 84, 93], ["Vitamin E", "SIMPLE_CHEMICAL", 84, 93], ["VE", "SIMPLE_CHEMICAL", 95, 97], ["these supplements", "TREATMENT", 21, 38], ["further study", "TEST", 48, 61], ["Anti-oxidant Chemicals", "TREATMENT", 62, 84], ["Vitamin E (VE)", "TREATMENT", 84, 98], ["an antioxidants", "TREATMENT", 108, 123]]], ["In our experiment using aging mice, we confirmed that VE enhances the immune functions of young, but not old mice (Wakikawa et al. 1999 ) (Fig. 8) .", [["mice", "ORGANISM", 30, 34], ["mice", "ORGANISM", 109, 113], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 109, 113]]], ["Other reports indicated that VE supplementation was not effective in humoral immune response modulation in young, middle-aged and elderly women (Park et al. 2003 ).", [["women", "ORGANISM", 138, 143], ["women", "SPECIES", 138, 143], ["VE supplementation", "TREATMENT", 29, 47]]], ["On the other hand, Meydani's group reported the positive effect of VE in both human and animal experiments (Meydani et al. 1998; Marko et al. 2007 ).", [["human", "ORGANISM", 78, 83], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83]]], ["These reports suggest that the effectiveness of supplements is not uniform, but differs with the individual and the genetic background.Anti-oxidant ChemicalsThe effectiveness of any antioxidants and related supplements usually varies with the individual.", [["supplements", "TREATMENT", 48, 59], ["Anti-oxidant Chemicals", "TREATMENT", 135, 157], ["any antioxidants", "TREATMENT", 178, 194], ["related supplements", "TREATMENT", 199, 218]]], ["Therefore, immunological assessment as performed in an objective manner, such as determining SIV, is always necessary to verify the effectiveness of chemicals and supplements on the immune system.VaccineVaccines are very useful to protect children who are susceptible to various infectious diseases due to immaturity of the immune system.", [["immune system", "ANATOMY", 182, 195], ["immune system", "ANATOMY", 324, 337], ["VaccineVaccines", "CHEMICAL", 196, 211], ["infectious diseases", "DISEASE", 279, 298], ["VaccineVaccines", "CHEMICAL", 196, 211], ["SIV", "ORGANISM", 93, 96], ["immune system", "ANATOMICAL_SYSTEM", 182, 195], ["VaccineVaccines", "SIMPLE_CHEMICAL", 196, 211], ["children", "ORGANISM", 239, 247], ["immune system", "ANATOMICAL_SYSTEM", 324, 337], ["children", "SPECIES", 239, 247], ["SIV", "SPECIES", 93, 96], ["immunological assessment", "TEST", 11, 35], ["chemicals and supplements", "TREATMENT", 149, 174], ["the immune system", "TREATMENT", 178, 195], ["VaccineVaccines", "TREATMENT", 196, 211], ["various infectious diseases", "PROBLEM", 271, 298], ["immaturity of the immune system", "PROBLEM", 306, 337], ["infectious", "OBSERVATION", 279, 289]]], ["The same effect could be expected for the elderly people with impaired immune functions.", [["impaired immune functions", "DISEASE", 62, 87], ["people", "ORGANISM", 50, 56], ["people", "SPECIES", 50, 56], ["impaired immune functions", "PROBLEM", 62, 87]]], ["However, vaccination in very old people may not work due to depressed immune functions.", [["depressed", "DISEASE", 60, 69], ["people", "ORGANISM", 33, 39], ["people", "SPECIES", 33, 39], ["vaccination", "TREATMENT", 9, 20], ["depressed immune functions", "PROBLEM", 60, 86]]], ["Thus, vaccination should be started latest before the age of 60, so that the individual still have sufficient capacity to respond to pathogenic organisms.", [["vaccination", "TREATMENT", 6, 17], ["sufficient capacity", "PROBLEM", 99, 118], ["pathogenic organisms", "PROBLEM", 133, 153]]], ["Alternatively, attempts should be made to enhance or stimulate the depressed immune capacity of elderly people at the time of vaccination.", [["depressed", "DISEASE", 67, 76], ["people", "ORGANISM", 104, 110], ["people", "SPECIES", 104, 110], ["the depressed immune capacity", "PROBLEM", 63, 92], ["vaccination", "TREATMENT", 126, 137]]], ["Susceptibility of old mice to infection is clearly observed in experimental infection with influenza virus.", [["infection", "DISEASE", 30, 39], ["infection", "DISEASE", 76, 85], ["influenza virus", "DISEASE", 91, 106], ["mice", "ORGANISM", 22, 26], ["influenza virus", "ORGANISM", 91, 106], ["mice", "SPECIES", 22, 26], ["influenza virus", "SPECIES", 91, 106], ["mice", "SPECIES", 22, 26], ["old mice to infection", "PROBLEM", 18, 39], ["experimental infection", "PROBLEM", 63, 85], ["influenza virus", "PROBLEM", 91, 106], ["infection", "OBSERVATION", 30, 39], ["experimental", "OBSERVATION_MODIFIER", 63, 75], ["infection", "OBSERVATION", 76, 85], ["influenza virus", "OBSERVATION", 91, 106]]], ["Old mice died of infection at a 10-fold lesser dose of influenza virus.", [["infection", "DISEASE", 17, 26], ["influenza virus", "DISEASE", 55, 70], ["mice", "ORGANISM", 4, 8], ["influenza virus", "ORGANISM", 55, 70], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["infection", "PROBLEM", 17, 26], ["influenza virus", "PROBLEM", 55, 70], ["infection", "OBSERVATION", 17, 26], ["influenza virus", "OBSERVATION", 55, 70]]], ["01d mice that survived after exposure to low doses showed strong immunity to the same virus and became resistant to the second infection with a high dose of influenza virus (Hirokawa and Utsuyama 2002) .", [["infection", "DISEASE", 127, 136], ["influenza virus", "DISEASE", 157, 172], ["01d", "ORGANISM", 0, 3], ["mice", "ORGANISM", 4, 8], ["influenza virus", "ORGANISM", 157, 172], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["the same virus", "PROBLEM", 77, 91], ["the second infection", "PROBLEM", 116, 136], ["influenza virus", "PROBLEM", 157, 172], ["infection", "OBSERVATION", 127, 136]]], ["These data suggest that vaccination is useful to protect the elderly people from various kinds of infection.VaccineIn humans, vaccination against pneumococcus and influenza virus is already clinically conducted for elderly people.", [["infection", "DISEASE", 98, 107], ["pneumococcus", "DISEASE", 146, 158], ["influenza virus", "DISEASE", 163, 178], ["people", "ORGANISM", 69, 75], ["VaccineIn", "ORGANISM", 108, 117], ["humans", "ORGANISM", 118, 124], ["pneumococcus", "ORGANISM", 146, 158], ["influenza virus", "ORGANISM", 163, 178], ["people", "ORGANISM", 223, 229], ["people", "SPECIES", 69, 75], ["humans", "SPECIES", 118, 124], ["influenza virus", "SPECIES", 163, 178], ["people", "SPECIES", 223, 229], ["humans", "SPECIES", 118, 124], ["influenza virus", "SPECIES", 163, 178], ["These data", "TEST", 0, 10], ["vaccination", "TREATMENT", 24, 35], ["infection", "PROBLEM", 98, 107], ["VaccineIn humans", "TREATMENT", 108, 124], ["vaccination", "TREATMENT", 126, 137], ["pneumococcus", "PROBLEM", 146, 158], ["influenza virus", "PROBLEM", 163, 178], ["infection", "OBSERVATION", 98, 107]]], ["As stated in the earlier section, there is individual variation even in elderly people.", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86], ["individual variation", "PROBLEM", 43, 63], ["variation", "OBSERVATION_MODIFIER", 54, 63]]], ["Those having higher SIV can respond to vaccination and show sufficient immunity against bacteria and virus.", [["SIV", "ORGANISM", 20, 23], ["SIV", "SPECIES", 20, 23], ["higher SIV", "PROBLEM", 13, 23], ["vaccination", "TREATMENT", 39, 50], ["bacteria", "PROBLEM", 88, 96], ["virus", "PROBLEM", 101, 106]]], ["Problem is in finding a way to enhance immunological functions of the elderly people with lower SIV so that they can effectively respond to vaccination.VaccineAnother point to be considered is the route of vaccination.", [["people", "ORGANISM", 78, 84], ["SIV", "ORGANISM", 96, 99], ["people", "SPECIES", 78, 84], ["SIV", "SPECIES", 96, 99], ["vaccination", "TREATMENT", 140, 151], ["vaccination", "TREATMENT", 206, 217]]], ["Since the nose and mouth are the major entries for respiratory infection, their mucosal immunity is important.", [["nose", "ANATOMY", 10, 14], ["mouth", "ANATOMY", 19, 24], ["respiratory", "ANATOMY", 51, 62], ["mucosal", "ANATOMY", 80, 87], ["respiratory infection", "DISEASE", 51, 72], ["nose", "ORGAN", 10, 14], ["mouth", "ORGAN", 19, 24], ["mucosal", "MULTI-TISSUE_STRUCTURE", 80, 87], ["respiratory infection", "PROBLEM", 51, 72], ["nose", "ANATOMY", 10, 14], ["mouth", "ANATOMY", 19, 24], ["respiratory", "ANATOMY", 51, 62], ["infection", "OBSERVATION", 63, 72]]], ["Using a mouse model, we found that the route of vaccination is important.", [["mouse", "ORGANISM", 8, 13], ["mouse", "SPECIES", 8, 13], ["mouse", "SPECIES", 8, 13], ["a mouse model", "TREATMENT", 6, 19], ["vaccination", "TREATMENT", 48, 59]]], ["Vaccination through the intranasal route provides high level of IgA production in nasal mucosa, but that through the intravenous and intraperitoneal routes does not.", [["nasal mucosa", "ANATOMY", 82, 94], ["intravenous", "ANATOMY", 117, 128], ["intraperitoneal", "ANATOMY", 133, 148], ["IgA", "GENE_OR_GENE_PRODUCT", 64, 67], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 82, 94], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 117, 128], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 133, 148], ["IgA", "PROTEIN", 64, 67], ["Vaccination", "TREATMENT", 0, 11], ["the intranasal route", "TREATMENT", 20, 40], ["IgA production in nasal mucosa", "PROBLEM", 64, 94], ["the intravenous and intraperitoneal routes", "TREATMENT", 113, 155], ["IgA production", "OBSERVATION", 64, 78], ["nasal mucosa", "ANATOMY", 82, 94]]], ["2 \u00b1 2 2 \u00b1 2 1) Mice were administered intranasally (i.n.) with A/PR/8/34 vaccine (10mg) and boosted 3 weeks later i.n. with the same vaccine.", [["intranasally", "ANATOMY", 38, 50], ["Mice", "ORGANISM", 15, 19], ["8/34", "ORGANISM", 68, 72], ["PR", "PROTEIN", 65, 67], ["Mice", "SPECIES", 15, 19], ["A/PR/8/34 vaccine", "TREATMENT", 63, 80], ["the same vaccine", "TREATMENT", 124, 140]]], ["Antibody was assessed 1 week after the boosting 2) Mice were administered intravenously (i.v.) with A/PR/8/34 vaccine (10mg) and boosted 3 weeks later intraperitoneally (i.p.) with the same vaccine.", [["intravenously", "ANATOMY", 74, 87], ["Mice", "ORGANISM", 51, 55], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 74, 87], ["8/34", "ORGANISM", 105, 109], ["PR", "PROTEIN", 102, 104], ["Mice", "SPECIES", 51, 55], ["Antibody", "TEST", 0, 8], ["the boosting 2) Mice", "TREATMENT", 35, 55], ["A/PR/8/34 vaccine", "TREATMENT", 100, 117], ["the same vaccine", "TREATMENT", 181, 197]]], ["Antibody was assessed 1 week after the boostingJapanese Herbal MedicinesA group of Japanese herbal medicines, called 'Kampo-Hozai' have been used to improve the physical condition of patients suffering from various diseases .", [["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["Antibody", "TEST", 0, 8], ["Japanese herbal medicines", "TREATMENT", 83, 108], ["Hozai'", "TREATMENT", 124, 130], ["various diseases", "PROBLEM", 207, 223]]], ["Among more than 100 kinds of Kampo-Hozais, Hochuekki-to(TJ-41) is a drug used to recover immune function and has been reported to be useful in healing infections (Yamaoka et al. 2000; Mori et a1.", [["TJ-41", "CHEMICAL", 56, 61], ["infections", "DISEASE", 151, 161], ["Hochuekki", "SIMPLE_CHEMICAL", 43, 52], ["TJ-41", "SIMPLE_CHEMICAL", 56, 61], ["Kampo", "TREATMENT", 29, 34], ["Hochuekki", "TREATMENT", 43, 52], ["a drug", "TREATMENT", 66, 72], ["healing infections", "PROBLEM", 143, 161], ["healing", "OBSERVATION_MODIFIER", 143, 150], ["infections", "OBSERVATION", 151, 161]]], ["1999) , oncostatics-induced leukopenia (Kaneko et al. 1999) , and allergies (Suzuki et a1.", [["oncostatics", "CHEMICAL", 8, 19], ["leukopenia", "DISEASE", 28, 38], ["allergies", "DISEASE", 66, 75], ["leukopenia", "PROBLEM", 28, 38], ["leukopenia", "OBSERVATION", 28, 38]]], ["Juzen-taiho-to (TJ-48) is useful not only for the recovery of immune function (Abe et a1.", [["TJ-48", "CELL", 16, 21]]], ["1998 ), but also for the enhancement of antitumor effects (Saiki et al. 1999; Onishi et al. 1998; Utsuyama et al. 2001) .Japanese Herbal MedicinesWe tested the effectiveness of Japanese herbal medicines in young and aged mice.", [["antitumor", "ANATOMY", 40, 49], ["antitumor", "CANCER", 40, 49], ["mice", "ORGANISM", 221, 225], ["mice", "SPECIES", 221, 225], ["mice", "SPECIES", 221, 225], ["antitumor effects", "PROBLEM", 40, 57], ["Japanese Herbal Medicines", "TREATMENT", 121, 146], ["Japanese herbal medicines", "TREATMENT", 177, 202]]], ["The data indicated that Hochu-ekki-to (TJ-41) was effective in the restoration of impaired immune functions of aged mice, in terms of the number of T-cells and NK-cells, and anti-SRBC antibody response.", [["T-cells", "ANATOMY", 148, 155], ["NK-cells", "ANATOMY", 160, 168], ["Hochu-ekki", "CHEMICAL", 24, 34], ["TJ-41", "CHEMICAL", 39, 44], ["Hochu-ekki", "SIMPLE_CHEMICAL", 24, 34], ["TJ-41", "SIMPLE_CHEMICAL", 39, 44], ["mice", "ORGANISM", 116, 120], ["T-cells", "CELL", 148, 155], ["NK-cells", "CELL", 160, 168], ["anti-SRBC antibody", "GENE_OR_GENE_PRODUCT", 174, 192], ["T-cells", "CELL_TYPE", 148, 155], ["NK-cells", "CELL_TYPE", 160, 168], ["anti-SRBC antibody", "PROTEIN", 174, 192], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 116, 120], ["The data", "TEST", 0, 8], ["Hochu", "TEST", 24, 29], ["anti-SRBC antibody response", "TEST", 174, 201]]], ["However, it was not effective in enhancing the immune functions of young mice (Fig. 9) .Japanese Herbal MedicinesJuzen-taiho-to was also effective in increasing the number of T-cells and NK-cells in aged mice, although a significant increase was not observed in young mice.", [["T-cells", "ANATOMY", 175, 182], ["NK-cells", "ANATOMY", 187, 195], ["Herbal MedicinesJuzen-taiho", "CHEMICAL", 97, 124], ["mice", "ORGANISM", 73, 77], ["T-cells", "CELL", 175, 182], ["NK-cells", "CELL", 187, 195], ["mice", "ORGANISM", 204, 208], ["mice", "ORGANISM", 268, 272], ["T-cells", "CELL_TYPE", 175, 182], ["NK-cells", "CELL_TYPE", 187, 195], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 204, 208], ["mice", "SPECIES", 268, 272], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 204, 208], ["mice", "SPECIES", 268, 272], ["Japanese Herbal MedicinesJuzen-taiho", "TREATMENT", 88, 124], ["significant", "OBSERVATION_MODIFIER", 221, 232], ["increase", "OBSERVATION", 233, 241]]], ["Functionally, however, NK activity increased both in young and old mice.", [["NK", "ANATOMY", 23, 25], ["NK", "CELL", 23, 25], ["mice", "ORGANISM", 67, 71], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 67, 71]]], ["A significant decrease was also observed in the number of metastatic pulmonary colonies of B16 melanoma cells both in young and old mice treated with Juzen-taiho-to for 16 weeks (Fig. 10) .Japanese Herbal MedicinesThese results suggested that some Japanese herbal medicines are useful in the restoration of impaired immune functions of old mice and could be recommended for the elderly people with immunological problems.Japanese Herbal MedicinesWe performed preliminary clinical trial of TJ-41 to observe its effect on immunological function in humans.", [["metastatic pulmonary colonies", "ANATOMY", 58, 87], ["B16 melanoma cells", "ANATOMY", 91, 109], ["melanoma", "DISEASE", 95, 103], ["Juzen-taiho", "CHEMICAL", 150, 161], ["TJ-41", "CHEMICAL", 489, 494], ["TJ-41", "CHEMICAL", 489, 494], ["pulmonary", "ORGAN", 69, 78], ["B16 melanoma cells", "CELL", 91, 109], ["mice", "ORGANISM", 132, 136], ["mice", "ORGANISM", 340, 344], ["people", "ORGANISM", 386, 392], ["TJ-41", "SIMPLE_CHEMICAL", 489, 494], ["humans", "ORGANISM", 546, 552], ["metastatic pulmonary colonies", "CELL_LINE", 58, 87], ["B16 melanoma cells", "CELL_LINE", 91, 109], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 340, 344], ["people", "SPECIES", 386, 392], ["humans", "SPECIES", 546, 552], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 340, 344], ["humans", "SPECIES", 546, 552], ["A significant decrease", "PROBLEM", 0, 22], ["metastatic pulmonary colonies of B16 melanoma cells", "PROBLEM", 58, 109], ["Juzen-taiho", "TREATMENT", 150, 161], ["Japanese Herbal Medicines", "TREATMENT", 189, 214], ["some Japanese herbal medicines", "TREATMENT", 243, 273], ["immunological problems", "PROBLEM", 398, 420], ["TJ", "TEST", 489, 491], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["decrease", "OBSERVATION", 14, 22], ["metastatic", "OBSERVATION_MODIFIER", 58, 68], ["pulmonary", "ANATOMY", 69, 78], ["colonies", "OBSERVATION", 79, 87], ["B16 melanoma cells", "OBSERVATION", 91, 109]]], ["Approximately half of the people who were given TJ41 showed a positive effect, but another half did not show any effect.", [["TJ41", "CHEMICAL", 48, 52], ["TJ41", "CHEMICAL", 48, 52], ["people", "ORGANISM", 26, 32], ["TJ41", "SIMPLE_CHEMICAL", 48, 52], ["people", "SPECIES", 26, 32], ["positive effect", "OBSERVATION", 62, 77]]], ["Fig. 11 shows an example case of the positive effect of TJ41.", [["TJ41", "CHEMICAL", 56, 60], ["TJ41", "GENE_OR_GENE_PRODUCT", 56, 60], ["TJ41", "PROTEIN", 56, 60], ["the positive effect of TJ41", "PROBLEM", 33, 60], ["positive effect", "OBSERVATION", 37, 52]]], ["Therefore, in these cases also, the assessment of immunological parameters is necessary to verify the effectiveness of herbal medicines for immunological restoration.Japanese Herbal Medicinesanti-SRBC antibodyHormonesAfter gonadectomy, hypertrophy of the thymus was observed in aging C57BL/6 mice, ranging in age from 4 to 20 months.", [["thymus", "ANATOMY", 255, 261], ["hypertrophy of the thymus", "DISEASE", 236, 261], ["thymus", "ORGAN", 255, 261], ["C57BL/6 mice", "ORGANISM", 284, 296], ["Japanese Herbal Medicinesanti-SRBC antibody", "PROTEIN", 166, 209], ["mice", "SPECIES", 292, 296], ["mice", "SPECIES", 292, 296], ["the assessment", "TEST", 32, 46], ["immunological parameters", "TEST", 50, 74], ["herbal medicines", "TREATMENT", 119, 135], ["immunological restoration", "TREATMENT", 140, 165], ["Japanese Herbal Medicinesanti", "TREATMENT", 166, 195], ["SRBC antibody", "TEST", 196, 209], ["HormonesAfter gonadectomy", "TREATMENT", 209, 234], ["hypertrophy of the thymus", "PROBLEM", 236, 261], ["hypertrophy", "OBSERVATION", 236, 247], ["thymus", "ANATOMY", 255, 261]]], ["The mice had been gonadectomized 1 month before the sacrifice, and the magnitude of thymic regeneration was more pronounced in males than in females (Fig. 12) .", [["thymic", "ANATOMY", 84, 90], ["mice", "ORGANISM", 4, 8], ["thymic", "ORGAN", 84, 90], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["thymic regeneration", "PROBLEM", 84, 103], ["thymic", "ANATOMY", 84, 90], ["regeneration", "OBSERVATION", 91, 103], ["pronounced", "OBSERVATION_MODIFIER", 113, 123]]], ["However, enhancement of anti-SRBC antibody response was observed only in females, but not in males regardless of age.", [["anti-SRBC antibody", "GENE_OR_GENE_PRODUCT", 24, 42], ["anti-SRBC antibody", "PROTEIN", 24, 42], ["anti-SRBC antibody response", "TEST", 24, 51], ["enhancement", "OBSERVATION_MODIFIER", 9, 20], ["anti-SRBC antibody response", "OBSERVATION", 24, 51]]], ["Gonadectomy brought about not only thymic hypertrophy but also an increase in T-cells and B-cells in the spleen.", [["thymic", "ANATOMY", 35, 41], ["T-cells", "ANATOMY", 78, 85], ["B-cells", "ANATOMY", 90, 97], ["spleen", "ANATOMY", 105, 111], ["hypertrophy", "DISEASE", 42, 53], ["thymic", "ORGAN", 35, 41], ["T-cells", "CELL", 78, 85], ["B-cells", "CELL", 90, 97], ["spleen", "ORGAN", 105, 111], ["T-cells", "CELL_TYPE", 78, 85], ["B-cells", "CELL_TYPE", 90, 97], ["Gonadectomy", "TREATMENT", 0, 11], ["thymic hypertrophy", "PROBLEM", 35, 53], ["an increase in T-cells", "PROBLEM", 63, 85], ["B-cells in the spleen", "PROBLEM", 90, 111], ["thymic", "ANATOMY", 35, 41], ["hypertrophy", "OBSERVATION", 42, 53], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["T-cells", "OBSERVATION", 78, 85], ["-cells", "ANATOMY_MODIFIER", 91, 97], ["spleen", "ANATOMY", 105, 111]]], ["An increase in T-cell subpopulations was proportional in female mice, but disproportional in male.", [["T-cell", "ANATOMY", 15, 21], ["T-cell", "CELL", 15, 21], ["mice", "ORGANISM", 64, 68], ["T-cell subpopulations", "CELL_TYPE", 15, 36], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["An increase in T-cell subpopulations", "PROBLEM", 0, 36], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["T-cell subpopulations", "OBSERVATION", 15, 36], ["disproportional", "OBSERVATION_MODIFIER", 74, 89]]], ["The disproportional increase of T-cell subpopulations could account for the failure to enhance the anti-SRBC antibody response in male mice .", [["T-cell", "ANATOMY", 32, 38], ["T-cell", "CELL", 32, 38], ["anti-SRBC antibody", "GENE_OR_GENE_PRODUCT", 99, 117], ["mice", "ORGANISM", 135, 139], ["T-cell subpopulations", "CELL_TYPE", 32, 53], ["anti-SRBC antibody", "PROTEIN", 99, 117], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 135, 139], ["T-cell subpopulations", "PROBLEM", 32, 53], ["the failure", "PROBLEM", 72, 83], ["the anti-SRBC antibody", "TEST", 95, 117], ["disproportional", "OBSERVATION_MODIFIER", 4, 19], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["T-cell subpopulations", "OBSERVATION", 32, 53], ["could account for", "UNCERTAINTY", 54, 71], ["failure", "OBSERVATION", 76, 83]]], ["Gonadectomy also resulted in the thymic hypertrophy in male and female young Wistar rats, but not in those that had been previously hypophysectomized .", [["thymic", "ANATOMY", 33, 39], ["thymic hypertrophy", "DISEASE", 33, 51], ["thymic", "ORGAN", 33, 39], ["Wistar rats", "ORGANISM", 77, 88], ["rats", "SPECIES", 84, 88], ["Gonadectomy", "TREATMENT", 0, 11], ["the thymic hypertrophy", "PROBLEM", 29, 51], ["thymic", "ANATOMY", 33, 39], ["hypertrophy", "OBSERVATION", 40, 51]]], ["Elderly males undergoing orchidectomy for prostatic carcinoma demonstrated an increase in circulating T-cell numbers, particularly naive (TREC+) T-cells.", [["prostatic carcinoma", "ANATOMY", 42, 61], ["T-cell", "ANATOMY", 102, 108], ["TREC+) T-cells", "ANATOMY", 138, 152], ["prostatic carcinoma", "DISEASE", 42, 61], ["prostatic carcinoma", "CANCER", 42, 61], ["T-cell", "CELL", 102, 108], ["TREC+) T-cells", "CELL", 138, 152], ["naive (TREC+) T-cells", "CELL_TYPE", 131, 152], ["orchidectomy", "TREATMENT", 25, 37], ["prostatic carcinoma", "PROBLEM", 42, 61], ["an increase", "PROBLEM", 75, 86], ["circulating T-cell numbers", "TEST", 90, 116], ["orchidectomy", "OBSERVATION", 25, 37], ["prostatic", "ANATOMY", 42, 51], ["carcinoma", "OBSERVATION", 52, 61], ["increase", "OBSERVATION_MODIFIER", 78, 86], ["cell numbers", "OBSERVATION", 104, 116]]], ["Chemical castration by administration of LHRH antagonist was also effective in activation of thymic regeneration in mice and humans .HormonesIn females, hormone replacement therapy (HRT) by estrogen has been prescribed to postmenopausal women for prevention of a variety of medical conditions including osteoporosis, cardiovascular diseases, stroke and Alzheimer's disease; yet HRT is often associated with altered immune parameters (Fahlman et al. 2000; Stopinska-Gluszak et al. 2006) .", [["thymic", "ANATOMY", 93, 99], ["cardiovascular", "ANATOMY", 317, 331], ["LHRH", "CHEMICAL", 41, 45], ["estrogen", "CHEMICAL", 190, 198], ["osteoporosis", "DISEASE", 303, 315], ["cardiovascular diseases", "DISEASE", 317, 340], ["stroke", "DISEASE", 342, 348], ["Alzheimer's disease", "DISEASE", 353, 372], ["estrogen", "CHEMICAL", 190, 198], ["LHRH", "SIMPLE_CHEMICAL", 41, 45], ["thymic", "ORGAN", 93, 99], ["mice", "ORGANISM", 116, 120], ["humans", "ORGANISM", 125, 131], ["estrogen", "SIMPLE_CHEMICAL", 190, 198], ["women", "ORGANISM", 237, 242], ["mice", "SPECIES", 116, 120], ["humans", "SPECIES", 125, 131], ["women", "SPECIES", 237, 242], ["mice", "SPECIES", 116, 120], ["humans", "SPECIES", 125, 131], ["Chemical castration", "TREATMENT", 0, 19], ["LHRH antagonist", "TREATMENT", 41, 56], ["thymic regeneration", "TREATMENT", 93, 112], ["hormone replacement therapy", "TREATMENT", 153, 180], ["HRT", "TREATMENT", 182, 185], ["medical conditions", "PROBLEM", 274, 292], ["osteoporosis", "PROBLEM", 303, 315], ["cardiovascular diseases", "PROBLEM", 317, 340], ["stroke", "PROBLEM", 342, 348], ["Alzheimer's disease", "PROBLEM", 353, 372], ["HRT", "PROBLEM", 378, 381], ["altered immune parameters", "PROBLEM", 407, 432], ["castration", "OBSERVATION", 9, 19], ["thymic regeneration", "OBSERVATION", 93, 112], ["osteoporosis", "OBSERVATION", 303, 315], ["cardiovascular", "ANATOMY", 317, 331], ["diseases", "OBSERVATION", 332, 340], ["stroke", "OBSERVATION", 342, 348]]], ["HRT is now going to be reconsidered, since estrogen is closely related with carcinogenesis of mammary cancer.HormonesGrowth hormone plays a key role in the development and aging of the thymus and T-cell-dependent immune system (Hirokawa et al. 1998 .", [["mammary cancer", "ANATOMY", 94, 108], ["thymus", "ANATOMY", 185, 191], ["T-cell", "ANATOMY", 196, 202], ["estrogen", "CHEMICAL", 43, 51], ["carcinogenesis", "DISEASE", 76, 90], ["mammary cancer", "DISEASE", 94, 108], ["estrogen", "CHEMICAL", 43, 51], ["estrogen", "SIMPLE_CHEMICAL", 43, 51], ["mammary cancer", "CANCER", 94, 108], ["Growth hormone", "GENE_OR_GENE_PRODUCT", 117, 131], ["thymus", "ORGAN", 185, 191], ["T-cell", "CELL", 196, 202], ["HRT", "TEST", 0, 3], ["estrogen", "TREATMENT", 43, 51], ["carcinogenesis of mammary cancer", "PROBLEM", 76, 108], ["mammary", "ANATOMY", 94, 101], ["cancer", "OBSERVATION", 102, 108], ["thymus", "ANATOMY", 185, 191]]], ["Activation of the immune functions occurred in both males and females by administration of GHRH (Khorram et al. 1997; Koo et al. 2001) .", [["GHRH", "CHEMICAL", 91, 95], ["GHRH", "GENE_OR_GENE_PRODUCT", 91, 95], ["the immune functions", "PROBLEM", 14, 34], ["immune functions", "OBSERVATION", 18, 34]]], ["Since elderly people frequently have occult carcinoma in thyroid, prostate and other organs, we need to consider the possibility that an increased level of growth hormone may stimulate proliferation of tumor cells, giving rise to the clinical manifestation of the occult carcinoma (Perry JK 2006).Immunological Enhancement by a Low Dose of Anti-cancer DrugCyclophosphamide (CY) is an antitumor drugs commonly used for the chemotherapy of human cancer.", [["occult carcinoma", "ANATOMY", 37, 53], ["thyroid", "ANATOMY", 57, 64], ["prostate", "ANATOMY", 66, 74], ["organs", "ANATOMY", 85, 91], ["tumor cells", "ANATOMY", 202, 213], ["occult carcinoma", "ANATOMY", 264, 280], ["antitumor", "ANATOMY", 384, 393], ["cancer", "ANATOMY", 444, 450], ["occult carcinoma", "DISEASE", 37, 53], ["tumor", "DISEASE", 202, 207], ["occult carcinoma", "DISEASE", 264, 280], ["DrugCyclophosphamide", "CHEMICAL", 352, 372], ["CY", "CHEMICAL", 374, 376], ["cancer", "DISEASE", 444, 450], ["DrugCyclophosphamide", "CHEMICAL", 352, 372], ["people", "ORGANISM", 14, 20], ["carcinoma", "CANCER", 44, 53], ["thyroid", "ORGAN", 57, 64], ["prostate", "CANCER", 66, 74], ["organs", "ORGAN", 85, 91], ["tumor cells", "CELL", 202, 213], ["carcinoma", "CANCER", 271, 280], ["Anti-cancer DrugCyclophosphamide", "SIMPLE_CHEMICAL", 340, 372], ["CY", "SIMPLE_CHEMICAL", 374, 376], ["antitumor", "CANCER", 384, 393], ["human", "ORGANISM", 438, 443], ["cancer", "CANCER", 444, 450], ["tumor cells", "CELL_TYPE", 202, 213], ["people", "SPECIES", 14, 20], ["human", "SPECIES", 438, 443], ["human", "SPECIES", 438, 443], ["occult carcinoma in thyroid, prostate and other organs", "PROBLEM", 37, 91], ["an increased level of growth hormone", "PROBLEM", 134, 170], ["tumor cells", "PROBLEM", 202, 213], ["the occult carcinoma", "PROBLEM", 260, 280], ["Immunological Enhancement", "PROBLEM", 297, 322], ["a Low Dose of Anti-cancer DrugCyclophosphamide (CY)", "TREATMENT", 326, 377], ["an antitumor drugs", "TREATMENT", 381, 399], ["the chemotherapy", "TREATMENT", 418, 434], ["human cancer", "PROBLEM", 438, 450], ["carcinoma", "OBSERVATION", 44, 53], ["thyroid", "ANATOMY", 57, 64], ["prostate", "ANATOMY", 66, 74], ["organs", "ANATOMY", 85, 91], ["increased", "OBSERVATION_MODIFIER", 137, 146], ["tumor cells", "OBSERVATION", 202, 213], ["occult carcinoma", "OBSERVATION", 264, 280], ["cancer", "OBSERVATION", 444, 450]]], ["It is also known to be a potent immunosuppressive drug in human and experimental animals.", [["human", "ORGANISM", 58, 63], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["a potent immunosuppressive drug", "TREATMENT", 23, 54], ["potent", "OBSERVATION_MODIFIER", 25, 31], ["immunosuppressive", "OBSERVATION", 32, 49]]], ["It is interesting how CY influences the impaired immunological function in aged mice (Ishiyama et al. 1999) .", [["CY", "CHEMICAL", 22, 24], ["CY", "SIMPLE_CHEMICAL", 22, 24], ["mice", "ORGANISM", 80, 84], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84]]], ["Aged mice treated with a low dose of CY showed significantly enhanced immune capacity in terms of T-cell proliferation and T-cell-dependent antibody response (Fig. 13 ).", [["T-cell", "ANATOMY", 98, 104], ["T-cell", "ANATOMY", 123, 129], ["CY", "CHEMICAL", 37, 39], ["mice", "ORGANISM", 5, 9], ["CY", "SIMPLE_CHEMICAL", 37, 39], ["T-cell", "CELL", 98, 104], ["T-cell", "CELL", 123, 129], ["mice", "SPECIES", 5, 9], ["mice", "SPECIES", 5, 9], ["a low dose of CY", "TREATMENT", 23, 39], ["significantly enhanced immune capacity", "PROBLEM", 47, 85], ["T-cell proliferation", "PROBLEM", 98, 118], ["T", "TEST", 123, 124], ["dependent antibody response", "PROBLEM", 130, 157], ["immune capacity", "OBSERVATION", 70, 85], ["cell proliferation", "OBSERVATION", 100, 118]]], ["In these mice, the total cell numbers of T-cells increased in both in the thymus and spleen, as compared with those in nontreated mice.", [["cell", "ANATOMY", 25, 29], ["T-cells", "ANATOMY", 41, 48], ["thymus", "ANATOMY", 74, 80], ["spleen", "ANATOMY", 85, 91], ["mice", "ORGANISM", 9, 13], ["cell", "CELL", 25, 29], ["T-cells", "CELL", 41, 48], ["thymus", "ORGAN", 74, 80], ["spleen", "ORGAN", 85, 91], ["mice", "ORGANISM", 130, 134], ["T-cells", "CELL_TYPE", 41, 48], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 130, 134], ["the total cell numbers", "TEST", 15, 37], ["total", "OBSERVATION_MODIFIER", 19, 24], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["both", "ANATOMY_MODIFIER", 62, 66], ["thymus", "ANATOMY", 74, 80], ["spleen", "ANATOMY", 85, 91]]], ["Treatment with a low dose of CY induced apoptosis of thymocytes in the atrophic thymus of aged mice and this was followed by an increase in proliferation of thymocytes and an increase in thymocytes and splenic T-cells.", [["thymocytes", "ANATOMY", 53, 63], ["thymus", "ANATOMY", 80, 86], ["thymocytes", "ANATOMY", 157, 167], ["thymocytes", "ANATOMY", 187, 197], ["splenic T-cells", "ANATOMY", 202, 217], ["CY", "CHEMICAL", 29, 31], ["CY", "SIMPLE_CHEMICAL", 29, 31], ["thymocytes", "CELL", 53, 63], ["thymus", "ORGAN", 80, 86], ["mice", "ORGANISM", 95, 99], ["thymocytes", "CELL", 157, 167], ["thymocytes", "CELL", 187, 197], ["splenic T-cells", "CELL", 202, 217], ["thymocytes", "CELL_TYPE", 53, 63], ["thymocytes", "CELL_TYPE", 157, 167], ["thymocytes", "CELL_TYPE", 187, 197], ["splenic T-cells", "CELL_TYPE", 202, 217], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99], ["Treatment", "TREATMENT", 0, 9], ["CY induced apoptosis", "TREATMENT", 29, 49], ["thymocytes", "PROBLEM", 53, 63], ["an increase in proliferation of thymocytes", "PROBLEM", 125, 167], ["an increase in thymocytes", "PROBLEM", 172, 197], ["splenic T-cells", "PROBLEM", 202, 217], ["thymocytes", "OBSERVATION", 53, 63], ["atrophic", "OBSERVATION_MODIFIER", 71, 79], ["thymus", "ANATOMY", 80, 86], ["increase", "OBSERVATION_MODIFIER", 128, 136], ["proliferation of thymocytes", "OBSERVATION", 140, 167], ["increase", "OBSERVATION_MODIFIER", 175, 183], ["thymocytes", "ANATOMY", 187, 197], ["splenic", "ANATOMY", 202, 209], ["T-cells", "OBSERVATION", 210, 217]]], ["Treatment with a high dose of CY also induced apoptosis in the thymus, but suppressed the proliferative capacity, thereby, not leading to an enhancement of immune capacity.", [["thymus", "ANATOMY", 63, 69], ["CY", "CHEMICAL", 30, 32], ["CY", "SIMPLE_CHEMICAL", 30, 32], ["thymus", "ORGAN", 63, 69], ["Treatment", "TREATMENT", 0, 9], ["a high dose of CY", "TREATMENT", 15, 32], ["apoptosis in the thymus", "PROBLEM", 46, 69], ["the proliferative capacity", "PROBLEM", 86, 112], ["an enhancement of immune capacity", "PROBLEM", 138, 171], ["apoptosis", "OBSERVATION", 46, 55], ["thymus", "ANATOMY", 63, 69], ["proliferative capacity", "OBSERVATION", 90, 112], ["immune capacity", "OBSERVATION", 156, 171]]], ["CY in young mice, however, suppressed immune capacity regardless of the dose.", [["CY", "CHEMICAL", 0, 2], ["CY", "SIMPLE_CHEMICAL", 0, 2], ["mice", "ORGANISM", 12, 16], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 12, 16], ["suppressed immune capacity", "PROBLEM", 27, 53]]], ["Thymocytes and splenic T-cells of young mice were more susceptible to CY than those of aged mice and decreased in number after treatment with even a low dose of CY.Immunological Enhancement by a Low Dose of Anti-cancer DrugFor human application, Berd et al. (1984) reported that a low dose of CY enhanced cell-mediated and humoral immunity in patients with advanced cancer.", [["Thymocytes", "ANATOMY", 0, 10], ["splenic T-cells", "ANATOMY", 15, 30], ["cell", "ANATOMY", 305, 309], ["cancer", "ANATOMY", 366, 372], ["CY", "CHEMICAL", 70, 72], ["CY", "CHEMICAL", 161, 163], ["CY", "CHEMICAL", 293, 295], ["cancer", "DISEASE", 366, 372], ["Thymocytes", "CELL", 0, 10], ["splenic T-cells", "CELL", 15, 30], ["mice", "ORGANISM", 40, 44], ["mice", "ORGANISM", 92, 96], ["CY", "SIMPLE_CHEMICAL", 161, 163], ["human", "ORGANISM", 227, 232], ["CY", "SIMPLE_CHEMICAL", 293, 295], ["cell", "CELL", 305, 309], ["patients", "ORGANISM", 343, 351], ["advanced cancer", "CANCER", 357, 372], ["Thymocytes", "CELL_TYPE", 0, 10], ["splenic T-cells", "CELL_TYPE", 15, 30], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 92, 96], ["human", "SPECIES", 227, 232], ["patients", "SPECIES", 343, 351], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 92, 96], ["human", "SPECIES", 227, 232], ["Thymocytes", "TEST", 0, 10], ["treatment", "TREATMENT", 127, 136], ["a low dose of CY", "TREATMENT", 147, 163], ["Anti-cancer DrugFor human application", "TREATMENT", 207, 244], ["CY enhanced cell-mediated and humoral immunity", "TREATMENT", 293, 339], ["advanced cancer", "PROBLEM", 357, 372], ["splenic", "ANATOMY", 15, 22], ["decreased", "OBSERVATION_MODIFIER", 101, 110], ["cancer", "OBSERVATION", 366, 372]]], ["We examined SIV in patients with colorectal cancer before and after chemotherapy and found that 8 out of 13 patients showed a trend of increased SIV 8 weeks after the start of chemotherapy (Fig. 14) .Grafting of Cells and TissuesIn animal experiments, the level of immune functions of aged mice can be restored to a level approaching that of young adult mice by grafting both newborn thymus and bone-marrow from young donors (Hirokawa et al. 1976 (Hirokawa et al. , 1982 Hirokawa and Utsuyama 1989) .", [["colorectal cancer", "ANATOMY", 33, 50], ["Cells", "ANATOMY", 212, 217], ["Tissues", "ANATOMY", 222, 229], ["thymus", "ANATOMY", 384, 390], ["bone-marrow", "ANATOMY", 395, 406], ["colorectal cancer", "DISEASE", 33, 50], ["SIV", "ORGANISM", 12, 15], ["patients", "ORGANISM", 19, 27], ["colorectal cancer", "CANCER", 33, 50], ["patients", "ORGANISM", 108, 116], ["SIV", "ORGANISM", 145, 148], ["Cells", "CELL", 212, 217], ["Tissues", "TISSUE", 222, 229], ["mice", "ORGANISM", 290, 294], ["mice", "ORGANISM", 354, 358], ["thymus", "ORGAN", 384, 390], ["bone-marrow", "MULTI-TISSUE_STRUCTURE", 395, 406], ["donors", "ORGANISM", 418, 424], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 108, 116], ["mice", "SPECIES", 290, 294], ["mice", "SPECIES", 354, 358], ["SIV", "SPECIES", 12, 15], ["SIV", "SPECIES", 145, 148], ["mice", "SPECIES", 290, 294], ["mice", "SPECIES", 354, 358], ["colorectal cancer", "PROBLEM", 33, 50], ["chemotherapy", "TREATMENT", 68, 80], ["increased SIV", "PROBLEM", 135, 148], ["chemotherapy", "TREATMENT", 176, 188], ["Grafting of Cells", "TREATMENT", 200, 217], ["colorectal", "ANATOMY", 33, 43], ["cancer", "OBSERVATION", 44, 50], ["Cells", "OBSERVATION", 212, 217], ["Tissues", "OBSERVATION_MODIFIER", 222, 229], ["grafting", "OBSERVATION", 362, 370], ["thymus", "ANATOMY", 384, 390], ["bone", "ANATOMY", 395, 399], ["marrow", "ANATOMY", 400, 406]]], ["The results suggest that intrinsic cellular change of the immune system is more responsible for the immune deficiencies in the aged than the environmental or structural tissue changes including connective tissues and humoral factors.", [["cellular", "ANATOMY", 35, 43], ["immune system", "ANATOMY", 58, 71], ["tissue", "ANATOMY", 169, 175], ["connective tissues", "ANATOMY", 194, 212], ["cellular", "CELL", 35, 43], ["tissue", "TISSUE", 169, 175], ["connective tissues", "TISSUE", 194, 212], ["humoral factors", "PROTEIN", 217, 232], ["intrinsic cellular change of the immune system", "PROBLEM", 25, 71], ["the immune deficiencies", "PROBLEM", 96, 119], ["structural tissue changes", "PROBLEM", 158, 183], ["connective tissues and humoral factors", "PROBLEM", 194, 232], ["intrinsic cellular change", "OBSERVATION", 25, 50], ["immune system", "OBSERVATION", 58, 71], ["more responsible for", "UNCERTAINTY", 75, 95], ["structural tissue", "OBSERVATION", 158, 175], ["connective tissues", "OBSERVATION", 194, 212]]], ["In thymus grafting, however, thymic stromal tissues rather than thymocytes are important for the restoration of T-cell-dependent immune system.", [["thymus", "ANATOMY", 3, 9], ["thymic stromal tissues", "ANATOMY", 29, 51], ["thymocytes", "ANATOMY", 64, 74], ["T-cell", "ANATOMY", 112, 118], ["immune system", "ANATOMY", 129, 142], ["thymus", "ORGAN", 3, 9], ["thymic stromal tissues", "TISSUE", 29, 51], ["thymocytes", "CELL", 64, 74], ["T-cell", "CELL", 112, 118], ["immune system", "ANATOMICAL_SYSTEM", 129, 142], ["thymocytes", "CELL_TYPE", 64, 74], ["thymus grafting", "TREATMENT", 3, 18], ["thymic stromal tissues", "PROBLEM", 29, 51], ["thymus", "ANATOMY", 3, 9], ["grafting", "OBSERVATION", 10, 18], ["thymic", "ANATOMY", 29, 35], ["stromal tissues", "OBSERVATION", 36, 51], ["immune system", "OBSERVATION", 129, 142]]], ["For human application, the transplantation of bone-marrow cells is becoming easier, but it is almost impossible to find donors of young thymuses.", [["bone-marrow cells", "ANATOMY", 46, 63], ["thymuses", "ANATOMY", 136, 144], ["human", "ORGANISM", 4, 9], ["bone-marrow cells", "CELL", 46, 63], ["donors", "ORGANISM", 120, 126], ["thymuses", "ORGAN", 136, 144], ["bone-marrow cells", "CELL_TYPE", 46, 63], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["human application", "TREATMENT", 4, 21], ["the transplantation of bone-marrow cells", "TREATMENT", 23, 63], ["bone", "ANATOMY", 46, 50], ["marrow cells", "OBSERVATION", 51, 63], ["thymuses", "OBSERVATION", 136, 144]]], ["Further, donors need to have the same MHC type as the recipients.", [["donors", "ORGANISM", 9, 15], ["MHC", "PROTEIN", 38, 41]]], ["Thymus transplantation may be performed, if an autologous thymus can be partially removed at a young age and stored in liquid nitrogen.Grafting of Cells and TissuesMeanwhile, researchers have been accumulating data on molecules of thymic epithelial cells that are essential for T-cell differentiation (Zuniga-Pfucker 2004; Utsuyama et al. 2003) .", [["Thymus", "ANATOMY", 0, 6], ["thymus", "ANATOMY", 58, 64], ["Cells", "ANATOMY", 147, 152], ["Tissues", "ANATOMY", 157, 164], ["thymic epithelial cells", "ANATOMY", 231, 254], ["T-cell", "ANATOMY", 278, 284], ["nitrogen", "CHEMICAL", 126, 134], ["Thymus", "ORGAN", 0, 6], ["thymus", "ORGAN", 58, 64], ["Cells", "CELL", 147, 152], ["thymic epithelial cells", "CELL", 231, 254], ["T-cell", "CELL", 278, 284], ["thymic epithelial cells", "CELL_TYPE", 231, 254], ["Thymus transplantation", "TREATMENT", 0, 22], ["an autologous thymus", "TREATMENT", 44, 64], ["liquid nitrogen", "TREATMENT", 119, 134], ["Grafting of Cells", "TREATMENT", 135, 152], ["thymic epithelial cells", "PROBLEM", 231, 254], ["transplantation", "OBSERVATION", 7, 22], ["Cells", "OBSERVATION", 147, 152], ["Tissues", "ANATOMY", 157, 164], ["thymic", "ANATOMY", 231, 237], ["epithelial cells", "OBSERVATION", 238, 254], ["cell differentiation", "OBSERVATION", 280, 300]]], ["Accordingly, in the near future it may be possible to reconstruct an artificial thymus using easily available cells of individuals.Infusion of Activated Autologous T-cellsCell transfer method using young and old mice showed that 10% of the age-related decline can be attributed to cellular environment and 90% to changes intrinsic to the old cells .", [["thymus", "ANATOMY", 80, 86], ["cells", "ANATOMY", 110, 115], ["Autologous T-cells", "ANATOMY", 153, 171], ["Cell", "ANATOMY", 171, 175], ["cellular", "ANATOMY", 281, 289], ["cells", "ANATOMY", 342, 347], ["thymus", "ORGAN", 80, 86], ["cells", "CELL", 110, 115], ["T-cells", "CELL", 164, 171], ["Cell", "CELL", 171, 175], ["mice", "ORGANISM", 212, 216], ["cellular", "CELL", 281, 289], ["cells", "CELL", 342, 347], ["Activated Autologous T-cells", "CELL_LINE", 143, 171], ["old cells", "CELL_TYPE", 338, 347], ["mice", "SPECIES", 212, 216], ["mice", "SPECIES", 212, 216], ["an artificial thymus", "TREATMENT", 66, 86], ["Infusion", "TREATMENT", 131, 139], ["Activated Autologous T-cells", "TREATMENT", 143, 171], ["cellular environment", "PROBLEM", 281, 301], ["may be possible", "UNCERTAINTY", 35, 50], ["thymus", "ANATOMY", 80, 86]]], ["Many studies including ours ) have revealed that the intrinsic cellular changes are mainly observed in T-cells; i.e., decrease in number, changes in composition of subpopulations and qualitative changes such as proliferative activity and cytokine production.", [["cellular", "ANATOMY", 63, 71], ["T-cells", "ANATOMY", 103, 110], ["cellular", "CELL", 63, 71], ["T-cells", "CELL", 103, 110], ["T-cells", "CELL_TYPE", 103, 110], ["cytokine", "PROTEIN", 238, 246], ["Many studies", "TEST", 0, 12], ["the intrinsic cellular changes", "PROBLEM", 49, 79], ["subpopulations", "PROBLEM", 164, 178], ["qualitative changes", "PROBLEM", 183, 202], ["proliferative activity", "PROBLEM", 211, 233], ["cytokine production", "PROBLEM", 238, 257], ["intrinsic cellular changes", "OBSERVATION", 53, 79], ["decrease", "OBSERVATION_MODIFIER", 118, 126], ["number", "OBSERVATION_MODIFIER", 130, 136], ["subpopulations", "OBSERVATION_MODIFIER", 164, 178], ["proliferative", "OBSERVATION_MODIFIER", 211, 224], ["activity", "OBSERVATION_MODIFIER", 225, 233], ["cytokine production", "OBSERVATION", 238, 257]]], ["In fact, T-cells from old individuals do not proliferate efficiently in vitro, but the proliferation can be promoted in the presence of anti-CD3 and IL-2.", [["T-cells", "ANATOMY", 9, 16], ["T-cells", "CELL", 9, 16], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 136, 144], ["IL-2", "GENE_OR_GENE_PRODUCT", 149, 153], ["T-cells", "CELL_TYPE", 9, 16], ["anti-CD3", "PROTEIN", 136, 144], ["IL", "PROTEIN", 149, 151], ["old individuals", "PROBLEM", 22, 37], ["anti-CD3 and IL", "TREATMENT", 136, 151]]], ["Thus, activated T-cells in vitro are expected to restore the declined immune functions of aged mice and humans.", [["T-cells", "ANATOMY", 16, 23], ["T-cells", "CELL", 16, 23], ["mice", "ORGANISM", 95, 99], ["humans", "ORGANISM", 104, 110], ["activated T-cells", "CELL_TYPE", 6, 23], ["mice", "SPECIES", 95, 99], ["humans", "SPECIES", 104, 110], ["mice", "SPECIES", 95, 99], ["humans", "SPECIES", 104, 110]]], ["This treatment was already employed for cancer treatment as an immunotherapy, e.g., lymphokine activated killer cells (LAK) (Rosenberg 2001 ).1 Animal ModelsWe tested the effect of infusing activated T-cells using young and old mice .", [["cancer", "ANATOMY", 40, 46], ["killer cells", "ANATOMY", 105, 117], ["LAK", "ANATOMY", 119, 122], ["T-cells", "ANATOMY", 200, 207], ["cancer", "DISEASE", 40, 46], ["cancer", "CANCER", 40, 46], ["killer cells", "CELL", 105, 117], ["LAK", "CELL", 119, 122], ["T-cells", "CELL", 200, 207], ["mice", "ORGANISM", 228, 232], ["lymphokine activated killer cells", "CELL_TYPE", 84, 117], ["LAK", "CELL_TYPE", 119, 122], ["activated T-cells", "CELL_TYPE", 190, 207], ["mice", "SPECIES", 228, 232], ["mice", "SPECIES", 228, 232], ["This treatment", "TREATMENT", 0, 14], ["cancer treatment", "TREATMENT", 40, 56], ["an immunotherapy", "TREATMENT", 60, 76], ["lymphokine activated killer cells", "TREATMENT", 84, 117], ["infusing activated T-cells", "TREATMENT", 181, 207]]], ["In this study we employed a congenic combination of B10.Thy1.1 mice (young and old) as donors and C57BL/6 Thy1.2 mice (young and old) as recipients, to determine how many activated T-cells survived in the recipients.", [["T-cells", "ANATOMY", 181, 188], ["Thy1.1 mice", "ORGANISM", 56, 67], ["donors", "ORGANISM", 87, 93], ["C57BL/6 Thy1.2 mice", "ORGANISM", 98, 117], ["recipients", "ORGANISM", 137, 147], ["T-cells", "CELL", 181, 188], ["recipients", "ORGANISM", 205, 215], ["activated T-cells", "CELL_TYPE", 171, 188], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 113, 117], ["this study", "TEST", 3, 13], ["a congenic combination of B10", "TREATMENT", 26, 55]]], ["The mice were sacrificed 11 days and 25 days after the infusion of activated T-cells and used for immunological assessment.", [["T-cells", "ANATOMY", 77, 84], ["mice", "ORGANISM", 4, 8], ["T-cells", "CELL", 77, 84], ["activated T-cells", "CELL_TYPE", 67, 84], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["activated T-cells", "TREATMENT", 67, 84], ["immunological assessment", "TEST", 98, 122]]], ["For the infusion of activated T-cells, splenic lymphocytes were expanded 10-to 15-folds in the presence of immobilized anti-CD3 monoclonal antibody and IL-2.", [["T-cells", "ANATOMY", 30, 37], ["splenic lymphocytes", "ANATOMY", 39, 58], ["T-cells", "CELL", 30, 37], ["splenic lymphocytes", "CELL", 39, 58], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 119, 127], ["IL-2", "GENE_OR_GENE_PRODUCT", 152, 156], ["activated T-cells", "CELL_TYPE", 20, 37], ["splenic lymphocytes", "CELL_TYPE", 39, 58], ["anti-CD3 monoclonal antibody", "PROTEIN", 119, 147], ["IL-2", "PROTEIN", 152, 156], ["activated T-cells", "TREATMENT", 20, 37], ["splenic lymphocytes", "PROBLEM", 39, 58], ["immobilized anti-CD3 monoclonal antibody", "TREATMENT", 107, 147], ["splenic", "ANATOMY", 39, 46], ["lymphocytes", "OBSERVATION", 47, 58]]], ["Lymphocytes activated in this way were composed of mostly T-cells in which approximately 70 to 80% were CD8 + T-cells and 7 to 14% were CD4 + T-cells.", [["Lymphocytes", "ANATOMY", 0, 11], ["T-cells", "ANATOMY", 58, 65], ["CD8 + T-cells", "ANATOMY", 104, 117], ["CD4 + T-cells", "ANATOMY", 136, 149], ["Lymphocytes", "CELL", 0, 11], ["T-cells", "CELL", 58, 65], ["CD8", "GENE_OR_GENE_PRODUCT", 104, 107], ["CD4", "GENE_OR_GENE_PRODUCT", 136, 139], ["Lymphocytes", "CELL_TYPE", 0, 11], ["T-cells", "CELL_TYPE", 58, 65], ["CD8", "PROTEIN", 104, 107], ["T-cells", "CELL_TYPE", 110, 117], ["CD4", "PROTEIN", 136, 139], ["T-cells", "CELL_TYPE", 142, 149], ["Lymphocytes", "TEST", 0, 11], ["mostly T-cells", "PROBLEM", 51, 65], ["CD8", "TEST", 104, 107], ["CD4", "TEST", 136, 139]]], ["The activated T-cells prepared from old mice donors contained many more CD8 T-cells.", [["T-cells", "ANATOMY", 14, 21], ["CD8 T-cells", "ANATOMY", 72, 83], ["T-cells", "CELL", 14, 21], ["mice", "ORGANISM", 40, 44], ["donors", "ORGANISM", 45, 51], ["CD8", "GENE_OR_GENE_PRODUCT", 72, 75], ["activated T-cells", "CELL_TYPE", 4, 21], ["CD8 T-cells", "CELL_TYPE", 72, 83], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["The activated T-cells", "TREATMENT", 0, 21], ["old mice donors", "TREATMENT", 36, 51]]], ["Although CD4+ T-cells were smaller in number than CD8+ T-cells, most of them expressed a phenotype of na\u00efve T-cells.", [["CD4+ T-cells", "ANATOMY", 9, 21], ["CD8+", "ANATOMY", 50, 54], ["T-cells", "ANATOMY", 55, 62], ["na\u00efve T-cells", "ANATOMY", 102, 115], ["CD4", "GENE_OR_GENE_PRODUCT", 9, 12], ["CD8", "GENE_OR_GENE_PRODUCT", 50, 53], ["T-cells", "CELL", 55, 62], ["na\u00efve T-cells", "CELL", 102, 115], ["CD4", "PROTEIN", 9, 12], ["T-cells", "CELL_TYPE", 14, 21], ["CD8", "PROTEIN", 50, 53], ["T-cells", "CELL_TYPE", 55, 62], ["na\u00efve T-cells", "CELL_TYPE", 102, 115], ["CD4", "TEST", 9, 12], ["smaller", "OBSERVATION_MODIFIER", 27, 34]]], ["After infusion of activated T-cells, the absolute number of T-cells significantly increased in the spleen of the recipient mice, especially of old mice.", [["T-cells", "ANATOMY", 28, 35], ["T-cells", "ANATOMY", 60, 67], ["spleen", "ANATOMY", 99, 105], ["T-cells", "CELL", 28, 35], ["T-cells", "CELL", 60, 67], ["spleen", "ORGAN", 99, 105], ["mice", "ORGANISM", 123, 127], ["mice", "ORGANISM", 147, 151], ["activated T-cells", "CELL_TYPE", 18, 35], ["T-cells", "CELL_TYPE", 60, 67], ["mice", "SPECIES", 123, 127], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 123, 127], ["mice", "SPECIES", 147, 151], ["activated T-cells", "TREATMENT", 18, 35], ["absolute", "OBSERVATION_MODIFIER", 41, 49], ["number", "OBSERVATION_MODIFIER", 50, 56], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["spleen", "ANATOMY", 99, 105]]], ["In the peripheral blood and spleen, donor-type Thy-1.1 T-cells were significantly more numerous in old recipients than in young ones.", [["peripheral blood", "ANATOMY", 7, 23], ["spleen", "ANATOMY", 28, 34], ["Thy-1.1 T-cells", "ANATOMY", 47, 62], ["peripheral blood", "ORGANISM_SUBSTANCE", 7, 23], ["spleen", "ORGAN", 28, 34], ["Thy-1.1 T-cells", "CELL", 47, 62], ["recipients", "ORGANISM", 103, 113], ["donor-type Thy-1.1 T-cells", "CELL_LINE", 36, 62], ["peripheral", "ANATOMY_MODIFIER", 7, 17], ["blood", "ANATOMY", 18, 23], ["spleen", "ANATOMY", 28, 34], ["significantly", "OBSERVATION_MODIFIER", 68, 81], ["more", "OBSERVATION_MODIFIER", 82, 86], ["numerous", "OBSERVATION_MODIFIER", 87, 95], ["recipients", "OBSERVATION", 103, 113]]], ["In addition, the number of donor-type T-cells that survived was significantly high in the spleen than in the peripheral blood in both young and old recipients.", [["donor-type T-cells", "ANATOMY", 27, 45], ["spleen", "ANATOMY", 90, 96], ["peripheral blood", "ANATOMY", 109, 125], ["T-cells", "CELL", 38, 45], ["spleen", "ORGAN", 90, 96], ["peripheral blood", "ORGANISM_SUBSTANCE", 109, 125], ["recipients", "ORGANISM", 148, 158], ["donor-type T-cells", "CELL_TYPE", 27, 45], ["donor-type T-cells", "PROBLEM", 27, 45], ["significantly", "OBSERVATION_MODIFIER", 64, 77], ["high", "OBSERVATION_MODIFIER", 78, 82], ["spleen", "ANATOMY", 90, 96], ["peripheral", "ANATOMY_MODIFIER", 109, 119], ["blood", "ANATOMY", 120, 125], ["recipients", "OBSERVATION", 148, 158]]], ["The magnitude of antibody formation against SRBC did not change significantly in young recipients.", [["recipients", "ORGANISM", 87, 97], ["antibody formation", "PROBLEM", 17, 35], ["SRBC", "PROBLEM", 44, 48], ["antibody formation", "OBSERVATION", 17, 35]]], ["About half of the old recipients, however, showed a significant enhancement of antibody formation.", [["recipients", "ORGANISM", 22, 32], ["a significant enhancement of antibody formation", "PROBLEM", 50, 97], ["significant", "OBSERVATION_MODIFIER", 52, 63], ["enhancement", "OBSERVATION", 64, 75], ["antibody formation", "OBSERVATION", 79, 97]]], ["It is of importance to note that such an enhanced antibody formation was observed in old recipients infused with activated T-cells either from young or old donors.2 Trials in Human Cancer PatientsT-cells from peripheral blood of healthy people can be easily expanded more than 1000-fold in vitro in the presence of immobilized anti-CD3 monoclonal antibody (MoAb) and IL-2.", [["T-cells", "ANATOMY", 123, 130], ["Cancer PatientsT-cells", "ANATOMY", 181, 203], ["peripheral blood", "ANATOMY", 209, 225], ["Cancer", "DISEASE", 181, 187], ["recipients", "ORGANISM", 89, 99], ["T-cells", "CELL", 123, 130], ["donors", "ORGANISM", 156, 162], ["Human", "ORGANISM", 175, 180], ["Cancer PatientsT-cells", "CELL", 181, 203], ["peripheral blood", "ORGANISM_SUBSTANCE", 209, 225], ["people", "ORGANISM", 237, 243], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 327, 335], ["MoAb", "GENE_OR_GENE_PRODUCT", 357, 361], ["IL-2", "GENE_OR_GENE_PRODUCT", 367, 371], ["activated T-cells", "CELL_TYPE", 113, 130], ["Human Cancer PatientsT-cells", "CELL_LINE", 175, 203], ["anti-CD3 monoclonal antibody", "PROTEIN", 327, 355], ["MoAb", "PROTEIN", 357, 361], ["IL-2", "PROTEIN", 367, 371], ["Human", "SPECIES", 175, 180], ["people", "SPECIES", 237, 243], ["an enhanced antibody formation", "PROBLEM", 38, 68], ["activated T-cells", "TREATMENT", 113, 130], ["peripheral blood of healthy people", "TREATMENT", 209, 243], ["immobilized anti-CD3 monoclonal antibody (MoAb", "TREATMENT", 315, 361], ["Cancer", "OBSERVATION", 181, 187], ["peripheral", "ANATOMY_MODIFIER", 209, 219], ["blood", "ANATOMY", 220, 225]]], ["The infusion of activated autologous T-cells has been widely used for cancer patients as a form of immunotherapy (Rosenberg 2001) , but without significant impact on cancer treatment in many cases.", [["T-cells", "ANATOMY", 37, 44], ["cancer", "ANATOMY", 70, 76], ["cancer", "ANATOMY", 166, 172], ["cancer", "DISEASE", 70, 76], ["cancer", "DISEASE", 166, 172], ["T-cells", "CELL", 37, 44], ["cancer", "CANCER", 70, 76], ["patients", "ORGANISM", 77, 85], ["cancer", "CANCER", 166, 172], ["activated autologous T-cells", "CELL_TYPE", 16, 44], ["patients", "SPECIES", 77, 85], ["The infusion of activated autologous T-cells", "TREATMENT", 0, 44], ["cancer", "PROBLEM", 70, 76], ["immunotherapy", "TREATMENT", 99, 112], ["cancer treatment", "TREATMENT", 166, 182], ["without", "UNCERTAINTY", 136, 143], ["cancer", "OBSERVATION", 166, 172]]], ["However, it can be expected that activated T-cells expanded in vitro in a nonspecific manner may improve the immune deficient status of elderly people and cancer patients.", [["T-cells", "ANATOMY", 43, 50], ["cancer", "ANATOMY", 155, 161], ["cancer", "DISEASE", 155, 161], ["T-cells", "CELL", 43, 50], ["people", "ORGANISM", 144, 150], ["cancer", "CANCER", 155, 161], ["patients", "ORGANISM", 162, 170], ["activated T-cells", "CELL_TYPE", 33, 50], ["people", "SPECIES", 144, 150], ["patients", "SPECIES", 162, 170], ["activated T-cells", "PROBLEM", 33, 50]]], ["T-cells expanded in a nonspecific manner may contain harmful T-cells exhibiting autoimmune activity.", [["T-cells", "ANATOMY", 0, 7], ["T-cells", "ANATOMY", 61, 68], ["T-cells", "CELL", 0, 7], ["T-cells", "CELL", 61, 68], ["T-cells", "CELL_TYPE", 0, 7], ["T-cells", "CELL_TYPE", 61, 68], ["autoimmune activity", "PROBLEM", 80, 99], ["autoimmune activity", "OBSERVATION", 80, 99]]], ["In this respect, a recent paper reported that the infusion of activated autologous T-cells did not enhance or promote autoimmune activity (Yamaguchi et al. 2004 ).2 Trials in Human Cancer PatientsIn the next step, we examined cancer patients in the advanced stage; patients with tongue cancer (1 case), esophageal cancer (2 cases), lung cancer (4 cases), gastric cancer, pancreatic cancer (3 cases), colon cancer, appendical cancer and ovarian cancer.", [["T-cells", "ANATOMY", 83, 90], ["Cancer", "ANATOMY", 181, 187], ["cancer", "ANATOMY", 226, 232], ["tongue cancer", "ANATOMY", 279, 292], ["esophageal cancer", "ANATOMY", 303, 320], ["lung cancer", "ANATOMY", 332, 343], ["gastric cancer", "ANATOMY", 355, 369], ["pancreatic cancer", "ANATOMY", 371, 388], ["colon cancer", "ANATOMY", 400, 412], ["appendical cancer", "ANATOMY", 414, 431], ["ovarian cancer", "ANATOMY", 436, 450], ["Cancer", "DISEASE", 181, 187], ["cancer", "DISEASE", 226, 232], ["tongue cancer", "DISEASE", 279, 292], ["esophageal cancer", "DISEASE", 303, 320], ["lung cancer", "DISEASE", 332, 343], ["gastric cancer", "DISEASE", 355, 369], ["pancreatic cancer", "DISEASE", 371, 388], ["colon cancer", "DISEASE", 400, 412], ["appendical cancer", "DISEASE", 414, 431], ["ovarian cancer", "DISEASE", 436, 450], ["T-cells", "CELL", 83, 90], ["Human", "ORGANISM", 175, 180], ["Cancer", "CANCER", 181, 187], ["Patients", "ORGANISM", 188, 196], ["cancer", "CANCER", 226, 232], ["patients", "ORGANISM", 233, 241], ["patients", "ORGANISM", 265, 273], ["tongue cancer", "CANCER", 279, 292], ["esophageal cancer", "CANCER", 303, 320], ["lung cancer", "CANCER", 332, 343], ["gastric cancer", "CANCER", 355, 369], ["pancreatic cancer", "CANCER", 371, 388], ["colon cancer", "CANCER", 400, 412], ["appendical cancer", "CANCER", 414, 431], ["ovarian cancer", "CANCER", 436, 450], ["activated autologous T-cells", "CELL_TYPE", 62, 90], ["Human", "SPECIES", 175, 180], ["Patients", "SPECIES", 188, 196], ["patients", "SPECIES", 233, 241], ["patients", "SPECIES", 265, 273], ["activated autologous T-cells", "TREATMENT", 62, 90], ["autoimmune activity", "PROBLEM", 118, 137], ["tongue cancer", "PROBLEM", 279, 292], ["esophageal cancer", "PROBLEM", 303, 320], ["lung cancer", "PROBLEM", 332, 343], ["gastric cancer", "PROBLEM", 355, 369], ["pancreatic cancer", "PROBLEM", 371, 388], ["colon cancer", "PROBLEM", 400, 412], ["appendical cancer", "PROBLEM", 414, 431], ["ovarian cancer", "PROBLEM", 436, 450], ["cancer", "OBSERVATION", 226, 232], ["tongue", "ANATOMY", 279, 285], ["cancer", "OBSERVATION", 286, 292], ["esophageal", "ANATOMY", 303, 313], ["cancer", "OBSERVATION", 314, 320], ["lung", "ANATOMY", 332, 336], ["cancer", "OBSERVATION", 337, 343], ["gastric", "ANATOMY", 355, 362], ["cancer", "OBSERVATION", 363, 369], ["pancreatic", "ANATOMY", 371, 381], ["cancer", "OBSERVATION", 382, 388], ["colon", "ANATOMY", 400, 405], ["cancer", "OBSERVATION", 406, 412], ["appendical cancer", "OBSERVATION", 414, 431], ["ovarian", "ANATOMY", 436, 443], ["cancer", "OBSERVATION", 444, 450]]], ["All the patients were in the advanced stages of cancer, with multiple metastases, and they underwent an infusion of autologous activated T-cells (so-called LAK cells).2 Trials in Human Cancer PatientsThe activated autologous T-cells prepared in the study comprised T-cells (99%), and the CD4/CD8 ratio was approximately 2-3.", [["cancer", "ANATOMY", 48, 54], ["metastases", "ANATOMY", 70, 80], ["T-cells", "ANATOMY", 137, 144], ["LAK cells", "ANATOMY", 156, 165], ["Cancer", "ANATOMY", 185, 191], ["T-cells", "ANATOMY", 225, 232], ["T-cells", "ANATOMY", 265, 272], ["cancer", "DISEASE", 48, 54], ["metastases", "DISEASE", 70, 80], ["Cancer", "DISEASE", 185, 191], ["patients", "ORGANISM", 8, 16], ["cancer", "CANCER", 48, 54], ["T-cells", "CELL", 137, 144], ["so-", "CELL", 146, 149], ["LAK cells", "CELL", 156, 165], ["Human", "ORGANISM", 179, 184], ["Cancer", "CANCER", 185, 191], ["Patients", "ORGANISM", 192, 200], ["T-cells", "CELL", 225, 232], ["T-cells", "CELL", 265, 272], ["CD4", "GENE_OR_GENE_PRODUCT", 288, 291], ["CD8", "GENE_OR_GENE_PRODUCT", 292, 295], ["autologous activated T-cells", "CELL_TYPE", 116, 144], ["so-called LAK cells", "CELL_TYPE", 146, 165], ["activated autologous T-cells", "CELL_TYPE", 204, 232], ["T-cells", "CELL_TYPE", 265, 272], ["CD4", "PROTEIN", 288, 291], ["CD8", "PROTEIN", 292, 295], ["patients", "SPECIES", 8, 16], ["Human", "SPECIES", 179, 184], ["Patients", "SPECIES", 192, 200], ["cancer", "PROBLEM", 48, 54], ["multiple metastases", "PROBLEM", 61, 80], ["an infusion of autologous activated T-cells (so-called LAK cells", "TREATMENT", 101, 165], ["The activated autologous T-cells", "TREATMENT", 200, 232], ["the study", "TEST", 245, 254], ["the CD4/CD8 ratio", "TEST", 284, 301], ["cancer", "OBSERVATION", 48, 54], ["multiple", "OBSERVATION_MODIFIER", 61, 69], ["metastases", "OBSERVATION", 70, 80], ["Cancer", "OBSERVATION", 185, 191]]], ["The proportion of NK-cells was less than 1% in the activated T-cells.2 Trials in Human Cancer PatientsThe number of cell per infusion was approximately 5\u00d710 9 , and the infusion was repeated 5-6 times for 10 weeks.", [["NK-cells", "ANATOMY", 18, 26], ["T-cells", "ANATOMY", 61, 68], ["Cancer", "ANATOMY", 87, 93], ["cell", "ANATOMY", 116, 120], ["Cancer", "DISEASE", 87, 93], ["NK-cells", "CELL", 18, 26], ["T-cells", "CELL", 61, 68], ["Human", "ORGANISM", 81, 86], ["Cancer", "CANCER", 87, 93], ["Patients", "ORGANISM", 94, 102], ["cell", "CELL", 116, 120], ["NK-cells", "CELL_TYPE", 18, 26], ["activated T-cells", "CELL_TYPE", 51, 68], ["Human", "SPECIES", 81, 86], ["Patients", "SPECIES", 94, 102], ["NK-cells", "TEST", 18, 26], ["the infusion", "TREATMENT", 165, 177], ["T-cells", "OBSERVATION", 61, 68], ["Cancer", "OBSERVATION", 87, 93]]], ["Various parameters were examined before and after the infusion of activated autologous T-cells.2 Trials in Human Cancer PatientsFigure15 shows the immunological parameters before and after the infusion of activated autologous T-cells in an advanced cancer patient.", [["T-cells", "ANATOMY", 87, 94], ["T-cells", "ANATOMY", 226, 233], ["cancer", "ANATOMY", 249, 255], ["Cancer", "DISEASE", 113, 119], ["cancer", "DISEASE", 249, 255], ["T-cells", "CELL", 87, 94], ["Human", "ORGANISM", 107, 112], ["Cancer", "CANCER", 113, 119], ["T-cells", "CELL", 226, 233], ["cancer", "CANCER", 249, 255], ["patient", "ORGANISM", 256, 263], ["activated autologous T-cells", "CELL_TYPE", 66, 94], ["activated autologous T-cells", "CELL_TYPE", 205, 233], ["Human", "SPECIES", 107, 112], ["patient", "SPECIES", 256, 263], ["Various parameters", "TEST", 0, 18], ["the infusion of activated autologous T-cells", "TREATMENT", 50, 94], ["the infusion", "TREATMENT", 189, 201], ["activated autologous T-cells", "TREATMENT", 205, 233], ["an advanced cancer", "PROBLEM", 237, 255], ["advanced", "OBSERVATION_MODIFIER", 240, 248], ["cancer", "OBSERVATION", 249, 255]]], ["Most of the immunological parameters that were examined improved after the infusion, except for the ratio of T-cell subpopulations.2 Trials in Human Cancer PatientsWe examined the effect of the infusion of activated autologous T-cells in 14 cases and found that the most pronounced improvement was observed in the T-cell proliferation index (TCPI).", [["T-cell", "ANATOMY", 109, 115], ["Cancer", "ANATOMY", 149, 155], ["T-cells", "ANATOMY", 227, 234], ["T-cell", "ANATOMY", 314, 320], ["Cancer", "DISEASE", 149, 155], ["T-cell", "CELL", 109, 115], ["Human", "ORGANISM", 143, 148], ["Cancer", "CANCER", 149, 155], ["Patients", "ORGANISM", 156, 164], ["T-cells", "CELL", 227, 234], ["T-cell", "CELL", 314, 320], ["T-cell subpopulations", "CELL_TYPE", 109, 130], ["activated autologous T-cells", "CELL_TYPE", 206, 234], ["Human", "SPECIES", 143, 148], ["Patients", "SPECIES", 156, 164], ["the immunological parameters", "TEST", 8, 36], ["the infusion", "TREATMENT", 71, 83], ["activated autologous T-cells", "TREATMENT", 206, 234], ["cell subpopulations", "OBSERVATION", 111, 130], ["Cancer", "OBSERVATION", 149, 155], ["most pronounced", "OBSERVATION_MODIFIER", 266, 281], ["cell", "OBSERVATION", 316, 320], ["proliferation index", "OBSERVATION", 321, 340]]], ["The values varied across cases and were unsuitable for statistical analysis.", [["The values", "TEST", 0, 10], ["statistical analysis", "TEST", 55, 75]]], ["After the infusion of activated autologous T-cells, an improvement in TCPI was observed in 11 out of 14 cases.", [["T-cells", "ANATOMY", 43, 50], ["T-cells", "CELL", 43, 50], ["TCPI", "CANCER", 70, 74], ["activated autologous T-cells", "CELL_TYPE", 22, 50], ["TCPI", "PROTEIN", 70, 74], ["activated autologous T-cells", "TREATMENT", 22, 50], ["TCPI", "TEST", 70, 74], ["improvement", "OBSERVATION_MODIFIER", 55, 66]]], ["The average value of TCPI before the infusion was 1.02, which is apparently lower than that observed in colonic cancer stages I to IV (1.21).", [["colonic cancer", "ANATOMY", 104, 118], ["colonic cancer", "DISEASE", 104, 118], ["colonic cancer", "CANCER", 104, 118], ["TCPI", "TREATMENT", 21, 25], ["the infusion", "TREATMENT", 33, 45], ["colonic cancer", "PROBLEM", 104, 118], ["colonic", "ANATOMY", 104, 111], ["cancer", "OBSERVATION", 112, 118]]], ["After the infusion, the average TCPI was increased to 1.49, although it was definitely lower than that of healthy controls (1.70).", [["the infusion", "TREATMENT", 6, 18], ["the average TCPI", "TREATMENT", 20, 36]]], ["It was not obvious whether the infusion of activated autologous T-cells was effective in reducing the tumor size, but most of the patients revealed that in general, they experienced an improvement in their health status after the infusion.", [["T-cells", "ANATOMY", 64, 71], ["tumor", "ANATOMY", 102, 107], ["tumor", "DISEASE", 102, 107], ["T-cells", "CELL", 64, 71], ["tumor", "CANCER", 102, 107], ["patients", "ORGANISM", 130, 138], ["activated autologous T-cells", "CELL_TYPE", 43, 71], ["patients", "SPECIES", 130, 138], ["activated autologous T-cells", "TREATMENT", 43, 71], ["the tumor size", "PROBLEM", 98, 112], ["the infusion", "TREATMENT", 226, 238], ["not obvious", "UNCERTAINTY", 7, 18], ["tumor", "OBSERVATION", 102, 107], ["size", "OBSERVATION_MODIFIER", 108, 112], ["improvement", "OBSERVATION_MODIFIER", 185, 196]]], ["Improvement of immunological function can not be expected in cancer patients whose T-cell expansion in vitro is less efficient.", [["cancer", "ANATOMY", 61, 67], ["T-cell", "ANATOMY", 83, 89], ["cancer", "DISEASE", 61, 67], ["cancer", "CANCER", 61, 67], ["patients", "ORGANISM", 68, 76], ["T-cell", "CELL", 83, 89], ["patients", "SPECIES", 68, 76], ["immunological function", "PROBLEM", 15, 37], ["immunological function", "OBSERVATION", 15, 37], ["can not be expected", "UNCERTAINTY", 38, 57], ["less efficient", "OBSERVATION_MODIFIER", 112, 126]]], ["Thus, we have to consider the source of T-cells.", [["T-cells", "ANATOMY", 40, 47], ["T-cells", "CELL", 40, 47], ["T-cells", "CELL_TYPE", 40, 47], ["T-cells", "PROBLEM", 40, 47]]], ["A good technique is to obtain T-cells not from patients suffering from cancer, but from individuals in healthy condition.", [["T-cells", "ANATOMY", 30, 37], ["cancer", "ANATOMY", 71, 77], ["cancer", "DISEASE", 71, 77], ["T-cells", "CELL", 30, 37], ["patients", "ORGANISM", 47, 55], ["cancer", "CANCER", 71, 77], ["T-cells", "CELL_TYPE", 30, 37], ["patients", "SPECIES", 47, 55], ["cancer", "PROBLEM", 71, 77], ["cancer", "OBSERVATION", 71, 77]]], ["For this purpose we need to obtain peripheral blood lymphocytes from healthy peoples and these lymphocytes should be kept in the frozen state.", [["peripheral blood lymphocytes", "ANATOMY", 35, 63], ["lymphocytes", "ANATOMY", 95, 106], ["peripheral blood lymphocytes", "CELL", 35, 63], ["lymphocytes", "CELL", 95, 106], ["peripheral blood lymphocytes", "CELL_TYPE", 35, 63], ["lymphocytes", "CELL_TYPE", 95, 106], ["peripheral blood lymphocytes", "PROBLEM", 35, 63], ["these lymphocytes", "PROBLEM", 89, 106], ["peripheral", "ANATOMY_MODIFIER", 35, 45], ["blood lymphocytes", "ANATOMY", 46, 63]]], ["The process can be named as T-cell-bank and the system to establish T-cells bank is now under way.", [["T-cell", "ANATOMY", 28, 34], ["T-cells", "ANATOMY", 68, 75], ["T-cell", "CELL", 28, 34], ["T-cells", "CELL", 68, 75], ["T-cells", "CELL_TYPE", 68, 75]]]], "PMC7335418": [], "PMC5485385": [["IntroductionAcute respiratory distress syndrome (ARDS), the most severe form of acute lung injury (ALI), is the main predisposing factor in highly pathogenic avian influenza virus-induced death cases [1, 2].", [["lung", "ANATOMY", 86, 90], ["IntroductionAcute respiratory distress syndrome", "DISEASE", 0, 47], ["ARDS", "DISEASE", 49, 53], ["acute lung injury", "DISEASE", 80, 97], ["ALI", "DISEASE", 99, 102], ["avian influenza virus", "DISEASE", 158, 179], ["death", "DISEASE", 188, 193], ["lung", "ORGAN", 86, 90], ["avian", "ORGANISM", 158, 163], ["influenza virus", "ORGANISM", 164, 179], ["avian influenza virus", "SPECIES", 158, 179], ["IntroductionAcute respiratory distress syndrome", "PROBLEM", 0, 47], ["ARDS", "PROBLEM", 49, 53], ["acute lung injury", "PROBLEM", 80, 97], ["highly pathogenic avian influenza virus", "PROBLEM", 140, 179], ["respiratory distress", "OBSERVATION", 18, 38], ["ARDS", "OBSERVATION", 49, 53], ["most severe", "OBSERVATION_MODIFIER", 60, 71], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["lung", "ANATOMY", 86, 90], ["injury", "OBSERVATION", 91, 97], ["ALI", "OBSERVATION", 99, 102]]], ["The ALI caused by influenza infection can facilitate bacterial superinfection, which is a major factor that promotes mortality and disease severity [3].", [["ALI", "DISEASE", 4, 7], ["influenza infection", "DISEASE", 18, 37], ["bacterial superinfection", "DISEASE", 53, 77], ["The ALI", "PROBLEM", 0, 7], ["influenza infection", "PROBLEM", 18, 37], ["bacterial superinfection", "PROBLEM", 53, 77], ["disease severity", "PROBLEM", 131, 147], ["ALI", "ANATOMY", 4, 7], ["influenza", "OBSERVATION", 18, 27], ["bacterial", "OBSERVATION_MODIFIER", 53, 62], ["superinfection", "OBSERVATION", 63, 77]]], ["From 2003 to 2016, highly pathogenic avian H5N1 influenza virus has caused 856 human infection cases worldwide with a high mortality rate of 52.8% (http://101.96.8.164/www.who.int/entity/influenza/human_animal_interface/2017_01_16_tableH5N1.pdf).", [["avian H5N1 influenza virus", "DISEASE", 37, 63], ["infection", "DISEASE", 85, 94], ["avian H5N1 influenza virus", "ORGANISM", 37, 63], ["human", "ORGANISM", 79, 84], ["avian H5N1 influenza virus", "SPECIES", 37, 63], ["human", "SPECIES", 79, 84], ["H5N1 influenza virus", "SPECIES", 43, 63], ["human", "SPECIES", 79, 84], ["highly pathogenic avian H5N1 influenza virus", "PROBLEM", 19, 63], ["a high mortality rate", "TEST", 116, 137]]], ["Currently, China is undergoing its fifth epidemic of human infections of avian H7N9 influenza virus.", [["infections", "DISEASE", 59, 69], ["avian H7N9 influenza virus", "DISEASE", 73, 99], ["human", "ORGANISM", 53, 58], ["avian H7N9 influenza virus", "ORGANISM", 73, 99], ["human", "SPECIES", 53, 58], ["avian H7N9 influenza virus", "SPECIES", 73, 99], ["human", "SPECIES", 53, 58], ["avian H7N9 influenza virus", "SPECIES", 73, 99], ["human infections", "PROBLEM", 53, 69], ["avian H7N9 influenza virus", "PROBLEM", 73, 99], ["infections", "OBSERVATION", 59, 69]]], ["Until 16 January 2017, 918 H7N9-infected human cases with at least 359 deaths have been reported to World Health Organization (http://101.96.8.165/www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_01_16_2017_FINAL.pdf?ua=1).", [["H7N9-infected", "DISEASE", 27, 40], ["deaths", "DISEASE", 71, 77], ["human", "ORGANISM", 41, 46], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46]]], ["With high mutation and reassortment rates, influenza viruses have evolved with a rapid resistance to the current vaccines and anti-viral drugs, making an avian influenza pandemic an urgent unresolved threat to human health [4\u20136].IntroductionAngiotensin-converting enzyme 2 (ACE2) was firstly identified from human cardiac left ventricle complementary DNA (cDNA) library and lymphoma cDNA library by two separate groups [7, 8].", [["cardiac left ventricle", "ANATOMY", 314, 336], ["influenza viruses", "DISEASE", 43, 60], ["influenza", "DISEASE", 160, 169], ["IntroductionAngiotensin", "CHEMICAL", 229, 252], ["influenza viruses", "ORGANISM", 43, 60], ["human", "ORGANISM", 210, 215], ["IntroductionAngiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 229, 272], ["ACE2", "GENE_OR_GENE_PRODUCT", 274, 278], ["human", "ORGANISM", 308, 313], ["ventricle", "MULTI-TISSUE_STRUCTURE", 327, 336], ["DNA", "CELLULAR_COMPONENT", 351, 354], ["cDNA", "CELLULAR_COMPONENT", 356, 360], ["lymphoma", "CANCER", 374, 382], ["IntroductionAngiotensin-converting enzyme 2", "PROTEIN", 229, 272], ["ACE2", "PROTEIN", 274, 278], ["human cardiac left ventricle complementary DNA (cDNA) library", "DNA", 308, 369], ["lymphoma cDNA library", "DNA", 374, 395], ["avian influenza pandemic", "SPECIES", 154, 178], ["human", "SPECIES", 210, 215], ["human", "SPECIES", 308, 313], ["influenza viruses", "SPECIES", 43, 60], ["human", "SPECIES", 210, 215], ["human", "SPECIES", 308, 313], ["high mutation", "PROBLEM", 5, 18], ["influenza viruses", "PROBLEM", 43, 60], ["a rapid resistance", "PROBLEM", 79, 97], ["the current vaccines", "TREATMENT", 101, 121], ["anti-viral drugs", "TREATMENT", 126, 142], ["an avian influenza pandemic", "PROBLEM", 151, 178], ["IntroductionAngiotensin", "TREATMENT", 229, 252], ["DNA (cDNA) library and lymphoma cDNA library", "PROBLEM", 351, 395], ["high mutation", "OBSERVATION", 5, 18], ["left ventricle", "ANATOMY", 322, 336]]], ["ACE2 inactivates angiotensin II (Ang II) by cleaving it to produce Ang 1\u20137 [9].", [["angiotensin II", "CHEMICAL", 17, 31], ["Ang II", "CHEMICAL", 33, 39], ["Ang", "CHEMICAL", 67, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 17, 31], ["Ang II", "GENE_OR_GENE_PRODUCT", 33, 39], ["Ang 1\u20137", "GENE_OR_GENE_PRODUCT", 67, 74], ["ACE2", "PROTEIN", 0, 4], ["angiotensin II", "PROTEIN", 17, 31], ["Ang II", "PROTEIN", 33, 39], ["ACE2 inactivates angiotensin II (Ang II)", "TREATMENT", 0, 40], ["Ang", "TEST", 67, 70]]], ["Ang II binds to the Ang II type 1 and type 2 receptors with strong affinity, mediating regulation of blood pressure, body fluid balance, inflammation, cell proliferation, hypertrophy and fibrosis [10\u201312].", [["blood", "ANATOMY", 101, 106], ["body fluid", "ANATOMY", 117, 127], ["cell", "ANATOMY", 151, 155], ["Ang II", "CHEMICAL", 0, 6], ["Ang", "CHEMICAL", 20, 23], ["inflammation", "DISEASE", 137, 149], ["hypertrophy", "DISEASE", 171, 182], ["fibrosis", "DISEASE", 187, 195], ["Ang II", "GENE_OR_GENE_PRODUCT", 0, 6], ["Ang II type 1", "GENE_OR_GENE_PRODUCT", 20, 33], ["type 2 receptors", "GENE_OR_GENE_PRODUCT", 38, 54], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["body", "ORGANISM_SUBDIVISION", 117, 121], ["fluid", "ORGANISM_SUBSTANCE", 122, 127], ["cell", "CELL", 151, 155], ["Ang II", "PROTEIN", 0, 6], ["Ang II type 1 and type 2 receptors", "PROTEIN", 20, 54], ["Ang II binds", "PROBLEM", 0, 12], ["strong affinity", "PROBLEM", 60, 75], ["blood pressure", "TEST", 101, 115], ["body fluid balance", "TEST", 117, 135], ["inflammation", "PROBLEM", 137, 149], ["cell proliferation", "PROBLEM", 151, 169], ["hypertrophy", "PROBLEM", 171, 182], ["fibrosis", "PROBLEM", 187, 195], ["fluid balance", "OBSERVATION", 122, 135], ["inflammation", "OBSERVATION_MODIFIER", 137, 149], ["cell proliferation", "OBSERVATION", 151, 169], ["hypertrophy", "OBSERVATION", 171, 182], ["fibrosis", "OBSERVATION", 187, 195]]], ["Reduced expression levels of ACE2 have been reported in hypertension and chronic kidney disease [13, 14].", [["kidney", "ANATOMY", 81, 87], ["hypertension", "DISEASE", 56, 68], ["chronic kidney disease", "DISEASE", 73, 95], ["ACE2", "GENE_OR_GENE_PRODUCT", 29, 33], ["kidney", "ORGAN", 81, 87], ["ACE2", "PROTEIN", 29, 33], ["Reduced expression levels of ACE2", "PROBLEM", 0, 33], ["hypertension", "PROBLEM", 56, 68], ["chronic kidney disease", "PROBLEM", 73, 95], ["hypertension", "OBSERVATION", 56, 68], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["kidney", "ANATOMY", 81, 87], ["disease", "OBSERVATION", 88, 95]]], ["In addition, ACE2 was identified as a key regulator of dietary amino-acid homeostasis and gut microbial ecology [15].", [["amino-acid", "CHEMICAL", 63, 73], ["amino-acid", "CHEMICAL", 63, 73], ["ACE2", "GENE_OR_GENE_PRODUCT", 13, 17], ["amino-acid", "SIMPLE_CHEMICAL", 63, 73], ["gut", "ORGANISM_SUBDIVISION", 90, 93], ["ACE2", "PROTEIN", 13, 17], ["ACE2", "TEST", 13, 17], ["dietary amino-acid homeostasis", "TREATMENT", 55, 85]]], ["We previously demonstrated that ACE2 counteracts the development of severe ALI or ARDS induced by avian influenza virus, severe acute respiratory syndrome-coronavirus spikes, sepsis and acid aspiration in mice [16\u201318].", [["ALI", "DISEASE", 75, 78], ["ARDS", "DISEASE", 82, 86], ["avian influenza virus", "DISEASE", 98, 119], ["acute respiratory syndrome-coronavirus spikes", "DISEASE", 128, 173], ["sepsis", "DISEASE", 175, 181], ["ACE2", "GENE_OR_GENE_PRODUCT", 32, 36], ["avian influenza virus", "ORGANISM", 98, 119], ["mice", "ORGANISM", 205, 209], ["ACE2", "PROTEIN", 32, 36], ["avian influenza virus", "SPECIES", 98, 119], ["mice", "SPECIES", 205, 209], ["avian influenza virus", "SPECIES", 98, 119], ["severe acute respiratory syndrome-coronavirus", "SPECIES", 121, 166], ["mice", "SPECIES", 205, 209], ["severe ALI", "PROBLEM", 68, 78], ["ARDS", "PROBLEM", 82, 86], ["avian influenza virus", "PROBLEM", 98, 119], ["severe acute respiratory syndrome", "PROBLEM", 121, 154], ["coronavirus spikes", "PROBLEM", 155, 173], ["sepsis", "PROBLEM", 175, 181], ["acid aspiration", "PROBLEM", 186, 201], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["ALI", "OBSERVATION", 75, 78], ["ARDS", "OBSERVATION", 82, 86], ["severe", "OBSERVATION_MODIFIER", 121, 127], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["respiratory syndrome", "OBSERVATION", 134, 154], ["coronavirus spikes", "OBSERVATION", 155, 173], ["sepsis", "OBSERVATION", 175, 181]]], ["Administration of recombinant ACE2 or the Ang II receptor blocker losartan can ameliorate H5N1 virus infection-induced ALI [16, 19].", [["Ang II", "CHEMICAL", 42, 48], ["losartan", "CHEMICAL", 66, 74], ["H5N1 virus infection", "DISEASE", 90, 110], ["ALI", "DISEASE", 119, 122], ["losartan", "CHEMICAL", 66, 74], ["ACE2", "GENE_OR_GENE_PRODUCT", 30, 34], ["Ang II receptor", "GENE_OR_GENE_PRODUCT", 42, 57], ["losartan", "SIMPLE_CHEMICAL", 66, 74], ["H5N1 virus", "ORGANISM", 90, 100], ["recombinant ACE2", "PROTEIN", 18, 34], ["Ang II receptor", "PROTEIN", 42, 57], ["H5N1 virus", "SPECIES", 90, 100], ["H5N1 virus", "SPECIES", 90, 100], ["recombinant ACE2", "TREATMENT", 18, 34], ["the Ang II receptor blocker losartan", "TREATMENT", 38, 74], ["H5N1 virus infection", "PROBLEM", 90, 110]]], ["Moreover, ACE2 was also reported to have a protective role in respiratory syncytial virus-induced lung injury [20].", [["lung", "ANATOMY", 98, 102], ["respiratory syncytial virus", "DISEASE", 62, 89], ["lung injury", "DISEASE", 98, 109], ["ACE2", "GENE_OR_GENE_PRODUCT", 10, 14], ["respiratory syncytial virus", "ORGANISM", 62, 89], ["lung", "ORGAN", 98, 102], ["ACE2", "PROTEIN", 10, 14], ["respiratory syncytial virus", "SPECIES", 62, 89], ["ACE2", "TEST", 10, 14], ["respiratory syncytial virus", "PROBLEM", 62, 89], ["lung injury", "PROBLEM", 98, 109], ["respiratory syncytial virus", "OBSERVATION", 62, 89], ["lung", "ANATOMY", 98, 102], ["injury", "OBSERVATION", 103, 109]]], ["Notably, plasma Ang II levels can indicate disease severity in H7N9 infections [21].", [["plasma", "ANATOMY", 9, 15], ["Ang II", "CHEMICAL", 16, 22], ["infections", "DISEASE", 68, 78], ["plasma", "ORGANISM_SUBSTANCE", 9, 15], ["Ang II", "GENE_OR_GENE_PRODUCT", 16, 22], ["Ang II", "PROTEIN", 16, 22], ["H7N9", "SPECIES", 63, 67], ["plasma Ang II levels", "TEST", 9, 29], ["disease severity", "PROBLEM", 43, 59], ["H7N9 infections", "PROBLEM", 63, 78], ["disease", "OBSERVATION", 43, 50]]], ["Downregulation of ACE2 appears to be a shared phenomenon in ALI or ARDS induced by viral or bacterial infection [18, 22\u201325].IntroductionMicroRNAs (miRNAs) are small non-coding RNAs that function primarily in regulating gene expression by binding to the 3\u2032-untranslated region (3\u2032-UTR) of the targeted mRNAs [26].", [["ALI", "DISEASE", 60, 63], ["ARDS", "DISEASE", 67, 71], ["viral or bacterial infection", "DISEASE", 83, 111], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["ACE2", "PROTEIN", 18, 22], ["miRNAs", "DNA", 147, 153], ["small non-coding RNAs", "RNA", 159, 180], ["3\u2032-untranslated region", "DNA", 253, 275], ["UTR", "DNA", 280, 283], ["Downregulation of ACE2", "PROBLEM", 0, 22], ["a shared phenomenon", "PROBLEM", 37, 56], ["ALI", "PROBLEM", 60, 63], ["ARDS", "PROBLEM", 67, 71], ["viral or bacterial infection", "PROBLEM", 83, 111], ["IntroductionMicroRNAs (miRNAs)", "TREATMENT", 124, 154], ["small non-coding RNAs", "PROBLEM", 159, 180], ["ACE2", "ANATOMY", 18, 22], ["appears to be", "UNCERTAINTY", 23, 36], ["phenomenon", "OBSERVATION", 46, 56], ["ALI", "OBSERVATION", 60, 63], ["ARDS", "OBSERVATION", 67, 71], ["viral", "OBSERVATION_MODIFIER", 83, 88], ["bacterial", "OBSERVATION_MODIFIER", 92, 101], ["infection", "OBSERVATION", 102, 111], ["small", "OBSERVATION_MODIFIER", 159, 164], ["non-coding RNAs", "OBSERVATION", 165, 180], ["gene expression", "OBSERVATION", 219, 234]]], ["Wide-spectrum diseases, such as pulmonary diseases, diabetes and cardiac disorders, can be attributed to miRNA dysfunction [27].", [["pulmonary", "ANATOMY", 32, 41], ["cardiac", "ANATOMY", 65, 72], ["pulmonary diseases", "DISEASE", 32, 50], ["diabetes", "DISEASE", 52, 60], ["cardiac disorders", "DISEASE", 65, 82], ["pulmonary", "ORGAN", 32, 41], ["cardiac", "ORGAN", 65, 72], ["Wide-spectrum diseases", "PROBLEM", 0, 22], ["pulmonary diseases", "PROBLEM", 32, 50], ["diabetes", "PROBLEM", 52, 60], ["cardiac disorders", "PROBLEM", 65, 82], ["miRNA dysfunction", "PROBLEM", 105, 122], ["-spectrum", "OBSERVATION_MODIFIER", 4, 13], ["diseases", "OBSERVATION", 14, 22], ["pulmonary", "ANATOMY", 32, 41], ["diseases", "OBSERVATION", 42, 50], ["diabetes", "OBSERVATION", 52, 60], ["cardiac", "ANATOMY", 65, 72], ["disorders", "OBSERVATION", 73, 82]]], ["In recent years, multiple miRNA-based drugs have been explored and have entered clinical testing [27, 28]. miR-200 family consists of two clusters: the miR-200a/b/429 cluster containing miR-200a-3p, miR-200a-5p, miR-200b-3p, miR-200b-5p and miR-429 on chromosome 1p36.33, and the miR-200c/141 cluster containing miR-200c-3p, miR-200c-5p, miR-141-3p and miR-141-5p on chromosome 12p13.31.", [["chromosome 1p36.33", "ANATOMY", 252, 270], ["chromosome 12p13.31", "ANATOMY", 367, 386], ["miR-200", "GENE_OR_GENE_PRODUCT", 107, 114], ["miR-200a", "GENE_OR_GENE_PRODUCT", 152, 160], ["b", "GENE_OR_GENE_PRODUCT", 161, 162], ["miR-200a-3p", "GENE_OR_GENE_PRODUCT", 186, 197], ["miR-200a-5p", "GENE_OR_GENE_PRODUCT", 199, 210], ["miR-200b-3p", "GENE_OR_GENE_PRODUCT", 212, 223], ["miR-200b-5p", "GENE_OR_GENE_PRODUCT", 225, 236], ["miR-429", "GENE_OR_GENE_PRODUCT", 241, 248], ["chromosome 1p36.33", "CELLULAR_COMPONENT", 252, 270], ["miR-200c", "GENE_OR_GENE_PRODUCT", 280, 288], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 312, 323], ["miR-200c-5p", "GENE_OR_GENE_PRODUCT", 325, 336], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 338, 348], ["miR-141-5p", "GENE_OR_GENE_PRODUCT", 353, 363], ["chromosome 12p13.31", "CELLULAR_COMPONENT", 367, 386], ["miR-200 family", "DNA", 107, 121], ["miR-200a-3p", "DNA", 186, 197], ["miR", "DNA", 199, 202], ["200a", "DNA", 203, 207], ["miR", "DNA", 212, 215], ["200b", "DNA", 216, 220], ["miR", "DNA", 225, 228], ["200b", "DNA", 229, 233], ["miR-429", "DNA", 241, 248], ["chromosome 1p36.33", "DNA", 252, 270], ["miR-200c/141 cluster", "DNA", 280, 300], ["miR-200c-3p", "DNA", 312, 323], ["miR", "DNA", 325, 328], ["200c", "DNA", 329, 333], ["miR-141-3p", "DNA", 338, 348], ["miR-141-5p", "DNA", 353, 363], ["chromosome 12p13.31", "DNA", 367, 386], ["multiple miRNA-based drugs", "TREATMENT", 17, 43], ["clinical testing", "TEST", 80, 96], ["chromosome", "TEST", 367, 377]]], ["Studies on this miRNA family revealed that it has versatile roles in cancer progression, drug resistance and oxidative stress [29, 30].IntroductionIn our study, we proposed to explore the mechanism behind the downregulation of ACE2 presenting in ALI or ARDS induced by avian influenza virus or other pathogens.", [["cancer", "ANATOMY", 69, 75], ["cancer", "DISEASE", 69, 75], ["ALI", "DISEASE", 246, 249], ["ARDS", "DISEASE", 253, 257], ["avian influenza virus", "DISEASE", 269, 290], ["cancer", "CANCER", 69, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 227, 231], ["avian influenza virus", "ORGANISM", 269, 290], ["ACE2", "PROTEIN", 227, 231], ["avian influenza virus", "SPECIES", 269, 290], ["avian influenza virus", "SPECIES", 269, 290], ["cancer progression", "PROBLEM", 69, 87], ["drug resistance", "PROBLEM", 89, 104], ["oxidative stress", "TEST", 109, 125], ["our study", "TEST", 150, 159], ["ACE2", "PROBLEM", 227, 231], ["ALI", "PROBLEM", 246, 249], ["ARDS", "PROBLEM", 253, 257], ["avian influenza virus", "PROBLEM", 269, 290], ["other pathogens", "PROBLEM", 294, 309], ["cancer", "OBSERVATION", 69, 75], ["ALI", "ANATOMY", 246, 249], ["ARDS", "OBSERVATION", 253, 257]]], ["We demonstrated that miR-200c-3p was markedly upregulated by the infection of H5N1 virus and the treatment of synthetic double-stranded RNA poly (I:C), bacterial lipopolysaccharide (LPS) and lipoteichoic acid (LTA) in a nuclear factor-\u03baB (NF-\u03baB)-dependent manner. miR-200c-3p directly targets the 3\u2032-UTR of ACE2 and downregulates ACE2 protein expression.", [["infection", "DISEASE", 65, 74], ["H5N1", "DISEASE", 78, 82], ["poly (I:C", "CHEMICAL", 140, 149], ["lipopolysaccharide", "CHEMICAL", 162, 180], ["LPS", "CHEMICAL", 182, 185], ["lipoteichoic acid", "CHEMICAL", 191, 208], ["LTA", "CHEMICAL", 210, 213], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 21, 32], ["H5N1 virus", "ORGANISM", 78, 88], ["poly (I:C", "SIMPLE_CHEMICAL", 140, 149], ["bacterial lipopolysaccharide", "SIMPLE_CHEMICAL", 152, 180], ["LPS", "SIMPLE_CHEMICAL", 182, 185], ["lipoteichoic acid", "SIMPLE_CHEMICAL", 191, 208], ["LTA", "SIMPLE_CHEMICAL", 210, 213], ["nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 220, 237], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 239, 244], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 264, 275], ["ACE2", "GENE_OR_GENE_PRODUCT", 307, 311], ["ACE2", "GENE_OR_GENE_PRODUCT", 330, 334], ["miR-200c-3p", "DNA", 21, 32], ["NF-\u03baB", "PROTEIN", 239, 244], ["miR-200c-3p", "DNA", 264, 275], ["3\u2032-UTR", "DNA", 297, 303], ["ACE2", "PROTEIN", 307, 311], ["ACE2", "PROTEIN", 330, 334], ["H5N1 virus", "SPECIES", 78, 88], ["H5N1 virus", "SPECIES", 78, 88], ["miR", "TEST", 21, 24], ["the infection of H5N1 virus", "PROBLEM", 61, 88], ["the treatment", "TREATMENT", 93, 106], ["synthetic double-stranded RNA poly (I:C)", "TREATMENT", 110, 150], ["bacterial lipopolysaccharide (LPS", "TREATMENT", 152, 185], ["lipoteichoic acid (LTA", "TEST", 191, 213], ["a nuclear factor", "TEST", 218, 234], ["ACE2", "TREATMENT", 307, 311], ["downregulates ACE2 protein expression", "TREATMENT", 316, 353], ["infection", "OBSERVATION", 65, 74], ["protein expression", "OBSERVATION", 335, 353]]], ["Moreover, elevated levels of miR-200c-3p were found in plasma samples of severe pneumonia patients.", [["plasma samples", "ANATOMY", 55, 69], ["pneumonia", "DISEASE", 80, 89], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 29, 40], ["plasma samples", "ORGANISM_SUBSTANCE", 55, 69], ["patients", "ORGANISM", 90, 98], ["miR-200c-3p", "DNA", 29, 40], ["patients", "SPECIES", 90, 98], ["elevated levels", "PROBLEM", 10, 25], ["miR", "TEST", 29, 32], ["plasma samples", "TEST", 55, 69], ["severe pneumonia patients", "PROBLEM", 73, 98], ["elevated", "OBSERVATION_MODIFIER", 10, 18], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["pneumonia", "OBSERVATION", 80, 89]]], ["Our in vivo results demonstrated that miR-200c-3p may be a therapeutic target for ALI.H5N1 infection induces the upregulation of miR-200c-3p in A549 cells ::: ResultsTo identify miRNAs potentially regulating ACE2 protein expression, the miRNA expression profile in A549 cells (human lung adenocarcinoma epithelial cell line) challenged with H1N1 or H5N1 influenza virus was compared with that in A549 cells mock infected with allantoic fluid (AF).", [["A549 cells", "ANATOMY", 144, 154], ["A549 cells", "ANATOMY", 265, 275], ["lung adenocarcinoma epithelial cell line", "ANATOMY", 283, 323], ["A549 cells", "ANATOMY", 396, 406], ["allantoic fluid", "ANATOMY", 426, 441], ["miR-200c-3p", "CHEMICAL", 38, 49], ["ALI", "DISEASE", 82, 85], ["H5N1 infection", "DISEASE", 86, 100], ["influenza", "DISEASE", 354, 363], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 38, 49], ["H5N1", "ORGANISM", 86, 90], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 129, 140], ["A549 cells", "CELL", 144, 154], ["ACE2", "GENE_OR_GENE_PRODUCT", 208, 212], ["A549 cells", "CELL", 265, 275], ["human", "ORGANISM", 277, 282], ["lung adenocarcinoma epithelial cell line", "CELL", 283, 323], ["H1N1", "ORGANISM", 341, 345], ["H5N1 influenza virus", "ORGANISM", 349, 369], ["A549 cells", "CELL", 396, 406], ["allantoic fluid", "ORGANISM_SUBSTANCE", 426, 441], ["miR-200c-3p", "DNA", 38, 49], ["miR-200c-3p", "DNA", 129, 140], ["A549 cells", "CELL_LINE", 144, 154], ["ACE2", "PROTEIN", 208, 212], ["A549 cells", "CELL_LINE", 265, 275], ["human lung adenocarcinoma epithelial cell line", "CELL_LINE", 277, 323], ["A549 cells", "CELL_LINE", 396, 406], ["H5N1", "SPECIES", 86, 90], ["human", "SPECIES", 277, 282], ["H5N1 influenza virus", "SPECIES", 349, 369], ["H5N1", "SPECIES", 86, 90], ["human", "SPECIES", 277, 282], ["H5N1 influenza virus", "SPECIES", 349, 369], ["ALI", "PROBLEM", 82, 85], ["H5N1 infection", "PROBLEM", 86, 100], ["ACE2 protein expression", "PROBLEM", 208, 231], ["the miRNA expression profile", "TEST", 233, 261], ["A549 cells", "PROBLEM", 265, 275], ["human lung adenocarcinoma epithelial cell line", "TREATMENT", 277, 323], ["H1N1", "PROBLEM", 341, 345], ["H5N1 influenza virus", "PROBLEM", 349, 369], ["allantoic fluid", "TREATMENT", 426, 441], ["ALI", "OBSERVATION", 82, 85], ["protein expression", "OBSERVATION", 213, 231], ["A549 cells", "OBSERVATION", 265, 275], ["lung", "ANATOMY", 283, 287], ["adenocarcinoma epithelial cell line", "OBSERVATION", 288, 323]]], ["With 978 human miRNAs at a meaningful level (read count>0), we listed the top 20 highly expressed miRNAs in H5N1-infected cells compared with H1N1-infected cells (Figure 1a).", [["cells", "ANATOMY", 122, 127], ["cells", "ANATOMY", 156, 161], ["H5N1-infected", "DISEASE", 108, 121], ["human", "ORGANISM", 9, 14], ["H5N1", "ORGANISM", 108, 112], ["cells", "CELL", 122, 127], ["cells", "CELL", 156, 161], ["H5N1-infected cells", "CELL_TYPE", 108, 127], ["H1N1-infected cells", "CELL_TYPE", 142, 161], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["read count", "TEST", 45, 55], ["H5N1", "PROBLEM", 108, 112], ["infected cells", "PROBLEM", 113, 127], ["H1N1", "PROBLEM", 142, 146], ["infected cells", "PROBLEM", 147, 161], ["infected cells", "OBSERVATION", 113, 127], ["infected cells", "OBSERVATION", 147, 161]]], ["Among them, miR-200c-3p and miR-141-3p were predicted to target ACE2 using TargetScan (Supplementary Figure S1a).", [["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 12, 23], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 28, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 64, 68], ["miR-200c-3p and miR-141-3p", "DNA", 12, 38], ["ACE2", "PROTEIN", 64, 68], ["TargetScan (Supplementary Figure S1a)", "TREATMENT", 75, 112]]], ["Quantitative real-time PCR (qRT-PCR) analysis confirmed the upregulation of miR-200c-3p and miR-141-3p in H5N1-infected A549 cells (Figure 1b and c).", [["A549 cells", "ANATOMY", 120, 130], ["miR-141-3p", "CHEMICAL", 92, 102], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 76, 87], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 92, 102], ["H5N1", "ORGANISM", 106, 110], ["A549 cells", "CELL", 120, 130], ["miR-200c-3p", "DNA", 76, 87], ["miR-141-3p", "DNA", 92, 102], ["A549 cells", "CELL_LINE", 120, 130], ["Quantitative real-time PCR", "TEST", 0, 26], ["qRT", "TEST", 28, 31], ["PCR", "TEST", 32, 35], ["analysis", "TEST", 37, 45], ["miR", "TEST", 76, 79], ["miR", "TEST", 92, 95], ["H5N1", "PROBLEM", 106, 110], ["infected A549 cells", "PROBLEM", 111, 130], ["Figure", "TEST", 132, 138], ["A549 cells", "OBSERVATION", 120, 130]]], ["Moreover, we observed that the expression of miR-421, which was reported to target ACE2 [31], was not upregulated after H1N1 and H5N1 virus infection (Supplementary Figure S1b).", [["H5N1 virus infection", "DISEASE", 129, 149], ["miR-421", "GENE_OR_GENE_PRODUCT", 45, 52], ["ACE2 [31]", "GENE_OR_GENE_PRODUCT", 83, 92], ["H5N1 virus", "ORGANISM", 129, 139], ["miR-421", "DNA", 45, 52], ["ACE2", "PROTEIN", 83, 87], ["H5N1 virus", "SPECIES", 129, 139], ["H5N1 virus", "SPECIES", 129, 139], ["ACE2", "TEST", 83, 87], ["H1N1", "PROBLEM", 120, 124], ["H5N1 virus infection", "PROBLEM", 129, 149]]], ["The pattern of the upregulation of miR-200c-3p and miR-141-3p was also validated in HEK293T cells (human embryonic kidney cells) (Supplementary Figure S1c and d).", [["HEK293T cells", "ANATOMY", 84, 97], ["embryonic kidney cells", "ANATOMY", 105, 127], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 35, 46], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 51, 61], ["HEK293T cells", "CELL", 84, 97], ["human", "ORGANISM", 99, 104], ["embryonic kidney cells", "CELL", 105, 127], ["miR-200c-3p", "DNA", 35, 46], ["miR-141-3p", "DNA", 51, 61], ["HEK293T cells", "CELL_LINE", 84, 97], ["human embryonic kidney cells", "CELL_TYPE", 99, 127], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["human embryonic kidney cells", "TREATMENT", 99, 127], ["kidney", "ANATOMY", 115, 121]]], ["Additionally, the ACE2 protein expression levels were downregulated in A549 cells (Supplementary Figure S1e) and HEK293T cells (Supplementary Figure S1f) after infection with H5N1 influenza virus, which were consistent with our previous observations in the H5N1-infected mice lung tissues [16].H5N1 infection induces the upregulation of miR-200c-3p in A549 cells ::: ResultsInterestingly, the H5N1-induced expression of miR-200c-3p and miR-141-3p was highly correlated with both cell viability (Figure 1d and f) and viral replication (Figure 1e and g).", [["A549 cells", "ANATOMY", 71, 81], ["HEK293T cells", "ANATOMY", 113, 126], ["lung tissues", "ANATOMY", 276, 288], ["A549 cells", "ANATOMY", 352, 362], ["cell", "ANATOMY", 479, 483], ["infection", "DISEASE", 160, 169], ["H5N1 influenza virus", "DISEASE", 175, 195], ["H5N1-infected", "DISEASE", 257, 270], ["H5N1 infection", "DISEASE", 294, 308], ["H5N1", "DISEASE", 393, 397], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["A549 cells", "CELL", 71, 81], ["HEK293T cells", "CELL", 113, 126], ["H5N1 influenza virus", "ORGANISM", 175, 195], ["H5N1", "ORGANISM", 257, 261], ["mice", "ORGANISM", 271, 275], ["lung tissues", "TISSUE", 276, 288], ["H5N1", "ORGANISM", 294, 298], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 337, 348], ["A549 cells", "CELL", 352, 362], ["H5N1", "ORGANISM", 393, 397], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 420, 431], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 436, 446], ["cell", "CELL", 479, 483], ["ACE2", "PROTEIN", 18, 22], ["A549 cells", "CELL_LINE", 71, 81], ["S1e", "CELL_LINE", 104, 107], ["HEK293T cells", "CELL_LINE", 113, 126], ["miR-200c-3p", "DNA", 337, 348], ["A549 cells", "CELL_LINE", 352, 362], ["miR-200c-3p", "DNA", 420, 431], ["miR-141-3p", "DNA", 436, 446], ["H5N1 influenza virus", "SPECIES", 175, 195], ["mice", "SPECIES", 271, 275], ["H5N1", "SPECIES", 294, 298], ["H5N1 influenza virus", "SPECIES", 175, 195], ["mice", "SPECIES", 271, 275], ["H5N1", "SPECIES", 294, 298], ["the ACE2 protein expression levels", "TEST", 14, 48], ["A549 cells", "TEST", 71, 81], ["HEK293T cells", "TREATMENT", 113, 126], ["Supplementary Figure S1f)", "TREATMENT", 128, 153], ["infection", "PROBLEM", 160, 169], ["H5N1 influenza virus", "PROBLEM", 175, 195], ["infected mice lung tissues", "PROBLEM", 262, 288], ["H5N1 infection", "PROBLEM", 294, 308], ["miR", "TEST", 420, 423], ["viral replication", "TREATMENT", 516, 533], ["A549 cells", "OBSERVATION", 71, 81], ["HEK293T cells", "OBSERVATION", 113, 126], ["consistent with", "UNCERTAINTY", 208, 223], ["infected", "OBSERVATION", 262, 270], ["lung", "ANATOMY", 276, 280], ["cell viability", "OBSERVATION", 479, 493]]], ["However, the expression of neither miR-200c-5p nor miR-141-5p was correlated with cell viability or viral replication (Supplementary Figure S1g and h).", [["cell", "ANATOMY", 82, 86], ["miR-200c-5p", "GENE_OR_GENE_PRODUCT", 35, 46], ["miR-141-5p", "GENE_OR_GENE_PRODUCT", 51, 61], ["cell", "CELL", 82, 86], ["miR-200c-5p", "DNA", 35, 46], ["miR-141-5p", "DNA", 51, 61], ["cell viability", "PROBLEM", 82, 96], ["viral replication", "TREATMENT", 100, 117], ["viral replication", "OBSERVATION", 100, 117]]], ["Then, we tested the effect of the different multiplicity of infection (MOI) on the expression of miR-200c-3p and miR-141-3p.", [["infection", "DISEASE", 60, 69], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 97, 108], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 113, 123], ["miR-200c-3p", "DNA", 97, 108], ["miR-141-3p", "DNA", 113, 123], ["infection", "PROBLEM", 60, 69], ["infection", "OBSERVATION", 60, 69]]], ["A549 cells were challenged with H5N1 virus at different viral titers (MOI=0.05, 0.5 and 5), and the expression of miR-200c-3p and miR-141-3p was detected.", [["A549 cells", "ANATOMY", 0, 10], ["A549 cells", "CELL", 0, 10], ["H5N1 virus", "ORGANISM", 32, 42], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 114, 125], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 130, 140], ["A549 cells", "CELL_LINE", 0, 10], ["miR-200c-3p and miR-141-3p", "DNA", 114, 140], ["H5N1 virus", "SPECIES", 32, 42], ["H5N1 virus", "SPECIES", 32, 42], ["A549 cells", "PROBLEM", 0, 10], ["H5N1 virus", "PROBLEM", 32, 42], ["MOI", "TEST", 70, 73]]], ["The larger the infective dose administered, the higher the expression of miR-200c-3p and miR-141-3p (Supplementary Figure S1i).", [["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 73, 84], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 89, 99], ["miR-200c-3p", "DNA", 73, 84], ["miR-141-3p", "DNA", 89, 99], ["The larger the infective dose", "TREATMENT", 0, 29], ["larger", "OBSERVATION_MODIFIER", 4, 10], ["infective", "OBSERVATION_MODIFIER", 15, 24]]], ["Successful viral infection was confirmed by detecting the expression of matrix protein 1 (M1) (Supplementary Figure S1j).", [["viral infection", "DISEASE", 11, 26], ["matrix protein 1", "GENE_OR_GENE_PRODUCT", 72, 88], ["matrix protein 1", "PROTEIN", 72, 88], ["M1", "PROTEIN", 90, 92], ["S1j", "PROTEIN", 116, 119], ["Successful viral infection", "PROBLEM", 0, 26], ["matrix protein", "TEST", 72, 86], ["viral", "OBSERVATION_MODIFIER", 11, 16], ["infection", "OBSERVATION", 17, 26]]], ["Collectively, miR-200c-3p and miR-141-3p may be capable of regulating the expression of ACE2 protein and have a critical role during H5N1 virus infection.miR-200c-3p downregulates ACE2 expression by directly targeting to the 3\u2032-UTR of ACE2 ::: ResultsIn accordance with the prediction, transfection of miR-200c-3p mimics into A549 cells significantly decreased the abundance of ACE2 protein, whereas miR-200c-3p inhibitors increased it (Figure 2a).", [["A549 cells", "ANATOMY", 326, 336], ["H5N1 virus infection", "DISEASE", 133, 153], ["miR-200c-3p", "CHEMICAL", 302, 313], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 14, 25], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 30, 40], ["ACE2", "GENE_OR_GENE_PRODUCT", 88, 92], ["H5N1 virus", "ORGANISM", 133, 143], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 154, 165], ["ACE2", "GENE_OR_GENE_PRODUCT", 180, 184], ["ACE2", "GENE_OR_GENE_PRODUCT", 235, 239], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 302, 313], ["A549 cells", "CELL", 326, 336], ["ACE2", "GENE_OR_GENE_PRODUCT", 378, 382], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 400, 411], ["miR-200c-3p and miR-141-3p", "DNA", 14, 40], ["ACE2 protein", "PROTEIN", 88, 100], ["miR-200c-3p", "DNA", 154, 165], ["ACE2", "PROTEIN", 180, 184], ["3\u2032-UTR", "DNA", 225, 231], ["ACE2", "PROTEIN", 235, 239], ["miR-200c-3p", "DNA", 302, 313], ["A549 cells", "CELL_LINE", 326, 336], ["ACE2 protein", "PROTEIN", 378, 390], ["H5N1 virus", "SPECIES", 133, 143], ["H5N1 virus", "SPECIES", 133, 143], ["ACE2 protein", "TREATMENT", 88, 100], ["H5N1 virus infection", "PROBLEM", 133, 153], ["A549 cells", "PROBLEM", 326, 336], ["ACE2 protein", "TEST", 378, 390], ["miR", "TEST", 400, 403], ["3p inhibitors", "TREATMENT", 409, 422]]], ["However, we did not observe any significant change of ACE2 expression in the group transfected with miR-141-3p mimics or inhibitors.", [["miR-141-3p", "CHEMICAL", 100, 110], ["ACE2", "GENE_OR_GENE_PRODUCT", 54, 58], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 100, 110], ["ACE2", "PROTEIN", 54, 58], ["ACE2 expression", "PROBLEM", 54, 69], ["inhibitors", "TREATMENT", 121, 131], ["ACE2 expression", "OBSERVATION", 54, 69]]], ["Previously, miR-141-3p has been reported to regulate tumor growth factor-\u03b22 by targeting its transcript during H5N1 infection [32].", [["miR-141-3p", "CHEMICAL", 12, 22], ["tumor", "DISEASE", 53, 58], ["H5N1 infection", "DISEASE", 111, 125], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 12, 22], ["tumor growth factor-\u03b22", "GENE_OR_GENE_PRODUCT", 53, 75], ["miR-141-3p", "DNA", 12, 22], ["tumor growth factor-\u03b22", "PROTEIN", 53, 75], ["tumor growth factor", "PROBLEM", 53, 72], ["H5N1 infection", "PROBLEM", 111, 125], ["tumor", "OBSERVATION", 53, 58]]], ["To demonstrate the interaction between miR-200c-3p and ACE2 transcripts, we constructed a reporter vector in which the 3\u2032-UTR of ACE2 was fused downstream of Renilla luciferase coding sequence (Supplementary Figure S2a).", [["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 39, 50], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["ACE2", "GENE_OR_GENE_PRODUCT", 129, 133], ["luciferase", "GENE_OR_GENE_PRODUCT", 166, 176], ["miR-200c-3p", "DNA", 39, 50], ["ACE2 transcripts", "RNA", 55, 71], ["3\u2032-UTR", "DNA", 119, 125], ["ACE2", "PROTEIN", 129, 133], ["Renilla luciferase coding sequence", "DNA", 158, 192], ["a reporter vector", "TREATMENT", 88, 105], ["the 3\u2032-UTR of ACE2", "TREATMENT", 115, 133], ["Renilla luciferase coding sequence", "TREATMENT", 158, 192], ["Renilla luciferase", "OBSERVATION", 158, 176]]], ["In HEK293T cells transfected with miR-200c-3p mimics rather than miR-200c-5p mimics, Renilla luciferase activity significantly decreased (Figure 2b).", [["HEK293T cells", "ANATOMY", 3, 16], ["HEK293T cells", "CELL", 3, 16], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 34, 45], ["miR-200c-5p", "GENE_OR_GENE_PRODUCT", 65, 76], ["Renilla", "GENE_OR_GENE_PRODUCT", 85, 92], ["luciferase", "GENE_OR_GENE_PRODUCT", 93, 103], ["HEK293T cells", "CELL_LINE", 3, 16], ["miR-200c-3p", "DNA", 34, 45], ["miR-200c-5p mimics", "DNA", 65, 83], ["luciferase", "PROTEIN", 93, 103], ["miR", "TEST", 34, 37], ["Renilla luciferase activity", "TEST", 85, 112]]], ["Successful transfection of miR-200c-3p mimics and miR-200c-5p mimics was confirmed by qRT-PCR (Supplementary Figure S2b).", [["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 27, 38], ["miR-200c-5p", "GENE_OR_GENE_PRODUCT", 50, 61], ["miR-200c-3p", "DNA", 27, 38], ["miR-200c-5p mimics", "DNA", 50, 68], ["PCR", "TEST", 90, 93]]], ["Additionally, the activity was inhibited by miR-200c-3p mimics in a concentration-dependent manner (Supplementary Figure S2c).", [["miR-200c-3p", "CHEMICAL", 44, 55], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 44, 55], ["miR-200c-3p mimics", "DNA", 44, 62]]], ["When the predicted miR-200c-3p binding site on ACE2 3\u2032-UTR was deleted, the inhibiting effects of miR-200c-3p mimics on the luciferase activity were diminished (Figure 2c).", [["miR-200c-3p", "CHEMICAL", 98, 109], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 19, 30], ["ACE2 3\u2032-UTR", "GENE_OR_GENE_PRODUCT", 47, 58], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 98, 109], ["luciferase", "GENE_OR_GENE_PRODUCT", 124, 134], ["miR-200c-3p binding site", "DNA", 19, 43], ["ACE2 3\u2032-UTR", "DNA", 47, 58], ["miR-200c-3p", "DNA", 98, 109], ["luciferase", "PROTEIN", 124, 134], ["ACE2", "TEST", 47, 51], ["miR", "TEST", 98, 101], ["diminished", "OBSERVATION_MODIFIER", 149, 159]]], ["Moreover, mutation of the site on miR-200c-3p binding to ACE2 3\u2032-UTR abolished the inhibiting effects of miR-200c-3p on Renilla luciferase activity (Supplementary Figure S2d).", [["miR-200c-3p", "CHEMICAL", 105, 116], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 34, 45], ["ACE2", "GENE_OR_GENE_PRODUCT", 57, 61], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 105, 116], ["Renilla", "GENE_OR_GENE_PRODUCT", 120, 127], ["luciferase", "GENE_OR_GENE_PRODUCT", 128, 138], ["miR-200c-3p", "DNA", 34, 45], ["ACE2 3\u2032-UTR", "DNA", 57, 68], ["miR-200c-3p", "DNA", 105, 116], ["luciferase", "PROTEIN", 128, 138], ["mutation of the site", "PROBLEM", 10, 30], ["ACE2", "TEST", 57, 61], ["UTR", "PROBLEM", 65, 68], ["miR", "TEST", 105, 108], ["Renilla luciferase activity", "TREATMENT", 120, 147]]], ["Taken together, these results indicate that miR-200c-3p, rather than miR-200c-5p and miR-141-3p, directly targets the 3\u2032-UTR of ACE2 and downregulates the expression of ACE2 protein.NS1 of H5N1 and H7N9 viruses can induce the upregulation of miR-200c-3p ::: ResultsTo elucidate how H5N1 influenza virus induces the upregulation of miR-200c-3p, vectors containing the H5N1 influenza viral protein coding genes, hemagglutinin, neuraminidase (NA), nonstructural protein 1 (NS1), nonstructural protein 2 (NS2), polymerase complex PA, polymerase complex PB1, polymerase complex PB2, M1, matrix protein 2 (M2) and nucleocapsid protein (NP) were each transfected into HEK293T cells for 48 h.", [["HEK293T cells", "ANATOMY", 661, 674], ["influenza", "DISEASE", 287, 296], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 44, 55], ["miR-200c-5p", "GENE_OR_GENE_PRODUCT", 69, 80], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 85, 95], ["ACE2", "GENE_OR_GENE_PRODUCT", 128, 132], ["ACE2", "GENE_OR_GENE_PRODUCT", 169, 173], ["NS1", "GENE_OR_GENE_PRODUCT", 182, 185], ["H5N1", "ORGANISM", 189, 193], ["H7N9 viruses", "ORGANISM", 198, 210], ["miR-200c", "GENE_OR_GENE_PRODUCT", 242, 250], ["H5N1 influenza virus", "ORGANISM", 282, 302], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 331, 342], ["H5N1 influenza viral", "ORGANISM", 367, 387], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 410, 423], ["neuraminidase (NA), nonstructural protein 1", "GENE_OR_GENE_PRODUCT", 425, 468], ["NS1", "GENE_OR_GENE_PRODUCT", 470, 473], ["nonstructural protein 2", "GENE_OR_GENE_PRODUCT", 476, 499], ["NS2", "GENE_OR_GENE_PRODUCT", 501, 504], ["PA", "GENE_OR_GENE_PRODUCT", 526, 528], ["polymerase complex PB1, polymerase complex PB2", "GENE_OR_GENE_PRODUCT", 530, 576], ["M1, matrix protein 2", "GENE_OR_GENE_PRODUCT", 578, 598], ["M2", "GENE_OR_GENE_PRODUCT", 600, 602], ["nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 608, 628], ["HEK293T cells", "CELL", 661, 674], ["miR-200c-3p", "DNA", 44, 55], ["miR-200c-5p", "DNA", 69, 80], ["miR-141-3p", "DNA", 85, 95], ["3\u2032-UTR", "DNA", 118, 124], ["ACE2", "PROTEIN", 128, 132], ["ACE2 protein", "PROTEIN", 169, 181], ["NS1", "PROTEIN", 182, 185], ["miR-200c-3p", "DNA", 242, 253], ["miR-200c-3p", "DNA", 331, 342], ["H5N1 influenza viral protein coding genes", "DNA", 367, 408], ["hemagglutinin", "PROTEIN", 410, 423], ["neuraminidase", "PROTEIN", 425, 438], ["NA", "PROTEIN", 440, 442], ["nonstructural protein 1", "PROTEIN", 445, 468], ["NS1", "PROTEIN", 470, 473], ["nonstructural protein 2", "PROTEIN", 476, 499], ["NS2", "PROTEIN", 501, 504], ["polymerase complex PA", "PROTEIN", 507, 528], ["polymerase complex", "PROTEIN", 530, 548], ["PB1", "PROTEIN", 549, 552], ["polymerase complex", "PROTEIN", 554, 572], ["PB2", "PROTEIN", 573, 576], ["M1", "PROTEIN", 578, 580], ["matrix protein 2", "PROTEIN", 582, 598], ["M2", "PROTEIN", 600, 602], ["nucleocapsid protein", "PROTEIN", 608, 628], ["NP", "PROTEIN", 630, 632], ["HEK293T cells", "CELL_LINE", 661, 674], ["H5N1 influenza virus", "SPECIES", 282, 302], ["H5N1 influenza viral", "SPECIES", 367, 387], ["H7N9", "SPECIES", 198, 202], ["H5N1 influenza virus", "SPECIES", 282, 302], ["ACE2", "TREATMENT", 128, 132], ["ACE2 protein", "TEST", 169, 181], ["H5N1", "PROBLEM", 189, 193], ["H7N9 viruses", "TREATMENT", 198, 210], ["H5N1 influenza virus", "PROBLEM", 282, 302], ["miR", "TEST", 331, 334], ["vectors", "TREATMENT", 344, 351], ["the H5N1 influenza viral protein coding genes", "TREATMENT", 363, 408], ["hemagglutinin", "TEST", 410, 423], ["neuraminidase", "TEST", 425, 438], ["NA", "TEST", 440, 442], ["nonstructural protein", "TEST", 445, 466], ["NS1", "TEST", 470, 473], ["nonstructural protein", "TEST", 476, 497], ["NS2", "TEST", 501, 504], ["polymerase complex PA", "TEST", 507, 528], ["polymerase complex PB1", "TEST", 530, 552], ["polymerase complex PB2", "TEST", 554, 576], ["M1", "TEST", 578, 580], ["matrix protein", "TEST", 582, 596], ["nucleocapsid protein", "TEST", 608, 628], ["H5N1", "OBSERVATION", 189, 193], ["M1", "ANATOMY", 578, 580]]], ["In HEK293T cells transfected with NS1 expressing vector, the upregulation of miR-200c-3p and miR-141-3p was observed (Figure 2d and Supplementary Figure S3a).", [["HEK293T cells", "ANATOMY", 3, 16], ["HEK293T cells", "CELL", 3, 16], ["NS1", "GENE_OR_GENE_PRODUCT", 34, 37], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 77, 88], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 93, 103], ["HEK293T cells", "CELL_LINE", 3, 16], ["NS1 expressing vector", "DNA", 34, 55], ["miR-200c-3p", "DNA", 77, 88], ["miR-141-3p", "DNA", 93, 103], ["NS1 expressing vector", "TREATMENT", 34, 55]]], ["In addition, M1 and NP also induced the upregulation of miR-200c-3p.", [["M1", "CELL", 13, 15], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 56, 67], ["miR-200c-3p", "DNA", 56, 67], ["M1", "ANATOMY", 13, 15]]], ["However, NS1 induced a much higher level of miR-200c-3p than M1 and NP.", [["NS1", "GENE_OR_GENE_PRODUCT", 9, 12], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 44, 55], ["NS1", "PROTEIN", 9, 12], ["miR-200c-3p", "DNA", 44, 55], ["NS1", "PROBLEM", 9, 12], ["NP", "TREATMENT", 68, 70]]], ["Therefore, in the subsequent experiments, we focused on the function of NS1.", [["NS1", "GENE_OR_GENE_PRODUCT", 72, 75], ["NS1", "PROTEIN", 72, 75], ["NS1", "PROBLEM", 72, 75]]], ["Compared with the NS1 of H1N1 virus, the NS1 of H5N1 and H7N9 viruses induced much higher expression of miR-200c-3p and miR-141-3p (Figure 2e and Supplementary Figure S3b).", [["NS1 of H1N1 virus", "ORGANISM", 18, 35], ["NS1 of H5N1", "ORGANISM", 41, 52], ["H7N9 viruses", "ORGANISM", 57, 69], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 104, 115], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 120, 130], ["NS1", "PROTEIN", 18, 21], ["NS1", "PROTEIN", 41, 44], ["miR-200c-3p", "DNA", 104, 115], ["miR-141-3p", "DNA", 120, 130], ["Supplementary Figure S3b", "DNA", 146, 170], ["H1N1 virus", "SPECIES", 25, 35], ["H1N1 virus", "SPECIES", 25, 35], ["H7N9", "SPECIES", 57, 61], ["H1N1 virus", "PROBLEM", 25, 35], ["H5N1", "PROBLEM", 48, 52], ["H7N9 viruses", "PROBLEM", 57, 69], ["miR", "TEST", 120, 123], ["H5N1", "OBSERVATION", 48, 52]]], ["However, NS1 of neither H5N1 nor H7N9 caused any significant change of the expression of miR-421 (Supplementary Figure S3c).", [["H5N1", "DISEASE", 24, 28], ["H7N9", "CHEMICAL", 33, 37], ["NS1", "GENE_OR_GENE_PRODUCT", 9, 12], ["H5N1 nor H7N9", "ORGANISM", 24, 37], ["miR-421", "GENE_OR_GENE_PRODUCT", 89, 96], ["NS1", "PROTEIN", 9, 12], ["miR-421", "DNA", 89, 96], ["H7N9", "SPECIES", 33, 37], ["NS1", "PROBLEM", 9, 12], ["H5N1", "PROBLEM", 24, 28], ["H7N9", "PROBLEM", 33, 37], ["H5N1", "OBSERVATION", 24, 28]]], ["Transfection of H5N1-NS1 and H7N9-NS1 expression vectors into HEK293T cells resulted in the downregulation of ACE2 protein levels (Figure 2f).", [["HEK293T cells", "ANATOMY", 62, 75], ["H5N1-NS1", "ORGANISM", 16, 24], ["H7N9-NS1", "ORGANISM", 29, 37], ["HEK293T cells", "CELL", 62, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 110, 114], ["H5N1-NS1 and H7N9-NS1 expression vectors", "DNA", 16, 56], ["HEK293T cells", "CELL_LINE", 62, 75], ["ACE2", "PROTEIN", 110, 114], ["Transfection", "TEST", 0, 12], ["H5N1", "TEST", 16, 20], ["NS1", "TREATMENT", 21, 24], ["H7N9", "TREATMENT", 29, 33], ["NS1 expression vectors", "TREATMENT", 34, 56], ["HEK293T cells", "TEST", 62, 75], ["ACE2 protein levels", "TEST", 110, 129]]], ["Our results suggest that NS1 of pathogenic avian influenza virus has an important role in the induction of miR-200c-3p and miR-141-3p.Induction of miR-200c-3p in cells treated with poly (I:C), and bacterial components LPS and LTA ::: ResultsTo examine whether the induction of miR-200c-3p to downregulate ACE2 is a specific mechanism of pathogenic avian influenza viruses, we challenged A549 cells with poly (I:C). miR-200c-3p was upregulated in a concentration-dependent manner in poly (I:C)-transfected A549 cells (Figure 3a).", [["cells", "ANATOMY", 162, 167], ["A549 cells", "ANATOMY", 387, 397], ["A549 cells", "ANATOMY", 505, 515], ["influenza", "DISEASE", 49, 58], ["poly (I:C", "CHEMICAL", 181, 190], ["LPS", "CHEMICAL", 218, 221], ["miR-200c-3p", "CHEMICAL", 277, 288], ["influenza viruses", "DISEASE", 354, 371], ["poly (I:C", "CHEMICAL", 403, 412], ["poly (I:C", "CHEMICAL", 482, 491], ["poly (I:C)", "CHEMICAL", 403, 413], ["NS1", "GENE_OR_GENE_PRODUCT", 25, 28], ["avian influenza virus", "ORGANISM", 43, 64], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 107, 118], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 123, 133], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 147, 158], ["cells", "CELL", 162, 167], ["poly (I:C", "SIMPLE_CHEMICAL", 181, 190], ["LPS", "SIMPLE_CHEMICAL", 218, 221], ["LTA", "SIMPLE_CHEMICAL", 226, 229], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 277, 288], ["ACE2", "GENE_OR_GENE_PRODUCT", 305, 309], ["avian influenza viruses", "ORGANISM", 348, 371], ["A549 cells", "CELL", 387, 397], ["poly (I:C", "SIMPLE_CHEMICAL", 403, 412], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 415, 426], ["poly (I:C", "SIMPLE_CHEMICAL", 482, 491], ["A549 cells", "CELL", 505, 515], ["Figure 3a", "CELL", 517, 526], ["NS1", "PROTEIN", 25, 28], ["miR-200c-3p and miR-141-3p", "DNA", 107, 133], ["miR-200c-3p", "DNA", 147, 158], ["miR-200c-3p", "DNA", 277, 288], ["ACE2", "PROTEIN", 305, 309], ["A549 cells", "CELL_LINE", 387, 397], ["miR-200c-3p", "DNA", 415, 426], ["poly (I:C)-transfected A549 cells", "CELL_LINE", 482, 515], ["avian influenza virus", "SPECIES", 43, 64], ["avian influenza virus", "SPECIES", 43, 64], ["NS1", "PROBLEM", 25, 28], ["pathogenic avian influenza virus", "PROBLEM", 32, 64], ["miR", "TEST", 147, 150], ["ACE2", "TEST", 305, 309], ["pathogenic avian influenza viruses", "PROBLEM", 337, 371], ["A549 cells", "OBSERVATION", 387, 397], ["A549 cells", "OBSERVATION", 505, 515]]], ["In addition, transfection of poly (I:C) also resulted in the downregulation of ACE2 protein expression, which was rescued by the transfection of inhibitors of miR-200c-3p (Figure 3d), indicating that downregulating ACE2 protein expression by miR-200c-3p may be a shared mechanism for RNA viruses.", [["poly (I:C", "CHEMICAL", 29, 38], ["miR-200c-3p", "CHEMICAL", 242, 253], ["poly (I:C", "GENE_OR_GENE_PRODUCT", 29, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 159, 170], ["Figure 3d", "GENE_OR_GENE_PRODUCT", 172, 181], ["ACE2", "GENE_OR_GENE_PRODUCT", 215, 219], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 242, 253], ["ACE2", "PROTEIN", 79, 83], ["miR-200c-3p", "DNA", 159, 170], ["ACE2", "PROTEIN", 215, 219], ["miR-200c-3p", "DNA", 242, 253], ["ACE2 protein expression", "PROBLEM", 79, 102], ["downregulating ACE2 protein expression", "PROBLEM", 200, 238], ["RNA viruses", "PROBLEM", 284, 295], ["protein expression", "OBSERVATION", 84, 102]]], ["Induction of interleukin-6, interleukin-29 and interferon-\u03b2 by poly (I:C) was confirmed by qRT-PCR analysis (Supplementary Figure S4a).", [["poly (I:C", "CHEMICAL", 63, 72], ["poly (I:C)", "CHEMICAL", 63, 73], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 13, 26], ["interleukin-29", "GENE_OR_GENE_PRODUCT", 28, 42], ["interferon-\u03b2", "GENE_OR_GENE_PRODUCT", 47, 59], ["poly (I:C", "SIMPLE_CHEMICAL", 63, 72], ["interleukin-6", "PROTEIN", 13, 26], ["interleukin-29", "PROTEIN", 28, 42], ["interferon-\u03b2", "PROTEIN", 47, 59], ["interleukin", "TEST", 13, 24], ["interleukin", "TEST", 28, 39], ["interferon", "TREATMENT", 47, 57], ["qRT", "TEST", 91, 94], ["PCR analysis", "TEST", 95, 107]]], ["Previous studies have reported that LPS, which is the major constituent of the outer membrane of Gram-negative bacteria, can induce the downregulation of ACE2 and the upregulation of Ang II [33, 34].", [["outer membrane", "ANATOMY", 79, 93], ["LPS", "CHEMICAL", 36, 39], ["Ang II", "CHEMICAL", 183, 189], ["LPS", "SIMPLE_CHEMICAL", 36, 39], ["outer membrane", "CELLULAR_COMPONENT", 79, 93], ["Gram", "GENE_OR_GENE_PRODUCT", 97, 101], ["ACE2", "GENE_OR_GENE_PRODUCT", 154, 158], ["Ang II", "GENE_OR_GENE_PRODUCT", 183, 189], ["ACE2", "PROTEIN", 154, 158], ["Ang II", "PROTEIN", 183, 189], ["Previous studies", "TEST", 0, 16], ["LPS", "TEST", 36, 39], ["Gram-negative bacteria", "PROBLEM", 97, 119], ["ACE2", "TEST", 154, 158], ["negative bacteria", "OBSERVATION", 102, 119]]], ["By exposing A549 and THP1 cells (human acute monocytic leukemia cell line) to LPS, we found that LPS can induce the upregulation of miR-200c-3p (Figure 3b and Supplementary Figure S5a).", [["A549", "ANATOMY", 12, 16], ["THP1 cells", "ANATOMY", 21, 31], ["acute monocytic leukemia cell line", "ANATOMY", 39, 73], ["acute monocytic leukemia", "DISEASE", 39, 63], ["LPS", "CHEMICAL", 78, 81], ["LPS", "CHEMICAL", 97, 100], ["A549", "CELL", 12, 16], ["THP1 cells", "CELL", 21, 31], ["human", "ORGANISM", 33, 38], ["acute monocytic leukemia cell line", "CELL", 39, 73], ["LPS", "SIMPLE_CHEMICAL", 78, 81], ["LPS", "SIMPLE_CHEMICAL", 97, 100], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 132, 143], ["A549", "CELL_LINE", 12, 16], ["THP1 cells", "CELL_LINE", 21, 31], ["human acute monocytic leukemia cell line", "CELL_LINE", 33, 73], ["miR-200c-3p", "DNA", 132, 143], ["S5a", "DNA", 180, 183], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["THP1 cells", "TEST", 21, 31], ["human acute monocytic leukemia cell line", "TREATMENT", 33, 73], ["LPS", "TEST", 78, 81], ["LPS", "PROBLEM", 97, 100], ["miR", "TEST", 132, 135], ["THP1 cells", "OBSERVATION", 21, 31], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["monocytic leukemia cell line", "OBSERVATION", 45, 73]]], ["LPS treatment also induced the downregulation of ACE2 protein expression (Figure 3e and Supplementary Figure S5c).", [["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["ACE2", "PROTEIN", 49, 53], ["LPS treatment", "TREATMENT", 0, 13], ["ACE2 protein expression", "PROBLEM", 49, 72]]], ["Compared with inhibitors of negative control (NC), transfection of miR-200c-3p inhibitors significantly inhibited the downregulation of ACE2 induced by LPS (Figure 3e).", [["LPS", "CHEMICAL", 152, 155], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 67, 78], ["ACE2", "GENE_OR_GENE_PRODUCT", 136, 140], ["LPS", "SIMPLE_CHEMICAL", 152, 155], ["ACE2", "PROTEIN", 136, 140], ["miR", "TEST", 67, 70], ["3p inhibitors", "TREATMENT", 76, 89]]], ["Interestingly, LTA, which is the major component of the cell wall of Gram-positive bacteria, can also induce the upregulation of miR-200c-3p (Figure 3c and Supplementary Figure S5b) and the downregulation of ACE2 (Figure 3f and Supplementary Figure S5d) in A549 and THP1 cells.", [["cell wall", "ANATOMY", 56, 65], ["A549", "ANATOMY", 257, 261], ["THP1 cells", "ANATOMY", 266, 276], ["LTA", "CHEMICAL", 15, 18], ["LTA", "GENE_OR_GENE_PRODUCT", 15, 18], ["cell wall", "CELLULAR_COMPONENT", 56, 65], ["Gram-positive bacteria", "GENE_OR_GENE_PRODUCT", 69, 91], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 129, 140], ["Figure 3c", "GENE_OR_GENE_PRODUCT", 142, 151], ["S5b", "GENE_OR_GENE_PRODUCT", 177, 180], ["ACE2", "GENE_OR_GENE_PRODUCT", 208, 212], ["Figure 3f", "GENE_OR_GENE_PRODUCT", 214, 223], ["S5d", "GENE_OR_GENE_PRODUCT", 249, 252], ["A549", "CELL", 257, 261], ["THP1 cells", "CELL", 266, 276], ["LTA", "PROTEIN", 15, 18], ["miR-200c-3p", "DNA", 129, 140], ["ACE2", "PROTEIN", 208, 212], ["Figure 3f and Supplementary Figure S5d", "PROTEIN", 214, 252], ["A549", "CELL_LINE", 257, 261], ["THP1 cells", "CELL_LINE", 266, 276], ["Gram-positive bacteria", "PROBLEM", 69, 91], ["Figure 3c", "TREATMENT", 142, 151], ["Supplementary Figure S5b", "TREATMENT", 156, 180], ["the downregulation of ACE2 (Figure 3f", "TREATMENT", 186, 223], ["LTA", "OBSERVATION_MODIFIER", 15, 18], ["major", "OBSERVATION_MODIFIER", 33, 38], ["component", "OBSERVATION_MODIFIER", 39, 48], ["cell", "OBSERVATION", 56, 60], ["wall", "ANATOMY_MODIFIER", 61, 65], ["Gram-positive bacteria", "OBSERVATION", 69, 91], ["THP1 cells", "OBSERVATION", 266, 276]]], ["Consistently, the downregulation of ACE2 protein was markedly inhibited by the transfection of miR-200c-3p inhibitors (Figure 3f).", [["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 95, 106], ["ACE2", "PROTEIN", 36, 40], ["ACE2 protein", "TEST", 36, 48], ["miR", "TEST", 95, 98]]], ["In poly (I:C)-treated cells, another miRNA previously reported targeting to ACE2 gene, miR-421, was measured slightly upregulated, whereas in LPS- and LTA-treated A549 cells, no significant changes of miR-421 were observed (Figure 3a\u2013c).", [["cells", "ANATOMY", 22, 27], ["A549 cells", "ANATOMY", 163, 173], ["poly (I:C", "CHEMICAL", 3, 12], ["LPS", "CHEMICAL", 142, 145], ["LTA", "CHEMICAL", 151, 154], ["poly (I:C", "CHEMICAL", 3, 12], ["poly (I:C", "SIMPLE_CHEMICAL", 3, 12], ["cells", "CELL", 22, 27], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["miR-421", "GENE_OR_GENE_PRODUCT", 87, 94], ["LPS", "SIMPLE_CHEMICAL", 142, 145], ["LTA", "SIMPLE_CHEMICAL", 151, 154], ["A549 cells", "CELL", 163, 173], ["miR-421", "GENE_OR_GENE_PRODUCT", 201, 208], ["poly (I:C)-treated cells", "CELL_LINE", 3, 27], ["ACE2 gene", "DNA", 76, 85], ["miR-421", "DNA", 87, 94], ["LTA", "PROTEIN", 151, 154], ["A549 cells", "CELL_LINE", 163, 173], ["miR-421", "DNA", 201, 208], ["LPS", "TEST", 142, 145], ["LTA", "TEST", 151, 154], ["A549 cells", "PROBLEM", 163, 173], ["significant changes of miR", "PROBLEM", 178, 204], ["A549 cells", "OBSERVATION", 163, 173], ["no", "UNCERTAINTY", 175, 177], ["significant", "OBSERVATION_MODIFIER", 178, 189]]], ["Induction of tumor necrosis factor-\u03b1, interleukin-6 and interleukin-1\u03b2 by LPS and LTA in A549 and THP1 cells were confirmed by qRT-PCR analysis (Supplementary Figure S4b and c and Supplementary Figure S5e and f).", [["A549", "ANATOMY", 89, 93], ["THP1 cells", "ANATOMY", 98, 108], ["tumor", "DISEASE", 13, 18], ["necrosis", "DISEASE", 19, 27], ["LPS", "CHEMICAL", 74, 77], ["LTA", "CHEMICAL", 82, 85], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 13, 36], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 38, 51], ["interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 56, 70], ["LPS", "SIMPLE_CHEMICAL", 74, 77], ["LTA", "SIMPLE_CHEMICAL", 82, 85], ["A549", "CELL", 89, 93], ["THP1 cells", "CELL", 98, 108], ["tumor necrosis factor-\u03b1", "PROTEIN", 13, 36], ["interleukin-6", "PROTEIN", 38, 51], ["interleukin-1\u03b2", "PROTEIN", 56, 70], ["LTA", "PROTEIN", 82, 85], ["A549", "CELL_LINE", 89, 93], ["THP1 cells", "CELL_LINE", 98, 108], ["tumor necrosis factor", "PROBLEM", 13, 34], ["interleukin", "TEST", 38, 49], ["interleukin", "TEST", 56, 67], ["LPS", "TEST", 74, 77], ["LTA in A549", "TEST", 82, 93], ["THP1 cells", "TEST", 98, 108], ["qRT", "TEST", 127, 130], ["PCR analysis", "TEST", 131, 143], ["tumor", "OBSERVATION_MODIFIER", 13, 18], ["necrosis", "OBSERVATION", 19, 27], ["A549", "ANATOMY", 89, 93], ["THP1 cells", "OBSERVATION", 98, 108]]], ["Collectively, our results suggest that miR-200c-3p is a crucial regulator of ACE2 protein expression in the above conditions and may be shared in certain types of viral and bacterial infections.Elevated plasma levels of miR-200c-3p in severe pneumonia patients ::: ResultsViruses and bacteria are usually the precipitating factors of severe pneumonia, which may induce severe respiratory failure by triggering ARDS [35, 36], a clinical syndrome characterized by pulmonary edema, hypoxemia and the accumulation of inflammatory cells [1].", [["plasma", "ANATOMY", 203, 209], ["respiratory", "ANATOMY", 376, 387], ["pulmonary", "ANATOMY", 462, 471], ["inflammatory cells", "ANATOMY", 513, 531], ["viral and bacterial infections", "DISEASE", 163, 193], ["miR-200c-3p", "CHEMICAL", 220, 231], ["pneumonia", "DISEASE", 242, 251], ["pneumonia", "DISEASE", 341, 350], ["respiratory failure", "DISEASE", 376, 395], ["ARDS", "DISEASE", 410, 414], ["pulmonary edema", "DISEASE", 462, 477], ["hypoxemia", "DISEASE", 479, 488], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 39, 50], ["ACE2", "GENE_OR_GENE_PRODUCT", 77, 81], ["plasma", "ORGANISM_SUBSTANCE", 203, 209], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 220, 231], ["patients", "ORGANISM", 252, 260], ["pulmonary", "ORGAN", 462, 471], ["cells", "CELL", 526, 531], ["miR-200c-3p", "DNA", 39, 50], ["ACE2", "PROTEIN", 77, 81], ["miR-200c-3p", "DNA", 220, 231], ["inflammatory cells", "CELL_TYPE", 513, 531], ["patients", "SPECIES", 252, 260], ["ACE2 protein expression", "PROBLEM", 77, 100], ["viral and bacterial infections", "PROBLEM", 163, 193], ["Elevated plasma levels", "PROBLEM", 194, 216], ["miR", "TEST", 220, 223], ["severe pneumonia", "PROBLEM", 235, 251], ["bacteria", "PROBLEM", 284, 292], ["severe pneumonia", "PROBLEM", 334, 350], ["severe respiratory failure", "PROBLEM", 369, 395], ["triggering ARDS", "PROBLEM", 399, 414], ["a clinical syndrome", "PROBLEM", 425, 444], ["pulmonary edema", "PROBLEM", 462, 477], ["hypoxemia", "PROBLEM", 479, 488], ["inflammatory cells", "PROBLEM", 513, 531], ["viral", "OBSERVATION", 163, 168], ["bacterial", "OBSERVATION_MODIFIER", 173, 182], ["infections", "OBSERVATION", 183, 193], ["severe", "OBSERVATION_MODIFIER", 235, 241], ["pneumonia", "OBSERVATION", 242, 251], ["bacteria", "OBSERVATION", 284, 292], ["severe", "OBSERVATION_MODIFIER", 334, 340], ["pneumonia", "OBSERVATION", 341, 350], ["severe", "OBSERVATION_MODIFIER", 369, 375], ["respiratory failure", "OBSERVATION", 376, 395], ["pulmonary", "ANATOMY", 462, 471], ["edema", "OBSERVATION", 472, 477], ["hypoxemia", "OBSERVATION", 479, 488], ["accumulation", "OBSERVATION_MODIFIER", 497, 509], ["inflammatory cells", "OBSERVATION", 513, 531]]], ["ARDS has a high mortality rate of 30\u201350%, thus demanding accurate prediction models [37, 38].", [["ARDS", "DISEASE", 0, 4], ["ARDS", "PROBLEM", 0, 4], ["high", "OBSERVATION_MODIFIER", 11, 15]]], ["Because H5N1 virus, poly (I:C), LPS and LTA can all induce the expression of miR-200c-3p to downregulate ACE2 protein expression, we speculate that the expression of miR-200c-3p may be aberrant in severe pneumonia infection.", [["poly (I:C", "CHEMICAL", 20, 29], ["LPS", "CHEMICAL", 32, 35], ["LTA", "CHEMICAL", 40, 43], ["pneumonia", "DISEASE", 204, 213], ["infection", "DISEASE", 214, 223], ["H5N1 virus", "ORGANISM", 8, 18], ["poly (I:C", "GENE_OR_GENE_PRODUCT", 20, 29], ["LPS", "SIMPLE_CHEMICAL", 32, 35], ["LTA", "SIMPLE_CHEMICAL", 40, 43], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 77, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 105, 109], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 166, 177], ["miR-200c-3p", "DNA", 77, 88], ["ACE2", "PROTEIN", 105, 109], ["miR-200c-3p", "DNA", 166, 177], ["H5N1 virus", "SPECIES", 8, 18], ["H5N1 virus", "SPECIES", 8, 18], ["H5N1 virus", "PROBLEM", 8, 18], ["LPS", "TEST", 32, 35], ["LTA", "TEST", 40, 43], ["ACE2 protein expression", "PROBLEM", 105, 128], ["severe pneumonia infection", "PROBLEM", 197, 223], ["severe", "OBSERVATION_MODIFIER", 197, 203], ["pneumonia", "OBSERVATION", 204, 213], ["infection", "OBSERVATION", 214, 223]]], ["To investigate whether miR-200c-3p is involved in severe pneumonia infection, we collected plasma from 56 severe pneumonia patients and 21 healthy volunteers and then detected the expression of miR-200c-3p in the plasma.", [["plasma", "ANATOMY", 91, 97], ["plasma", "ANATOMY", 213, 219], ["pneumonia infection", "DISEASE", 57, 76], ["pneumonia", "DISEASE", 113, 122], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 23, 34], ["plasma", "ORGANISM_SUBSTANCE", 91, 97], ["patients", "ORGANISM", 123, 131], ["volunteers", "ORGANISM", 147, 157], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 194, 205], ["plasma", "ORGANISM_SUBSTANCE", 213, 219], ["miR-200c-3p", "DNA", 23, 34], ["miR-200c-3p", "DNA", 194, 205], ["patients", "SPECIES", 123, 131], ["severe pneumonia infection", "PROBLEM", 50, 76], ["plasma", "TEST", 91, 97], ["severe pneumonia", "PROBLEM", 106, 122], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["pneumonia", "OBSERVATION", 57, 66], ["infection", "OBSERVATION", 67, 76], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["pneumonia", "OBSERVATION", 113, 122]]], ["The characteristics of the study subjects are shown in Supplementary Table S1.", [["the study", "TEST", 23, 32]]], ["Of the 56 patients, 53 (94.64%) fulfilled ARDS criteria [39].", [["ARDS", "DISEASE", 42, 46], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["ARDS criteria", "TEST", 42, 55], ["ARDS", "OBSERVATION", 42, 46]]], ["In accordance with our speculation, the plasma levels of miR-200c-3p were significantly elevated in severe pneumonia patients (Figure 3g).", [["plasma", "ANATOMY", 40, 46], ["pneumonia", "DISEASE", 107, 116], ["plasma", "ORGANISM_SUBSTANCE", 40, 46], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 57, 68], ["patients", "ORGANISM", 117, 125], ["miR-200c-3p", "DNA", 57, 68], ["patients", "SPECIES", 117, 125], ["the plasma levels", "TEST", 36, 53], ["miR", "TEST", 57, 60], ["significantly elevated", "PROBLEM", 74, 96], ["severe pneumonia", "PROBLEM", 100, 116], ["elevated", "OBSERVATION_MODIFIER", 88, 96], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["pneumonia", "OBSERVATION", 107, 116]]], ["Downregulation of ACE2 may result in the elevated plasma level of Ang II, which is a major substrate of ACE2.", [["plasma", "ANATOMY", 50, 56], ["Ang II", "CHEMICAL", 66, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["plasma", "ORGANISM_SUBSTANCE", 50, 56], ["Ang II", "GENE_OR_GENE_PRODUCT", 66, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 104, 108], ["ACE2", "PROTEIN", 18, 22], ["Ang II", "PROTEIN", 66, 72], ["ACE2", "PROTEIN", 104, 108], ["Downregulation of ACE2", "PROBLEM", 0, 22], ["the elevated plasma level of Ang II", "PROBLEM", 37, 72], ["elevated", "OBSERVATION", 41, 49], ["Ang II", "OBSERVATION_MODIFIER", 66, 72]]], ["Additionally, Ang II is claimed considerably increased in ARDS patients [40].", [["Ang II", "CHEMICAL", 14, 20], ["ARDS", "DISEASE", 58, 62], ["Ang II", "GENE_OR_GENE_PRODUCT", 14, 20], ["patients", "ORGANISM", 63, 71], ["Ang II", "PROTEIN", 14, 20], ["patients", "SPECIES", 63, 71], ["considerably", "OBSERVATION_MODIFIER", 32, 44], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["ARDS", "OBSERVATION", 58, 62]]], ["Consistent with this report, the plasma levels of Ang II were also markedly upregulated in severe pneumonia patients (Figure 3h).", [["plasma", "ANATOMY", 33, 39], ["Ang II", "CHEMICAL", 50, 56], ["pneumonia", "DISEASE", 98, 107], ["plasma", "ORGANISM_SUBSTANCE", 33, 39], ["Ang II", "GENE_OR_GENE_PRODUCT", 50, 56], ["patients", "ORGANISM", 108, 116], ["Ang II", "PROTEIN", 50, 56], ["patients", "SPECIES", 108, 116], ["the plasma levels", "TEST", 29, 46], ["severe pneumonia", "PROBLEM", 91, 107], ["markedly", "OBSERVATION_MODIFIER", 67, 75], ["upregulated", "OBSERVATION_MODIFIER", 76, 87], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["pneumonia", "OBSERVATION", 98, 107]]], ["Notably, the plasma level of Ang II changed over miR-200c-3p in severe pneumonia patient (patient 48th) whose plasma samples were consecutively collected (Figure 3i), suggesting that miR-200c-3p may participate in the upregulation of plasma Ang II and then induces lung injury through Ang II type 1 receptor.", [["plasma", "ANATOMY", 13, 19], ["plasma samples", "ANATOMY", 110, 124], ["plasma", "ANATOMY", 234, 240], ["lung", "ANATOMY", 265, 269], ["Ang II", "CHEMICAL", 29, 35], ["miR-200c-3p", "CHEMICAL", 49, 60], ["pneumonia", "DISEASE", 71, 80], ["Ang II", "CHEMICAL", 241, 247], ["lung injury", "DISEASE", 265, 276], ["Ang II", "CHEMICAL", 285, 291], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["Ang II", "GENE_OR_GENE_PRODUCT", 29, 35], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 49, 60], ["patient", "ORGANISM", 81, 88], ["patient", "ORGANISM", 90, 97], ["plasma samples", "ORGANISM_SUBSTANCE", 110, 124], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 183, 194], ["plasma", "ORGANISM_SUBSTANCE", 234, 240], ["Ang II", "GENE_OR_GENE_PRODUCT", 241, 247], ["lung", "ORGAN", 265, 269], ["Ang II type 1 receptor", "GENE_OR_GENE_PRODUCT", 285, 307], ["Ang II", "PROTEIN", 29, 35], ["miR-200c-3p", "DNA", 49, 60], ["miR-200c-3p", "DNA", 183, 194], ["Ang II", "PROTEIN", 241, 247], ["Ang II type 1 receptor", "PROTEIN", 285, 307], ["patient", "SPECIES", 81, 88], ["patient", "SPECIES", 90, 97], ["the plasma level", "TEST", 9, 25], ["Ang II", "PROBLEM", 29, 35], ["severe pneumonia", "PROBLEM", 64, 80], ["plasma samples", "TEST", 110, 124], ["plasma", "TEST", 234, 240], ["Ang II", "TREATMENT", 241, 247], ["lung injury", "PROBLEM", 265, 276], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["pneumonia", "OBSERVATION", 71, 80], ["lung", "ANATOMY", 265, 269], ["injury", "OBSERVATION", 270, 276]]], ["Consequently, our results raise the possibility that miR-200c-3p can serve as a biomarker or therapeutic target for severe pneumonia.NF-\u03baB signaling pathway mediates the upregulation of miR-200c-3p induced by H5N1, poly (I:C), LPS and LTA ::: ResultsThe transcription factor NF-\u03baB heterodimer (p65/RelA and p50) has an important role in cellular responses to viral and bacterial infections [41, 42].", [["cellular", "ANATOMY", 337, 345], ["miR-200c-3p", "CHEMICAL", 53, 64], ["pneumonia", "DISEASE", 123, 132], ["poly (I:C", "CHEMICAL", 215, 224], ["LPS", "CHEMICAL", 227, 230], ["viral and bacterial infections", "DISEASE", 359, 389], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 53, 64], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 133, 138], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 186, 197], ["poly (I:C", "SIMPLE_CHEMICAL", 215, 224], ["LPS", "SIMPLE_CHEMICAL", 227, 230], ["LTA", "SIMPLE_CHEMICAL", 235, 238], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 275, 280], ["p65", "GENE_OR_GENE_PRODUCT", 294, 297], ["RelA", "GENE_OR_GENE_PRODUCT", 298, 302], ["p50", "GENE_OR_GENE_PRODUCT", 307, 310], ["cellular", "CELL", 337, 345], ["miR-200c-3p", "DNA", 53, 64], ["NF-\u03baB", "PROTEIN", 133, 138], ["miR-200c-3p", "DNA", 186, 197], ["transcription factor NF-\u03baB heterodimer", "PROTEIN", 254, 292], ["p65", "PROTEIN", 294, 297], ["RelA", "PROTEIN", 298, 302], ["p50", "PROTEIN", 307, 310], ["a biomarker", "TEST", 78, 89], ["severe pneumonia", "PROBLEM", 116, 132], ["LPS", "TEST", 227, 230], ["LTA", "TEST", 235, 238], ["The transcription factor NF", "TEST", 250, 277], ["B heterodimer", "TEST", 279, 292], ["RelA", "TEST", 298, 302], ["p50", "TEST", 307, 310], ["viral and bacterial infections", "PROBLEM", 359, 389], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["pneumonia", "OBSERVATION", 123, 132], ["cellular responses", "OBSERVATION", 337, 355], ["bacterial", "OBSERVATION_MODIFIER", 369, 378], ["infections", "OBSERVATION", 379, 389]]], ["Besides, the determinant role of NF-\u03baB in the regulation of miRNA expression has been revealed by previous studies [43\u201345].", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 33, 38], ["NF-\u03baB", "PROTEIN", 33, 38], ["previous studies", "TEST", 98, 114]]], ["It is well known that the activation of NF-\u03baB signaling is essential in H5N1 infection and propagation [46\u201348].", [["H5N1 infection", "DISEASE", 72, 86], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 40, 45], ["H5N1", "ORGANISM", 72, 76], ["NF-\u03baB", "PROTEIN", 40, 45], ["H5N1", "SPECIES", 72, 76], ["H5N1 infection", "PROBLEM", 72, 86], ["H5N1", "OBSERVATION_MODIFIER", 72, 76], ["infection", "OBSERVATION", 77, 86]]], ["Disabling the function of NF-\u03baB heterodimer with small interfering RNAs (siRNAs) (si-p65 and si-p50) or its specific inhibitors, caffeic acid phenethyl ester (CAPE) and JSH-23, we found that the induction of miR-200c-3p by H5N1 infection was significantly repressed (Figure 4a and b and Supplementary Figure S6a).", [["caffeic acid phenethyl ester", "CHEMICAL", 129, 157], ["CAPE", "CHEMICAL", 159, 163], ["JSH-23", "CHEMICAL", 169, 175], ["miR-200c-3p", "CHEMICAL", 208, 219], ["H5N1 infection", "DISEASE", 223, 237], ["caffeic acid phenethyl ester", "CHEMICAL", 129, 157], ["CAPE", "CHEMICAL", 159, 163], ["JSH-23", "CHEMICAL", 169, 175], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 26, 31], ["small interfering RNAs", "GENE_OR_GENE_PRODUCT", 49, 71], ["si-p65", "GENE_OR_GENE_PRODUCT", 82, 88], ["si-p50", "GENE_OR_GENE_PRODUCT", 93, 99], ["caffeic acid phenethyl ester", "SIMPLE_CHEMICAL", 129, 157], ["CAPE", "SIMPLE_CHEMICAL", 159, 163], ["JSH-23", "SIMPLE_CHEMICAL", 169, 175], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 208, 219], ["H5N1", "ORGANISM", 223, 227], ["NF-\u03baB heterodimer", "PROTEIN", 26, 43], ["small interfering RNAs", "RNA", 49, 71], ["p65", "PROTEIN", 85, 88], ["si-p50", "PROTEIN", 93, 99], ["miR-200c-3p", "DNA", 208, 219], ["NF", "TEST", 26, 28], ["B heterodimer", "TREATMENT", 30, 43], ["small interfering RNAs (siRNAs)", "PROBLEM", 49, 80], ["its specific inhibitors", "PROBLEM", 104, 127], ["caffeic acid phenethyl ester", "TEST", 129, 157], ["JSH", "TEST", 169, 172], ["miR", "TEST", 208, 211], ["H5N1 infection", "PROBLEM", 223, 237], ["small", "OBSERVATION_MODIFIER", 49, 54], ["interfering RNAs", "OBSERVATION", 55, 71]]], ["Considering that NS1 was reported to inhibit NF-\u03baB activation, we proposed that there is an NF-\u03baB-dependent manner for influenza virus to induce the expression of miR-200c-3p besides NS1-mediated induction of miR-200c-3p [49].", [["NS1", "GENE_OR_GENE_PRODUCT", 17, 20], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 45, 50], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 92, 97], ["influenza virus", "ORGANISM", 119, 134], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 163, 174], ["NS1", "GENE_OR_GENE_PRODUCT", 183, 186], ["miR-200c", "GENE_OR_GENE_PRODUCT", 209, 217], ["NS1", "PROTEIN", 17, 20], ["NF-\u03baB", "PROTEIN", 45, 50], ["NF-\u03baB", "PROTEIN", 92, 97], ["miR-200c-3p", "DNA", 163, 174], ["NS1", "PROTEIN", 183, 186], ["miR", "DNA", 209, 212], ["influenza virus", "SPECIES", 119, 134], ["NS1", "PROBLEM", 17, 20], ["influenza virus", "PROBLEM", 119, 134], ["NS1", "TREATMENT", 183, 186]]], ["As influenza A virus infection-generated single-stranded viral RNA (vRNA) can be recognized by RIG-I to activate NF-\u03baB and induce multiple gene expressions [43], we transfected RNA extracted from H5N1-infected cells (H5N1-vRNA) into A549 cells with Lipofectamine 2000 to test whether vRNA can induce the upregulation of miR-200c-3p.", [["cells", "ANATOMY", 210, 215], ["A549 cells", "ANATOMY", 233, 243], ["infection", "DISEASE", 21, 30], ["H5N1-infected", "DISEASE", 196, 209], ["influenza A virus", "ORGANISM", 3, 20], ["RIG-I", "GENE_OR_GENE_PRODUCT", 95, 100], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 113, 118], ["H5N1", "ORGANISM", 196, 200], ["cells", "CELL", 210, 215], ["H5N1-vRNA", "ORGANISM", 217, 226], ["A549 cells", "CELL", 233, 243], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 320, 331], ["single-stranded viral RNA", "RNA", 41, 66], ["vRNA", "RNA", 68, 72], ["RIG-I", "PROTEIN", 95, 100], ["NF-\u03baB", "PROTEIN", 113, 118], ["H5N1-infected cells", "CELL_TYPE", 196, 215], ["A549 cells", "CELL_LINE", 233, 243], ["miR-200c-3p", "DNA", 320, 331], ["influenza A virus", "SPECIES", 3, 20], ["influenza A virus", "SPECIES", 3, 20], ["influenza A virus infection", "PROBLEM", 3, 30], ["stranded viral RNA", "PROBLEM", 48, 66], ["multiple gene expressions", "PROBLEM", 130, 155], ["H5N1", "PROBLEM", 196, 200], ["infected cells", "PROBLEM", 201, 215], ["H5N1-vRNA", "TREATMENT", 217, 226], ["Lipofectamine", "TREATMENT", 249, 262], ["vRNA", "PROBLEM", 284, 288], ["viral RNA", "OBSERVATION_MODIFIER", 57, 66], ["infected cells", "OBSERVATION", 201, 215]]], ["Interestingly, we found that transfection of H5N1-vRNA significantly elevated the expression level of miR-200c-3p compared with transfection of RNA extracted from AF-treated cells (Supplementary Figure S6b).", [["cells", "ANATOMY", 174, 179], ["H5N1-vRNA", "ORGANISM", 45, 54], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 102, 113], ["cells", "CELL", 174, 179], ["miR-200c-3p", "DNA", 102, 113], ["AF-treated cells", "CELL_LINE", 163, 179], ["H5N1", "PROBLEM", 45, 49], ["vRNA", "PROBLEM", 50, 54], ["RNA extracted", "PROBLEM", 144, 157], ["AF", "PROBLEM", 163, 165]]], ["In addition, repressing the function of NF-\u03baB heterodimer with siRNAs (si-p65 or si-p50) or its specific inhibitors (CAPE and JSH-23) also resulted in the inhibition of the upregulation of miR-200c-3p induced by H5N1-vRNA transfection (Figure 4c and d and Supplementary Figure S6c), suggesting that H5N1-vRNA-induced expression of miR-200c-3p requires NF-\u03baB activation.NF-\u03baB signaling pathway mediates the upregulation of miR-200c-3p induced by H5N1, poly (I:C), LPS and LTA ::: ResultsPrevious studies have established that NF-\u03baB signaling activation is crucial in cellular responses to stimuli such as poly (I:C), LPS and LTA [50\u201352].", [["cellular", "ANATOMY", 566, 574], ["CAPE", "CHEMICAL", 117, 121], ["JSH-23", "CHEMICAL", 126, 132], ["poly (I:C", "CHEMICAL", 451, 460], ["LPS", "CHEMICAL", 463, 466], ["poly (I:C", "CHEMICAL", 604, 613], ["LPS", "CHEMICAL", 616, 619], ["LTA", "CHEMICAL", 624, 627], ["CAPE", "CHEMICAL", 117, 121], ["JSH-23", "CHEMICAL", 126, 132], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 40, 45], ["si-p65", "GENE_OR_GENE_PRODUCT", 71, 77], ["si-p50", "GENE_OR_GENE_PRODUCT", 81, 87], ["CAPE", "SIMPLE_CHEMICAL", 117, 121], ["JSH-23", "GENE_OR_GENE_PRODUCT", 126, 132], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 189, 200], ["H5N1-vRNA", "ORGANISM", 212, 221], ["S6c", "GENE_OR_GENE_PRODUCT", 277, 280], ["H5N1-vRNA", "ORGANISM", 299, 308], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 331, 342], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 352, 357], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 369, 374], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 422, 433], ["poly (I:C", "SIMPLE_CHEMICAL", 451, 460], ["LPS", "SIMPLE_CHEMICAL", 463, 466], ["LTA", "SIMPLE_CHEMICAL", 471, 474], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 525, 530], ["cellular", "CELL", 566, 574], ["poly (I:C", "SIMPLE_CHEMICAL", 604, 613], ["LPS", "SIMPLE_CHEMICAL", 616, 619], ["LTA", "SIMPLE_CHEMICAL", 624, 627], ["NF-\u03baB heterodimer", "PROTEIN", 40, 57], ["p65", "PROTEIN", 74, 77], ["si-p50", "PROTEIN", 81, 87], ["miR-200c-3p", "DNA", 189, 200], ["miR-200c-3p", "DNA", 331, 342], ["NF-\u03baB", "PROTEIN", 352, 357], ["NF-\u03baB", "PROTEIN", 369, 374], ["miR-200c-3p", "DNA", 422, 433], ["NF-\u03baB", "PROTEIN", 525, 530], ["NF", "TEST", 40, 42], ["siRNAs", "PROBLEM", 63, 69], ["CAPE", "TEST", 117, 121], ["JSH", "TEST", 126, 129], ["miR", "TEST", 189, 192], ["H5N1", "PROBLEM", 212, 216], ["vRNA transfection", "TREATMENT", 217, 234], ["H5N1", "PROBLEM", 299, 303], ["vRNA", "PROBLEM", 304, 308], ["LPS", "TEST", 463, 466], ["LTA", "TEST", 471, 474], ["ResultsPrevious studies", "TEST", 479, 502], ["NF", "TEST", 525, 527], ["LPS", "TEST", 616, 619], ["LTA", "TEST", 624, 627], ["H5N1", "OBSERVATION", 299, 303]]], ["To assess whether the induction of miR-200c-3p by poly (I:C), LPS and LTA is also mediated by NF-\u03baB signaling pathway, we again disabled the function of NF-\u03baB heterodimer by using siRNAs or its specific inhibitors.", [["miR-200c-3p", "CHEMICAL", 35, 46], ["poly (I:C", "CHEMICAL", 50, 59], ["LPS", "CHEMICAL", 62, 65], ["LTA", "CHEMICAL", 70, 73], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 35, 46], ["poly (I:C", "GENE_OR_GENE_PRODUCT", 50, 59], ["LPS", "SIMPLE_CHEMICAL", 62, 65], ["LTA", "SIMPLE_CHEMICAL", 70, 73], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 94, 99], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 153, 158], ["miR-200c-3p", "DNA", 35, 46], ["NF-\u03baB", "PROTEIN", 94, 99], ["NF-\u03baB heterodimer", "PROTEIN", 153, 170], ["LPS", "TEST", 62, 65], ["LTA", "TEST", 70, 73], ["B heterodimer", "TREATMENT", 157, 170], ["siRNAs", "TREATMENT", 180, 186], ["its specific inhibitors", "TREATMENT", 190, 213]]], ["Knockdown of p65 and p50 significantly repressed the upregulation of miR-200c-3p induced by the treatment of poly (I:C), LPS or LTA (Figure 4e,g and i and Supplementary Figure S6d, e and f).", [["poly (I:C", "CHEMICAL", 109, 118], ["LPS", "CHEMICAL", 121, 124], ["p65", "GENE_OR_GENE_PRODUCT", 13, 16], ["p50", "GENE_OR_GENE_PRODUCT", 21, 24], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 69, 80], ["poly (I:C", "SIMPLE_CHEMICAL", 109, 118], ["LPS", "SIMPLE_CHEMICAL", 121, 124], ["LTA", "SIMPLE_CHEMICAL", 128, 131], ["p65", "PROTEIN", 13, 16], ["p50", "PROTEIN", 21, 24], ["miR-200c-3p", "DNA", 69, 80], ["Knockdown of p65", "TEST", 0, 16], ["miR", "TEST", 69, 72], ["LPS", "TEST", 121, 124], ["LTA", "TEST", 128, 131], ["Figure", "TEST", 133, 139], ["g", "TEST", 143, 144], ["p65", "OBSERVATION_MODIFIER", 13, 16], ["p50 significantly", "OBSERVATION_MODIFIER", 21, 38]]], ["In addition, pretreatment with CAPE or JSH-23 also blocked the induction of miR-200c-3p in cells treated with poly (I:C), LPS or LTA (Figure 4f,h and j).", [["cells", "ANATOMY", 91, 96], ["CAPE", "CHEMICAL", 31, 35], ["JSH-23", "CHEMICAL", 39, 45], ["poly (I:C", "CHEMICAL", 110, 119], ["LPS", "CHEMICAL", 122, 125], ["CAPE", "CHEMICAL", 31, 35], ["JSH-23", "CHEMICAL", 39, 45], ["CAPE", "SIMPLE_CHEMICAL", 31, 35], ["JSH-23", "SIMPLE_CHEMICAL", 39, 45], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 76, 87], ["cells", "CELL", 91, 96], ["poly (I:C", "SIMPLE_CHEMICAL", 110, 119], ["LPS", "SIMPLE_CHEMICAL", 122, 125], ["LTA", "SIMPLE_CHEMICAL", 129, 132], ["miR-200c-3p", "DNA", 76, 87], ["JSH", "TEST", 39, 42], ["miR", "TEST", 76, 79], ["poly (I:C)", "TREATMENT", 110, 120], ["LPS", "TREATMENT", 122, 125]]], ["The knockdown efficiency of siRNAs on p65 and p50 gene expression was validated by qRT-PCR (Supplementary Figure S6g).", [["p65", "GENE_OR_GENE_PRODUCT", 38, 41], ["p50", "GENE_OR_GENE_PRODUCT", 46, 49], ["p65", "PROTEIN", 38, 41], ["p50", "PROTEIN", 46, 49], ["The knockdown efficiency of siRNAs", "PROBLEM", 0, 34], ["p50 gene expression", "TREATMENT", 46, 65], ["knockdown efficiency", "OBSERVATION", 4, 24], ["siRNAs", "OBSERVATION", 28, 34]]], ["These data suggest that the induction of miR-200c-3p by avian influenza A virus H5N1, double-stranded RNA poly (I:C), bacterial LPS and LTA is NF-\u03baB-dependent.Inhibition of miR-200c-3p protects against H5N1 virus infection ::: ResultsTo inhibit the function of miR-200c-3p in H5N1 virus infection, inhibitors of miR-200c-3p or an NC were transfected into A549 cells before virus infection.", [["A549 cells", "ANATOMY", 355, 365], ["miR-200c-3p", "CHEMICAL", 41, 52], ["poly (I:C", "CHEMICAL", 106, 115], ["LPS", "CHEMICAL", 128, 131], ["LTA", "CHEMICAL", 136, 139], ["miR-200c-3p", "CHEMICAL", 173, 184], ["H5N1 virus infection", "DISEASE", 202, 222], ["miR-200c-3p", "CHEMICAL", 261, 272], ["H5N1 virus infection", "DISEASE", 276, 296], ["infection", "DISEASE", 379, 388], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 41, 52], ["avian influenza A virus H5N1", "ORGANISM", 56, 84], ["LPS", "SIMPLE_CHEMICAL", 128, 131], ["LTA", "SIMPLE_CHEMICAL", 136, 139], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 143, 148], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 173, 184], ["H5N1 virus", "ORGANISM", 202, 212], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 261, 272], ["H5N1 virus", "ORGANISM", 276, 286], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 312, 323], ["NC", "GENE_OR_GENE_PRODUCT", 330, 332], ["A549 cells", "CELL", 355, 365], ["miR-200c-3p", "DNA", 41, 52], ["NF-\u03baB", "PROTEIN", 143, 148], ["miR-200c-3p", "DNA", 173, 184], ["miR-200c-3p", "DNA", 261, 272], ["miR-200c-3p", "DNA", 312, 323], ["A549 cells", "CELL_LINE", 355, 365], ["avian influenza A virus H5N1", "SPECIES", 56, 84], ["H5N1 virus", "SPECIES", 202, 212], ["H5N1 virus", "SPECIES", 276, 286], ["A virus H5N1", "SPECIES", 72, 84], ["H5N1 virus", "SPECIES", 202, 212], ["H5N1 virus", "SPECIES", 276, 286], ["avian influenza A virus H5N1", "TREATMENT", 56, 84], ["double-stranded RNA poly (I:C)", "TREATMENT", 86, 116], ["bacterial LPS", "TEST", 118, 131], ["LTA", "TEST", 136, 139], ["NF", "PROBLEM", 143, 145], ["\u03baB", "PROBLEM", 146, 148], ["H5N1 virus infection", "PROBLEM", 202, 222], ["miR", "TEST", 261, 264], ["H5N1 virus infection", "PROBLEM", 276, 296], ["miR", "TEST", 312, 315], ["an NC", "TREATMENT", 327, 332], ["virus infection", "PROBLEM", 373, 388], ["bacterial LPS", "OBSERVATION_MODIFIER", 118, 131]]], ["Inhibition of miR-200c-3p significantly blocked the downregulation of ACE2 protein induced by H5N1 virus infection (Supplementary Figure S7a).", [["miR-200c-3p", "CHEMICAL", 14, 25], ["H5N1 virus infection", "DISEASE", 94, 114], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 14, 25], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["H5N1 virus", "ORGANISM", 94, 104], ["miR-200c-3p", "DNA", 14, 25], ["ACE2 protein", "PROTEIN", 70, 82], ["H5N1 virus", "SPECIES", 94, 104], ["H5N1 virus", "SPECIES", 94, 104], ["ACE2 protein", "PROBLEM", 70, 82], ["H5N1 virus infection", "PROBLEM", 94, 114], ["H5N1 virus", "OBSERVATION", 94, 104]]], ["ARDS induced by H5N1 virus in mice was used to mimic and investigate the pathogenesis of H5N1-induced human ARDS [53].", [["ARDS", "DISEASE", 0, 4], ["H5N1", "DISEASE", 89, 93], ["ARDS", "DISEASE", 108, 112], ["H5N1 virus", "ORGANISM", 16, 26], ["mice", "ORGANISM", 30, 34], ["H5N1", "ORGANISM", 89, 93], ["human", "ORGANISM", 102, 107], ["H5N1 virus", "SPECIES", 16, 26], ["mice", "SPECIES", 30, 34], ["human", "SPECIES", 102, 107], ["H5N1 virus", "SPECIES", 16, 26], ["mice", "SPECIES", 30, 34], ["human", "SPECIES", 102, 107], ["ARDS", "PROBLEM", 0, 4], ["H5N1 virus", "PROBLEM", 16, 26], ["H5N1", "PROBLEM", 89, 93], ["human ARDS", "PROBLEM", 102, 112], ["H5N1 virus", "OBSERVATION", 16, 26], ["H5N1", "OBSERVATION", 89, 93], ["ARDS", "OBSERVATION", 108, 112]]], ["H5N1 virus infection results in lung edema, inflammatory cellular infiltration and lung injury in mice [53].", [["lung", "ANATOMY", 32, 36], ["cellular", "ANATOMY", 57, 65], ["lung", "ANATOMY", 83, 87], ["H5N1 virus infection", "DISEASE", 0, 20], ["lung edema", "DISEASE", 32, 42], ["lung injury", "DISEASE", 83, 94], ["H5N1 virus", "ORGANISM", 0, 10], ["lung edema", "PATHOLOGICAL_FORMATION", 32, 42], ["cellular", "CELL", 57, 65], ["lung", "ORGAN", 83, 87], ["mice", "ORGANISM", 98, 102], ["H5N1 virus", "SPECIES", 0, 10], ["mice", "SPECIES", 98, 102], ["H5N1 virus", "SPECIES", 0, 10], ["mice", "SPECIES", 98, 102], ["H5N1 virus infection", "PROBLEM", 0, 20], ["lung edema", "PROBLEM", 32, 42], ["inflammatory cellular infiltration", "PROBLEM", 44, 78], ["lung injury", "PROBLEM", 83, 94], ["lung", "ANATOMY", 32, 36], ["edema", "OBSERVATION", 37, 42], ["inflammatory", "OBSERVATION_MODIFIER", 44, 56], ["cellular", "OBSERVATION_MODIFIER", 57, 65], ["infiltration", "OBSERVATION", 66, 78], ["lung", "ANATOMY", 83, 87], ["injury", "OBSERVATION", 88, 94]]], ["Our results showed that the expression of miR-200c-3p in the lung tissue of H5N1-infected mice was also markedly upregulated (Figure 5a).", [["lung tissue", "ANATOMY", 61, 72], ["miR-200c-3p", "CHEMICAL", 42, 53], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 42, 53], ["lung tissue", "TISSUE", 61, 72], ["H5N1", "ORGANISM", 76, 80], ["mice", "ORGANISM", 90, 94], ["miR-200c-3p", "DNA", 42, 53], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 90, 94], ["H5N1", "PROBLEM", 76, 80], ["lung", "ANATOMY", 61, 65], ["tissue", "ANATOMY_MODIFIER", 66, 72], ["H5N1", "OBSERVATION", 76, 80]]], ["Previously, we reported that the expression of ACE2 protein was downregulated in H5N1-infected mouse lung tissue [16].", [["lung tissue", "ANATOMY", 101, 112], ["ACE2", "GENE_OR_GENE_PRODUCT", 47, 51], ["H5N1", "ORGANISM", 81, 85], ["mouse", "ORGANISM", 95, 100], ["lung tissue", "TISSUE", 101, 112], ["ACE2 protein", "PROTEIN", 47, 59], ["mouse", "SPECIES", 95, 100], ["mouse", "SPECIES", 95, 100], ["ACE2 protein", "PROBLEM", 47, 59], ["H5N1", "PROBLEM", 81, 85], ["infected mouse lung tissue", "PROBLEM", 86, 112], ["infected mouse lung tissue", "OBSERVATION", 86, 112]]], ["As inhibition of miR-200c-3p resulted in recovery of ACE2 protein level in H5N1-infected A549 cells, miR-200c-3p may be a therapeutic target for H5N1-infected mice.", [["A549 cells", "ANATOMY", 89, 99], ["miR-200c-3p", "CHEMICAL", 17, 28], ["miR-200c-3p", "CHEMICAL", 101, 112], ["H5N1-infected", "DISEASE", 145, 158], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 17, 28], ["ACE2", "GENE_OR_GENE_PRODUCT", 53, 57], ["H5N1", "ORGANISM", 75, 79], ["A549 cells", "CELL", 89, 99], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 101, 112], ["H5N1", "ORGANISM", 145, 149], ["mice", "ORGANISM", 159, 163], ["miR-200c-3p", "DNA", 17, 28], ["ACE2", "PROTEIN", 53, 57], ["H5N1-infected A549 cells", "CELL_LINE", 75, 99], ["miR-200c-3p", "DNA", 101, 112], ["mice", "SPECIES", 159, 163], ["mice", "SPECIES", 159, 163], ["ACE2 protein level", "TEST", 53, 71], ["H5N1", "PROBLEM", 75, 79], ["infected A549 cells", "PROBLEM", 80, 99], ["miR", "TEST", 101, 104], ["H5N1", "PROBLEM", 145, 149], ["A549 cells", "OBSERVATION", 89, 99], ["infected", "OBSERVATION", 150, 158]]], ["In fact, administration of miR-200c-3p antagomir (24 h before, 6 and 24 h after infection, intraperitoneally 10 mg kg\u22121) indeed improved wet-to-dry lung tissue weight ratio, which indicates the degree of lung edema (Figure 5b).", [["wet", "ANATOMY", 137, 140], ["lung tissue", "ANATOMY", 148, 159], ["lung", "ANATOMY", 204, 208], ["miR-200c-3p antagomir", "CHEMICAL", 27, 48], ["infection", "DISEASE", 80, 89], ["lung edema", "DISEASE", 204, 214], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 27, 38], ["lung tissue", "TISSUE", 148, 159], ["lung", "ORGAN", 204, 208], ["miR-200c-3p antagomir", "DNA", 27, 48], ["antagomir", "TREATMENT", 39, 48], ["infection", "PROBLEM", 80, 89], ["weight ratio", "TEST", 160, 172], ["lung edema", "PROBLEM", 204, 214], ["lung", "ANATOMY", 148, 152], ["tissue", "OBSERVATION", 153, 159], ["lung", "ANATOMY", 204, 208], ["edema", "OBSERVATION", 209, 214]]], ["In mice administered with miR-200c-3p antagomir, lung injury scores (including alveolar wall thickening, hyaline membranes formatting and airspaces filling with proteinaceous debris) [54] were decreased, and inflammatory cell infiltration was alleviated (Figure 5c).", [["lung", "ANATOMY", 49, 53], ["alveolar wall", "ANATOMY", 79, 92], ["hyaline membranes", "ANATOMY", 105, 122], ["airspaces", "ANATOMY", 138, 147], ["inflammatory cell", "ANATOMY", 208, 225], ["miR-200c-3p", "CHEMICAL", 26, 37], ["lung injury", "DISEASE", 49, 60], ["mice", "ORGANISM", 3, 7], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 26, 37], ["lung", "ORGAN", 49, 53], ["alveolar wall", "MULTI-TISSUE_STRUCTURE", 79, 92], ["hyaline membranes", "TISSUE", 105, 122], ["airspaces", "MULTI-TISSUE_STRUCTURE", 138, 147], ["inflammatory cell", "CELL", 208, 225], ["miR-200c-3p antagomir", "DNA", 26, 47], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["antagomir", "TREATMENT", 38, 47], ["lung injury scores", "PROBLEM", 49, 67], ["alveolar wall thickening", "PROBLEM", 79, 103], ["hyaline membranes formatting", "PROBLEM", 105, 133], ["airspaces filling", "PROBLEM", 138, 155], ["proteinaceous debris", "PROBLEM", 161, 181], ["inflammatory cell infiltration", "PROBLEM", 208, 238], ["lung", "ANATOMY", 49, 53], ["injury", "OBSERVATION", 54, 60], ["alveolar", "ANATOMY_MODIFIER", 79, 87], ["wall", "ANATOMY_MODIFIER", 88, 92], ["thickening", "OBSERVATION", 93, 103], ["hyaline membranes", "OBSERVATION", 105, 122], ["airspaces", "ANATOMY_MODIFIER", 138, 147], ["proteinaceous debris", "OBSERVATION", 161, 181], ["decreased", "OBSERVATION_MODIFIER", 193, 202], ["inflammatory cell infiltration", "OBSERVATION", 208, 238]]], ["Moreover, administration of miR-200c-3p antagomir (1, 24 and 48 h after infection, intraperitoneally 20 mg kg\u22121) markedly improved the survival rate of mice infected with H5N1 virus (Figure 5d) and restrained the viral replication in the lungs (Figure 5e and Supplementary Figure S7b).", [["lungs", "ANATOMY", 238, 243], ["miR-200c-3p antagomir", "CHEMICAL", 28, 49], ["infection", "DISEASE", 72, 81], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 28, 39], ["mice", "ORGANISM", 152, 156], ["H5N1 virus", "ORGANISM", 171, 181], ["lungs", "ORGAN", 238, 243], ["miR-200c-3p antagomir", "DNA", 28, 49], ["mice", "SPECIES", 152, 156], ["H5N1 virus", "SPECIES", 171, 181], ["mice", "SPECIES", 152, 156], ["H5N1 virus", "SPECIES", 171, 181], ["antagomir", "TREATMENT", 40, 49], ["infection", "PROBLEM", 72, 81], ["H5N1 virus", "PROBLEM", 171, 181], ["the viral replication", "TREATMENT", 209, 230], ["viral replication", "OBSERVATION", 213, 230], ["lungs", "ANATOMY", 238, 243]]], ["The body weight loss of surviving H5N1-infected mice administered with miR-200c-3p antagomir was recovered (Supplementary Figure S7c).", [["body", "ANATOMY", 4, 8], ["weight loss", "DISEASE", 9, 20], ["H5N1-infected", "DISEASE", 34, 47], ["miR-200c-3p", "CHEMICAL", 71, 82], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["H5N1", "ORGANISM", 34, 38], ["mice", "ORGANISM", 48, 52], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 71, 82], ["miR-200c-3p antagomir", "DNA", 71, 92], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["The body weight loss", "PROBLEM", 0, 20], ["surviving H5N1", "PROBLEM", 24, 38], ["antagomir", "TREATMENT", 83, 92], ["body", "ANATOMY", 4, 8], ["H5N1", "OBSERVATION", 34, 38]]], ["Administration of miR-200c-3p antagomir also resulted in the recovery of ACE2 protein level in the lung tissue (Figure 5f).", [["lung tissue", "ANATOMY", 99, 110], ["miR-200c-3p", "CHEMICAL", 18, 29], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 18, 29], ["ACE2", "GENE_OR_GENE_PRODUCT", 73, 77], ["lung tissue", "TISSUE", 99, 110], ["miR-200c-3p antagomir", "DNA", 18, 39], ["ACE2", "PROTEIN", 73, 77], ["miR-200c-3p antagomir", "TREATMENT", 18, 39], ["ACE2 protein level", "TEST", 73, 91], ["lung tissue", "ANATOMY", 99, 110]]], ["Accordingly, treatment with miR-200c-3p antagomir markedly reduced the plasma level of Ang II of H5N1-infected mice as well (Figure 5g).", [["plasma", "ANATOMY", 71, 77], ["miR-200c-3p", "CHEMICAL", 28, 39], ["Ang II", "CHEMICAL", 87, 93], ["H5N1-infected", "DISEASE", 97, 110], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 28, 39], ["plasma", "ORGANISM_SUBSTANCE", 71, 77], ["Ang II", "GENE_OR_GENE_PRODUCT", 87, 93], ["H5N1", "ORGANISM", 97, 101], ["mice", "ORGANISM", 111, 115], ["miR-200c-3p antagomir", "DNA", 28, 49], ["Ang II", "PROTEIN", 87, 93], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["miR", "TREATMENT", 28, 31], ["antagomir", "TREATMENT", 40, 49], ["the plasma level", "TEST", 67, 83], ["H5N1", "PROBLEM", 97, 101]]], ["In summary, our data demonstrated that inhibiting the function of miR-200c-3p improves lung injury and ARDS induced by H5N1 virus infection, rendering miR-200c-3p as a potential therapeutic target.DiscussionAlthough influenza infection and severe pneumonia are known to cause much of their mortality by inducing ARDS, the mechanisms are still not fully understood, and effective drugs are still lacking [36, 55, 56].", [["lung", "ANATOMY", 87, 91], ["miR-200c-3p", "CHEMICAL", 66, 77], ["lung injury", "DISEASE", 87, 98], ["ARDS", "DISEASE", 103, 107], ["H5N1 virus infection", "DISEASE", 119, 139], ["miR-200c-3p", "CHEMICAL", 151, 162], ["influenza infection", "DISEASE", 216, 235], ["pneumonia", "DISEASE", 247, 256], ["ARDS", "DISEASE", 312, 316], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 66, 77], ["lung", "ORGAN", 87, 91], ["H5N1 virus", "ORGANISM", 119, 129], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 151, 162], ["miR-200c-3p", "DNA", 66, 77], ["miR-200c-3p", "DNA", 151, 162], ["H5N1 virus", "SPECIES", 119, 129], ["H5N1 virus", "SPECIES", 119, 129], ["our data", "TEST", 12, 20], ["miR", "TEST", 66, 69], ["lung injury", "PROBLEM", 87, 98], ["ARDS", "PROBLEM", 103, 107], ["H5N1 virus infection", "PROBLEM", 119, 139], ["influenza infection", "PROBLEM", 216, 235], ["severe pneumonia", "PROBLEM", 240, 256], ["ARDS", "PROBLEM", 312, 316], ["effective drugs", "TREATMENT", 369, 384], ["lung", "ANATOMY", 87, 91], ["injury", "OBSERVATION", 92, 98], ["ARDS", "OBSERVATION", 103, 107], ["H5N1 virus", "OBSERVATION", 119, 129], ["infection", "OBSERVATION", 226, 235], ["severe", "OBSERVATION_MODIFIER", 240, 246], ["pneumonia", "OBSERVATION", 247, 256], ["ARDS", "OBSERVATION", 312, 316]]], ["Our study indicates that miR-200c-3p has a crucial role in the regulation of ACE2 in ALI or ARDS induced by H5N1 virus infection and severe pneumonia.", [["miR-200c-3p", "CHEMICAL", 25, 36], ["ALI", "DISEASE", 85, 88], ["ARDS", "DISEASE", 92, 96], ["H5N1 virus infection", "DISEASE", 108, 128], ["pneumonia", "DISEASE", 140, 149], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 25, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 77, 81], ["H5N1 virus", "ORGANISM", 108, 118], ["miR-200c-3p", "DNA", 25, 36], ["ACE2", "PROTEIN", 77, 81], ["H5N1 virus", "SPECIES", 108, 118], ["H5N1 virus", "SPECIES", 108, 118], ["Our study", "TEST", 0, 9], ["ACE2 in ALI", "PROBLEM", 77, 88], ["ARDS", "PROBLEM", 92, 96], ["H5N1 virus infection", "PROBLEM", 108, 128], ["severe pneumonia", "PROBLEM", 133, 149], ["ALI", "ANATOMY", 85, 88], ["ARDS", "OBSERVATION", 92, 96], ["H5N1 virus", "OBSERVATION", 108, 118], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["pneumonia", "OBSERVATION", 140, 149]]], ["Our previous studies have demonstrated that ACE2 protects mice against ALI induced by severe acute respiratory syndrome-coronavirus spikes, acid aspiration, sepsis and avian influenza virus [16, 18].", [["ALI", "DISEASE", 71, 74], ["acute respiratory syndrome-coronavirus spikes", "DISEASE", 93, 138], ["sepsis", "DISEASE", 157, 163], ["avian influenza virus", "DISEASE", 168, 189], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["mice", "ORGANISM", 58, 62], ["avian influenza virus", "ORGANISM", 168, 189], ["ACE2", "PROTEIN", 44, 48], ["mice", "SPECIES", 58, 62], ["avian influenza virus", "SPECIES", 168, 189], ["mice", "SPECIES", 58, 62], ["severe acute respiratory syndrome-coronavirus", "SPECIES", 86, 131], ["Our previous studies", "TEST", 0, 20], ["ACE2 protects", "TREATMENT", 44, 57], ["ALI", "PROBLEM", 71, 74], ["severe acute respiratory syndrome", "PROBLEM", 86, 119], ["coronavirus spikes", "PROBLEM", 120, 138], ["acid aspiration", "PROBLEM", 140, 155], ["sepsis", "PROBLEM", 157, 163], ["avian influenza virus", "PROBLEM", 168, 189], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["respiratory syndrome", "OBSERVATION", 99, 119], ["coronavirus spikes", "OBSERVATION", 120, 138], ["sepsis", "OBSERVATION", 157, 163]]], ["In this study, we showed that avian influenza virus, poly (I:C), bacterial LPS and LTA use a similar approach to reduce ACE2 level: the elevated miR-200c-3p directly downregulates ACE2 expression.", [["influenza virus", "DISEASE", 36, 51], ["poly (I:C", "CHEMICAL", 53, 62], ["LPS", "CHEMICAL", 75, 78], ["LTA", "CHEMICAL", 83, 86], ["avian influenza virus", "ORGANISM", 30, 51], ["poly (I:C", "GENE_OR_GENE_PRODUCT", 53, 62], ["LPS", "SIMPLE_CHEMICAL", 75, 78], ["LTA", "SIMPLE_CHEMICAL", 83, 86], ["ACE2", "GENE_OR_GENE_PRODUCT", 120, 124], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 145, 156], ["ACE2", "GENE_OR_GENE_PRODUCT", 180, 184], ["ACE2", "PROTEIN", 120, 124], ["miR-200c-3p", "DNA", 145, 156], ["ACE2", "PROTEIN", 180, 184], ["avian influenza virus", "SPECIES", 30, 51], ["avian influenza virus", "SPECIES", 30, 51], ["this study", "TEST", 3, 13], ["avian influenza virus", "PROBLEM", 30, 51], ["bacterial LPS", "TREATMENT", 65, 78], ["a similar approach", "TREATMENT", 91, 109], ["ACE2 level", "TEST", 120, 130], ["the elevated miR", "PROBLEM", 132, 148], ["influenza virus", "OBSERVATION", 36, 51]]], ["Moreover, plasma levels of miR-200c-3p and its downstream effector Ang II were significantly elevated in severe pneumonia patients.DiscussionWhile NS1 was reported to inhibit the activation of NF-\u03baB, it is a matter of common observation that NF-\u03baB signaling pathway is still significantly activated upon H5N1 virus infection and multiple NF-\u03baB-dependent genes are expressed [46\u201349].", [["plasma", "ANATOMY", 10, 16], ["pneumonia", "DISEASE", 112, 121], ["infection", "DISEASE", 315, 324], ["plasma", "ORGANISM_SUBSTANCE", 10, 16], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 27, 38], ["Ang II", "GENE_OR_GENE_PRODUCT", 67, 73], ["patients", "ORGANISM", 122, 130], ["NS1", "GENE_OR_GENE_PRODUCT", 147, 150], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 193, 198], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 242, 247], ["H5N1 virus", "ORGANISM", 304, 314], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 338, 343], ["miR-200c-3p", "DNA", 27, 38], ["Ang II", "PROTEIN", 67, 73], ["NS1", "PROTEIN", 147, 150], ["NF-\u03baB", "PROTEIN", 193, 198], ["NF-\u03baB", "PROTEIN", 242, 247], ["NF-\u03baB-dependent genes", "DNA", 338, 359], ["patients", "SPECIES", 122, 130], ["H5N1 virus", "SPECIES", 304, 314], ["H5N1 virus", "SPECIES", 304, 314], ["plasma levels", "TEST", 10, 23], ["miR", "TEST", 27, 30], ["Ang II", "TEST", 67, 73], ["significantly elevated", "PROBLEM", 79, 101], ["severe pneumonia patients", "PROBLEM", 105, 130], ["NF", "TEST", 242, 244], ["H5N1 virus infection", "PROBLEM", 304, 324], ["multiple NF", "TEST", 329, 340], ["elevated", "OBSERVATION_MODIFIER", 93, 101], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["pneumonia", "OBSERVATION", 112, 121]]], ["Interestingly, here we found that pathogenic avian influenza virus can induce the upregulation of miR-200c-3p through both the expression of NS1 protein and the accumulation of vRNA (Figure 6).", [["influenza virus", "DISEASE", 51, 66], ["avian influenza virus", "ORGANISM", 45, 66], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 98, 109], ["NS1", "GENE_OR_GENE_PRODUCT", 141, 144], ["miR-200c-3p", "DNA", 98, 109], ["NS1 protein", "PROTEIN", 141, 152], ["avian influenza virus", "SPECIES", 45, 66], ["avian influenza virus", "SPECIES", 45, 66], ["pathogenic avian influenza virus", "PROBLEM", 34, 66], ["NS1 protein", "TREATMENT", 141, 152], ["vRNA", "PROBLEM", 177, 181], ["NS1 protein", "OBSERVATION", 141, 152], ["accumulation of vRNA", "OBSERVATION", 161, 181]]], ["NS1 is a multifunctional protein that interacts with more than 50 proteins to regulate innate immune pathways, splicing and mRNA export [57, 58].", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS1", "PROTEIN", 0, 3], ["multifunctional protein", "PROTEIN", 9, 32], ["mRNA export", "TEST", 124, 135]]], ["Unlike NS1 of human pandemic H1N1/2009, NS1 of avian highly pathogenic H5N1 effectively inhibits the polyadenylation of cellular pre-mRNA in A549 cells [59].", [["cellular", "ANATOMY", 120, 128], ["A549 cells", "ANATOMY", 141, 151], ["H5N1", "DISEASE", 71, 75], ["NS1", "GENE_OR_GENE_PRODUCT", 7, 10], ["human pandemic H1N1/2009", "ORGANISM", 14, 38], ["NS1", "ORGANISM", 40, 43], ["avian highly pathogenic H5N1", "ORGANISM", 47, 75], ["cellular", "CELL", 120, 128], ["A549 cells", "CELL", 141, 151], ["NS1", "PROTEIN", 7, 10], ["NS1", "PROTEIN", 40, 43], ["cellular pre-mRNA", "RNA", 120, 137], ["A549 cells", "CELL_LINE", 141, 151], ["human", "SPECIES", 14, 19], ["pandemic H1N1", "SPECIES", 20, 33], ["human pandemic H1N1/2009", "SPECIES", 14, 38], ["NS1", "TREATMENT", 40, 43], ["pathogenic H5N1", "PROBLEM", 60, 75], ["H5N1", "OBSERVATION", 71, 75], ["cellular pre-mRNA", "OBSERVATION", 120, 137], ["A549 cells", "OBSERVATION", 141, 151]]], ["Batista et al. [60] have shown that the transcription of miR-200c/141 can be induced by the bypass of the usual PTPN6 polyadenylation.", [["miR-200c/141", "GENE_OR_GENE_PRODUCT", 57, 69], ["PTPN6", "GENE_OR_GENE_PRODUCT", 112, 117], ["miR-200c", "DNA", 57, 65], ["PTPN6", "PROTEIN", 112, 117], ["the bypass", "TREATMENT", 88, 98], ["the usual PTPN6 polyadenylation", "TREATMENT", 102, 133], ["bypass", "OBSERVATION", 92, 98]]], ["NS1 of pathogenic avian influenza viruses may induce the expression of miR-200c-3p and miR-141-3p by bypassing the usual PTPN6 polyadenylation, which needed to be further investigated.", [["influenza viruses", "DISEASE", 24, 41], ["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["avian influenza viruses", "ORGANISM", 18, 41], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 71, 82], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 87, 97], ["PTPN6", "GENE_OR_GENE_PRODUCT", 121, 126], ["NS1", "PROTEIN", 0, 3], ["miR-200c-3p", "DNA", 71, 82], ["miR-141-3p", "DNA", 87, 97], ["PTPN6", "DNA", 121, 126], ["avian influenza viruses", "SPECIES", 18, 41], ["pathogenic avian influenza viruses", "PROBLEM", 7, 41], ["the usual PTPN6 polyadenylation", "TREATMENT", 111, 142], ["pathogenic avian", "OBSERVATION", 7, 23], ["influenza viruses", "OBSERVATION", 24, 41]]], ["Moreover, a study has reported that NA protein of influenza A/Puerto Rico/8/1934 (H1N1, PR8) can downregulate ACE2 [61]; therefore, whether NA of H5N1 and H7N9 viruses can downregulate ACE2 requires further investigation.DiscussionNF-\u03baB is a critical regulator of defensive response to diverse pathogens.", [["NA", "CHEMICAL", 36, 38], ["influenza A", "ORGANISM", 50, 61], ["Puerto Rico/8/1934", "ORGANISM", 62, 80], ["H1N1", "ORGANISM", 82, 86], ["PR8", "ORGANISM", 88, 91], ["ACE2", "GENE_OR_GENE_PRODUCT", 110, 114], ["NA of H5N1", "ORGANISM", 140, 150], ["H7N9 viruses", "ORGANISM", 155, 167], ["ACE2", "GENE_OR_GENE_PRODUCT", 185, 189], ["DiscussionNF-\u03baB", "GENE_OR_GENE_PRODUCT", 221, 236], ["NA protein", "PROTEIN", 36, 46], ["ACE2", "PROTEIN", 110, 114], ["ACE2", "PROTEIN", 185, 189], ["DiscussionNF", "PROTEIN", 221, 233], ["-\u03baB", "PROTEIN", 233, 236], ["influenza A/Puerto Rico/8/1934 (H1N1, PR8", "SPECIES", 50, 91], ["H7N9", "SPECIES", 155, 159], ["a study", "TEST", 10, 17], ["NA protein", "TEST", 36, 46], ["influenza", "PROBLEM", 50, 59], ["ACE2", "TEST", 110, 114], ["H5N1", "PROBLEM", 146, 150], ["H7N9 viruses", "PROBLEM", 155, 167], ["further investigation", "TEST", 199, 220], ["diverse pathogens", "PROBLEM", 286, 303], ["diverse", "OBSERVATION_MODIFIER", 286, 293], ["pathogens", "OBSERVATION", 294, 303]]], ["Viruses, bacteria, parasites and injury initiate distinct signal-transduction pathways to activate NF-\u03baB.", [["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 99, 103], ["NF-\u03baB.", "PROTEIN", 99, 105], ["Viruses", "PROBLEM", 0, 7], ["bacteria", "PROBLEM", 9, 17], ["parasites", "PROBLEM", 19, 28], ["injury", "PROBLEM", 33, 39], ["bacteria", "OBSERVATION", 9, 17]]], ["Influenza virus can induce the activation of NF-\u03baB by the accumulation of viral products, including viral protein and vRNA [62, 63].", [["Influenza", "DISEASE", 0, 9], ["Influenza virus", "ORGANISM", 0, 15], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 45, 50], ["NF-\u03baB", "PROTEIN", 45, 50], ["viral products", "PROTEIN", 74, 88], ["viral protein", "PROTEIN", 100, 113], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "PROBLEM", 0, 15], ["viral products", "TREATMENT", 74, 88], ["viral protein", "TEST", 100, 113], ["vRNA", "TEST", 118, 122], ["viral products", "OBSERVATION", 74, 88]]], ["In this study, we found that transfection of RNA extracted from H5N1 virus-infected cells elicited the upregulation of miR-200c-3p, which can be suppressed by the loss of p65 function (Figure 6).", [["cells", "ANATOMY", 84, 89], ["H5N1 virus", "ORGANISM", 64, 74], ["cells", "CELL", 84, 89], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 119, 130], ["p65", "GENE_OR_GENE_PRODUCT", 171, 174], ["miR-200c-3p", "DNA", 119, 130], ["p65", "PROTEIN", 171, 174], ["H5N1 virus", "SPECIES", 64, 74], ["H5N1 virus", "SPECIES", 64, 74], ["this study", "TEST", 3, 13], ["transfection of RNA", "PROBLEM", 29, 48], ["H5N1 virus", "PROBLEM", 64, 74], ["infected cells", "PROBLEM", 75, 89]]], ["The expression levels of miR-200c-3p have been found to be markedly upregulated in the livers of hepatocellular carcinoma patients [64].", [["livers", "ANATOMY", 87, 93], ["hepatocellular carcinoma", "ANATOMY", 97, 121], ["hepatocellular carcinoma", "DISEASE", 97, 121], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 25, 36], ["livers", "ORGAN", 87, 93], ["hepatocellular carcinoma", "CANCER", 97, 121], ["patients", "ORGANISM", 122, 130], ["miR-200c-3p", "DNA", 25, 36], ["patients", "SPECIES", 122, 130], ["The expression levels", "TEST", 0, 21], ["miR", "TEST", 25, 28], ["hepatocellular carcinoma", "PROBLEM", 97, 121], ["markedly", "OBSERVATION_MODIFIER", 59, 67], ["upregulated", "OBSERVATION", 68, 79], ["livers", "ANATOMY", 87, 93], ["hepatocellular", "ANATOMY", 97, 111], ["carcinoma", "OBSERVATION", 112, 121]]], ["Among these patients, nine patients were diagnosed with HBV infection and five patients were diagnosed with HCV infection, thus suggesting that HBV and HCV infection may induce the expression of miR-200c-3p.", [["HBV infection", "DISEASE", 56, 69], ["HCV infection", "DISEASE", 108, 121], ["HCV infection", "DISEASE", 152, 165], ["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 27, 35], ["HBV", "ORGANISM", 56, 59], ["patients", "ORGANISM", 79, 87], ["HCV", "ORGANISM", 108, 111], ["HBV", "ORGANISM", 144, 147], ["HCV", "ORGANISM", 152, 155], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 195, 206], ["miR-200c-3p", "DNA", 195, 206], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 79, 87], ["HBV", "SPECIES", 56, 59], ["HCV", "SPECIES", 108, 111], ["HBV", "SPECIES", 144, 147], ["HCV", "SPECIES", 152, 155], ["HBV infection", "PROBLEM", 56, 69], ["HCV infection", "PROBLEM", 108, 121], ["HBV", "PROBLEM", 144, 147], ["HCV infection", "PROBLEM", 152, 165], ["infection", "OBSERVATION", 60, 69], ["HCV", "OBSERVATION_MODIFIER", 108, 111], ["infection", "OBSERVATION", 112, 121], ["HBV", "OBSERVATION", 144, 147], ["HCV", "OBSERVATION", 152, 155]]], ["Whether HCV or HBV RNA can induce the upregulation of miR-200c-3p requires further study.DiscussionAs we know, poly (I:C), LPS and LTA can induce the activation of NF-\u03baB via Toll-like receptor 3, Toll-like receptor 4 and Toll-like receptor 2, respectively [65\u201367].", [["poly (I:C", "CHEMICAL", 111, 120], ["LPS", "CHEMICAL", 123, 126], ["LTA", "CHEMICAL", 131, 134], ["poly (I:C)", "CHEMICAL", 111, 121], ["HCV", "ORGANISM", 8, 11], ["HBV", "ORGANISM", 15, 18], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 54, 65], ["poly (I:C", "SIMPLE_CHEMICAL", 111, 120], ["LPS", "SIMPLE_CHEMICAL", 123, 126], ["LTA", "SIMPLE_CHEMICAL", 131, 134], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 164, 169], ["Toll-like receptor 3", "GENE_OR_GENE_PRODUCT", 174, 194], ["Toll-like receptor 4", "GENE_OR_GENE_PRODUCT", 196, 216], ["Toll-like receptor 2", "GENE_OR_GENE_PRODUCT", 221, 241], ["HCV or HBV RNA", "RNA", 8, 22], ["miR-200c-3p", "DNA", 54, 65], ["NF-\u03baB", "PROTEIN", 164, 169], ["Toll-like receptor 3", "PROTEIN", 174, 194], ["Toll-like receptor 4", "PROTEIN", 196, 216], ["Toll-like receptor 2", "PROTEIN", 221, 241], ["HCV", "SPECIES", 8, 11], ["HBV", "SPECIES", 15, 18], ["HCV", "PROBLEM", 8, 11], ["HBV RNA", "PROBLEM", 15, 22], ["further study", "TEST", 75, 88]]], ["In fact, we also noticed that poly (I:C), bacterial LPS and LTA can induce the upregulation of miR-200c-3p to downregulate ACE2 protein expression in an NF-\u03baB signaling pathway-dependent manner (Figure 6).", [["poly (I:C", "CHEMICAL", 30, 39], ["LPS", "CHEMICAL", 52, 55], ["LTA", "CHEMICAL", 60, 63], ["poly (I:C)", "CHEMICAL", 30, 40], ["poly (I:C", "SIMPLE_CHEMICAL", 30, 39], ["LPS", "SIMPLE_CHEMICAL", 52, 55], ["LTA", "SIMPLE_CHEMICAL", 60, 63], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 95, 106], ["ACE2", "GENE_OR_GENE_PRODUCT", 123, 127], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 153, 158], ["miR-200c-3p", "DNA", 95, 106], ["ACE2", "PROTEIN", 123, 127], ["poly (I:C)", "PROBLEM", 30, 40], ["bacterial LPS", "TEST", 42, 55], ["LTA", "TEST", 60, 63], ["miR", "TEST", 95, 98], ["ACE2 protein expression", "TEST", 123, 146], ["an NF", "TEST", 150, 155], ["protein expression", "OBSERVATION", 128, 146]]], ["Previous study has shown that overexpression of ACE2 protects against LPS-induced lung injury in rat [23].", [["lung", "ANATOMY", 82, 86], ["LPS", "CHEMICAL", 70, 73], ["lung injury", "DISEASE", 82, 93], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["LPS", "SIMPLE_CHEMICAL", 70, 73], ["lung", "ORGAN", 82, 86], ["rat", "ORGANISM", 97, 100], ["ACE2", "PROTEIN", 48, 52], ["rat", "SPECIES", 97, 100], ["rat", "SPECIES", 97, 100], ["Previous study", "TEST", 0, 14], ["ACE2 protects", "TREATMENT", 48, 61], ["LPS", "PROBLEM", 70, 73], ["lung injury", "PROBLEM", 82, 93], ["lung", "ANATOMY", 82, 86], ["injury", "OBSERVATION", 87, 93]]], ["The downregulation of ACE2 might be mediated by miR-200c-3p and inhibition of miR-200c-3p might protect against LPS-induced lung injury as well.", [["lung", "ANATOMY", 124, 128], ["miR-200c-3p", "CHEMICAL", 78, 89], ["LPS", "CHEMICAL", 112, 115], ["lung injury", "DISEASE", 124, 135], ["ACE2", "GENE_OR_GENE_PRODUCT", 22, 26], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 48, 59], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 78, 89], ["LPS", "SIMPLE_CHEMICAL", 112, 115], ["lung", "ORGAN", 124, 128], ["ACE2", "PROTEIN", 22, 26], ["miR-200c-3p", "DNA", 48, 59], ["miR-200c-3p", "DNA", 78, 89], ["The downregulation of ACE2", "TREATMENT", 0, 26], ["LPS", "PROBLEM", 112, 115], ["lung injury", "PROBLEM", 124, 135], ["lung", "ANATOMY", 124, 128], ["injury", "OBSERVATION", 129, 135]]], ["The observations represented in this study may provide an example how pathogenic avian influenza viruses and bacteria use NF-\u03baB activity.DiscussionCompared with healthy controls, the plasma levels of both miR-200c-3p and its downstream effector Ang II were much higher in severe pneumonia patients.", [["plasma", "ANATOMY", 183, 189], ["influenza viruses", "DISEASE", 87, 104], ["pneumonia", "DISEASE", 279, 288], ["avian influenza viruses", "ORGANISM", 81, 104], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 122, 127], ["plasma", "ORGANISM_SUBSTANCE", 183, 189], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 205, 216], ["Ang II", "GENE_OR_GENE_PRODUCT", 245, 251], ["patients", "ORGANISM", 289, 297], ["NF-\u03baB", "PROTEIN", 122, 127], ["miR-200c-3p", "DNA", 205, 216], ["Ang II", "PROTEIN", 245, 251], ["avian influenza", "SPECIES", 81, 96], ["patients", "SPECIES", 289, 297], ["this study", "TEST", 32, 42], ["pathogenic avian influenza viruses", "PROBLEM", 70, 104], ["bacteria", "PROBLEM", 109, 117], ["NF", "TEST", 122, 124], ["the plasma levels", "TEST", 179, 196], ["severe pneumonia patients", "PROBLEM", 272, 297], ["severe", "OBSERVATION_MODIFIER", 272, 278], ["pneumonia", "OBSERVATION", 279, 288]]], ["As previous studies have reported that angiotensin-converting enzyme inhibitors, which reduce the production of Ang II, and Ang II receptor blockers, which block the function of Ang II, do have some beneficial effects on pneumonia-related clinical outcomes [68, 69], inhibition of miR-200c-3p may also produce a positive clinical outcome for pneumonia.", [["angiotensin", "CHEMICAL", 39, 50], ["Ang II", "CHEMICAL", 112, 118], ["Ang II", "CHEMICAL", 124, 130], ["Ang II", "CHEMICAL", 178, 184], ["pneumonia", "DISEASE", 221, 230], ["miR-200c-3p", "CHEMICAL", 281, 292], ["pneumonia", "DISEASE", 342, 351], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 39, 68], ["Ang II", "GENE_OR_GENE_PRODUCT", 112, 118], ["Ang II receptor", "GENE_OR_GENE_PRODUCT", 124, 139], ["Ang II", "GENE_OR_GENE_PRODUCT", 178, 184], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 281, 292], ["Ang II", "PROTEIN", 112, 118], ["Ang II receptor", "PROTEIN", 124, 139], ["Ang II", "PROTEIN", 178, 184], ["miR-200c-3p", "DNA", 281, 292], ["previous studies", "TEST", 3, 19], ["angiotensin-converting enzyme inhibitors", "TREATMENT", 39, 79], ["Ang II", "TREATMENT", 112, 118], ["Ang II receptor blockers", "TREATMENT", 124, 148], ["Ang II", "PROBLEM", 178, 184], ["pneumonia", "PROBLEM", 221, 230], ["pneumonia", "PROBLEM", 342, 351], ["pneumonia", "OBSERVATION", 221, 230], ["pneumonia", "OBSERVATION", 342, 351]]], ["In addition, previous study has reported that the miR-200c-3p level was positively related to the severity of interstitial lung disease [70].", [["interstitial lung", "ANATOMY", 110, 127], ["interstitial lung disease", "DISEASE", 110, 135], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 50, 61], ["lung", "ORGAN", 123, 127], ["miR-200c-3p", "DNA", 50, 61], ["previous study", "TEST", 13, 27], ["the miR", "TEST", 46, 53], ["interstitial lung disease", "PROBLEM", 110, 135], ["interstitial", "ANATOMY_MODIFIER", 110, 122], ["lung", "ANATOMY", 123, 127], ["disease", "OBSERVATION", 128, 135]]], ["Further studies are needed to explore whether plasma levels of miR-200c-3p or Ang II can serve as a biomarker or therapeutic target for severe pneumonia.DiscussionIn recent years, miRNA-based strategies for exploring novel therapeutic drugs have experienced rapid development.", [["plasma", "ANATOMY", 46, 52], ["Ang II", "CHEMICAL", 78, 84], ["pneumonia", "DISEASE", 143, 152], ["plasma", "ORGANISM_SUBSTANCE", 46, 52], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 63, 74], ["Ang II", "GENE_OR_GENE_PRODUCT", 78, 84], ["miR-200c-3p", "DNA", 63, 74], ["Ang II", "PROTEIN", 78, 84], ["Further studies", "TEST", 0, 15], ["plasma levels", "TEST", 46, 59], ["miR", "TEST", 63, 66], ["a biomarker", "TEST", 98, 109], ["severe pneumonia", "PROBLEM", 136, 152], ["miRNA-based strategies", "TREATMENT", 180, 202], ["novel therapeutic drugs", "TREATMENT", 217, 240], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["pneumonia", "OBSERVATION", 143, 152]]], ["Several miRNA-targeting drugs have now entered clinical testing or are even close to gaining access to markets [28].", [["Several miRNA-targeting drugs", "TREATMENT", 0, 29], ["clinical testing", "TEST", 47, 63]]], ["We found that administration of antagomirs of miR-200c-3p can ameliorate ALI and lung edema in mice induced by H5N1 virus infection, suggesting a potential miRNA-targeting drug for avian influenza viruses-mediated ALI.", [["lung edema", "ANATOMY", 81, 91], ["miR-200c-3p", "CHEMICAL", 46, 57], ["ALI", "DISEASE", 73, 76], ["lung edema", "DISEASE", 81, 91], ["H5N1 virus infection", "DISEASE", 111, 131], ["influenza viruses", "DISEASE", 187, 204], ["ALI", "DISEASE", 214, 217], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 46, 57], ["ALI", "PATHOLOGICAL_FORMATION", 73, 76], ["lung edema", "PATHOLOGICAL_FORMATION", 81, 91], ["mice", "ORGANISM", 95, 99], ["H5N1 virus", "ORGANISM", 111, 121], ["avian influenza viruses", "ORGANISM", 181, 204], ["miR-200c-3p", "DNA", 46, 57], ["mice", "SPECIES", 95, 99], ["H5N1 virus", "SPECIES", 111, 121], ["avian influenza", "SPECIES", 181, 196], ["mice", "SPECIES", 95, 99], ["H5N1 virus", "SPECIES", 111, 121], ["antagomirs of miR", "TREATMENT", 32, 49], ["ALI", "PROBLEM", 73, 76], ["lung edema", "PROBLEM", 81, 91], ["H5N1 virus infection", "PROBLEM", 111, 131], ["avian influenza viruses", "PROBLEM", 181, 204], ["ALI", "ANATOMY", 73, 76], ["lung", "ANATOMY", 81, 85], ["edema", "OBSERVATION", 86, 91], ["ALI", "OBSERVATION", 214, 217]]], ["One study has demonstrated that administration of anti-miR-200c-5p oligonucleotide attenuates pulmonary inflammatory responses and lung injury by inhibiting the downregulation of dual-specificity phosphatase 1 in an LPS-induced mouse model [71].", [["pulmonary", "ANATOMY", 94, 103], ["lung", "ANATOMY", 131, 135], ["anti-miR-200c-5p oligonucleotide", "CHEMICAL", 50, 82], ["lung injury", "DISEASE", 131, 142], ["LPS", "CHEMICAL", 216, 219], ["anti-miR-200c", "GENE_OR_GENE_PRODUCT", 50, 63], ["pulmonary", "ORGAN", 94, 103], ["lung", "ORGAN", 131, 135], ["dual-specificity phosphatase 1", "GENE_OR_GENE_PRODUCT", 179, 209], ["LPS", "SIMPLE_CHEMICAL", 216, 219], ["mouse", "ORGANISM", 228, 233], ["dual-specificity phosphatase 1", "PROTEIN", 179, 209], ["mouse", "SPECIES", 228, 233], ["mouse", "SPECIES", 228, 233], ["One study", "TEST", 0, 9], ["anti-miR", "TREATMENT", 50, 58], ["pulmonary inflammatory responses", "PROBLEM", 94, 126], ["lung injury", "PROBLEM", 131, 142], ["dual-specificity phosphatase", "TEST", 179, 207], ["an LPS", "TEST", 213, 219], ["pulmonary", "ANATOMY", 94, 103], ["inflammatory", "OBSERVATION", 104, 116], ["lung", "ANATOMY", 131, 135], ["injury", "OBSERVATION", 136, 142]]], ["In accordance with our result, ACE2 was not a target of miR-200c-5p (Figure 2b).DiscussionCollectively, we found that NS1 and vRNA of avian influenza virus can induce the upregulation of miR-200c-3p to downregulate ACE2 protein expression.", [["ACE2", "GENE_OR_GENE_PRODUCT", 31, 35], ["miR-200c-5p", "GENE_OR_GENE_PRODUCT", 56, 67], ["Figure 2b", "GENE_OR_GENE_PRODUCT", 69, 78], ["NS1", "GENE_OR_GENE_PRODUCT", 118, 121], ["vRNA", "GENE_OR_GENE_PRODUCT", 126, 130], ["avian influenza virus", "ORGANISM", 134, 155], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 187, 198], ["ACE2", "GENE_OR_GENE_PRODUCT", 215, 219], ["ACE2", "PROTEIN", 31, 35], ["miR-200c-5p", "DNA", 56, 67], ["NS1", "PROTEIN", 118, 121], ["miR-200c-3p", "DNA", 187, 198], ["ACE2", "PROTEIN", 215, 219], ["avian influenza virus", "SPECIES", 134, 155], ["avian influenza virus", "SPECIES", 134, 155], ["ACE2", "TEST", 31, 35], ["NS1", "PROBLEM", 118, 121], ["vRNA", "PROBLEM", 126, 130], ["avian influenza virus", "PROBLEM", 134, 155], ["protein expression", "OBSERVATION", 220, 238]]], ["NF-\u03baB-dependent induction of miR-200c-3p is a shared mechanism of H5N1-vRNA, poly (I:C), LPS and LTA induced ACE2 reduction, suggesting a molecular mechanism of ALI/ARDS caused by bacterial and viral infections: the elevated miR-200c-3p downregulated ACE2 expression, increased Ang II levels and caused lung injury through Ang II type 1 receptor.", [["lung", "ANATOMY", 303, 307], ["poly (I:C", "CHEMICAL", 77, 86], ["LPS", "CHEMICAL", 89, 92], ["LTA", "CHEMICAL", 97, 100], ["ALI", "DISEASE", 161, 164], ["ARDS", "DISEASE", 165, 169], ["bacterial and viral infections", "DISEASE", 180, 210], ["Ang II", "CHEMICAL", 278, 284], ["lung injury", "DISEASE", 303, 314], ["Ang II", "CHEMICAL", 323, 329], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 29, 40], ["H5N1-v", "GENE_OR_GENE_PRODUCT", 66, 72], ["poly (I:C)", "GENE_OR_GENE_PRODUCT", 77, 87], ["LPS", "SIMPLE_CHEMICAL", 89, 92], ["LTA", "SIMPLE_CHEMICAL", 97, 100], ["ACE2", "GENE_OR_GENE_PRODUCT", 109, 113], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 225, 236], ["ACE2", "GENE_OR_GENE_PRODUCT", 251, 255], ["Ang II", "GENE_OR_GENE_PRODUCT", 278, 284], ["lung", "ORGAN", 303, 307], ["Ang II type 1 receptor", "GENE_OR_GENE_PRODUCT", 323, 345], ["NF-\u03baB", "PROTEIN", 0, 5], ["miR-200c-3p", "DNA", 29, 40], ["H5N1-vRNA", "RNA", 66, 75], ["ACE2", "PROTEIN", 109, 113], ["miR-200c-3p", "DNA", 225, 236], ["ACE2", "PROTEIN", 251, 255], ["Ang II", "PROTEIN", 278, 284], ["Ang II type 1 receptor", "PROTEIN", 323, 345], ["H5N1", "PROBLEM", 66, 70], ["LPS", "TEST", 89, 92], ["LTA induced ACE2 reduction", "TREATMENT", 97, 123], ["ALI", "PROBLEM", 161, 164], ["ARDS", "PROBLEM", 165, 169], ["bacterial and viral infections", "PROBLEM", 180, 210], ["the elevated miR", "PROBLEM", 212, 228], ["ACE2 expression", "TEST", 251, 266], ["increased Ang II levels", "PROBLEM", 268, 291], ["lung injury", "PROBLEM", 303, 314], ["H5N1", "OBSERVATION", 66, 70], ["ALI", "OBSERVATION", 161, 164], ["ARDS", "OBSERVATION", 165, 169], ["bacterial", "OBSERVATION_MODIFIER", 180, 189], ["viral infections", "OBSERVATION", 194, 210], ["lung", "ANATOMY", 303, 307], ["injury", "OBSERVATION", 308, 314]]], ["Consistently, blocking the function of miR-200c-3p protects H5N1-infected mice from ALI, indicating miR-200c-3p as a potential therapeutic target.Influenza viruses ::: Materials and MethodsThe influenza viruses A/Jilin/9/2004 (H5N1) and A/New Caledonia/20/1999 (H1N1) were used in this study.", [["miR-200c-3p", "CHEMICAL", 39, 50], ["H5N1-infected", "DISEASE", 60, 73], ["ALI", "DISEASE", 84, 87], ["miR-200c-3p", "CHEMICAL", 100, 111], ["Influenza viruses", "DISEASE", 146, 163], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 39, 50], ["H5N1", "ORGANISM", 60, 64], ["mice", "ORGANISM", 74, 78], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 100, 111], ["Influenza viruses", "ORGANISM", 146, 163], ["influenza viruses", "ORGANISM", 193, 210], ["Jilin/9/2004", "ORGANISM", 213, 225], ["H5N1", "ORGANISM", 227, 231], ["A/New Caledonia", "ORGANISM", 237, 252], ["H1N1", "ORGANISM", 262, 266], ["miR-200c-3p", "DNA", 39, 50], ["miR-200c-3p", "DNA", 100, 111], ["mice", "SPECIES", 74, 78], ["Influenza", "SPECIES", 146, 155], ["mice", "SPECIES", 74, 78], ["Jilin/9/2004 (H5N1", "SPECIES", 213, 231], ["A/New Caledonia/20/1999 (H1N1)", "SPECIES", 237, 267], ["miR", "TEST", 39, 42], ["The influenza viruses", "PROBLEM", 189, 210], ["this study", "TEST", 281, 291], ["ALI", "ANATOMY", 84, 87], ["influenza viruses", "OBSERVATION", 193, 210]]], ["All live influenza virus experiments were performed in biosafety level 3 facilities according to governmental guidelines.Cell culture ::: Materials and MethodsA549 cells (human lung adenocarcinoma epithelial cells) were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in Ham's F12 nutrient medium (HyClone, Logan, UT, USA).", [["Cell", "ANATOMY", 121, 125], ["A549 cells", "ANATOMY", 159, 169], ["lung adenocarcinoma epithelial cells", "ANATOMY", 177, 213], ["Cell", "CELL", 121, 125], ["A549 cells", "CELL", 159, 169], ["human", "ORGANISM", 171, 176], ["lung adenocarcinoma epithelial cells", "CELL", 177, 213], ["A549 cells", "CELL_LINE", 159, 169], ["human lung adenocarcinoma epithelial cells", "CELL_TYPE", 171, 213], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 171, 176], ["ATCC", "SPECIES", 273, 277], ["All live influenza virus experiments", "PROBLEM", 0, 36], ["Cell culture", "TEST", 121, 133], ["MethodsA549 cells (human lung adenocarcinoma epithelial cells", "PROBLEM", 152, 213], ["A549 cells", "OBSERVATION", 159, 169], ["lung", "ANATOMY", 177, 181], ["adenocarcinoma epithelial cells", "OBSERVATION", 182, 213]]], ["HEK293T and THP1 cells were purchased from the Peking Union Medical College Cell Culture Center (Beijing, China).", [["HEK293T", "ANATOMY", 0, 7], ["THP1 cells", "ANATOMY", 12, 22], ["HEK293T", "CELL", 0, 7], ["THP1 cells", "CELL", 12, 22], ["HEK293T", "CELL_LINE", 0, 7], ["THP1 cells", "CELL_LINE", 12, 22], ["HEK293T", "TEST", 0, 7], ["THP1 cells", "TEST", 12, 22], ["THP1 cells", "OBSERVATION", 12, 22]]], ["HEK293T cells were propagated in Dulbecco\u2019s modified Eagle\u2019s medium (HyClone).", [["HEK293T cells", "ANATOMY", 0, 13], ["HEK293T cells", "CELL", 0, 13], ["HyClone", "ORGANISM_SUBSTANCE", 69, 76], ["HEK293T cells", "CELL_LINE", 0, 13], ["HEK293T cells", "PROBLEM", 0, 13]]], ["THP1 cells were cultured in RPMI-1640 medium (HyClone).", [["THP1 cells", "ANATOMY", 0, 10], ["RPMI-1640", "CHEMICAL", 28, 37], ["THP1 cells", "CELL", 0, 10], ["RPMI-1640 medium", "CELL", 28, 44], ["HyClone", "ORGANISM_SUBSTANCE", 46, 53], ["THP1 cells", "CELL_LINE", 0, 10], ["THP1 cells", "TEST", 0, 10], ["RPMI", "TEST", 28, 32]]], ["Cells were cultured in the appropriate medium supplemented with 10% (v v\u22121) fetal bovine serum (Gibco, Grand Island, NY, USA), 100 U ml\u22121 penicillin and 100 U ml\u22121 streptomycin at 37 \u00b0C.miRNA-seq data analysis ::: Materials and MethodsInfected with H1N1 or H5N1 virus (MOI=4) or AF control for 18 h, A549 cells were collected using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA).", [["Cells", "ANATOMY", 0, 5], ["fetal bovine serum", "ANATOMY", 76, 94], ["A549 cells", "ANATOMY", 300, 310], ["penicillin", "CHEMICAL", 138, 148], ["streptomycin", "CHEMICAL", 164, 176], ["H1N1 or H5N1 virus", "DISEASE", 249, 267], ["AF", "DISEASE", 279, 281], ["penicillin", "CHEMICAL", 138, 148], ["streptomycin", "CHEMICAL", 164, 176], ["Cells", "CELL", 0, 5], ["bovine", "ORGANISM", 82, 88], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["Gibco", "ORGANISM_SUBSTANCE", 96, 101], ["penicillin", "SIMPLE_CHEMICAL", 138, 148], ["streptomycin", "SIMPLE_CHEMICAL", 164, 176], ["H5N1 virus", "ORGANISM", 257, 267], ["A549 cells", "CELL", 300, 310], ["A549 cells", "CELL_LINE", 300, 310], ["bovine", "SPECIES", 82, 88], ["H5N1 virus", "SPECIES", 257, 267], ["bovine", "SPECIES", 82, 88], ["H5N1 virus", "SPECIES", 257, 267], ["Cells", "TEST", 0, 5], ["fetal bovine serum", "TEST", 76, 94], ["penicillin", "TREATMENT", 138, 148], ["streptomycin", "TEST", 164, 176], ["H1N1", "PROBLEM", 249, 253], ["H5N1 virus", "PROBLEM", 257, 267], ["MOI", "TEST", 269, 272], ["AF control", "TREATMENT", 279, 289], ["A549 cells", "PROBLEM", 300, 310], ["TRIzol Reagent", "TREATMENT", 332, 346]]], ["Total RNA of the cells was isolated following the standard protocol.", [["cells", "ANATOMY", 17, 22], ["cells", "CELL", 17, 22], ["the standard protocol", "TREATMENT", 46, 67]]], ["RNA libraries were sequenced using an Illumina HiSeq 2500 Platform (Illumina, San Diego, CA, USA) with single-end (SE) 50 nt (SE50), and each sample yielded an average of 20 M reads.", [["SE50", "DNA", 126, 130], ["RNA libraries", "TEST", 0, 13]]], ["The software fastx_toolkit (version: fastx_toolkit_0_0_13) was used to preprocess small RNA-seq raw data.", [["software fastx_toolkit", "DNA", 4, 26]]], ["The software Bowtie2 (version: Bowtie2-2.1.0) and Rfam database (http://rfam.xfam.org/) were used to filter ribosomal RNA or transfer RNA.", [["ribosomal", "CELLULAR_COMPONENT", 108, 117], ["ribosomal RNA", "RNA", 108, 121], ["transfer RNA", "RNA", 125, 137], ["Bowtie2", "TEST", 31, 38], ["ribosomal RNA", "OBSERVATION", 108, 121]]], ["The commands mapper.pl and miRDeep2.pl in the software miRDeep2 (version: miRDeep2_0_0_7) were used for mapping sample reads to the human genome (version hg19, http://hgdownload.cse.ucsc.edu/downloads.html) and detecting conserved miRNA.Quantitative real-time PCR ::: Materials and MethodsFollowing the standard protocol, total RNA was isolated in RNase-free environment using TRIzol Reagent (Invitrogen).", [["miRDeep2", "GENE_OR_GENE_PRODUCT", 27, 35], ["miRDeep2", "GENE_OR_GENE_PRODUCT", 55, 63], ["human", "ORGANISM", 132, 137], ["RNase", "GENE_OR_GENE_PRODUCT", 348, 353], ["mapper.pl", "PROTEIN", 13, 22], ["miRDeep2", "PROTEIN", 27, 35], ["software miRDeep2", "DNA", 46, 63], ["human genome", "DNA", 132, 144], ["version hg19", "DNA", 146, 158], ["conserved miRNA", "DNA", 221, 236], ["RNase", "PROTEIN", 348, 353], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["mapping sample", "TEST", 104, 118], ["the standard protocol", "TREATMENT", 299, 320], ["total RNA", "TREATMENT", 322, 331], ["TRIzol Reagent (Invitrogen)", "TREATMENT", 377, 404], ["miRNA", "ANATOMY", 231, 236]]], ["For gene expression analysis, cDNA was synthesized from 1.5 \u03bcg of total RNA with random primers using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA).", [["cDNA", "CELLULAR_COMPONENT", 30, 34], ["cDNA", "DNA", 30, 34], ["gene expression analysis", "TEST", 4, 28], ["cDNA", "TEST", 30, 34], ["total RNA", "TREATMENT", 66, 75], ["random primers", "TREATMENT", 81, 95], ["the High-Capacity cDNA", "TREATMENT", 102, 124]]], ["For miRNA expression analysis, cDNA was synthesized with stem-looped miRNA-specific reverse transcription primers by using the same kit.", [["cDNA", "CELLULAR_COMPONENT", 31, 35], ["cDNA", "DNA", 31, 35], ["reverse transcription primers", "DNA", 84, 113], ["miRNA expression analysis", "TEST", 4, 29], ["stem-looped miRNA", "TREATMENT", 57, 74]]], ["Amplified products were detected using the FastStart Universal SYBR Green Master Mix II (Roche, Basel, Switzerland) on a LightCycler 480 PCR System (Roche).", [["Amplified products", "TREATMENT", 0, 18]]], ["The relative gene expression levels were normalized to the reference gene, human glyceraldehyde-3-phosphate dehydrogenase (GAPDH).", [["glyceraldehyde-3-phosphate", "CHEMICAL", 81, 107], ["glyceraldehyde-3-phosphate", "CHEMICAL", 81, 107], ["human", "ORGANISM", 75, 80], ["glyceraldehyde-3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 81, 121], ["GAPDH", "GENE_OR_GENE_PRODUCT", 123, 128], ["reference gene", "DNA", 59, 73], ["human glyceraldehyde-3-phosphate dehydrogenase", "PROTEIN", 75, 121], ["GAPDH", "PROTEIN", 123, 128], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["The relative gene expression levels", "TEST", 0, 35], ["human glyceraldehyde-3-phosphate dehydrogenase", "TEST", 75, 121]]], ["The relative miRNA expression levels were normalized to small non-coding RNA U6.", [["U6", "GENE_OR_GENE_PRODUCT", 77, 79], ["small non-coding RNA U6", "RNA", 56, 79], ["The relative miRNA expression levels", "TEST", 0, 36], ["small non-coding RNA U6", "PROBLEM", 56, 79], ["miRNA expression", "OBSERVATION", 13, 29], ["small", "OBSERVATION_MODIFIER", 56, 61], ["non-coding RNA U6", "OBSERVATION", 62, 79]]], ["The specific primers used were synthesized by Invitrogen and listed in Supplementary Table S2.Cell viability assays ::: Materials and MethodsThe A549 cells were infected with H1N1 or H5N1 influenza virus titrated to an MOI of 4 or an equal volume of vehicle.", [["Cell", "ANATOMY", 94, 98], ["A549 cells", "ANATOMY", 145, 155], ["Cell", "CELL", 94, 98], ["A549 cells", "CELL", 145, 155], ["H1N1", "ORGANISM", 175, 179], ["H5N1 influenza virus", "ORGANISM", 183, 203], ["A549 cells", "CELL_LINE", 145, 155], ["H5N1 influenza virus", "SPECIES", 183, 203], ["H5N1 influenza virus", "SPECIES", 183, 203], ["The specific primers", "TREATMENT", 0, 20], ["Cell viability assays", "TEST", 94, 115], ["H1N1", "PROBLEM", 175, 179], ["H5N1 influenza virus", "TREATMENT", 183, 203], ["A549 cells", "OBSERVATION", 145, 155]]], ["Cell viability was determined by an MTT assay (Promega, Madison, WI, USA) at 1, 3, 6, 9, 12, 18, 24 and 36 h postinfection in the A549 cell line.Western blot analysis ::: Materials and MethodsA549 cells were transfected with 50 nM mimics of NC (5\u2032-UUGUACUACACAAAAGUACUG-3\u2032), miR-200c-3p (5\u2032-UAAUACUGCCGGGUAAUGAUGGA-3\u2032) and miR-141-3p (5\u2032-UAACACUGUCUGGUAAAGAUGG-3\u2032), or inhibitors of NC (5\u2032-CAGUACUUUUGUGUAGUACAA-3\u2032), miR-200c-3p (5\u2032-UCCAUCAUUACCCGGCAGUAUUA-3\u2032) and miR-141-3p (5\u2032-CCAUCUUUACCAGACAGUGUUA-3\u2032) for 36 h.", [["Cell", "ANATOMY", 0, 4], ["A549 cell line", "ANATOMY", 130, 144], ["A549 cells", "ANATOMY", 192, 202], ["MTT", "CHEMICAL", 36, 39], ["Cell", "CELL", 0, 4], ["A549 cell line", "CELL", 130, 144], ["A549 cells", "CELL", 192, 202], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 275, 286], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 323, 333], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 417, 428], ["5\u2032-UCCAUCAUUACCCGGCAGUAUUA-3", "GENE_OR_GENE_PRODUCT", 430, 458], ["miR-141-3p", "GENE_OR_GENE_PRODUCT", 465, 475], ["A549 cell line", "CELL_LINE", 130, 144], ["A549 cells", "CELL_LINE", 192, 202], ["miR-200c-3p", "DNA", 275, 286], ["miR-141", "DNA", 323, 330], ["NC (5\u2032-CAGUACUUUUGUGUAGUACAA-3\u2032", "DNA", 383, 414], ["miR-200c-3p (5\u2032-UCCAUCAUUACCCGGCAGUAUUA-3\u2032", "DNA", 417, 459], ["miR-141-3p (5\u2032-CCAUCUUUACCAGACAGUGUUA-3\u2032", "DNA", 465, 505], ["Cell viability", "TEST", 0, 14], ["an MTT assay", "TEST", 33, 45], ["the A549 cell line", "TREATMENT", 126, 144], ["MethodsA549 cells", "TEST", 185, 202], ["NC", "TEST", 241, 243], ["UUGUACUACACAAAAGUACUG", "TEST", 248, 269], ["miR", "TEST", 275, 278], ["UAAUACUGCCGGGUAAUGAUGGA", "TEST", 291, 314], ["miR", "TEST", 323, 326], ["UAACACUGUCUGGUAAAGAUGG", "TEST", 338, 360], ["inhibitors", "TEST", 369, 379], ["NC", "TEST", 383, 385], ["5\u2032-CAGUACUUUUGUGUAGUACAA", "TEST", 387, 411], ["miR", "TEST", 417, 420], ["5\u2032-UCCAUCAUUACCCGGCAGUAUUA", "TEST", 430, 456], ["miR", "TEST", 465, 468], ["5\u2032-CCAUCUUUACCAGACAGUGUUA", "TEST", 477, 502], ["A549 cell line", "OBSERVATION", 130, 144], ["NC", "ANATOMY", 383, 385]]], ["The mimics and inhibitors were synthesized by GenePharma (Shanghai, China).", [["The mimics and inhibitors", "TREATMENT", 0, 25]]], ["Then, the cells were collected with RIPA lysis buffer.", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15], ["RIPA lysis buffer", "TREATMENT", 36, 53]]], ["Protein was detected by western blotting following the procedures described previously [72].", [["Protein", "TEST", 0, 7], ["the procedures", "TEST", 51, 65]]], ["Anti-ACE2 antibody was purchased from Abcam (Cambridge, MA, USA; ab108252).", [["Anti-ACE2 antibody", "PROTEIN", 0, 18], ["Anti-ACE2 antibody", "TEST", 0, 18]]], ["Antibodies against \u03b2-actin (clone AC-15, A5441) and Flag tag (F7425) were purchased from Sigma-Aldrich, St Louis, MO, USA.Luciferase activity assay ::: Materials and MethodsThe wild-type and mutant-type 3\u2032-UTRs of the ACE2 transcript were cloned into the psiCHECK-2 vector (Promega) through the NotI and XhoI restriction enzyme cutting sites. miRNA mimics were transfected into HEK293T cells using Lipofectamine RNAiMAX (Invitrogen).", [["HEK293T cells", "ANATOMY", 378, 391], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 19, 26], ["clone AC-15", "ORGANISM", 28, 39], ["Flag tag", "GENE_OR_GENE_PRODUCT", 52, 60], ["Sigma-Aldrich", "ORGANISM", 89, 102], ["St Louis", "ORGANISM", 104, 112], ["MO", "ORGANISM", 114, 116], ["ACE2", "GENE_OR_GENE_PRODUCT", 218, 222], ["psiCHECK-2", "GENE_OR_GENE_PRODUCT", 255, 265], ["Promega", "GENE_OR_GENE_PRODUCT", 274, 281], ["NotI", "GENE_OR_GENE_PRODUCT", 295, 299], ["XhoI", "GENE_OR_GENE_PRODUCT", 304, 308], ["HEK293T cells", "CELL", 378, 391], ["Lipofectamine RNAiMAX", "SIMPLE_CHEMICAL", 398, 419], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 421, 431], ["\u03b2-actin", "PROTEIN", 19, 26], ["Flag tag", "PROTEIN", 52, 60], ["wild-type and mutant-type 3\u2032-UTRs", "DNA", 177, 210], ["ACE2 transcript", "RNA", 218, 233], ["psiCHECK-2 vector", "DNA", 255, 272], ["NotI and XhoI restriction enzyme cutting sites", "DNA", 295, 341], ["HEK293T cells", "CELL_LINE", 378, 391], ["Antibodies", "TEST", 0, 10], ["\u03b2-actin", "TEST", 19, 26], ["clone AC", "TEST", 28, 36], ["Flag tag", "TEST", 52, 60], ["the ACE2 transcript", "TREATMENT", 214, 233], ["the NotI and XhoI restriction enzyme cutting sites", "TREATMENT", 291, 341], ["miRNA mimics", "PROBLEM", 343, 355], ["Lipofectamine RNAiMAX (Invitrogen)", "TREATMENT", 398, 432]]], ["After 24 h, 1 \u03bcg of wild-type vector or mutant vector was transfected into HEK293T cells using Lipofectamine 2000 (Invitrogen).", [["HEK293T cells", "ANATOMY", 75, 88], ["HEK293T cells", "CELL", 75, 88], ["Invitrogen", "SIMPLE_CHEMICAL", 115, 125], ["wild-type vector", "DNA", 20, 36], ["mutant vector", "DNA", 40, 53], ["HEK293T cells", "CELL_LINE", 75, 88], ["wild-type vector", "TREATMENT", 20, 36], ["mutant vector", "TREATMENT", 40, 53], ["Lipofectamine", "TREATMENT", 95, 108]]], ["At 48 h after transfection of miRNA mimics, relative luciferase activity was calculated according to the manufacturer\u2019s instructions.", [["luciferase", "GENE_OR_GENE_PRODUCT", 53, 63], ["luciferase", "PROTEIN", 53, 63], ["transfection of miRNA mimics", "TREATMENT", 14, 42], ["relative luciferase activity", "PROBLEM", 44, 72]]], ["Wild-type or mutant-type miR-200c-3p mimics were transfected into HEK293T cells using Lipofectamine RNAiMAX (Invitrogen).", [["HEK293T cells", "ANATOMY", 66, 79], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 25, 36], ["HEK293T cells", "CELL", 66, 79], ["Lipofectamine RNAiMAX", "SIMPLE_CHEMICAL", 86, 107], ["Invitrogen", "SIMPLE_CHEMICAL", 109, 119], ["mutant-type miR-200c-3p mimics", "DNA", 13, 43], ["HEK293T cells", "CELL_LINE", 66, 79], ["Lipofectamine RNAiMAX (Invitrogen)", "TREATMENT", 86, 120]]], ["After 24 h, 1 \u03bcg of wild-type vector was transfected into HEK293T cells using Lipofectamine 2000 (Invitrogen).", [["HEK293T cells", "ANATOMY", 58, 71], ["HEK293T cells", "CELL", 58, 71], ["wild-type vector", "DNA", 20, 36], ["HEK293T cells", "CELL_LINE", 58, 71], ["wild-type vector", "TREATMENT", 20, 36], ["Lipofectamine", "TREATMENT", 78, 91]]], ["At 48 h after transfection of miRNA mimics, relative luciferase activity was calculated according to the manufacturer\u2019s instructions.Plasmids ::: Materials and MethodsH5N1 influenza viral protein coding genes, hemagglutinin, NA, NS1, nonstructural protein 2, polymerase complex PA, polymerase complex PB1, polymerase complex PB2, M1, M2 and NP were cloned into the Peak13 vector (provided by B Seed, Harvard Medical School, Boston, MA, USA).", [["luciferase", "GENE_OR_GENE_PRODUCT", 53, 63], ["H5N1 influenza", "ORGANISM", 167, 181], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 210, 223], ["NS1", "GENE_OR_GENE_PRODUCT", 229, 232], ["nonstructural protein 2", "GENE_OR_GENE_PRODUCT", 234, 257], ["polymerase complex PA, polymerase complex PB1, polymerase complex PB2", "GENE_OR_GENE_PRODUCT", 259, 328], ["M1", "GENE_OR_GENE_PRODUCT", 330, 332], ["M2", "GENE_OR_GENE_PRODUCT", 334, 336], ["NP", "GENE_OR_GENE_PRODUCT", 341, 343], ["Peak13", "GENE_OR_GENE_PRODUCT", 365, 371], ["luciferase", "PROTEIN", 53, 63], ["H5N1 influenza viral protein coding genes", "DNA", 167, 208], ["hemagglutinin", "DNA", 210, 223], ["NA", "DNA", 225, 227], ["NS1", "PROTEIN", 229, 232], ["nonstructural protein 2", "PROTEIN", 234, 257], ["polymerase complex PA", "PROTEIN", 259, 280], ["polymerase complex", "PROTEIN", 282, 300], ["PB1", "PROTEIN", 301, 304], ["polymerase complex", "PROTEIN", 306, 324], ["PB2", "PROTEIN", 325, 328], ["M1", "PROTEIN", 330, 332], ["M2", "PROTEIN", 334, 336], ["NP", "PROTEIN", 341, 343], ["Peak13 vector", "DNA", 365, 378], ["H5N1 influenza viral", "SPECIES", 167, 187], ["transfection of miRNA mimics", "TREATMENT", 14, 42], ["relative luciferase activity", "PROBLEM", 44, 72], ["Materials", "PROBLEM", 146, 155], ["Methods", "TEST", 160, 167], ["H5N1 influenza viral protein coding genes", "PROBLEM", 167, 208], ["hemagglutinin", "TEST", 210, 223], ["NA", "TEST", 225, 227], ["NS1", "TEST", 229, 232], ["nonstructural protein", "TEST", 234, 255], ["polymerase complex PA", "TEST", 259, 280], ["polymerase complex PB1", "TEST", 282, 304], ["polymerase complex PB2", "TEST", 306, 328], ["NP", "TEST", 341, 343], ["M1", "ANATOMY", 330, 332], ["M2", "ANATOMY", 334, 336]]], ["Coding genes of NS1 protein of H1N1 and H7N9 influenza virus were also cloned into the Peak13 vector.vRNA, poly (I:C), LPS and LTA experiments ::: Materials and MethodsPoly (I:C) (P0913; Sigma, St Louis, MO, USA) was transfected into A549 cells with Lipofectamine 2000 for 6 h.", [["A549 cells", "ANATOMY", 234, 244], ["LPS", "CHEMICAL", 119, 122], ["Poly", "CHEMICAL", 168, 172], ["I:C", "CHEMICAL", 174, 177], ["poly (I:C)", "CHEMICAL", 107, 117], ["Poly (I:C)", "CHEMICAL", 168, 178], ["P0913", "CHEMICAL", 180, 185], ["NS1", "GENE_OR_GENE_PRODUCT", 16, 19], ["H1N1", "ORGANISM", 31, 35], ["H7N9 influenza virus", "ORGANISM", 40, 60], ["Peak13", "GENE_OR_GENE_PRODUCT", 87, 93], ["LPS", "SIMPLE_CHEMICAL", 119, 122], ["I:C", "SIMPLE_CHEMICAL", 174, 177], ["A549 cells", "CELL", 234, 244], ["NS1 protein", "PROTEIN", 16, 27], ["Peak13 vector", "DNA", 87, 100], ["A549 cells", "CELL_LINE", 234, 244], ["H7N9 influenza virus", "SPECIES", 40, 60], ["H7N9 influenza virus", "SPECIES", 40, 60], ["NS1 protein", "TEST", 16, 27], ["H1N1", "PROBLEM", 31, 35], ["H7N9 influenza virus", "PROBLEM", 40, 60], ["poly (I:C", "TEST", 107, 116], ["LPS", "TEST", 119, 122], ["LTA experiments", "TEST", 127, 142], ["MethodsPoly (I:C", "TEST", 161, 177], ["Lipofectamine", "TREATMENT", 250, 263], ["NS1 protein", "OBSERVATION", 16, 27], ["H1N1", "OBSERVATION", 31, 35]]], ["LPS (from Escherichia coli O111:B4, L4391; Sigma) or LTA (from Staphylococcus aureus, L2515; Sigma) were added to A549 and THP1 cells for 24 h.", [["A549", "ANATOMY", 114, 118], ["THP1 cells", "ANATOMY", 123, 133], ["LPS", "CHEMICAL", 0, 3], ["LTA", "CHEMICAL", 53, 56], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["Escherichia coli", "ORGANISM", 10, 26], ["Sigma", "GENE_OR_GENE_PRODUCT", 43, 48], ["LTA", "GENE_OR_GENE_PRODUCT", 53, 56], ["Staphylococcus aureus", "ORGANISM", 63, 84], ["Sigma", "ORGANISM_SUBSTANCE", 93, 98], ["A549", "CELL", 114, 118], ["THP1 cells", "CELL", 123, 133], ["A549", "CELL_LINE", 114, 118], ["THP1 cells", "CELL_LINE", 123, 133], ["Escherichia coli", "SPECIES", 10, 26], ["Staphylococcus aureus", "SPECIES", 63, 84], ["Escherichia coli", "SPECIES", 10, 26], ["Staphylococcus aureus", "SPECIES", 63, 84], ["LPS", "TEST", 0, 3], ["Escherichia coli", "TEST", 10, 26], ["B4", "TEST", 32, 34], ["LTA", "TEST", 53, 56], ["Staphylococcus aureus", "PROBLEM", 63, 84], ["THP1 cells", "TEST", 123, 133], ["Staphylococcus aureus", "OBSERVATION", 63, 84]]], ["RNA extracted from A549 cells challenged with H1N1 virus, H5N1 virus or AF control was transfected into A549 cells with Lipofectamine 2000 for 12 h.", [["A549 cells", "ANATOMY", 19, 29], ["A549 cells", "ANATOMY", 104, 114], ["A549 cells", "CELL", 19, 29], ["H1N1 virus", "ORGANISM", 46, 56], ["H5N1 virus", "ORGANISM", 58, 68], ["A549 cells", "CELL", 104, 114], ["RNA", "RNA", 0, 3], ["A549 cells", "CELL_LINE", 19, 29], ["A549 cells", "CELL_LINE", 104, 114], ["H1N1 virus", "SPECIES", 46, 56], ["H5N1 virus", "SPECIES", 58, 68], ["H1N1 virus", "SPECIES", 46, 56], ["H5N1 virus", "SPECIES", 58, 68], ["A549 cells", "PROBLEM", 19, 29], ["H1N1 virus", "PROBLEM", 46, 56], ["H5N1 virus", "PROBLEM", 58, 68], ["AF control", "TREATMENT", 72, 82], ["Lipofectamine", "TREATMENT", 120, 133], ["A549 cells", "OBSERVATION", 19, 29], ["H1N1 virus", "OBSERVATION", 46, 56]]], ["Then, RNA and protein samples were collected and analyzed.Clinical specimens ::: Materials and MethodsSevere pneumonia patients were recruited at the Peking Union Medical College Hospital (PUMCH, Beijing, China).", [["samples", "ANATOMY", 22, 29], ["specimens", "ANATOMY", 67, 76], ["pneumonia", "DISEASE", 109, 118], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["RNA and protein samples", "TEST", 6, 29], ["MethodsSevere pneumonia", "PROBLEM", 95, 118], ["Severe", "OBSERVATION_MODIFIER", 102, 108], ["pneumonia", "OBSERVATION", 109, 118]]], ["Healthy volunteers were recruited as controls.", [["volunteers", "ORGANISM", 8, 18]]], ["All participants had written informed consent.", [["participants", "SPECIES", 4, 16]]], ["With the approval of the Institutional Review Board of PUMCH, this study was performed following the ethical guidelines of the 1975 Declaration of Helsinki.", [["this study", "TEST", 62, 72]]], ["The concentration of Ang II in plasma was detected using the ELISA Kit (RapidBio Lab, Calabasas, CA, USA).Plasma miRNA extraction and detection ::: Materials and MethodsmiRNAs were extracted from 400 \u03bcl plasma using an miRNeasy Serum/Plasma Kit (Qiagen, Hilden, Germany).", [["plasma", "ANATOMY", 31, 37], ["\u03bcl plasma", "ANATOMY", 200, 209], ["Ang II", "CHEMICAL", 21, 27], ["Ang II", "GENE_OR_GENE_PRODUCT", 21, 27], ["plasma", "ORGANISM_SUBSTANCE", 31, 37], ["Plasma", "ORGANISM_SUBSTANCE", 106, 112], ["plasma", "ORGANISM_SUBSTANCE", 203, 209], ["Serum", "ORGANISM_SUBSTANCE", 228, 233], ["Plasma", "ORGANISM_SUBSTANCE", 234, 240], ["Ang II", "PROTEIN", 21, 27], ["the ELISA Kit", "TEST", 57, 70], ["Plasma miRNA extraction", "TREATMENT", 106, 129], ["MethodsmiRNAs", "TREATMENT", 162, 175], ["an miRNeasy Serum", "TEST", 216, 233], ["Plasma Kit", "TEST", 234, 244], ["Ang II", "OBSERVATION_MODIFIER", 21, 27]]], ["A synthetic spike-in control, Caenorhabditis elegans miR-39 (cel-miR-39), was added to the lysed samples for internal normalization. cDNA was synthesized using the TaqMan MicroRNA Assays Kit and High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems).", [["samples", "ANATOMY", 97, 104], ["Caenorhabditis elegans", "ORGANISM", 30, 52], ["miR-39", "GENE_OR_GENE_PRODUCT", 53, 59], ["cel-miR-39", "GENE_OR_GENE_PRODUCT", 61, 71], ["Caenorhabditis elegans miR-39", "DNA", 30, 59], ["cel-miR-39", "DNA", 61, 71], ["cDNA", "DNA", 133, 137], ["Caenorhabditis elegans", "SPECIES", 30, 52], ["Caenorhabditis elegans", "SPECIES", 30, 52], ["A synthetic spike", "TEST", 0, 17], ["Caenorhabditis elegans miR", "TEST", 30, 56], ["the TaqMan MicroRNA Assays", "TEST", 160, 186], ["Kit", "TEST", 187, 190], ["High-Capacity cDNA", "TREATMENT", 195, 213], ["synthetic spike", "OBSERVATION", 2, 17], ["normalization", "OBSERVATION", 118, 131]]], ["PCR reactions were performed on a LightCycler 480 PCR system (Roche) using the TaqMan Universal Master Mix II (Applied Biosystems).RNA interference knockdown ::: Materials and MethodsNF-\u03baB p65/RelA-specific siRNA, p50-specific siRNA and nonspecific control siRNA were synthesized by GenePharma.", [["MethodsNF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 176, 192], ["RelA", "GENE_OR_GENE_PRODUCT", 193, 197], ["p50", "GENE_OR_GENE_PRODUCT", 214, 217], ["p65", "PROTEIN", 189, 192], ["RelA", "PROTEIN", 193, 197], ["p50", "PROTEIN", 214, 217], ["PCR reactions", "TEST", 0, 13], ["a LightCycler", "TEST", 32, 45], ["the TaqMan Universal Master Mix II (Applied Biosystems", "TREATMENT", 75, 129], ["Materials", "TEST", 162, 171], ["MethodsNF", "TEST", 176, 185], ["RelA", "TEST", 193, 197], ["specific siRNA", "TEST", 198, 212], ["p50", "TEST", 214, 217], ["specific siRNA", "TREATMENT", 218, 232], ["nonspecific control siRNA", "TREATMENT", 237, 262], ["interference knockdown", "OBSERVATION", 135, 157]]], ["The p65 siRNA duplexes (siRNA1: 5\u2032-GGACAUAUGAGACCUUCAA-3\u2032; siRNA2: 5\u2032-CUUCCAAGUUCCUAUAGAA-3\u2032), the p50 siRNA (5\u2032-CGCCAUCUAUGACAGUAAAUU-3\u2032) or a control siRNA were transfected into cells (with a final concentration as 100 \u03bcM) with Lipofectamine RNAiMAX (Invitrogen) for 24 h, and then subsequent experiments were performed.Inhibition of NF-\u03baB transcriptional activity ::: Materials and MethodsCAPE (S7414) and JSH-23 (S7351) were purchased from Selleck Chemicals (Houston, TX, USA) and resolved in dimethyl sulfoxide.", [["cells", "ANATOMY", 180, 185], ["RNAiMAX", "CHEMICAL", 244, 251], ["JSH-23", "CHEMICAL", 409, 415], ["S7351", "CHEMICAL", 417, 422], ["dimethyl sulfoxide", "CHEMICAL", 497, 515], ["JSH-23", "CHEMICAL", 409, 415], ["dimethyl sulfoxide", "CHEMICAL", 497, 515], ["p65", "GENE_OR_GENE_PRODUCT", 4, 7], ["p50", "GENE_OR_GENE_PRODUCT", 99, 102], ["cells", "CELL", 180, 185], ["RNAiMAX", "SIMPLE_CHEMICAL", 244, 251], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 336, 341], ["JSH-23", "SIMPLE_CHEMICAL", 409, 415], ["S7351", "SIMPLE_CHEMICAL", 417, 422], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 497, 515], ["p65", "PROTEIN", 4, 7], ["p50 siRNA", "DNA", 99, 108], ["NF-\u03baB", "PROTEIN", 336, 341], ["JSH-23", "SPECIES", 409, 415], ["The p65 siRNA duplexes", "TEST", 0, 22], ["siRNA1", "TEST", 24, 30], ["\u2032", "TEST", 33, 34], ["GGACAUAUGAGACCUUCAA", "TEST", 35, 54], ["siRNA2", "TEST", 59, 65], ["CUUCCAAGUUCCUAUAGAA", "TEST", 70, 89], ["the p50 siRNA", "TEST", 95, 108], ["CGCCAUCUAUGACAGUAAAUU", "TEST", 113, 134], ["a control siRNA", "TREATMENT", 142, 157], ["Lipofectamine RNAiMAX (Invitrogen)", "TREATMENT", 230, 264], ["MethodsCAPE", "TEST", 385, 396], ["JSH", "TEST", 409, 412], ["dimethyl sulfoxide", "TREATMENT", 497, 515], ["siRNA duplexes", "OBSERVATION", 8, 22]]], ["CAPE and JSH-23 were added to cells (with a final concentration of 75 and 100 \u03bcM, respectively) for 2 h, and then subsequent experiments were performed.In vivo experiments ::: Materials and MethodsWild-type C57BL/6 mice were purchased from Vital River (Beijing, China).", [["cells", "ANATOMY", 30, 35], ["CAPE", "CHEMICAL", 0, 4], ["JSH-23", "CHEMICAL", 9, 15], ["CAPE", "CHEMICAL", 0, 4], ["JSH-23", "CHEMICAL", 9, 15], ["CAPE", "SIMPLE_CHEMICAL", 0, 4], ["JSH-23", "SIMPLE_CHEMICAL", 9, 15], ["cells", "CELL", 30, 35], ["MethodsWild-type C57BL/6 mice", "ORGANISM", 190, 219], ["mice", "SPECIES", 215, 219], ["mice", "SPECIES", 215, 219], ["JSH", "TEST", 9, 12], ["MethodsWild", "TEST", 190, 201]]], ["Antagomirs of NC (5\u2032-CAGUACUUUUGUGUAGUACAA-3\u2032) and miR-200c-3p (5\u2032-UCCAUCAUUACCCGGCAGUAUUA-3\u2032) (10 mg kg\u22121; GenePharma) were intraperitoneally injected into C57BL/6 mice 24 h before, and 6 and 24 h after intratracheal instillation of H5N1 virus.", [["miR-200c-3p", "CHEMICAL", 51, 62], ["miR-200c", "GENE_OR_GENE_PRODUCT", 51, 59], ["C57BL/6 mice", "ORGANISM", 157, 169], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 204, 217], ["H5N1 virus", "ORGANISM", 234, 244], ["mice", "SPECIES", 165, 169], ["mice", "SPECIES", 165, 169], ["H5N1 virus", "SPECIES", 234, 244], ["Antagomirs", "TEST", 0, 10], ["NC", "TEST", 14, 16], ["CAGUACUUUUGUGUAGUACAA", "TEST", 21, 42], ["intratracheal instillation", "TREATMENT", 204, 230], ["H5N1 virus", "PROBLEM", 234, 244], ["NC", "ANATOMY", 14, 16], ["H5N1 virus", "OBSERVATION", 234, 244]]], ["At 3 days postinfection, the mice were killed, and lung injury was assessed as described previously [16].", [["lung", "ANATOMY", 51, 55], ["lung injury", "DISEASE", 51, 62], ["mice", "ORGANISM", 29, 33], ["lung", "ORGAN", 51, 55], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["lung injury", "PROBLEM", 51, 62], ["lung", "ANATOMY", 51, 55], ["injury", "OBSERVATION", 56, 62]]], ["For the assessment of survival rates, virus replication and Ang II, antagomirs of NC and miR-200c-3p (5\u2032-UCCAUCAUUACCCGGCAGUAUUA-3\u2032) (20 mg kg\u22121; RiboBio, Guangzhou, China) were intraperitoneally injected into C57BL/6 mice 1, 24 and 48 h after intratracheal instillation of H5N1 virus.", [["Ang II", "CHEMICAL", 60, 66], ["Ang II", "GENE_OR_GENE_PRODUCT", 60, 66], ["miR-200c-3p", "GENE_OR_GENE_PRODUCT", 89, 100], ["C57BL/6 mice", "ORGANISM", 210, 222], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 244, 257], ["H5N1 virus", "ORGANISM", 274, 284], ["Ang II", "PROTEIN", 60, 66], ["mice", "SPECIES", 218, 222], ["mice", "SPECIES", 218, 222], ["H5N1 virus", "SPECIES", 274, 284], ["the assessment", "TEST", 4, 18], ["survival rates", "TREATMENT", 22, 36], ["virus replication", "TREATMENT", 38, 55], ["NC", "TREATMENT", 82, 84], ["intratracheal instillation", "TREATMENT", 244, 270], ["H5N1 virus", "PROBLEM", 274, 284], ["H5N1 virus", "OBSERVATION", 274, 284]]], ["The animal experiments were performed in the Institute of Military Veterinary Medicine, Academy of Military Medical Sciences following governmental and institutional guidelines.Statistical analysis ::: Materials and MethodsUnpaired t-tests were used for the cell culture and luciferase reporter assay data analysis.", [["cell", "ANATOMY", 258, 262], ["cell", "CELL", 258, 262], ["luciferase", "GENE_OR_GENE_PRODUCT", 275, 285], ["MethodsUnpaired t-tests", "TEST", 216, 239], ["the cell culture", "TEST", 254, 270], ["luciferase reporter assay data analysis", "TEST", 275, 314]]], ["Pearson's correlation analysis was used to analyze the relationship between miRNAs and virus-infected cell viability or viral replication.", [["cell", "ANATOMY", 102, 106], ["cell", "CELL", 102, 106], ["Pearson's correlation analysis", "TEST", 0, 30], ["miRNAs and virus", "PROBLEM", 76, 92], ["infected cell viability", "PROBLEM", 93, 116], ["viral replication", "TREATMENT", 120, 137], ["infected cell viability", "OBSERVATION", 93, 116], ["viral replication", "OBSERVATION", 120, 137]]], ["The Mann\u2013Whitney U-test was used for the analysis of clinical data.", [["The Mann\u2013Whitney U-test", "TEST", 0, 23], ["the analysis", "TEST", 37, 49], ["clinical data", "TEST", 53, 66]]], ["All statistical tests were calculated using GraphPad Prism 5.0 (La Jolla, CA, USA).", [["All statistical tests", "TEST", 0, 21], ["GraphPad Prism", "TEST", 44, 58]]], ["A two-tailed P-value <0.05 was considered statistically significant.", [["A two-tailed P-value", "TEST", 0, 20]]]], "efdc5d569bff1bbf7b2233e6b3a84a0c61a10d17": [["INTRODUCTIONIt is commonly assumed that older persons have largely been spared the effects of the Great Recession.", [["persons", "ORGANISM", 46, 53], ["persons", "SPECIES", 46, 53], ["Great", "OBSERVATION_MODIFIER", 98, 103], ["Recession", "OBSERVATION", 104, 113]]], ["1 Rising unemployment and stagnating wages-two major consequences of the economic crisis-would not be expected to have directly undermined pensioners' financial security, although there is some evidence that retirees now provide greater financial support to their younger relatives.", [["the economic crisis", "PROBLEM", 69, 88]]], ["2 Austere welfare measures have been concentrated on working-age adults, 3 largely for political reasons.INTRODUCTIONDespite apparently being spared the worst of austerity policies, there is cause for concern.", [["Austere welfare measures", "TREATMENT", 2, 26]]], ["Since the onset of the Great Recession, unmet need for medical care-a comparative measure of healthcare access defined as being unable to obtain care when the person believed it to be medically necessaryhas been increasing in many European countries, especially in persons aged 65 or older.", [["persons", "ORGANISM", 265, 272], ["person", "SPECIES", 159, 165], ["persons", "SPECIES", 265, 272], ["medical care", "TREATMENT", 55, 67], ["Great", "OBSERVATION_MODIFIER", 23, 28], ["Recession", "OBSERVATION", 29, 38]]], ["Increasing unmet medical need, while potentially reducing spending in the short term, might increase future healthcare costs because treatment is postponed.", [["treatment", "TREATMENT", 133, 142]]], ["6 Moreover, the increase in unmet need is taking place at a time when many European countries are cutting budgets for social care.", [["increase", "OBSERVATION_MODIFIER", 16, 24]]], ["One possibility is that older people may face barriers to accessing health facilities, for example, because of the cost or availability of transport, especially if public pensions have failed to keep pace with living costs.", [["people", "ORGANISM", 30, 36], ["people", "SPECIES", 30, 36]]], ["8 Although in recent years public pensions have avoided the brunt of budget cuts, over the last decade, pensioners have actually faced various forms of retrenchment in pension spending in some European countries so that, in 2013, the Organisation for Economic Co-operation and Development (OECD) expressed concern that raising state retirement ages and freezing (and, in some case, cutting) public pensions any further would negatively influence older persons' financial security.", [["persons", "SPECIES", 452, 459]]], ["9 The magnitude of this retrenchment has been obscured, in data on aggregate spending, by the increase in the number of pensioners during this same period, so that total expenditure on public pensions has risen.", [["magnitude", "OBSERVATION_MODIFIER", 6, 15], ["retrenchment", "OBSERVATION", 24, 36], ["obscured", "OBSERVATION_MODIFIER", 46, 54], ["increase", "OBSERVATION_MODIFIER", 94, 102]]], ["Greece's reforms have been particularly severe.", [["Greece's reforms", "TREATMENT", 0, 16], ["severe", "OBSERVATION_MODIFIER", 40, 46]]], ["The distributional effect of these reforms vary across countries, with reforms reducing replacement rates among some of the poorest groups in some (the UK) but not all (Italy) countries.", [["reforms reducing replacement rates", "TREATMENT", 71, 105], ["distributional", "OBSERVATION_MODIFIER", 4, 18], ["effect", "OBSERVATION_MODIFIER", 19, 25]]], ["9 In short, reduced public pension entitlement may reduce the ability to pay for the various costs involved in seeking healthcare and in keeping healthy and staying independent, particularly for those at the bottom of the income distribution.", [["short", "OBSERVATION_MODIFIER", 5, 10]]], ["[10] [11] [12] Reduced public pension entitlements may also reduce access to care among those not of pension age.", [["Reduced public pension entitlements", "TREATMENT", 15, 50]]], ["Financial transfers from older people to their children and grandchildren have increased over time and such transfers directly impact health outcomes in some contexts.", [["people", "ORGANISM", 31, 37], ["children", "ORGANISM", 47, 55], ["people", "SPECIES", 31, 37], ["children", "SPECIES", 47, 55]]], ["2 13 Cuts to public pensions may therefore also put additional financial pressure on low-wage workers, potentially reducing access to care.", [["financial pressure on low-wage workers", "TREATMENT", 63, 101]]], ["5 Any such problems have only been compounded by greater user charges, which have increased the cost of pharmaceuticals, outpatient care and accident and emergency (A&E) visits in some countries.", [["Any such problems", "PROBLEM", 2, 19]]], ["14 Even where older people are insured, out-of-pocket payments deter them from accessing the care they believe they need.", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26]]], ["5 15 In 2009-2010, user charges for prescription drugs and dentistry in the UK's National Health Service generated around \u00a31 billion a year.", [["prescription drugs", "TREATMENT", 36, 54]]], ["Even though exemptions exist for children, older people and people on low incomes, these charges have been described as a 'mess' in part because they still create financial barriers to access for these economically vulnerable groups.", [["children", "ORGANISM", 33, 41], ["people", "ORGANISM", 49, 55], ["people", "ORGANISM", 60, 66], ["children", "SPECIES", 33, 41], ["people", "SPECIES", 49, 55], ["people", "SPECIES", 60, 66]]], ["15 17 User charges were increased for inpatient care in France in 2010 and other charges were increased for outpatient prescription drugs and primary care during this same period.", [["User charges", "TREATMENT", 6, 18], ["outpatient prescription drugs", "TREATMENT", 108, 137], ["primary care", "TREATMENT", 142, 154]]], ["16 Yet while, in theory, user charges may encourage people to be more discerning in choosing healthcare services, 20 there is considerable evidence that most are unable to make such complex decisions and so reduce necessary and unnecessary healthcare, particularly low-income patients.", [["people", "ORGANISM", 52, 58], ["patients", "ORGANISM", 276, 284], ["people", "SPECIES", 52, 58], ["patients", "SPECIES", 276, 284]]], ["While some studies have been too short to document the health effects of such decisions, there is evidence that substantial rises in unmet medical need can adversely affect health.", [["some studies", "TEST", 6, 18], ["substantial rises", "PROBLEM", 112, 129], ["substantial", "OBSERVATION_MODIFIER", 112, 123], ["rises", "OBSERVATION_MODIFIER", 124, 129]]], ["Longitudinal data over 6 years from the USA found that greater access to care among those insured increased survival chances and reduced the likelihood of transitioning into disability by roughly 30%.", [["disability", "DISEASE", 174, 184], ["increased survival chances", "PROBLEM", 98, 124]]], ["25 Wang and colleagues find that in 2003, when healthcare usage decreased because of fear of contracting severe acute respiratory syndrome (SARS) when visiting health facilities, mortality from diabetes mellitus and cerebrovascular diseases significantly increased by 8.4% and 6.2%, respectively.", [["cerebrovascular", "ANATOMY", 216, 231], ["acute respiratory syndrome", "DISEASE", 112, 138], ["SARS", "DISEASE", 140, 144], ["diabetes mellitus", "DISEASE", 194, 211], ["cerebrovascular diseases", "DISEASE", 216, 240], ["cerebrovascular", "ANATOMICAL_SYSTEM", 216, 231], ["contracting severe acute respiratory syndrome", "PROBLEM", 93, 138], ["diabetes mellitus", "PROBLEM", 194, 211], ["cerebrovascular diseases", "PROBLEM", 216, 240], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["respiratory syndrome", "OBSERVATION", 118, 138], ["cerebrovascular", "ANATOMY", 216, 231], ["diseases", "OBSERVATION", 232, 240]]], ["26 Of course, unmet medical needs may have long-term consequences that are difficult to assess, such as if cancer is undiagnosed.", [["cancer", "ANATOMY", 107, 113], ["cancer", "DISEASE", 107, 113], ["cancer", "CANCER", 107, 113], ["long-term consequences", "PROBLEM", 43, 65], ["cancer", "PROBLEM", 107, 113], ["undiagnosed", "PROBLEM", 117, 128], ["cancer", "OBSERVATION", 107, 113]]], ["6 Given the potential health consequences of rising unmet medical need, we test the hypothesis that greater public pension entitlement reduces unmet medical need in older persons during the Great Recession.", [["persons", "ORGANISM", 171, 178], ["persons", "SPECIES", 171, 178], ["Great", "OBSERVATION_MODIFIER", 190, 195], ["Recession", "OBSERVATION", 196, 205]]], ["We also test a number of subhypotheses that the association between public pensions and unmet medical need will be greater (i) for poorest income groups and (ii) in countries where there is a high reliance on out-of-pocket spending.", [["a high reliance", "PROBLEM", 190, 205]]], ["Finally, because greater public pension entitlements also benefit people who are not of pension age, 13 we test whether public pension entitlements may have spillover effects for access to care among those not of pension age, hypothesising that public pensions will also reduce unmet medical need among working-age populations but to a lesser extent.Data and methodWe collected data from 16 European countries (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the UK) between 2004 and 2010 from EuroStat and the Comparative Welfare Entitlements Dataset (CWED).", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72], ["methodWe collected data", "TEST", 359, 382], ["lesser extent", "OBSERVATION_MODIFIER", 336, 349]]], ["27 Data on unmet medical need due to cost are from EuroStat 2014 edition, which derive from nationally representative individual-level surveys (EU Statistics on Income and Living Conditions, EU-SILC).", [["SILC", "ANATOMY", 194, 198]]], ["28 EU-SILC survey participants are asked: 'Was there any time during the last twelve months when, in your opinion, you personally needed a medical examination or treatment for a health problem but you did not receive it?'.", [["participants", "ORGANISM", 18, 30], ["participants", "SPECIES", 18, 30], ["a medical examination", "TEST", 137, 158], ["treatment", "TREATMENT", 162, 171]]], ["As a falsification test, we examine data on unmet medical need for other reasons (not cost related).", [["a falsification test", "TEST", 3, 23]]], ["All other macroeconomic data, including gross domestic product (GDP) and government health spending per capita, were adjusted for inflation and purchasing power, and taken from EuroStat.", [["inflation", "TREATMENT", 130, 139]]], ["Welfare entitlement is composed of three separate measures, including entitlement to public pensions, sickness benefit and unemployment benefit.", [["sickness", "PROBLEM", 102, 110]]], ["It is calculated by combining country-year observations of (1) minimum income replacement rate of the public pension, (2) the average income replacement rate of all pensions, (3) the expected duration of the pension, (4) the number of years of insurance needed for a standard pension, (5) a measure of the ratio of the proportion of employee to employee-plus-employer contributions for the pension and (6) an estimate of the portion of those above retirement age who are in receipt of a public pension.", [["minimum income replacement rate of the public pension", "TREATMENT", 63, 116], ["the average income replacement rate of all pensions", "TREATMENT", 122, 173], ["a standard pension", "TREATMENT", 265, 283]]], ["Measuring pension entitlement in this way (eg, public pension) also allows us to observe whether changes in income due to state pensions reduce inequalities in unmet medical need across income groups.", [["Measuring pension entitlement", "TREATMENT", 0, 29]]], ["Throughout the study period, most of the variation in public pension entitlement was attributable to changes in the minimum income replacement rate of pensions and, to some extent, the standard replacement rate, suggesting that changes were primarily driven by the amount received.", [["the minimum income replacement rate of pensions", "TREATMENT", 112, 159], ["the standard replacement rate", "TREATMENT", 181, 210]]], ["For this measure, a 1-unit change in public pension entitlement is the equivalent of a 10 percentage-point increase in the minimum income replacement rate, something Ireland implemented between 2005 and 2007.", [["a 1-unit change in public pension entitlement", "TREATMENT", 18, 63], ["the minimum income replacement rate", "TREATMENT", 119, 154], ["increase", "OBSERVATION_MODIFIER", 107, 115]]], ["Comparable measures of unmet medical need are only available from EuroStat from 2004 onward, via the EU-SILC, and comparable measures of public pension generosity are only available up to 2010 for OECD countries included in the dataset created by Scruggs and colleagues.", [["SILC", "ANATOMY", 104, 108]]], ["These constraints define our analytic sample.Data and methodTo address our research questions, we estimate an ecological model of the association between public pension entitlement and unmet medical need.", [["our analytic sample", "TEST", 25, 44], ["public pension entitlement", "TREATMENT", 154, 180]]], ["We do not estimate a multilevel model (including individual-level predictors) because public pension entitlements are largely independent of individual covariates.", [["a multilevel model", "PROBLEM", 19, 37]]], ["We test this assumption as part of our sensitivity tests described below.", [["our sensitivity tests", "TEST", 35, 56]]], ["As a falsification test, we examine the association between public pensions and unmet medical need for other reasons.Data and methodPension is a measure of public pension entitlement.", [["a falsification test", "TEST", 3, 23]]], ["Sick is a measure of welfare entitlement to those who experience medium-term or long-term sickness and are unable to work, which is available to pensioners in some countries.", [["long-term sickness", "PROBLEM", 80, 98]]], ["Unemployment is a measure of welfare entitlement for those who are unemployed, which captures the degree of decommodification in a given society and reflects the strength of the social safety net and is also a proxy for the decommodification of healthcare provision.", [["Unemployment", "DISEASE", 0, 12]]], ["GDP measures change in GDP per capita over time, adjusted for inflation and purchasing power, capturing the real value of the average level of individual income.Data and methodHealth is a measure of total government health spending per capita, also adjusted for inflation and purchasing power.", [["GDP", "CHEMICAL", 0, 3], ["GDP", "CHEMICAL", 23, 26], ["GDP", "CHEMICAL", 0, 3], ["GDP", "SIMPLE_CHEMICAL", 0, 3], ["GDP", "SIMPLE_CHEMICAL", 23, 26], ["GDP measures change", "PROBLEM", 0, 19], ["inflation", "TREATMENT", 62, 71], ["GDP", "OBSERVATION_MODIFIER", 23, 26]]], ["Finally, Private includes a measure of private pensions from the OECD, which includes mandatory and voluntary contributions, which may predict access to healthcare.", [["the OECD", "TEST", 61, 69]]], ["13 29 30 This indicator is not directly comparable with our measure of public pension entitlement but does capture alternative sources of income for pension citizens.", [["public pension entitlement", "TREATMENT", 71, 97], ["pension citizens", "TREATMENT", 149, 165]]], ["27 m is a country-specific indicator which captures differences between countries that remain relatively stable over time.Data and methodThese so-called fixed-effects models remove between-country differences and examine only the change within countries over time.", [["relatively", "OBSERVATION_MODIFIER", 94, 104], ["stable", "OBSERVATION", 105, 111]]], ["In those models where we specifically examine the unmet medical need of older persons (65+), we also include a measure of the proportion of the older population who self-report a chronic illness as this will capture changes in medical need over time.", [["chronic illness", "DISEASE", 179, 194], ["persons", "ORGANISM", 78, 85], ["persons", "SPECIES", 78, 85], ["a chronic illness", "PROBLEM", 177, 194], ["chronic", "OBSERVATION_MODIFIER", 179, 186], ["illness", "OBSERVATION", 187, 194]]], ["This is also taken from EuroStat and drawn from the EU-SILC data, which asks respondents whether they 'suffer from any chronic (long-standing) illness or condition'.", [["illness", "DISEASE", 143, 150], ["any chronic (long-standing) illness or condition'", "PROBLEM", 115, 164], ["chronic", "OBSERVATION_MODIFIER", 119, 126]]], ["Finally, to test whether any association between public pensions and unmet medical due to cost is moderated by the extent of out-of-pocket payments, we include a measure of out-of-pocket payments for healthcare (measured as a proportion of GDP) into equation 1 and an interaction term between this measure of out-of-pocket payments and our measure of pension entitlements.", [["pocket payments", "TREATMENT", 316, 331]]], ["Descriptive statistics for these variables are in web appendix 1.", [["appendix", "ANATOMY", 54, 62]]], ["All models were estimated using STATA V.12.RESULTSDoes greater public pension entitlement reduce unmet medical need among older persons?RESULTSFirst, we examined the effect of public pension entitlement on those who were over the age of 65 (table 1) .", [["persons", "ORGANISM", 128, 135], ["persons", "SPECIES", 128, 135]]], ["In these models, we include a measure of the proportion of the population over the age of 65 that has a chronic illness.", [["chronic illness", "DISEASE", 104, 119], ["a chronic illness", "PROBLEM", 102, 119], ["chronic", "OBSERVATION_MODIFIER", 104, 111], ["illness", "OBSERVATION", 112, 119]]], ["A 1-unit increase in public pension entitlement (the equivalent of 10 percentage-point increase in the minimum income replacement rate) is associated with a 1.11 percentage-point decline in unmet medical need among over 65s (95% CI \u22120.55 to \u22121.66).", [["public pension entitlement", "TREATMENT", 21, 47], ["the minimum income replacement rate", "TREATMENT", 99, 134], ["CI", "TEST", 229, 231], ["1-unit", "OBSERVATION_MODIFIER", 2, 8], ["increase", "OBSERVATION_MODIFIER", 9, 17]]], ["There is no clear association between unmet medical need and sickness insurance entitlement ( p=0.55), unemployment insurance entitlement ( p=0.57), government expenditure on health (p=0.13) or the proportion of older persons who report living with chronic illnesses ( p=0.60).", [["chronic illnesses", "DISEASE", 249, 266], ["persons", "ORGANISM", 218, 225], ["persons", "SPECIES", 218, 225], ["chronic illnesses", "PROBLEM", 249, 266], ["no", "UNCERTAINTY", 9, 11]]], ["An increase in GDP tends to reduce unmet medical need (b=\u22120.03, p=0.08), but the association is not significant at the \u03b1=0.05 level.", [["GDP", "CHEMICAL", 15, 18], ["GDP", "CHEMICAL", 15, 18], ["GDP", "SIMPLE_CHEMICAL", 15, 18], ["An increase in GDP", "PROBLEM", 0, 18], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["GDP", "OBSERVATION_MODIFIER", 15, 18], ["significant", "OBSERVATION_MODIFIER", 100, 111]]], ["Private pensions play an important role in many European countries, and so we include a measure of private pension expenditure (incorporating mandatory and voluntary contributions) as a percentage of GDP from the OECD.", [["GDP", "CHEMICAL", 200, 203], ["GDP", "CHEMICAL", 200, 203], ["GDP", "SIMPLE_CHEMICAL", 200, 203]]], ["This is consistent with previous work finding that basic pensions (but not earnings-related pensions) reduce premature mortality among the elderly.", [["premature mortality", "PROBLEM", 109, 128], ["consistent with", "UNCERTAINTY", 8, 23]]], ["10 Does greater public pension entitlement reduce inequalities in access to healthcare?RESULTSNext, we tested whether the benefits of public pension entitlement were greater in older persons who were in the lowest income quintile.", [["persons", "ORGANISM", 183, 190], ["persons", "SPECIES", 183, 190], ["public pension entitlement", "TREATMENT", 134, 160]]], ["As shown in Model 1 in web appendix 3, each 1-unit increase in public pension entitlement is estimated to reduce unmet medical need by 1.65 percentage points (95% CI \u22121.19 to \u22122.10).RESULTSIf the benefits of public pension entitlement are greatest in older persons in the poorest income quintile, then it would be expected that public pension entitlement may reduce inequalities in access to healthcare.", [["persons", "ORGANISM", 257, 264], ["persons", "SPECIES", 257, 264], ["public pension entitlement", "TREATMENT", 63, 89], ["CI", "TEST", 163, 165], ["public pension entitlement", "TREATMENT", 208, 234], ["public pension entitlement", "TREATMENT", 328, 354]]], ["To test this, we estimate the association between public pension entitlement and unmet medical need (specifically due to cost) in the remaining four income quintiles.", [["public pension entitlement", "TREATMENT", 50, 76]]], ["Web appendix 3 reports the estimates for all of these five separate models.", [["appendix", "OBSERVATION", 4, 12]]], ["In contrast to the poorest income quintile, the association between public pension entitlement and unmet medical need due to cost in the wealthiest quintile is not significantly different from zero (0.03, 95% CI \u22120.16 to 0.21).", [["public pension entitlement", "TREATMENT", 68, 94], ["CI", "TEST", 209, 211], ["significantly different", "OBSERVATION_MODIFIER", 164, 187]]], ["As shown in figure 1 , the association between public pension entitlement and reductions in unmet medical need becomes progressively attenuated at higher points in the income distribution so that, at the top quintile, there is no significant relationship ( p=0.73; figure 1) .RESULTSOne mechanism linking public pension entitlement and unmet medical need is the financial cost of accessing healthcare, which is mitigated by generous public pensions.", [["public pension entitlement", "TREATMENT", 47, 73], ["reductions", "OBSERVATION_MODIFIER", 78, 88], ["progressively", "OBSERVATION_MODIFIER", 119, 132], ["attenuated", "OBSERVATION_MODIFIER", 133, 143], ["higher points", "OBSERVATION_MODIFIER", 147, 160], ["no", "UNCERTAINTY", 227, 229], ["significant", "OBSERVATION_MODIFIER", 230, 241]]], ["Given cross-national variation in the commodification of healthcare, we anticipate that the influence of public pension entitlement on unmet medical need would be greatest in countries where out-of-pocket payments are high.", [["public pension entitlement", "TREATMENT", 105, 131]]], ["It does not include direct payment to corporations and therefore predominantly captures the amount spent on user charges, deductibles and patient's direct payments.", [["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 138, 145], ["amount", "OBSERVATION_MODIFIER", 92, 98]]], ["To test this mechanism, we re-estimate our model but include an interaction term between public pension entitlement and out-of-pocket payments as a proportion of GDP.", [["GDP", "CHEMICAL", 162, 165], ["GDP", "CHEMICAL", 162, 165], ["GDP", "SIMPLE_CHEMICAL", 162, 165], ["public pension entitlement", "TREATMENT", 89, 115], ["GDP", "OBSERVATION", 162, 165]]], ["The average level of out-of-pocket expenditure as a proportion of GDP was 1.69%, the minimum was 0.63% and the maximum was 3.49%.", [["GDP", "CHEMICAL", 66, 69], ["GDP", "CHEMICAL", 66, 69], ["GDP", "SIMPLE_CHEMICAL", 66, 69], ["GDP", "TEST", 66, 69], ["average", "OBSERVATION_MODIFIER", 4, 11]]], ["We find that public pension entitlement mitigates the influence of out-of-pocket payments on unmet medical need due to cost (\u03b2=\u22121.21 percentage points, 95% CI \u22120.37 to \u22122.06) (figure 2).", [["cost", "TEST", 119, 123], ["CI", "TEST", 156, 158]]], ["In contrast, if we re-estimate this interaction between out-of-pocket payments and public pension entitlements among the working-age population (ages 16-64), there is no longer a clear association between these variables and unmet medical need ( p=0.13), giving our findings greater specificity.", [["public pension entitlements", "TREATMENT", 83, 110], ["no longer", "UNCERTAINTY", 167, 176], ["clear", "OBSERVATION", 179, 184]]], ["In short, public pensions reduce unmet medical need but only in countries with high levels of out-of-pocket payments (3% of GDP), whereas in countries where out-of-pocket payments are low (1% of GDP) they have no effect.Does greater public pension entitlement have spillover effects for other age groups?Pensioners may share their income with non-pensioners because they are married to or living with people who are working-age non-pensioners.", [["GDP", "CHEMICAL", 195, 198], ["GDP", "SIMPLE_CHEMICAL", 195, 198], ["people", "ORGANISM", 401, 407], ["people", "SPECIES", 401, 407], ["no", "UNCERTAINTY", 210, 212]]], ["Previous work finds that pension generosity improves the health of children in the same household.", [["children", "ORGANISM", 67, 75], ["children", "SPECIES", 67, 75]]], ["13 To examine whether public pension entitlement has any spillover effects for those not yet 65, we examined the association between increased welfare entitlement (including public pension, sickness and unemployment), economic growth and government health spending on unmet medical needs for those aged 16-64 (table 2) .", [["sickness", "DISEASE", 190, 198], ["any spillover effects", "PROBLEM", 53, 74], ["sickness", "PROBLEM", 190, 198]]], ["A 1-unit increase in public pension entitlement (the equivalent of a 10 percentage-point increase in the minimum income replacement rate) is associated with a 0.56 percentage-point decline in unmet medical need due to cost for these younger age groups (95% CI \u22120.043 to \u22121.07).", [["public pension entitlement", "TREATMENT", 21, 47], ["the minimum income replacement rate", "TREATMENT", 101, 136], ["CI", "TEST", 257, 259], ["1-unit", "OBSERVATION_MODIFIER", 2, 8], ["increase", "OBSERVATION_MODIFIER", 9, 17]]], ["Welfare entitlement for those receiving sickness and disability support ( p=0.63) or unemployment benefit ( p=0.71) had no association with unmet medical need.", [["sickness and disability", "DISEASE", 40, 63], ["sickness and disability support", "TREATMENT", 40, 71]]], ["Similarly, there was no clear relationship between government health spending on health and unmet medical need ( p=0.45).", [["no", "UNCERTAINTY", 21, 23]]], ["A purchasing power parity (PPP)$100 increase in GDP per capita was associated with a 0.022 percentage-point decline in unmet medical need (95% CI 0.0032 to \u22120.048); suggesting growth in real incomes may reduce barriers to accessing healthcare for these younger age groups.", [["GDP", "CHEMICAL", 48, 51], ["GDP", "SIMPLE_CHEMICAL", 48, 51], ["A purchasing power parity (PPP)", "TREATMENT", 0, 31], ["CI", "TEST", 143, 145], ["increase", "OBSERVATION_MODIFIER", 36, 44]]], ["Again, our measure of private pensions is not associated with changes in unmet medical need ( p=0.59).Sensitivity analysesAs a falsification test, we evaluated outcomes which would not plausibly be linked with public pension entitlement.", [["a falsification test", "TEST", 125, 145], ["public pension entitlement", "TREATMENT", 210, 236], ["not associated with", "UNCERTAINTY", 42, 61]]], ["Specifically, we would not anticipate an association of public pension entitlement with unmet medical needs due to non-financial constraints.", [["non-financial constraints", "PROBLEM", 115, 140]]], ["Although the replacement rates are calculated for the average wage of a production worker (a fictitious baseline for different household types), we also adjust for changes in this average that might alter the relative level of public pension entitlement.", [["the replacement rates", "TREATMENT", 9, 30], ["replacement", "OBSERVATION", 13, 24]]], ["Changes in healthcare infrastructure may account for some of the changes in unmet medical need and so we include the number of hospital beds per 100,000 inhabitants into our models.", [["Changes in healthcare infrastructure", "PROBLEM", 0, 36], ["may account for", "UNCERTAINTY", 37, 52]]], ["We find that the association between public pension generosity and unmet medical need remains stable (web appendix 7).", [["public pension generosity", "TREATMENT", 37, 62], ["stable", "OBSERVATION_MODIFIER", 94, 100]]], ["Our aggregate-level models do not include individual covariates, such age, sex, marital status, the presence of chronic illness.", [["chronic illness", "DISEASE", 112, 127], ["Our aggregate-level models", "TEST", 0, 26], ["chronic illness", "PROBLEM", 112, 127], ["chronic", "OBSERVATION_MODIFIER", 112, 119], ["illness", "OBSERVATION", 120, 127]]], ["We re-estimate our models using a multilevel modelling approach (incorporating individual-and country-level variables) and continue to find that-as expected-greater public pension entitlements are associated with lower unmet medical need (web appendix 8).", [["a multilevel modelling approach", "TREATMENT", 32, 63]]], ["Further, the benefits of these entitlements remain concentrated among the poorest groups in these multilevel models (web appendix 9), which is consistent with web appendix 2.", [["multilevel", "ANATOMY_MODIFIER", 98, 108], ["consistent with", "UNCERTAINTY", 143, 158], ["web appendix", "OBSERVATION", 159, 171]]], ["This also addresses the problem of changing sample sizes observed in those models, because there are no missing data at the country level for the results in web appendix 9.DISCUSSIONOur study highlights three important findings.", [["changing sample sizes", "PROBLEM", 35, 56], ["missing data", "PROBLEM", 104, 116], ["DISCUSSIONOur study", "TEST", 172, 191], ["sizes", "OBSERVATION_MODIFIER", 51, 56], ["appendix", "ANATOMY", 161, 169]]], ["First, greater public pension entitlement is associated with reduced unmet medical need, especially among older people.", [["people", "ORGANISM", 112, 118], ["people", "SPECIES", 112, 118]]], ["Third, the association between public pension entitlement and unmet need is greatest among those in the poorest income quintiles, without harming access to healthcare in the wealthiest quintiles.", [["public pension entitlement", "TREATMENT", 31, 57]]], ["Even a 1% increase in the minimum income replacement rate for public pensions would reduce unmet medical need by \u223c0.2% among older people who are income poor.", [["people", "ORGANISM", 131, 137], ["people", "SPECIES", 131, 137], ["the minimum income replacement rate", "TREATMENT", 22, 57], ["public pensions", "TREATMENT", 62, 77], ["increase", "OBSERVATION_MODIFIER", 10, 18]]], ["Germany has a higher rate of out-of-pocket payments than the Netherlands (1.4% of GDP compared to 0.6% of GDP, respectively).", [["GDP", "CHEMICAL", 82, 85], ["GDP", "CHEMICAL", 106, 109], ["GDP", "CHEMICAL", 106, 109], ["GDP", "SIMPLE_CHEMICAL", 106, 109], ["GDP", "TEST", 82, 85], ["GDP", "TEST", 106, 109], ["higher", "OBSERVATION_MODIFIER", 14, 20], ["rate", "OBSERVATION_MODIFIER", 21, 25]]], ["Yet, if Germany had the same public pension entitlement as the Netherlands, our model predicts that Germany would reduce unmet medical need among the poorest income quintile from 2.2% to 0.2%, thereby eliminating income inequalities in unmet medical need among older people.", [["people", "ORGANISM", 267, 273], ["people", "SPECIES", 267, 273]]], ["However, these results are suggestive only and more research is needed on this question; and we plan to examine this in more detail in future papers.DISCUSSIONThere are important limitations to this study.", [["this study", "TEST", 194, 204]]], ["Given the small number of countries, we have estimated country-level, fixed-effects regression models, but our results are stable even when we use multilevel models with individual-level and country-level predictors.", [["fixed-effects regression models", "PROBLEM", 70, 101], ["multilevel models", "TEST", 147, 164], ["small", "OBSERVATION_MODIFIER", 10, 15], ["number", "OBSERVATION_MODIFIER", 16, 22], ["stable", "OBSERVATION_MODIFIER", 123, 129]]], ["Despite this, our results have a high degree of specificity in terms of age, income, and the reason why these medical needs are unmet.", [["high degree", "OBSERVATION_MODIFIER", 33, 44]]], ["However, throughout this period, almost all of the variation in public pensions is attributable to the level of minimum replacement rates, that is, the degree of income replacement offered by pension programmes, suggesting financial mechanisms are driving these associations.", [["minimum replacement rates", "TREATMENT", 112, 137], ["income replacement", "TREATMENT", 162, 180], ["minimum replacement", "OBSERVATION", 112, 131], ["income replacement", "OBSERVATION", 162, 180]]], ["Our measure of public pension entitlement only captures the effect of state pensions and does not incorporate the role of occupational pensions on income, which is substantial in many European countries.", [["public pension entitlement", "TREATMENT", 15, 41], ["substantial", "OBSERVATION_MODIFIER", 164, 175]]], ["However, examining the influence of changes to public pensions allows us to more clearly identify the effect of a change in income for those most at risk of unmet medical need; because groups at the bottom of the income distribution are most likely to experience unmet medical need and rely most heavily on public pensions.", [["most likely", "UNCERTAINTY", 237, 248]]], ["Our panel of countries is relatively small, but even in these circumstances (eg, when the number of countries >10 and the number time points >5) regression models that account for country-specific difference which are constant over time (so-called 'fixed-effects' models) are still preferable over models which do not account for these differences.", [["Our panel", "TEST", 0, 9], ["'fixed-effects' models", "TREATMENT", 248, 270], ["relatively", "OBSERVATION_MODIFIER", 26, 36], ["small", "OBSERVATION_MODIFIER", 37, 42], ["specific", "OBSERVATION_MODIFIER", 188, 196], ["difference", "OBSERVATION_MODIFIER", 197, 207], ["constant", "OBSERVATION_MODIFIER", 218, 226], ["do not account for", "UNCERTAINTY", 311, 329]]], ["10 13 Notwithstanding the measurement error in this indicator, we find that public pension entitlements remain closely associated with access to healthcare even when we adjust for private pension provision.", [["the measurement error", "TEST", 22, 43], ["public pension entitlements", "TREATMENT", 76, 103], ["private pension provision", "TREATMENT", 180, 205]]], ["To partially address changes in demand, we adjust for the proportion of chronically ill people aged 65 or over.DISCUSSIONThese findings have important policy implications.", [["chronically ill", "DISEASE", 72, 87], ["people", "ORGANISM", 88, 94], ["people", "SPECIES", 88, 94], ["changes in demand", "PROBLEM", 21, 38]]], ["Many European countries have reduced public pension entitlement since the Great Recession 9 leading to increased unmet medical need, particularly in countries with commodified healthcare systems.", [["reduced", "OBSERVATION_MODIFIER", 29, 36], ["increased", "OBSERVATION_MODIFIER", 103, 112]]], ["In Greece, for example, the introduction of user charges coupled with public pension reform will likely exacerbate unmet medical need among pensioners and those at risk of poverty to the greatest extent.", [["user charges", "TREATMENT", 44, 56], ["public pension", "TREATMENT", 70, 84], ["greatest extent", "OBSERVATION_MODIFIER", 187, 202]]], ["4 9 The long-term implications of these changes for pensioners remain unclear, but previous evidence indicates increased healthcare costs and may even increase the risk of frailty and mortality.", [["frailty", "DISEASE", 172, 179], ["increased healthcare costs", "PROBLEM", 111, 137], ["long-term", "OBSERVATION_MODIFIER", 8, 17], ["increased", "OBSERVATION_MODIFIER", 111, 120]]], ["7 While the recession has already increased financial insecurity among older people, public pension austerity is likely to further deepen precariousness and increase unmet medical needs, particularly among the income poor.DISCUSSIONWhat is already known on this subject \u25b8 Unmet medical need has been rising across many European countries. \u25b8 This rise has been concentrated among older people and those at the bottom of the income distribution. \u25b8 Greater public pension entitlements may reduce unmet medical need among older people by reducing old-age poverty, but this relationship remains uncertain.DISCUSSIONWhat this study adds \u25b8 Greater public pension entitlements are associated with reduced unmet medical need among the older people. \u25b8 The association between public pension entitlements and unmet medical need is greater for those at the bottom of the income distribution than those at the top. \u25b8 The link between public pension entitlement and unmet medical need is only observed in countries in commodified health systems.DISCUSSIONContributors AR and DS designed the research, performed the research, wrote the first draft of the paper and analysed the data.", [["poverty", "DISEASE", 551, 558], ["people", "ORGANISM", 77, 83], ["people", "ORGANISM", 385, 391], ["people", "ORGANISM", 524, 530], ["people", "ORGANISM", 732, 738], ["AR", "PROTEIN", 1054, 1056], ["people", "SPECIES", 77, 83], ["people", "SPECIES", 385, 391], ["people", "SPECIES", 524, 530], ["people", "SPECIES", 732, 738], ["this study", "TEST", 615, 625], ["public pension entitlements", "TREATMENT", 766, 793], ["recession", "OBSERVATION", 12, 21], ["increased", "OBSERVATION_MODIFIER", 34, 43], ["concentrated", "OBSERVATION_MODIFIER", 360, 372], ["bottom", "ANATOMY_MODIFIER", 409, 415], ["greater", "OBSERVATION_MODIFIER", 820, 827]]], ["AR, DS, JM, MM and MW contributed to the interpretation of the data and writing of the manuscript.DISCUSSIONFunding This study was undertaken as part of the Demetriq project, funded from the Commission of the European Communities 7th Framework Programme under grant agreement No. 278511.", [["AR", "GENE_OR_GENE_PRODUCT", 0, 2], ["AR", "PROTEIN", 0, 2], ["This study", "TEST", 116, 126]]], ["The study does not necessarily reflect the Commission's views and in no way anticipates the Commission's future policy in this area.", [["The study", "TEST", 0, 9], ["the Commission's views", "TEST", 39, 61]]]]}